- entity: node
  type: pdq_cancer_information_summary
  title: 'Childhood Brain Stem Glioma Treatment (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: childhood brain stem glioma, childhood brain tumor
  moderation_state:
    value: published
  field_pdq_url:
    value: /types/brain/hp/child-glioma-treatment-pdq
  field_pdq_cdr_id:
    value: 62761
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Treatment
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2018-09-28'
  field_browser_title:
    value: 'Childhood Brain Stem Glioma Treatment'
  field_page_description:
    value: 'Childhood brain stem glioma presents as a diffuse intrinsic pontine glioma (DIPG; a fast-growing tumor that is difficult to treat and has a poor prognosis) or a focal glioma (grows more slowly, is easier to treat, and has a better prognosis). Learn about the diagnosis, cellular classification, staging, treatment, and c'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'General Information About Childhood Brain Stem Glioma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/types/brain/patient/child-glioma-treatment-pdq">Go to Patient Version</a></div><p id="_289" tabindex="-1">Primary brain tumors, including brain stem gliomas, are a diverse group of diseases that together constitute the most common solid tumor of childhood. Immunohistochemical analysis, cytogenetic and molecular genetic findings, and measures of mitotic activity are increasingly used in tumor diagnosis and classification. Brain tumors are classified according to histology, but tumor location and extent of spread are important factors that affect treatment and prognosis.</p><p id="_62" tabindex="-1">The PDQ  childhood brain tumor treatment summaries are organized primarily according to the World Health Organization (WHO) classification of nervous system tumors.[<a href="#cit/section_1.1">1</a>,<a href="#cit/section_1.2">2</a>] For a full description of the classification of nervous system tumors and a link to the corresponding treatment summary for each type of brain tumor, refer to the PDQ summary on <a href="/types/brain/hp/child-brain-treatment-pdq">Childhood Brain and Spinal Cord Tumors Treatment Overview</a>.</p><p id="_290" tabindex="-1">The term <em>brain stem glioma</em> is a generic description that refers to any tumor of glial origin arising in the brain stem, inclusive of the midbrain, pons, and medulla.  The following two histologies predominate:</p><div class="pdq-content-list"><ul id="_291"><li>Diffuse (infiltrating) astrocytomas centered in the pons, also called diffuse intrinsic pontine glioma (DIPG).</li><li>Pilocytic astrocytomas,  which occur throughout the brain stem.</li></ul></div><section id="_273"><h3 id="_273_toc">Incidence</h3><p id="_274" tabindex="-1">Approximately 300 to 400 pediatric brain stem tumors are diagnosed each year in the United States. DIPG accounts for approximately 75% to 80% of pediatric brain stem tumors.[<a href="#cit/section_1.3">3</a>] Most children with DIPG are diagnosed between the ages of 5 and 10 years. Focal pilocytic astrocytomas in the brain stem occur less frequently.[<a href="#cit/section_1.4">4</a>]</p></section><section id="_303"><h3 id="_303_toc">Anatomy</h3><p id="_305" tabindex="-1"><figure id="figure_304" class="image-center"><a href="https://www.cancer.gov/images/cdr/live/CDR748659.jpg" target="_blank" class="article-image-enlarge">Enlarge</a><img id="_304" alt="Drawing of the inside of the brain showing  the supratentorial area (the upper part of the brain) and the posterior fossa/infratentorial area (the lower back part of the brain). The supratentorial area contains the cerebrum, lateral ventricle, third ventricle, choroid plexus, hypothalamus, pineal gland, pituitary gland, and optic nerve. The posterior fossa/infratentorial area contains the cerebellum, tectum, fourth ventricle, and   brain stem (pons and medulla). The tentorium and spinal cord are also shown." title="Drawing of the inside of the brain showing  the supratentorial area (the upper part of the brain) and the posterior fossa/infratentorial area (the lower back part of the brain). The supratentorial area contains the cerebrum, lateral ventricle, third ventricle, choroid plexus, hypothalamus, pineal gland, pituitary gland, and optic nerve. The posterior fossa/infratentorial area contains the cerebellum, tectum, fourth ventricle, and   brain stem (pons and medulla). The tentorium and spinal cord are also shown." src="https://www.cancer.gov/images/cdr/live/CDR748659-750.jpg"><figcaption class="caption-container">Anatomy of the inside of the brain, showing the pineal and pituitary glands, optic nerve, ventricles (with cerebrospinal fluid shown in blue), and other parts of the brain. The posterior fossa is the region below the tentorium, which separates the cortex from the cerebellum and essentially denotes the region containing the brain stem, cerebellum, and fourth ventricle.</figcaption></figure></p></section><section id="_275"><h3 id="_275_toc">Clinical Features</h3><p id="_280" tabindex="-1">In children with DIPG, a classic triad of symptoms (cranial neuropathies, long tract signs, and ataxia) is often described. However, children often present with only one or two of these findings. Obstructive hydrocephalus due to expansion of the pons can also be a presenting symptom. Nonspecific symptoms may also occur, including behavioral changes and decreased school performance.    </p><p id="_292" tabindex="-1">Focal pilocytic astrocytomas in the brain stem present in multiple ways depending on tumor location. Common presenting symptoms include the following:[<a href="#cit/section_1.4">4</a>]</p><div class="pdq-content-list"><ul id="_293"><li>Raised intracranial pressure with associated hydrocephalus.</li><li>Unilateral hemiparesis.</li><li>Unilateral cranial neuropathies.</li><li>Ataxia.</li></ul></div></section><section id="_277"><h3 id="_277_toc">Diagnosis</h3><p id="_278" tabindex="-1">Primary tumors of the brain stem are most often diagnosed based on clinical findings
            and on neuroimaging studies using magnetic resonance imaging (MRI).[<a href="#cit/section_1.5">5</a>] Histologic confirmation of presumed DIPGs is usually
            unnecessary. However, histologic confirmation is currently performed for research studies and may be more routinely considered in the future.[<a href="#cit/section_1.6">6</a>]    Biopsy or resection  may be indicated for brain stem tumors that are not diffuse and
            intrinsic or when there is diagnostic uncertainty based on imaging findings.  New approaches with stereotactic needle biopsy may make biopsy
            safer.[<a href="#cit/section_1.7">7</a>-<a href="#cit/section_1.9">9</a>]</p><p id="_279" tabindex="-1">Children with neurofibromatosis type 1 (NF1) are at an increased risk of developing a brain stem glioma. They may present with a long history of symptoms or be
            identified by screening tests.</p></section><section id="_237"><h3 id="_237_toc">Prognosis and Prognostic Factors </h3><p id="_238" tabindex="-1">The median survival for children with DIPGs is less than 1 year.[<a href="#cit/section_1.10">10</a>] In contrast, focal astrocytomas (e.g., pilocytic astrocytomas) have a markedly improved prognosis, with 5-year overall survival exceeding 90%.[<a href="#cit/section_1.4">4</a>]</p><p id="_239" tabindex="-1">Prognostic factors include the following:</p><div class="pdq-content-list"><ul id="_240"><li><strong>Histology/grade of the tumor:</strong> Astrocytic tumors predominate in the brain stem.  WHO grade 1 tumors (e.g., pilocytic astrocytomas and gangliogliomas) have a favorable prognosis and can arise throughout the brain stem, including the tectum of the midbrain, focally within the pons, or at the cervicomedullary junction where they are often exophytic.  In contrast, DIPGs are diffuse astrocytomas which, when biopsied at diagnosis, can range from a low-grade fibrillary astrocytoma (WHO grade 2) to glioblastoma (WHO grade 4). At postmortem evaluation, DIPGs are also generally anaplastic astrocytoma (WHO grade 3) or glioblastoma (WHO grade 4) by morphological criteria, although WHO grade 2 regions can also be identified.[<a href="#cit/section_1.11">11</a>-<a href="#cit/section_1.15">15</a>]  Low-grade fibrillary astrocytomas (WHO grade 2) occurring outside the pons in other brain stem locations tend to be focal tumors with a more favorable prognosis.[<a href="#cit/section_1.16">16</a>]  </li><li><strong>Age at diagnosis:</strong> Children younger than 3 years diagnosed with DIPG may have a more favorable prognosis, perhaps reflecting different biologic characteristics.[<a href="#cit/section_1.17">17</a>]</li><li><strong>NF1:</strong> Children with NF1 and brain stem gliomas may have a
            better prognosis than other patients who have intrinsic lesions.[<a href="#cit/section_1.18">18</a>,<a href="#cit/section_1.19">19</a>]</li></ul></div></section><section id="_282"><h3 id="_282_toc">Follow-up After Treatment</h3><p id="_283" tabindex="-1">For children with brain stem tumors and anticipated long-term survival, standard follow-up tends to include interval clinical assessments and periodic imaging with MRI.  The required duration of follow-up with MRI varies; it largely depends on the presence or absence of residual imaging abnormalities and the original histology of the tumor after treatment.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Louis DN, Ohgaki H, Wiestler OD, et al., eds.: WHO Classification of Tumours of the Central Nervous System. 4th ed. Lyon, France: IARC Press, 2007.</li><li id="section_1.2">Louis DN, Ohgaki H, Wiestler OD, et al.: The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114 (2): 97-109, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17618441&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17618441&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Warren KE: Diffuse intrinsic pontine glioma: poised for progress. Front Oncol 2: 205, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23293772&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23293772&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Klimo P Jr, Pai Panandiker AS, Thompson CJ, et al.: Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience. J Neurosurg Pediatr 11 (3): 274-81, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23289916&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23289916&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.5">Liu AK, Brandon J, Foreman NK, et al.: Conventional MRI at presentation does not predict clinical response to radiation therapy in children with diffuse pontine glioma. Pediatr Radiol 39 (12): 1317-20, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19657635&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19657635&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.6">Walker DA, Liu J, Kieran M, et al.: A multi-disciplinary consensus statement concerning surgical approaches to low-grade, high-grade astrocytomas and diffuse intrinsic pontine gliomas in childhood (CPN Paris 2011) using the Delphi method. Neuro Oncol 15 (4): 462-8, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23502427&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23502427&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.7">Cage TA, Samagh SP, Mueller S, et al.: Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Childs Nerv Syst 29 (8): 1313-9, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23666401&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23666401&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.8">Grill J, Puget S, Andreiuolo F, et al.: Critical oncogenic mutations in newly diagnosed pediatric diffuse intrinsic pontine glioma. Pediatr Blood Cancer 58 (4): 489-91, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22190243&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22190243&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.9">Puget S, Beccaria K, Blauwblomme T, et al.: Biopsy in a series of 130 pediatric diffuse intrinsic Pontine gliomas. Childs Nerv Syst 31 (10): 1773-80, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26351229&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26351229&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.10">Cohen KJ, Pollack IF, Zhou T, et al.: Temozolomide in the treatment of high-grade gliomas in children: a report from the Children's Oncology Group. Neuro Oncol 13 (3): 317-23, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21339192&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21339192&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.11">Ballester LY, Wang Z, Shandilya S, et al.: Morphologic characteristics and immunohistochemical profile of diffuse intrinsic pontine gliomas. Am J Surg Pathol 37 (9): 1357-64, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24076776&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24076776&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.12">Wu G, Diaz AK, Paugh BS, et al.: The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46 (5): 444-50, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.13">Taylor KR, Mackay A, Truffaux N, et al.: Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46 (5): 457-61, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705252&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705252&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.14">Buczkowicz P, Hoeman C, Rakopoulos P, et al.: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46 (5): 451-6, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705254&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705254&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.15">Hoffman LM, DeWire M, Ryall S, et al.: Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun 4: 1, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26727948&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26727948&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.16">McAbee JH, Modica J, Thompson CJ, et al.: Cervicomedullary tumors in children. J Neurosurg Pediatr 16 (4): 357-66, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26114990&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26114990&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.17">Broniscer A, Laningham FH, Sanders RP, et al.: Young age may predict a better outcome for children with diffuse pontine glioma. Cancer 113 (3): 566-72, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18484645&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18484645&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.18">Pascual-Castroviejo I, Pascual-Pascual SI, Via&#xF1;o J, et al.: Posterior fossa tumors in children with neurofibromatosis type 1 (NF1). Childs Nerv Syst 26 (11): 1599-603, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20464401&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20464401&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.19">Albers AC, Gutmann DH: Gliomas in patients with neurofibromatosis type 1. Expert Rev Neurother 9 (4): 535-9, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19344304&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19344304&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _35
      field_pdq_section_title:
        - format: plain_text
          value: 'Cellular Classification of Childhood Brain Stem Glioma '
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_35" class="pdq-sections"><section id="_244"><h3 id="_244_toc">Cytogenetic Characteristics of Diffuse Intrinsic Pontine Gliomas (DIPGs)</h3><section id="_sm_CDR0000779374_1"><p id="_sm_CDR0000779374_245" tabindex="-1">The genomic characteristics of DIPGs appear to differ from those of most other pediatric high-grade gliomas and from those of adult high-grade gliomas. The molecular and clinical characteristics of DIPGs align with those of other midline high-grade gliomas with a specific <em>H3 K27M</em> mutation in histone H3.1 (<em>H3F3A</em>) or H3.3 (<em>HIST1H3B</em> and <em>HIST1H3C</em>), which led the World Health Organization to group these tumors together into a single entity.[<a href="#cit/section_2.1">1</a>] In one report of 64 children with thalamic tumors, 50% of high-grade gliomas (11 of 22) had an <em>H3 K27M</em> mutation, and approximately 10% of tumors with low-grade morphological characteristics (5 of 42) had an <em>H3 K27M</em> mutation.[<a href="#cit/section_2.2">2</a>] Five-year overall survival (OS) was only 6% (1 of 16). In another study that included 202 children with glioblastoma, 68 of the tumors were midline (primarily thalamic) and had an <em>H3 K27M</em> mutation.[<a href="#cit/section_2.3">3</a>] Five-year OS for this group was only 5%, which was significantly inferior to the survival rates of the remaining patients in the study.</p><p id="_sm_CDR0000779374_248" tabindex="-1">A number of chromosomal and genomic abnormalities have been reported for DIPG, including the following:</p><div class="pdq-content-list"><ul id="_sm_CDR0000779374_246"><li><strong>Histone H3 genes:</strong> Approximately 80% of DIPG tumors have a mutation in a specific amino acid in the histone H3.1 (<em>H3F3A</em>) or H3.3 (<em>HIST1H3B</em> and <em>HIST1H3C</em>) genes.[<a href="#cit/section_2.4">4</a>-<a href="#cit/section_2.8">8</a>]  This <em>H3 K27M</em> mutation is observed in pediatric high-grade gliomas at other midline locations but is uncommon in cortical pediatric high-grade gliomas and in adult high-grade gliomas.[<a href="#cit/section_2.4">4</a>-<a href="#cit/section_2.9">9</a>] An autopsy study that examined multiple tumor sites (primary, contiguous, and metastatic) in seven DIPG patients found that the <em>H3 K27M</em> mutation was invariably present, supporting its role as a driver mutation for DIPG.[<a href="#cit/section_2.10">10</a>]</li><li><strong>Activin A receptor, type I (<em>ACVR1</em>) gene:</strong> Approximately 20% of DIPG cases have activating mutations in the <em>ACVR1</em> gene, with most occurring concurrently with H3.3 mutations.[<a href="#cit/section_2.5">5</a>-<a href="#cit/section_2.8">8</a>] Germline mutations in <em>ACVR1</em> cause the autosomal dominant syndrome fibrodysplasia ossificans progressiva (FOP), although there is no cancer predisposition in FOP.[<a href="#cit/section_2.11">11</a>]</li><li><strong>Receptor tyrosine kinase  amplification:</strong> <em>PDGFRA</em> amplification occurs in approximately 30% of cases, with lower rates of amplification observed for some other receptor tyrosine kinases (e.g., <em>MET</em> and <em>IGF1R</em>).[<a href="#cit/section_2.12">12</a>,<a href="#cit/section_2.13">13</a>]  An autopsy study that examined multiple tumor sites (primary, contiguous, and metastatic) in seven DIPG patients found that <em>PDGFRA</em> amplification was variably present across these sites, suggesting that this change is a secondary genomic alteration in DIPG.[<a href="#cit/section_2.10">10</a>]</li><li><strong><em>TP53</em> deletion:</strong> DIPG tumors commonly show deletion of the <em>TP53</em> gene on chromosome 17p.[<a href="#cit/section_2.13">13</a>] Additionally, <em>TP53</em> is commonly mutated in DIPG tumors, particularly those with histone H3 gene mutations.[<a href="#cit/section_2.5">5</a>-<a href="#cit/section_2.8">8</a>,<a href="#cit/section_2.14">14</a>] Aneuploidy is commonly observed in cases with <em>TP53</em> mutations.[<a href="#cit/section_2.8">8</a>]</li></ul></div><p id="_sm_CDR0000779374_247" tabindex="-1">   The gene expression profile of DIPG differs from that of non&#x2013;brain stem pediatric high-grade gliomas, further supporting a distinctive biology for this subset of pediatric gliomas.[<a href="#cit/section_2.13">13</a>] Pediatric <em>H3 K27M</em>-mutant tumors rarely show MGMT promoter methylation,[<a href="#cit/section_2.3">3</a>] which explains the lack of efficacy of temozolomide when it was tested in patients with DIPG.[<a href="#cit/section_2.15">15</a>]</p></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Louis DN, Perry A, Reifenberger G, et al.: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (6): 803-20, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27157931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27157931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Ryall S, Krishnatry R, Arnoldo A, et al.: Targeted detection of genetic alterations reveal the prognostic impact of H3K27M and MAPK pathway aberrations in paediatric thalamic glioma. Acta Neuropathol Commun 4 (1): 93, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27577993&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27577993&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Korshunov A, Ryzhova M, Hovestadt V, et al.: Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers. Acta Neuropathol 129 (5): 669-78, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25752754&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25752754&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Wu G, Broniscer A, McEachron TA, et al.: Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas. Nat Genet 44 (3): 251-3, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22286216&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22286216&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Wu G, Diaz AK, Paugh BS, et al.: The genomic landscape of diffuse intrinsic pontine glioma and pediatric non-brainstem high-grade glioma. Nat Genet 46 (5): 444-50, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705251&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705251&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.6">Fontebasso AM, Papillon-Cavanagh S, Schwartzentruber J, et al.: Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nat Genet 46 (5): 462-6, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.7">Taylor KR, Mackay A, Truffaux N, et al.: Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nat Genet 46 (5): 457-61, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705252&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705252&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.8">Buczkowicz P, Hoeman C, Rakopoulos P, et al.: Genomic analysis of diffuse intrinsic pontine gliomas identifies three molecular subgroups and recurrent activating ACVR1 mutations. Nat Genet 46 (5): 451-6, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705254&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24705254&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.9">Schwartzentruber J, Korshunov A, Liu XY, et al.: Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma. Nature 482 (7384): 226-31, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22286061&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22286061&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.10">Hoffman LM, DeWire M, Ryall S, et al.: Spatial genomic heterogeneity in diffuse intrinsic pontine and midline high-grade glioma: implications for diagnostic biopsy and targeted therapeutics. Acta Neuropathol Commun 4: 1, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26727948&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26727948&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.11">Shore EM, Xu M, Feldman GJ, et al.: A recurrent mutation in the BMP type I receptor ACVR1 causes inherited and sporadic fibrodysplasia ossificans progressiva. Nat Genet 38 (5): 525-7, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16642017&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16642017&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.12">Zarghooni M, Bartels U, Lee E, et al.: Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol 28 (8): 1337-44, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20142589&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20142589&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.13">Paugh BS, Broniscer A, Qu C, et al.: Genome-wide analyses identify recurrent amplifications of receptor tyrosine kinases and cell-cycle regulatory genes in diffuse intrinsic pontine glioma. J Clin Oncol 29 (30): 3999-4006, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21931021&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21931021&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.14">Khuong-Quang DA, Buczkowicz P, Rakopoulos P, et al.: K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas. Acta Neuropathol 124 (3): 439-47, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22661320&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22661320&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.15">Cohen KJ, Heideman RL, Zhou T, et al.: Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 13 (4): 410-6, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21345842&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21345842&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _38
      field_pdq_section_title:
        - format: plain_text
          value: 'Stage Information for Childhood Brain Stem Glioma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_38" class="pdq-sections"><p id="_39" tabindex="-1">There is no generally applied staging system for childhood brain stem
            glioma.[<a href="#cit/section_3.1">1</a>]  </p><p id="_285" tabindex="-1">Brain stem gliomas are classified according to the following:  </p><div class="pdq-content-list"><ul id="_306"><li>Location.</li><li>Radiographic appearance.</li><li>Histology (when obtained).</li></ul></div><p id="_307" tabindex="-1">Brain stem gliomas may occur
            in the pons, midbrain, tectum, dorsum of the medulla at the
            cervicomedullary junction, or in multiple regions of the brain stem.  The tumor
            may contiguously involve the cerebellar peduncles, cerebellum, the cervical spinal cord, and/or thalamus.
            The majority of childhood brain stem gliomas are diffuse astrocytomas that
            involve the pons (diffuse intrinsic pontine gliomas [DIPGs]), often with contiguous involvement of other brain stem
            sites.[<a href="#cit/section_3.2">2</a>,<a href="#cit/section_3.3">3</a>]</p><p id="_248" tabindex="-1">Spread of malignant brain stem tumors is usually contiguous, with
            metastasis via the subarachnoid space. Such dissemination may occur prior to local relapse
            but usually occurs simultaneously with or after local disease relapse.[<a href="#cit/section_3.4">4</a>]</p><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Freeman CR, Farmer JP: Pediatric brain stem gliomas: a review. Int J Radiat Oncol Biol Phys 40 (2): 265-71, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9457808&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9457808&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Laigle-Donadey F, Doz F, Delattre JY: Brainstem gliomas in children and adults. Curr Opin Oncol 20 (6): 662-7, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18841048&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18841048&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Khatua S, Moore KR, Vats TS, et al.: Diffuse intrinsic pontine glioma-current status and future strategies. Childs Nerv Syst 27 (9): 1391-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21533575&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21533575&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Sethi R, Allen J, Donahue B, et al.: Prospective neuraxis MRI surveillance reveals a high risk of leptomeningeal dissemination in diffuse intrinsic pontine glioma. J Neurooncol 102 (1): 121-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20623246&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20623246&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _40
      field_pdq_section_title:
        - format: plain_text
          value: 'Treatment Option Overview for Childhood Brain Stem Glioma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_40" class="pdq-sections"><p id="_41" tabindex="-1">Dramatic improvements in survival have been achieved for children and adolescents with cancer. Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[<a href="#cit/section_4.1">1</a>] Many of the improvements in survival in childhood cancer have been made as a
            result of clinical trials that have attempted to improve on the best available,
            accepted therapy.  Clinical trials in pediatrics are designed to compare new
            therapy with therapy that is currently accepted as standard.  This comparison
            may be done in a randomized study of two treatment arms or by evaluating a
            single new treatment and comparing the results with those that were previously
            obtained with existing therapy.
            </p><p id="_42" tabindex="-1">Because of the relative rarity of cancer in children, all patients with brain
            tumors should be considered for entry into a clinical trial.  To determine and
            implement optimum treatment, planning by a multidisciplinary team of
            cancer specialists who have experience treating childhood brain tumors is
            required.  Radiation therapy (including <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=270731&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000270731&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet'); return(false);">3-dimensional conformal radiation therapy</a>) of pediatric brain tumors is technically very
            demanding and should be carried out in centers that have experience in that
            area in order to ensure optimal results.</p><p id="_340" tabindex="-1"><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_284">Table 1</a> describes the standard treatment options for newly diagnosed and recurrent or progressive childhood brain stem gliomas.</p><table id="_284" class="table-default expandable-container"><caption> Table 1.  Standard Treatment Options for Childhood Brain Stem Gliomas</caption><colgroup><col width="7.29%"><col width="37.81%"><col width="54.89%"></colgroup><THead><tr><th colspan="2">Treatment Group</th><th>Standard Treatment Options</th></tr></THead><tbody><tr><td colspan="2"><strong>Newly diagnosed childhood brain stem gliomas:</strong></td><td>&#xA0;</td></tr><tr><td>&#xA0;</td><td>Diffuse intrinsic pontine gliomas</td><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_251">Radiation therapy</a> </td></tr><tr><td rowspan="3">&#xA0;</td><td rowspan="3">Focal brain stem gliomas</td><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_261">Surgical resection (with or without chemotherapy and/or radiation therapy)</a></td></tr><tr><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_264">Observation (with or without cerebrospinal fluid diversion)</a></td></tr><tr><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_297">Radiation therapy, chemotherapy, or alternative approaches for unresectable tumors</a></td></tr><tr><td colspan="2"><strong>Recurrent/progressive childhood brain stem gliomas:</strong> </td><td>&#xA0;</td></tr><tr><td>&#xA0;</td><td>Diffuse intrinsic pontine gliomas</td><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_86">There is no standard treatment</a></td></tr><tr><td rowspan="3">&#xA0;</td><td rowspan="3">Focal brain stem gliomas</td><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_270">Repeat surgical resection</a></td></tr><tr><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_270">Radiation therapy</a></td></tr><tr><td><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_270">Chemotherapy</a></td></tr></tbody></table><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _45
      field_pdq_section_title:
        - format: plain_text
          value: 'Newly Diagnosed Childhood Brain Stem Glioma Treatment'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_45" class="pdq-sections"><section id="_46"><h3 id="_46_toc">Standard Treatment Options for Diffuse Intrinsic Pontine Gliomas (DIPGs)</h3><p id="_308" tabindex="-1">While numerous clinical trials are available for children with newly diagnosed DIPGs, the utility of any therapy besides radiation therapy in the treatment of patients with newly diagnosed DIPG remains unproven.[<a href="#cit/section_5.1">1</a>-<a href="#cit/section_5.6">6</a>]; [<a href="#cit/section_5.7">7</a>,<a href="#cit/section_5.8">8</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335132&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2A</a>]; [<a href="#cit/section_5.9">9</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335150&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335150&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiA</a>] </p><p id="_309" tabindex="-1">Currently, no chemotherapeutic strategy&#x2014;including neoadjuvant, concurrent, postradiation therapy, or immunotherapy&#x2014;when added to radiation therapy has led to long-term  survival for children with DIPGs.[<a href="#cit/section_5.10">10</a>-<a href="#cit/section_5.12">12</a>]; [<a href="#cit/section_5.13">13</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335132&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2A</a>]  This includes studies utilizing high-dose, marrow-ablative chemotherapy with autologous hematopoietic stem cell rescue, which have also been ineffective in extending survival.[<a href="#cit/section_5.14">14</a>]</p><p id="_249" tabindex="-1">Standard treatment  options for newly diagnosed DIPGs include the following:</p><div class="pdq-content-list"><ol id="_250"><li><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_251">Radiation therapy</a>.</li></ol></div><section id="_251"><h4 id="_251_toc">Radiation therapy</h4><p id="_252" tabindex="-1">Conventional treatment for children with DIPGs
            is radiation therapy to involved areas.  The conventional dose of radiation
            ranges between 54 Gy and 60 Gy given locally to the primary tumor
            site in single daily fractions.  Such treatment will result in transient
            benefit for  most patients, but more than 90% of patients will die within 18 months of diagnosis.[<a href="#cit/section_5.15">15</a>]</p><p id="_286" tabindex="-1">Radiation-induced changes may occur a few months after the completion of radiation therapy and may mimic tumor progression. When considering the efficacy of additional treatment, care needs to be taken to separate radiation-induced change from progressive disease.[<a href="#cit/section_5.16">16</a>]</p><p id="_287" tabindex="-1">Research studies evaluating the efficacy of hyperfractionated and hypofractionated radiation therapy and radiosensitizers have not demonstrated improved outcomes using these radiation techniques.</p><div class="pdq-content-list"><ol id="_288"><li>Hyperfractionated (twice daily) radiation therapy techniques have been used to deliver a higher dose, and studies using doses as high as 78 Gy have been completed. Evidence demonstrates that these increased radiation therapy doses do not improve the duration or rate of survival for patients with DIPGs, whether given alone [<a href="#cit/section_5.1">1</a>,<a href="#cit/section_5.17">17</a>] or in combination with chemotherapy.[<a href="#cit/section_5.3">3</a>]</li><li>Hypofractionated radiation therapy  results in survival rates comparable to conventional fractionated radiation therapy techniques, possibly with less treatment burden.[<a href="#cit/section_5.18">18</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335125&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335125&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiA</a>]; [<a href="#cit/section_5.15">15</a>,<a href="#cit/section_5.19">19</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335132&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2A</a>]</li><li>Studies evaluating the efficacy of various radiosensitizers as a means for enhancing the therapeutic effect of radiation therapy have been undertaken but to date have failed to show any significant improvement in outcome.[<a href="#cit/section_5.1">1</a>,<a href="#cit/section_5.3">3</a>-<a href="#cit/section_5.5">5</a>,<a href="#cit/section_5.20">20</a>,<a href="#cit/section_5.21">21</a>] </li></ol></div></section><section id="_294"><h4 id="_294_toc">Chemotherapy only (infants)</h4><p id="_295" tabindex="-1">Similar to the treatment of other brain tumors, radiation therapy is often omitted for infants with DIPGs, and chemotherapy-only approaches are utilized. However, published data supporting the utility of this approach is lacking.</p></section><section id="_255"><h4 id="_255_toc">Treatment options under clinical evaluation </h4><p id="_310" tabindex="-1">Early-phase therapeutic trials may be available for selected patients.  These trials may be available via the Children&#x2019;s Oncology Group, the <a href="https://www.pbtc.org/" title="https://www.pbtc.org/">Pediatric Brain Tumor Consortium</a>, or other entities. Information about National Cancer Institute (NCI)&#x2013;supported clinical trials can be found on the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search">NCI website</a>. For information about clinical trials sponsored by other organizations, refer to the <a href="https://clinicaltrials.gov/" title="https://clinicaltrials.gov/">ClinicalTrials.gov website</a>.</p></section></section><section id="_50"><h3 id="_50_toc">Standard Treatment Options for Focal Brain Stem Gliomas</h3><p id="_259" tabindex="-1">Standard treatment  options for newly diagnosed focal brain stem gliomas include the following:</p><div class="pdq-content-list"><ol id="_260"><li><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_261">Surgical resection (with or without chemotherapy and/or radiation therapy)</a>.</li><li><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_264">Observation (with or without cerebrospinal fluid diversion)</a>.</li><li><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_297">Radiation therapy, chemotherapy, or alternative approaches for unresectable tumors</a>.</li></ol></div><section id="_261"><h4 id="_261_toc">Surgical resection (with or without chemotherapy and/or radiation therapy)</h4><p id="_262" tabindex="-1"> In general, maximal surgical resection is attempted.[<a href="#cit/section_5.22">22</a>,<a href="#cit/section_5.23">23</a>] </p><p id="_263" tabindex="-1">Patients with residual tumor may be candidates for additional therapy. Treatment options include chemotherapy and/or radiation therapy.</p></section><section id="_264"><h4 id="_264_toc">Observation (with or without cerebrospinal fluid diversion)</h4><p id="_265" tabindex="-1">Patients with small tectal lesions and hydrocephalus but no other neurological
            deficits may be treated with cerebrospinal fluid diversion alone and have follow-up
            with sequential neuroradiographic studies  unless there is evidence of
            progressive disease.[<a href="#cit/section_5.22">22</a>]</p><p id="_296" tabindex="-1">A period of observation may be indicated before
            instituting any treatment for patients with neurofibromatosis type 1.[<a href="#cit/section_5.24">24</a>]  Brain stem gliomas in these children may be
            indolent and may require no specific treatment for years.[<a href="#cit/section_5.25">25</a>]</p></section><section id="_297"><h4 id="_297_toc">Radiation therapy, chemotherapy, or alternative approaches for unresectable tumors</h4><p id="_298" tabindex="-1">In selected circumstances, adjuvant therapy in the form of radiation therapy or chemotherapy can be considered in a child with a newly diagnosed focal brain stem glioma.[<a href="#cit/section_5.26">26</a>,<a href="#cit/section_5.27">27</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335141&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335141&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iDi</a>]  Decisions regarding the need for such therapy depend on the age of the child, the extent of resection obtainable, and associated neurologic deficits.</p><p id="_299" tabindex="-1">Alternative approaches that have proven beneficial in selected cases include the following:</p><div class="pdq-content-list"><ul id="_300"><li><a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=44464&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000044464&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet'); return(false);">Stereotactic</a> iodine I 125 brachytherapy approaches, with or without adjuvant chemotherapy.[<a href="#cit/section_5.28">28</a>]</li><li>The use of <em>BRAF</em> inhibitors for tumors harboring a <em>BRAF</em> V600E mutation.[<a href="#cit/section_5.29">29</a>]</li></ul></div></section></section><section id="_TrialSearch_45_sid_5"><h3 id="_TrialSearch_45_sid_5_toc">Current Clinical Trials</h3><p id="_TrialSearch_45_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_5.1">Mandell LR, Kadota R, Freeman C, et al.: There is no role for hyperfractionated radiotherapy in the management of children with newly diagnosed diffuse intrinsic brainstem tumors: results of a Pediatric Oncology Group phase III trial comparing conventional vs. hyperfractionated radiotherapy. Int J Radiat Oncol Biol Phys 43 (5): 959-64, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10192340&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10192340&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Jennings MT, Sposto R, Boyett JM, et al.: Preradiation chemotherapy in primary high-risk brainstem tumors: phase II study CCG-9941 of the Children's Cancer Group. J Clin Oncol 20 (16): 3431-7, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12177103&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12177103&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Allen J, Siffert J, Donahue B, et al.: A phase I/II study of carboplatin combined with hyperfractionated radiotherapy for brainstem gliomas. Cancer 86 (6): 1064-9, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10491535&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10491535&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Broniscer A, Leite CC, Lanchote VL, et al.: Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gliomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. J Clin Oncol 18 (6): 1246-53, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10715294&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10715294&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Doz F, Neuenschwander S, Bouffet E, et al.: Carboplatin before and during radiation therapy for the treatment of malignant brain stem tumours: a study by the Soci&#xE9;t&#xE9; Fran&#xE7;aise d'Oncologie P&#xE9;diatrique. Eur J Cancer 38 (6): 815-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11937316&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11937316&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Wolff JE, Westphal S, M&#xF6;lenkamp G, et al.: Treatment of paediatric pontine glioma with oral trophosphamide and etoposide. Br J Cancer 87 (9): 945-9, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12434281&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12434281&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.7">Korones DN, Fisher PG, Kretschmar C, et al.: Treatment of children with diffuse intrinsic brain stem glioma with radiotherapy, vincristine and oral VP-16: a Children's Oncology Group phase II study. Pediatr Blood Cancer 50 (2): 227-30, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17278121&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17278121&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Cohen KJ, Heideman RL, Zhou T, et al.: Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children's Oncology Group. Neuro Oncol 13 (4): 410-6, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21345842&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21345842&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Jalali R, Raut N, Arora B, et al.: Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 77 (1): 113-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19647954&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19647954&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Frappaz D, Schell M, Thiesse P, et al.: Preradiation chemotherapy may improve survival in pediatric diffuse intrinsic brainstem gliomas: final results of BSG 98 prospective trial. Neuro Oncol 10 (4): 599-607, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18577561&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18577561&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Frazier JL, Lee J, Thomale UW, et al.: Treatment of diffuse intrinsic brainstem gliomas: failed approaches and future strategies. J Neurosurg Pediatr 3 (4): 259-69, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19338403&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19338403&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Hargrave D, Bartels U, Bouffet E: Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7 (3): 241-8, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16510333&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16510333&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Warren K, Bent R, Wolters PL, et al.: A phase 2 study of pegylated interferon &#x3B1;-2b (PEG-Intron(&#xAE;)) in children with diffuse intrinsic pontine glioma. Cancer 118 (14): 3607-13, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22086404&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22086404&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Bouffet E, Raquin M, Doz F, et al.: Radiotherapy followed by high dose busulfan and thiotepa: a prospective assessment of high dose chemotherapy in children with diffuse pontine gliomas. Cancer 88 (3): 685-92, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10649264&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10649264&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Janssens GO, Jansen MH, Lauwers SJ, et al.: Hypofractionation vs conventional radiation therapy for newly diagnosed diffuse intrinsic pontine glioma: a matched-cohort analysis. Int J Radiat Oncol Biol Phys 85 (2): 315-20, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22682807&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22682807&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Liu AK, Macy ME, Foreman NK: Bevacizumab as therapy for radiation necrosis in four children with pontine gliomas. Int J Radiat Oncol Biol Phys 75 (4): 1148-54, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19857784&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19857784&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Freeman CR, Krischer JP, Sanford RA, et al.: Final results of a study of escalating doses of hyperfractionated radiotherapy in brain stem tumors in children: a Pediatric Oncology Group study. Int J Radiat Oncol Biol Phys 27 (2): 197-206, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8407392&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8407392&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Zaghloul MS, Eldebawy E, Ahmed S, et al.: Hypofractionated conformal radiotherapy for pediatric diffuse intrinsic pontine glioma (DIPG): a randomized controlled trial. Radiother Oncol 111 (1): 35-40, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24560760&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24560760&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Negretti L, Bouchireb K, Levy-Piedbois C, et al.: Hypofractionated radiotherapy in the treatment of diffuse intrinsic pontine glioma in children: a single institution's experience. J Neurooncol 104 (3): 773-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21327862&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21327862&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Freeman CR, Kepner J, Kun LE, et al.: A detrimental effect of a combined chemotherapy-radiotherapy approach in children with diffuse intrinsic brain stem gliomas? Int J Radiat Oncol Biol Phys 47 (3): 561-4, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10837936&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10837936&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Bradley KA, Zhou T, McNall-Knapp RY, et al.: Motexafin-gadolinium and involved field radiation therapy for intrinsic pontine glioma of childhood: a children's oncology group phase 2 study. Int J Radiat Oncol Biol Phys 85 (1): e55-60, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23092726&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23092726&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.22">Vandertop WP, Hoffman HJ, Drake JM, et al.: Focal midbrain tumors in children. Neurosurgery 31 (2): 186-94, 1992.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1308661&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=1308661&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.23">Kestle J, Townsend JJ, Brockmeyer DL, et al.: Juvenile pilocytic astrocytoma of the brainstem in children. J Neurosurg 101 (1 Suppl): 1-6, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16206964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16206964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.24">Bilaniuk LT, Molloy PT, Zimmerman RA, et al.: Neurofibromatosis type 1: brain stem tumours. Neuroradiology 39 (9): 642-53, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9335063&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9335063&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.25">Molloy PT, Bilaniuk LT, Vaughan SN, et al.: Brainstem tumors in patients with neurofibromatosis type 1: a distinct clinical entity. Neurology 45 (10): 1897-902, 1995.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7477989&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7477989&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.26">Klimo P Jr, Pai Panandiker AS, Thompson CJ, et al.: Management and outcome of focal low-grade brainstem tumors in pediatric patients: the St. Jude experience. J Neurosurg Pediatr 11 (3): 274-81, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23289916&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23289916&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.27">Ronghe M, Hargrave D, Bartels U, et al.: Vincristine and carboplatin chemotherapy for unresectable and/or recurrent low-grade astrocytoma of the brainstem. Pediatr Blood Cancer 55 (3): 471-7, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20535831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20535831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.28">Ruge MI, Kickingereder P, Simon T, et al.: Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome. J Neurooncol 109 (2): 273-83, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22580799&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22580799&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.29">Rush S, Foreman N, Liu A: Brainstem ganglioglioma successfully treated with vemurafenib. J Clin Oncol 31 (10): e159-60, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23358987&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23358987&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _55
      field_pdq_section_title:
        - format: plain_text
          value: 'Progressive/Recurrent Childhood Brain Stem Glioma Treatment'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_55" class="pdq-sections"><section id="_86"><h3 id="_86_toc">Treatment Options for Progressive Diffuse Intrinsic Pontine Gliomas (DIPGs)</h3><p id="_87" tabindex="-1">Progression of the tumor is anticipated generally within 1 year of completing radiation therapy.  In most cases, biopsy at the time of clinical or radiologic progression is neither necessary nor recommended. Reirradiation has been shown to prolong survival and can be considered at first progression in children who have had an initial response to radiation therapy.[<a href="#cit/section_6.1">1</a>,<a href="#cit/section_6.2">2</a>]</p><p id="_1804" tabindex="-1">Patients or families who desire additional disease-directed therapy should consider entering trials of novel therapeutic approaches because no standard agents have demonstrated clinically significant activity.</p><p id="_330" tabindex="-1">Regardless of whether a decision is made to pursue disease-directed therapy at the time of progression, palliative care remains a central focus of management.  This ensures that quality of life is maximized while attempting to reduce symptoms and stress related to the terminal illness.</p></section><section id="_88"><h3 id="_88_toc">Treatment Options for Recurrent Focal Brain Stem Gliomas </h3><p id="_89" tabindex="-1">At the time of recurrence, a complete evaluation to determine the extent of the relapse may be indicated for selected focal lesions. Biopsy or surgical resection should be considered for confirmation of relapse when other entities such as secondary tumor and treatment-related brain necrosis, which may be clinically indistinguishable from tumor recurrence, are in the differential diagnosis. Other tests, including positron emission tomography, magnetic resonance spectroscopy, and single-photon emission computed tomography, have not yet been shown to be reliable in distinguishing necrosis from tumor recurrence in brain stem gliomas.</p><p id="_1805" tabindex="-1"> Radiation-induced changes may occur a few months after the completion of radiation therapy and may mimic tumor progression. When considering the efficacy of additional treatment, care needs to be taken to separate radiation-induced change from progressive disease.</p><p id="_270" tabindex="-1">Treatment considerations at the time of recurrence or progression are dependent on prior treatment.  Treatment  options for recurrent focal brain stem gliomas include the following:</p><div class="pdq-content-list"><ol id="_271"><li><strong>Repeat surgical resection:</strong> The need for surgical intervention must be individualized on the basis of the initial tumor type, the location within the brain stem, the length of time between initial treatment, the appearance of the mass lesion, and the clinical picture.[<a href="#cit/section_6.3">3</a>]</li><li><strong>Radiation therapy</strong>.[<a href="#cit/section_6.4">4</a>]</li><li><strong>Chemotherapy:</strong> Chemotherapy with agents such as a carboplatin and vincristine may be effective in children with recurrent focal exophytic gliomas.[<a href="#cit/section_6.5">5</a>]</li></ol></div></section><section id="_1796"><h3 id="_1796_toc">Treatment Options Under Clinical Evaluation</h3><p id="_1797" tabindex="-1">Early-phase therapeutic trials may be available for selected patients. These trials may be available via the Children&#x2019;s Oncology Group (COG), the <a href="https://www.pbtc.org/" title="https://www.pbtc.org/">Pediatric Brain Tumor Consortium</a>, or other entities.  Information about National Cancer Institute (NCI)&#x2013;supported clinical trials can be found on the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search">NCI website</a>. For information about clinical trials sponsored by other organizations, refer to the <a href="https://clinicaltrials.gov/" title="https://clinicaltrials.gov/">ClinicalTrials.gov website</a>.</p><p id="_1799" tabindex="-1">The following is an example of a national and/or institutional clinical trial that is currently being conducted:</p><div class="pdq-content-list"><ul id="_1798"><li><strong><a href="/clinicaltrials/NCT03155620">APEC1621 (NCT03155620)</a></strong> (Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders)<strong>:</strong> NCI-COG Pediatric Molecular Analysis for Therapeutic Choice (MATCH), referred to as Pediatric MATCH, will match targeted agents with specific molecular changes identified using a next-generation sequencing targeted assay of more than 3,000 different mutations across more than 160 genes in refractory and recurrent solid tumors.   Children and adolescents aged 1 to 21 years are eligible for the trial. Patients with a brain stem glioma may be enrolled if tissue is available from a diagnostic biopsy.<p id="_1795" tabindex="-1">Tumor tissue from progressive or recurrent disease must be available for molecular characterization.  Patients with tumors that have molecular variants addressed by treatment arms included in the trial will be offered treatment on Pediatric MATCH.  Additional information can be obtained on the <a href="https://clinicaltrials.gov/" title="https://clinicaltrials.gov/">ClinicalTrials.gov website</a> for <a href="https://clinicaltrials.gov/ct2/show/NCT03155620" title="https://clinicaltrials.gov/ct2/show/NCT03155620">APEC1621 (NCT03155620)</a>.</p>
            </li></ul></div></section><section id="_TrialSearch_55_sid_6"><h3 id="_TrialSearch_55_sid_6_toc">Current Clinical Trials</h3><p id="_TrialSearch_55_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_6.1">Janssens GO, Gandola L, Bolle S, et al.: Survival benefit for patients with diffuse intrinsic pontine glioma (DIPG) undergoing re-irradiation at first progression: A matched-cohort analysis on behalf of the SIOP-E-HGG/DIPG working group. Eur J Cancer 73: 38-47, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28161497&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28161497&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Lassaletta A, Strother D, Laperriere N, et al.: Reirradiation in patients with diffuse intrinsic pontine gliomas: The Canadian experience. Pediatr Blood Cancer 65 (6): e26988, 2018.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29369515&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=29369515&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Bowers DC, Krause TP, Aronson LJ, et al.: Second surgery for recurrent pilocytic astrocytoma in children. Pediatr Neurosurg 34 (5): 229-34, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11423771&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11423771&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Huynh-Le MP, Walker AJ, Burger PC, et al.: Management of pediatric intracranial low-grade gliomas: long-term follow-up after radiation therapy. Childs Nerv Syst 32 (8): 1425-30, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27179530&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27179530&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Ater JL, Zhou T, Holmes E, et al.: Randomized study of two chemotherapy regimens for treatment of low-grade glioma in young children: a report from the Children's Oncology Group. J Clin Oncol 30 (21): 2641-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22665535&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22665535&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _63
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (09/28/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_63" class="pdq-sections"><p id="_64" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as
            new information becomes available.  This section describes the latest
            changes made to this summary as of the date above.</p><p id="_1809" tabindex="-1"><strong><a href="/types/brain/hp/child-glioma-treatment-pdq#link/_55">Progressive/Recurrent Childhood Brain Stem Glioma Treatment</a></strong></p><p id="_1810" tabindex="-1">Added Lassaletta et al. as <a href="/types/brain/hp/child-glioma-treatment-pdq#link/_87">reference 2</a>.</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/types/brain/hp/child-glioma-treatment-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of childhood brain stem glioma. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="" tabindex="-1">The lead reviewers for Childhood Brain Stem Glioma Treatment are:</p><div class="pdq-content-list"><ul id=""><li>Kenneth J. Cohen, MD, MBA (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital)</li><li>Karen J. Marcus, MD (Dana-Farber Cancer Institute/Boston Children's Hospital)</li><li>Roger J. Packer, MD (Children's National Health System)</li><li>Malcolm A. Smith, MD, PhD (National Cancer Institute)</li></ul></div><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <a href="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Pediatric Treatment Editorial Board. PDQ Childhood Brain Stem Glioma Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/types/brain/hp/child-glioma-treatment-pdq" title="https://www.cancer.gov/types/brain/hp/child-glioma-treatment-pdq">https://www.cancer.gov/types/brain/hp/child-glioma-treatment-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389253]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_18" tabindex="-1">Based on the strength of the available evidence, treatment options may be described as either &#x201C;standard&#x201D; or &#x201C;under clinical evaluation.&#x201D; These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Descripción del tratamiento de tumores de encéfalo y de médula espinal infantiles (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq
  field_pdq_cdr_id__ES:
    value: 256675
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Treatment
  field_date_posted__ES:
    value: '2019-03-11'
  field_date_updated__ES:
    value: '2017-08-15'
  field_browser_title__ES:
    value: 'Tumores de encéfalo y de médula espinal infantiles'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos acerca del tratamiento de varios tumores de encéfalo infantiles.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información general sobre los tumores de encéfalo y de médula espinal infantiles'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/tipos/cerebro/paciente/tratamiento-cerebro-infantil-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_2" tabindex="-1">Se han logrado mejoras notables en la supervivencia de ni&#xF1;os y adolescentes con c&#xE1;ncer. Entre 1975 y 2010, la mortalidad por c&#xE1;ncer infantil disminuy&#xF3; en m&#xE1;s de 50&#xA0;%.[<a href="#cit/section_1.1">1</a>] Los ni&#xF1;os y adolescentes sobrevivientes de c&#xE1;ncer necesitan un seguimiento minucioso, ya que  los efectos secundarios del tratamiento del c&#xE1;ncer pueden persistir o presentarse meses o a&#xF1;os despu&#xE9;s de este. Para obtener informaci&#xF3;n espec&#xED;fica acerca de la incidencia, tipo y vigilancia de los efectos tard&#xED;os en los ni&#xF1;os y adolescentes sobrevivientes de c&#xE1;ncer, consultar el sumario del PDQ <a href="/espanol/tipos/infantil/efectos-tardios-pro-pdq">Efectos tard&#xED;os del tratamiento anticanceroso en la ni&#xF1;ez</a>.</p><p id="_3" tabindex="-1">Los tumores de enc&#xE9;falo primarios son un grupo diverso de enfermedades que juntas constituyen el tumor s&#xF3;lido m&#xE1;s com&#xFA;n de la ni&#xF1;ez. Los tumores de enc&#xE9;falo se clasifican seg&#xFA;n sus caracter&#xED;sticas histol&#xF3;gicas, pero la ubicaci&#xF3;n del tumor y el grado de diseminaci&#xF3;n son tambi&#xE9;n factores importantes que afectan el tratamiento y el pron&#xF3;stico. Para el diagn&#xF3;stico y la clasificaci&#xF3;n tumoral, se usan cada vez m&#xE1;s los an&#xE1;lisis inmunohistoqu&#xED;micos, los hallazgos citogen&#xE9;ticos y gen&#xE9;tico moleculares, y las mediciones de la actividad proliferativa.[<a href="#cit/section_1.2">2</a>]</p><section id="_4"><h3 id="_4_toc">Incidencia</h3><p id="_5" tabindex="-1">En el Central Brain Tumor Registry of the United States (CBTRUS), se calcula que alrededor de 4300  ni&#xF1;os reciben este diagn&#xF3;stico cada a&#xF1;o en los Estados Unidos.[<a href="#cit/section_1.3">3</a>]</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_1.1">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.2">Louis DN, Perry A, Reifenberger G, et al.: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (6): 803-20, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27157931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27157931&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Ostrom QT, Gittleman H, Farah P, et al.: CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol 15 (Suppl 2): ii1-56, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24137015&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24137015&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _6
      field_pdq_section_title:
        - format: plain_text
          value: 'Clasificación de los tumores del sistema nervioso central'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_6" class="pdq-sections"><p id="_7" tabindex="-1"> La clasificaci&#xF3;n de los tumores del sistema nervioso central (SNC) en ni&#xF1;os se basa en sus caracter&#xED;sticas histol&#xF3;gicas y localizaci&#xF3;n.[<a href="#cit/section_2.1">1</a>] De manera cl&#xE1;sica, los tumores se categorizan como infratentoriales, supratentoriales, paraselares o espinales. Para el diagn&#xF3;stico y la clasificaci&#xF3;n de los tumores, se emplean cada vez m&#xE1;s los an&#xE1;lisis inmunohistoqu&#xED;micos, los hallazgos citogen&#xE9;ticos y gen&#xE9;tico moleculares, as&#xED; como las mediciones de la actividad proliferativa; esto probablemente afecte la clasificaci&#xF3;n y la nomenclatura en el futuro.</p><p id="_33" tabindex="-1">Los tumores del SNC primarios de la m&#xE9;dula espinal comprenden alrededor de 1 a 2&#xA0;% de todos los tumores del SNC infantil. La clasificaci&#xF3;n de los tumores de m&#xE9;dula espinal se basa en las caracter&#xED;sticas histopatol&#xF3;gicas del tumor y no difiere de la clasificaci&#xF3;n de los tumores de enc&#xE9;falo primarios.[<a href="#cit/section_2.1">1</a>]</p><p id="_8" tabindex="-1">Los tumores infratentoriales (fosa posterior) son los siguientes:</p><div class="pdq-content-list"><ol id="_9"><li>Astrocitomas cerebelares (con mayor frecuencia piloc&#xED;ticos, pero tambi&#xE9;n difusos y, con menor frecuencia, astrocitoma anapl&#xE1;sico o glioblastoma).</li><li>Meduloblastomas (incluyen cl&#xE1;sico, desmopl&#xE1;sico/nodular, de nodularidad extensa, anapl&#xE1;sico o variantes de c&#xE9;lulas grandes).</li><li>Ependimomas (papilar, de c&#xE9;lulas claras, tanic&#xED;tico o anapl&#xE1;sico).</li><li>Gliomas del tronco encef&#xE1;lico (normalmente, glioma de la l&#xED;nea media con mutaci&#xF3;n de <em>H3 K27M</em> y otros gliomas difusos de la l&#xED;nea media;   focal, tectal y gliomas exof&#xED;ticos cervicomedulares que, con mayor frecuencia, son astrocitomas piloc&#xED;ticos).</li><li>Tumores teratoideos/rabdoides at&#xED;picos.</li><li>Tumores del plexo coroideo (papilomas y carcinomas).
            </li></ol></div><p id="_10" tabindex="-1">
            Los tumores supratentoriales son los siguientes:</p><div class="pdq-content-list"><ol id="_11"><li>Astrocitomas de hemisferio cerebral de grado bajo (astrocitomas de grado I [piloc&#xED;ticos] o astrocitomas de grado II [difusos]).
            </li><li>Astrocitomas de grado alto o malignos (astrocitomas anapl&#xE1;sicos y glioblastoma).
            </li><li>Oligodendrogliomas (de grado bajo, anapl&#xE1;sico y oligoastrocitomas mixtos).</li><li>Tumores neuronales y gliales neuronales mixtos (gangliogliomas, astrocitoma desmopl&#xE1;sico infantil/gangliogliomas, tumores neuroepiteliales disembriopl&#xE1;sicos y tumores glioneuronales papilares).</li><li>Otros gliomas de grado bajo (incluso tumores subependimarios de c&#xE9;lulas gigantes y xantroastrocitomas pleom&#xF3;rficos).</li><li>Tumores embrionarios, incluso tumor embrionario con rosetas m&#xFA;ltiples (ETMR) (con alteraci&#xF3;n de <em>C19MC</em> o sin otra indicaci&#xF3;n), meduloepitelioma, neuroblastoma del SNC, ganglioneuroblastoma del SNC, tumor embrionario del SNC y tumor embrionario del SNC con caracter&#xED;sticas rabdoides.</li><li>Tumores teratoideos/rabdoides at&#xED;picos.
            </li><li>Ependimomas (papilar, c&#xE9;lulas claras, tanic&#xED;tico,  con fusi&#xF3;n de <em>RELA</em> o anapl&#xE1;sico).
            </li><li>Meningiomas (grados I, II  y III).
            </li><li>Tumores del plexo coroideo (papilomas, carcinomas y tumor at&#xED;pico del plexo coroideo).
            </li><li>Tumores de la regi&#xF3;n pineal (pineocitomas, pineoblastomas, tumores del par&#xE9;nquima pineal de diferenciaci&#xF3;n intermedia y tumores papilares de la regi&#xF3;n pineal) y tumores de c&#xE9;lulas germinativas.</li><li>Met&#xE1;stasis (poco frecuentes) de neoplasias malignas extraneurales.</li></ol></div><p id="_12" tabindex="-1">Los tumores paraselares son los siguientes:</p><div class="pdq-content-list"><ol id="_13"><li>Craneofaringiomas.</li><li>
            Astrocitomas diencef&#xE1;licos (tumores centrales que comprometen el quiasma, el hipot&#xE1;lamo o el t&#xE1;lamo) que, por lo general, son de grado bajo (incluso los astrocitomas de grado I [piloc&#xED;ticos] o de grado II [difusos]).</li><li>Tumores de las c&#xE9;lulas germinales (germinomas o tumores no germinomatosos).
            </li></ol></div><p id="_15" tabindex="-1">Los tumores de m&#xE9;dula espinal son los siguientes:</p><div class="pdq-content-list"><ol id="_16"><li>Astrocitomas de grado bajo (astrocitomas de grado I [piloc&#xED;ticos] o astrocitomas de grado II [difusos]).</li><li>
            Astrocitomas de grado alto o malignos (astrocitomas anapl&#xE1;sicos y glioblastoma [grado III o grado IV]).</li><li>Gangliogliomas.</li><li>Ependimomas (a menudo, mixopapilares).</li></ol></div><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">Louis DN, Perry A, Reifenberger G, et al.: The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol 131 (6): 803-20, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27157931&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27157931&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _17
      field_pdq_section_title:
        - format: plain_text
          value: 'Abordaje general para la atención de niños con tumores de encéfalo y de médula espinal'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_17" class="pdq-sections"><p id="_18" tabindex="-1">Entre los conceptos importantes que deber&#xE1;n entender quienes tratan y atienden a un ni&#xF1;o con un tumor de enc&#xE9;falo o de m&#xE9;dula espinal, se encuentran los siguientes:
            </p><div class="pdq-content-list"><ol id="_19"><li>A&#xFA;n se desconoce la causa de la mayor&#xED;a de los tumores de enc&#xE9;falo infantiles; sin embargo, las mutaciones de l&#xED;nea germinal se aceptan cada vez m&#xE1;s como predisponentes de c&#xE1;ncer: se identifican en hasta 8&#xA0;% de los ni&#xF1;os con c&#xE1;ncer.[<a href="#cit/section_3.1">1</a>,<a href="#cit/section_3.2">2</a>]</li><li>Solo se puede seleccionar la terapia apropiada si se hace un diagn&#xF3;stico correcto y se determina con precisi&#xF3;n el estadio de la enfermedad.</li><li>Los ni&#xF1;os con tumores primarios de enc&#xE9;falo o de m&#xE9;dula espinal constituyen un reto terap&#xE9;utico importante. Por lo tanto, para obtener resultados terap&#xE9;uticos &#xF3;ptimos son necesarios los esfuerzos coordinados de especialistas en &#xE1;reas de la pediatr&#xED;a como neurocirug&#xED;a, neuropatolog&#xED;a, radioncolog&#xED;a, oncolog&#xED;a pedi&#xE1;trica, neuroncolog&#xED;a, neurolog&#xED;a, rehabilitaci&#xF3;n, neurorradiolog&#xED;a, endocrinolog&#xED;a y psicolog&#xED;a, que tengan conocimientos especializados para la atenci&#xF3;n de pacientes con estas enfermedades.[<a href="#cit/section_3.3">3</a>,<a href="#cit/section_3.4">4</a>] Por ejemplo, la radioterapia de los tumores de enc&#xE9;falo infantiles tiene grandes exigencias t&#xE9;cnicas y se debe administrar en centros con experiencia en esta &#xE1;rea.</li><li>Todav&#xED;a no se ha determinado el r&#xE9;gimen de tratamiento &#xF3;ptimo para la mayor&#xED;a de los tumores de enc&#xE9;falo y de m&#xE9;dula espinal en ni&#xF1;os. Se debe considerar la inscripci&#xF3;n en un ensayo cl&#xED;nico de los ni&#xF1;os que tienen tumores de enc&#xE9;falo y de m&#xE9;dula espinal cuando est&#xE9; disponible un estudio apropiado. Instituciones y grupos cooperativos llevan a cabo este tipo de ensayos cl&#xED;nicos. La supervivencia del c&#xE1;ncer infantil ha aumentado como resultado de los ensayos cl&#xED;nicos que intentaron superar el mejor tratamiento disponible que se acepta actualmente como est&#xE1;ndar. Los ensayos cl&#xED;nicos se dise&#xF1;an para comparar un tratamiento nuevo con el tratamiento que actualmente se acepta como est&#xE1;ndar. Esta comparaci&#xF3;n se puede realizar mediante un estudio aleatorizado con dos grupos de tratamiento o mediante la evaluaci&#xF3;n de un solo tratamiento nuevo y, luego,  la comparaci&#xF3;n de estos resultados con los que se obtuvieron previamente con el tratamiento existente. Para obtener informaci&#xF3;n sobre ensayos cl&#xED;nicos en curso, consultar el <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">portal de Internet del NCI</a>.</li><li>Si bien m&#xE1;s de 70&#xA0;% de los ni&#xF1;os a quienes se les diagnostican tumores de enc&#xE9;falo sobrevivir&#xE1;n m&#xE1;s de 5 a&#xF1;os despu&#xE9;s del diagn&#xF3;stico, las tasas de supervivencia var&#xED;an ampliamente seg&#xFA;n el tipo y estadio del  tumor. Son comunes las secuelas a largo plazo relacionadas con la presencia inicial del tumor y el tratamiento posterior.[<a href="#cit/section_3.5">5</a>-<a href="#cit/section_3.7">7</a>] Con frecuencia, se observan efectos debilitantes sobre el crecimiento y el desarrollo neurol&#xF3;gico despu&#xE9;s de la radioterapia, en especial, en los ni&#xF1;os m&#xE1;s peque&#xF1;os. Cada vez m&#xE1;s se diagnostican tumores secundarios en los sobrevivientes a largo plazo.[<a href="#cit/section_3.8">8</a>] Por esta raz&#xF3;n, est&#xE1; en estudio la funci&#xF3;n de la quimioterapia para permitir demorar o reducir la administraci&#xF3;n de la radioterapia; los resultados preliminares indican que se puede usar la quimioterapia para demorar, limitar y, en algunos casos, obviar la necesidad de administrar radioterapia a ni&#xF1;os con lesiones benignas o malignas.[<a href="#cit/section_3.9">9</a>-<a href="#cit/section_3.11">11</a>]
            El tratamiento a largo plazo de estos pacientes es complejo y exige un abordaje multidisciplinario.<p id="_20" tabindex="-1">Para obtener m&#xE1;s informaci&#xF3;n sobre los posibles efectos a largo plazo o tard&#xED;os, consultar el sumario del PDQ <a href="/espanol/tipos/infantil/efectos-tardios-pro-pdq">Efectos tard&#xED;os del tratamiento anticanceroso en la ni&#xF1;ez</a>.
            </p></li><li>La American Academy of Pediatrics estableci&#xF3; pautas para los centros de oncolog&#xED;a pedi&#xE1;trica y su funci&#xF3;n en el tratamiento de los pacientes con c&#xE1;ncer infantil.[<a href="#cit/section_3.12">12</a>]</li></ol></div><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Fisher JL, Schwartzbaum JA, Wrensch M, et al.: Epidemiology of brain tumors. Neurol Clin 25 (4): 867-90, vii, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17964019&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17964019&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Zhang J, Walsh MF, Wu G, et al.: Germline Mutations in Predisposition Genes in Pediatric Cancer. N Engl J Med 373 (24): 2336-46, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26580448&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26580448&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Parsons DW, Pollack IF, Hass-Kogan DA, et al.: Gliomas, ependymomas, and other nonembryonal tumors of the central nervous system. In: Pizzo PA, Poplack DG, eds.: Principles and Practice of Pediatric Oncology. 7th ed. Philadelphia, Pa: Lippincott Williams and Wilkins, 2015, pp 628-70.</li><li id="section_3.4">Pollack IF: Brain tumors in children. N Engl J Med 331 (22): 1500-7, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7969301&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=7969301&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Smith MA, Seibel NL, Altekruse SF, et al.: Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol 28 (15): 2625-34, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20404250&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20404250&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.6">Reimers TS, Mortensen EL, Nysom K, et al.: Health-related quality of life in long-term survivors of childhood brain tumors. Pediatr Blood Cancer 53 (6): 1086-91, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19499581&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19499581&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Iuvone L, Peruzzi L, Colosimo C, et al.: Pretreatment neuropsychological deficits in children with brain tumors. Neuro Oncol 13 (5): 517-24, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21372071&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21372071&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Armstrong GT: Long-term survivors of childhood central nervous system malignancies: the experience of the Childhood Cancer Survivor Study. Eur J Paediatr Neurol 14 (4): 298-303, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20110182&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20110182&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.9">Duffner PK, Horowitz ME, Krischer JP, et al.: Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med 328 (24): 1725-31, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8388548&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8388548&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.10">Packer RJ, Lange B, Ater J, et al.: Carboplatin and vincristine for recurrent and newly diagnosed low-grade gliomas of childhood. J Clin Oncol 11 (5): 850-6, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8487049&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8487049&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.11">Mason WP, Grovas A, Halpern S, et al.: Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors. J Clin Oncol 16 (1): 210-21, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440745&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9440745&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.12">Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173520&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _21
      field_pdq_section_title:
        - format: plain_text
          value: 'Tratamiento de los tumores de encéfalo infantiles recién diagnosticados y recidivantes'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_21" class="pdq-sections"><p id="_22" tabindex="-1">En estos momentos no hay un sistema de estadificaci&#xF3;n aceptado de manera uniforme para la mayor&#xED;a de los tumores de enc&#xE9;falo infantiles. Estos tumores se clasifican y tratan de acuerdo con sus caracter&#xED;sticas histol&#xF3;gicas y localizaci&#xF3;n en el enc&#xE9;falo (consultar el <a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_23">Cuadro</a> m&#xE1;s abajo). Gracias a los avances logrados en la recolecci&#xF3;n de datos moleculares, es concebible que los factores gen&#xF3;micos refinen los enfoques de clasificaci&#xF3;n y se usen de manera gradual para estratificar a los pacientes que participan en ensayos cl&#xED;nicos.</p><table id="_23" class="table-default expandable-container"><caption> Tipo de tumor reci&#xE9;n diagnosticado o recidivante, y el sumario de tratamiento del PDQ correspondiente</caption><colgroup><col width="33.22%"><col width="33.55%"><col width="33.22%"></colgroup><THead><tr><th>Tipo de tumor</th><th>Subtipo patol&#xF3;gico</th><th>Sumario del PDQ de tratamiento correspondiente</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="3">OMS = Organizaci&#xF3;n Mundial de la Salud; SNC = sistema nervioso central; SAI = sin otra indicaci&#xF3;n.</td></tr><tr><td colspan="3"><span class="sup">a</span>Grado incierto.</td></tr></TFoot><tbody><tr><td><strong>Astrocitomas y otros tumores de origen glial</strong></td><td>&#xA0;</td><td>&#xA0;</td></tr><tr><td rowspan="4" valign="Middle">&#x2013; <em>Astrocitomas de grado bajo</em></td><td>Astrocitoma difuso, con mutaci&#xF3;n de <em>IDH</em>, con <em>IDH</em> natural o SAI</td><td rowspan="4" valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-astrocitomas-infantiles-pdq">Tratamiento de los astrocitomas infantiles</a></td></tr><tr><td>
            Astrocitoma piloc&#xED;tico</td></tr><tr><td>Xantoastrocitoma pleom&#xF3;rfico</td></tr><tr><td>Astrocitoma subependimario de c&#xE9;lulas gigantes</td></tr><tr><td rowspan="5" valign="Middle">&#x2013; <em>Astrocitomas de grado alto</em></td><td>Astrocitoma anapl&#xE1;sico, con mutaci&#xF3;n de <em>IDH</em> o con <em>IDH</em>  natural</td><td rowspan="5" valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-astrocitomas-infantiles-pdq">Tratamiento de los astrocitomas infantiles</a></td></tr><tr><td> Xantoastrocitoma pleom&#xF3;rfico anapl&#xE1;sico</td></tr><tr><td>Glioma difuso de la l&#xED;nea media, con mutaci&#xF3;n de <em>H3 K27M</em> </td></tr><tr><td>Glioblastoma, con mutaci&#xF3;n de <em>IDH</em> </td></tr><tr><td>Glioblastoma, con <em>IDH</em> natural</td></tr><tr><td rowspan="4" valign="Middle">&#x2013; <em>Otros astrocitomas o gliomas</em></td><td>Glioma angioc&#xE9;ntrico</td><td rowspan="4" valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-astrocitomas-infantiles-pdq">Tratamiento de los astrocitomas infantiles</a></td></tr><tr><td>Astroblastoma<span class="sup">a</span></td></tr><tr><td>Glioma coroideo del tercer ventr&#xED;culo </td></tr><tr><td>Astrocitoma pilomixoide<span class="sup">a</span></td></tr><tr><td colspan="3">&#xA0;</td></tr><tr><td><strong>Gliomas del tronco encef&#xE1;lico</strong></td><td>&#xA0;</td><td>&#xA0;</td></tr><tr><td rowspan="2">&#xA0;</td><td>Glioma pontino intr&#xED;nseco difuso, con mutaci&#xF3;n de <em>H3 K27M</em></td><td rowspan="2" valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-glioma-infantil-pdq">Tratamiento del glioma de tronco encef&#xE1;lico infantil</a></td></tr><tr><td>Glioma del tronco encef&#xE1;lico focal o de grado bajo</td></tr><tr><td colspan="3">&#xA0;</td></tr><tr><td><strong>Tumores embrionarios del SNC</strong></td><td>&#xA0;</td><td>&#xA0;</td></tr><tr><td rowspan="4" valign="Middle">&#x2013; <em>Meduloblastomas</em></td><td>Meduloblastoma, con activaci&#xF3;n de WNT</td><td rowspan="8" valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-embrionarios-snc-infantil-pdq">Tratamiento de los tumores embrionarios del sistema nervioso central infantil</a></td></tr><tr><td>Meduloblastoma, con activaci&#xF3;n de SHH y mutaci&#xF3;n de <em>TP53</em></td></tr><tr><td>Meduloblastoma, con activaci&#xF3;n de SHH y <em>TP53</em> natural</td></tr><tr><td>Meduloblastoma, sin alteraci&#xF3;n de WNT/sin alteraci&#xF3;n de SHH</td></tr><tr><td rowspan="4" valign="Middle">&#x2013; <em>Tumores distintos del meduloblastoma</em></td><td>Ganglioneuroblastoma del SNC</td></tr><tr><td>Neuroblastoma del SNC</td></tr><tr><td>Tumor embrionario con rosetas de capas m&#xFA;ltiples (ETMR), con alteraci&#xF3;n de <em>C19MC</em> o SAI</td></tr><tr><td>Meduloepitelioma</td></tr><tr><td valign="Middle">&#x2013; <em>Tumores teratoideos/rabdoides at&#xED;picos del SNC</em></td><td>&#xA0;</td><td valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-atrt-snc-infantil-pdq">Tratamiento del tumor teratoideo/rabdoide at&#xED;pico del sistema nervioso central infantil</a></td></tr><tr><td colspan="3" valign="Middle">&#xA0;</td></tr><tr><td valign="Middle"><strong>Tumores del par&#xE9;nquima pineal</strong></td><td>Pineoblastoma</td><td valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-embrionarios-snc-infantil-pdq">Tratamiento de los tumores embrionarios del sistema nervioso central infantil</a></td></tr><tr><td colspan="3">&#xA0;</td></tr><tr><td><strong>Tumores de c&#xE9;lulas germinativas del SNC</strong></td><td>&#xA0;</td><td>&#xA0;</td></tr><tr><td valign="Middle">&#x2013; <em>Germinomas</em></td><td>&#xA0;</td><td rowspan="8" valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-celulas-germinativas-snc-infantil-pdq">Tratamiento de los tumores de c&#xE9;lulas germinativas del sistema nervioso central infantil</a></td></tr><tr><td rowspan="3" valign="Middle">&#x2013; <em>Teratomas</em></td><td>Teratoma inmaduro</td></tr><tr><td>Teratoma maduro</td></tr><tr><td>Teratoma con transformaci&#xF3;n maligna</td></tr><tr><td rowspan="4" valign="Middle">&#x2013; <em>Tumores de c&#xE9;lulas germinativas no germinomatosos</em></td><td>Coriocarcinoma</td></tr><tr><td>
            Carcinoma embrionario</td></tr><tr><td>Tumor mixto de c&#xE9;lulas germinales </td></tr><tr><td>Tumor del saco vitelino</td></tr><tr><td colspan="3">&#xA0;</td></tr><tr><td><strong>Craneofaringioma</strong></td><td>&#xA0;</td><td valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-craneo-infantil-pdq">Tratamiento del craneofaringioma infantil</a></td></tr><tr><td colspan="3">&#xA0;</td></tr><tr><td><strong>Ependimomas</strong></td><td>&#xA0;</td><td>&#xA0;</td></tr><tr><td rowspan="5">&#xA0;</td><td>Subependimoma (grado l de la OMS)</td><td rowspan="5" valign="Middle"><a href="/espanol/tipos/cerebro/pro/tratamiento-ependimoma-infantil-pdq">Tratamiento del ependimoma infantil</a></td></tr><tr><td>Ependimoma mixopapilar (grado l de la OMS)</td></tr><tr><td>Ependimoma con fusi&#xF3;n de <em>RELA</em> (grado II o III de la OMS)</td></tr><tr><td>Ependimoma (grado ll de la OMS)</td></tr><tr><td>Ependimoma anapl&#xE1;sico (grado lll de la OMS) </td></tr><tr><td colspan="3">&#xA0;</td></tr><tr><td><strong>Tumores del plexo coroideo</strong></td><td>&#xA0;</td><td>&#xA0;</td></tr></tbody></table><p id="_24" tabindex="-1">La recidiva es com&#xFA;n, tanto en los tumores de enc&#xE9;falo infantiles de grado bajo como en los malignos, y se puede presentar muchos a&#xF1;os despu&#xE9;s del tratamiento inicial. Es posible que la enfermedad se presente en el sitio del tumor primario o, especialmente en el caso de los tumores malignos, en sitios no contiguos del sistema nervioso central (SNC). La reca&#xED;da sist&#xE9;mica es poco frecuente, pero puede ocurrir. En el momento de la recidiva, se indica una evaluaci&#xF3;n completa del alcance de la reca&#xED;da para todos los tumores malignos y, a veces, para las lesiones de grado m&#xE1;s bajo. Tal vez se necesite una biopsia o una nueva resecci&#xF3;n quir&#xFA;rgica con el fin de confirmar una recidiva o transformaci&#xF3;n tumoral en el tiempo, incluso cambios en el grado y la composici&#xF3;n molecular.[<a href="#cit/section_4.1">1</a>,<a href="#cit/section_4.2">2</a>] Otras entidades, como un tumor secundario y la necrosis encef&#xE1;lica relacionada con el tratamiento, quiz&#xE1; sean cl&#xED;nicamente indistinguibles de la recidiva tumoral.[<a href="#cit/section_4.3">3</a>] La decisi&#xF3;n de la necesidad de una intervenci&#xF3;n quir&#xFA;rgica se debe individualizar de acuerdo con el tipo del tumor inicial, el tiempo transcurrido entre el tratamiento inicial y la reaparici&#xF3;n de la lesi&#xF3;n, y otros par&#xE1;metros cl&#xED;nicos.</p><p id="_25" tabindex="-1">Para pacientes seleccionados, es posible que est&#xE9;n disponibles ensayos terap&#xE9;uticos de fase temprana en las instituciones de fase I del Children's Oncology Group, el Pediatric Brain Tumor Consortium u otras entidades.</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_4.1">Morrissy AS, Garzia L, Shih DJ, et al.: Divergent clonal selection dominates medulloblastoma at recurrence. Nature 529 (7586): 351-7, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26760213&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26760213&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Mistry M, Zhukova N, Merico D, et al.: BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. J Clin Oncol 33 (9): 1015-22, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25667294&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25667294&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Packer RJ, Zhou T, Holmes E, et al.: Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro Oncol 15 (1): 97-103, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23099653&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23099653&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _26
      field_pdq_section_title:
        - format: plain_text
          value: 'Tratamiento de los tumores de médula espinal infantiles recién diagnosticados o recidivantes'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_26" class="pdq-sections"><p id="_27" tabindex="-1">No hay un sistema de estadificaci&#xF3;n aceptado de manera uniforme para los tumores de m&#xE9;dula espinal primarios en los ni&#xF1;os. Estos tumores se clasifican y tratan de acuerdo con su ubicaci&#xF3;n en la m&#xE9;dula espinal, el alcance tumoral en el momento del diagn&#xF3;stico y sus caracter&#xED;sticas histol&#xF3;gicas. Para obtener m&#xE1;s informaci&#xF3;n sobre la estadificaci&#xF3;n y el tratamiento de  los tumores de m&#xE9;dula espinal infantiles reci&#xE9;n diagnosticados o recidivantes, consultar los siguientes sumarios del PDQ:</p><div class="pdq-content-list"><ul id="_28"><li><a href="/espanol/tipos/cerebro/pro/tratamiento-astrocitomas-infantiles-pdq">Tratamiento de  los astrocitomas infantiles</a>.</li><li><a href="/espanol/tipos/cerebro/pro/tratamiento-embrionarios-snc-infantil-pdq">Tratamiento de  los tumores embrionarios del sistema nervioso central infantil</a>.</li><li><a href="/espanol/tipos/cerebro/pro/tratamiento-ependimoma-infantil-pdq">Tratamiento del ependimoma infantil</a>.</li></ul></div></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _30
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (08/15/2017)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_30" class="pdq-sections"><p id="_31" tabindex="-1">Los sumarios del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer se revisan con regularidad y se actualizan en la medida en que se obtiene nueva informaci&#xF3;n.  Esta secci&#xF3;n describe los cambios m&#xE1;s recientes introducidos en este sumario a partir de la fecha arriba indicada.</p><p id="_50" tabindex="-1">Este sumario fue objeto de revisi&#xF3;n amplia e integral.</p><p id="_51" tabindex="-1"><strong><a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_1">Informaci&#xF3;n general sobre los tumores de enc&#xE9;falo y de m&#xE9;dula espinal infantiles</a></strong></p><p id="_52" tabindex="-1">Se agreg&#xF3; a Louis et al. como <a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_3">referencia 2</a>.</p><p id="_49" tabindex="-1"><strong><a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_6">Clasificaci&#xF3;n de los tumores del sistema nervioso central</a></strong></p><p id="_48" tabindex="-1">Esta secci&#xF3;n fue objeto de amplia revisi&#xF3;n.</p><p id="_53" tabindex="-1"><strong><a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_17">Abordaje general para la atenci&#xF3;n de ni&#xF1;os con tumores de enc&#xE9;falo y de m&#xE9;dula espinal</a></strong></p><p id="_54" tabindex="-1">Se revis&#xF3; el <a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_19">texto</a> para indicar que a&#xFA;n se desconoce la causa de la mayor&#xED;a de los tumores de enc&#xE9;falo infantiles; sin embargo, las mutaciones de l&#xED;nea germinal se aceptan cada vez m&#xE1;s como predisponentes de c&#xE1;ncer: se identifican en hasta 8&#xA0;% de los ni&#xF1;os con c&#xE1;ncer (se cit&#xF3; a Zhang et al. como referencia 2).</p><p id="_47" tabindex="-1"><strong><a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_21">Tratamiento de  los tumores de enc&#xE9;falo infantiles reci&#xE9;n diagnosticados y recidivantes</a></strong></p><p id="_46" tabindex="-1">Se revis&#xF3; el <a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_22">texto</a> para indicar que gracias a los avances logrados en la recolecci&#xF3;n de datos moleculares, es concebible que los factores gen&#xF3;micos refinen los enfoques de clasificaci&#xF3;n y se usen de manera gradual para estratificar a los pacientes que participan en ensayos cl&#xED;nicos.</p><p id="_55" tabindex="-1">Se revis&#xF3; el <a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_23">Cuadro</a> para reflejar los cambios recientes en la clasificaci&#xF3;n de la Organizaci&#xF3;n Mundial de la Salud de los tumores del sistema nervioso central.</p><p id="_56" tabindex="-1">Se revis&#xF3; el <a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_24">texto</a> para indicar que tal vez se necesite una biopsia o una nueva resecci&#xF3;n quir&#xFA;rgica con el fin de confirmar una recidiva o transformaci&#xF3;n tumoral en el tiempo, incluso cambios en el grado y composici&#xF3;n molecular (se cit&#xF3; a Morrissy et al. y Mistry et al. como referencias 1 y 2, respectivamente). Tambi&#xE9;n se a&#xF1;adi&#xF3; a  Packer et al. como referencia 3.</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico">Consejo editorial del PDQ sobre el tratamiento pedi&#xE1;trico</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre el tratamiento de tumores de enc&#xE9;falo y de m&#xE9;dula espinal infantiles. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico">Consejo editorial del PDQ sobre el tratamiento pedi&#xE1;trico</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="" tabindex="-1">Los revisores principales del sumario sobre Descripci&#xF3;n del tratamiento de tumores de enc&#xE9;falo y de m&#xE9;dula espinal infantiles son:</p><div class="pdq-content-list"><ul id=""><li>Kenneth J. Cohen, MD, MBA (Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital)</li><li>Louis S. Constine, MD (James P. Wilmot Cancer Center at University of Rochester Medical Center)</li><li>Roger J. Packer, MD (Children's National Health System)</li><li>Malcolm A. Smith, MD, PhD (National Cancer Institute)</li></ul></div><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ sobre el tratamiento pedi&#xE1;trico emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/tratamiento">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; sobre el tratamiento pedi&#xE1;trico. PDQ Descripci&#xF3;n del tratamiento de tumores de enc&#xE9;falo y de m&#xE9;dula espinal infantiles. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq" title="https://www.cancer.gov/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq">https://www.cancer.gov/espanol/tipos/cerebro/pro/tratamiento-cerebro-infantil-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_17" tabindex="-1">Seg&#xFA;n la solidez de los datos probatorios, las opciones de tratamiento se clasifican  como &#x201C;est&#xE1;ndar&#x201D; o &#x201C;en evaluaci&#xF3;n cl&#xED;nica&#x201D;. Estas clasificaciones no  deben fundamentar ninguna decisi&#xF3;n sobre reintegros de seguros. Para obtener m&#xE1;s informaci&#xF3;n  sobre cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a>
            disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>

- entity: node
  type: pdq_cancer_information_summary
  title: 'Retinoblastoma Treatment (PDQ®)–Health Professional Version'
  status: 1
  langcode: en
  field_hhs_syndication:
    - syndicate: 1
      keywords: retinoblastoma
  moderation_state:
    value: published
  field_pdq_url:
    value: /types/retinoblastoma/hp/retinoblastoma-treatment-pdq
  field_pdq_cdr_id:
    value: 62846
  field_pdq_audience:
    value: Health Professionals
  field_pdq_summary_type:
    value: Treatment
  field_date_posted:
    value: '2019-03-11'
  field_date_updated:
    value: '2018-08-22'
  field_browser_title:
    value: 'Retinoblastoma Treatment'
  field_page_description:
    value: 'Retinoblastoma treatment is tailored and uses treatment options including enucleation, local treatments, chemotherapy, and radiation therapy. Get detailed treatment information for newly diagnosed and recurrent retinoblastoma in this summary for clinicians.'
  field_public_use:
    value: 1
  field_summary_sections:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'General Information About Retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/types/retinoblastoma/patient/retinoblastoma-treatment-pdq">Go to Patient Version</a></div><p id="_729" tabindex="-1">Retinoblastoma is a pediatric cancer that requires a careful integration of multidisciplinary care. Treatment of retinoblastoma aims to save the patient's life and preserve useful vision and, therefore, needs to be individualized. The management of intraocular retinoblastoma has evolved to a more risk-adapted approach that aims to minimize systemic exposure to drugs, optimize ocular drug delivery, and preserve useful vision. For patients presenting with extraocular retinoblastoma, treatment with intensive chemotherapy is required, including consolidation with high-dose chemotherapy and autologous hematopoietic stem cell rescue. While most patients with orbital disease and a large proportion of patients with systemic extra&#x2013;central nervous system (CNS) metastases can be cured, the prognosis for patients with intracranial disease is dismal.</p><section id="_486"><h3 id="_486_toc">Incidence</h3><p id="_487" tabindex="-1">Retinoblastoma is a relatively uncommon tumor of childhood that arises in the
            retina and accounts for about 3% of the cancers occurring in children younger
            than 15 years. </p><p id="_730" tabindex="-1">Retinoblastoma is a cancer of the very young child; two-thirds of all cases of retinoblastoma are diagnosed before age 2 years.[<a href="#cit/section_1.1">1</a>]  Thus, while the estimated annual incidence in the United States is approximately 4 cases per 1 million children younger than 15 years, the age-adjusted annual incidence in children aged 0 to 4 years is 10 to 14 cases per 1 million (approximately 1 in 14,000&#x2013;18,000 live births).</p></section><section id="_716"><h3 id="_716_toc">Anatomy</h3><p id="_717" tabindex="-1">Retinoblastoma arises from the retina, and its growth is usually under the retina and toward the vitreous. Involvement of the ocular coats and optic nerve occurs as a sequence of events as the tumor progresses. Invasion of the choroid is common, although occurrence of massive invasion is usually limited to advanced disease. After invading the choroid, the tumor gains access to systemic circulation and creates the potential for metastases. Further progression through the ocular coats leads to invasion of the sclera and the orbit. Anteriorly, tumor invading the anterior chamber may gain access to systemic circulation through the canal of Schlemm. Progression through the optic nerve and past the lamina cribrosa increases the risk of systemic and CNS dissemination (refer to <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_753">Figure 1</a>). </p><p id="_727" tabindex="-1"><figure id="figure_753" class="image-center"><a href="https://www.cancer.gov/images/cdr/live/CDR765179.jpg" target="_blank" class="article-image-enlarge">Enlarge</a><img id="_753" alt="Anatomy of the eye; two-panel drawing showing the outside and inside of the eye. The top panel shows the outside of the eye, including the eyelid, pupil, sclera, and iris. The bottom panel shows the inside of the eye, including the ciliary body, canal of Schlemm, cornea, lens, vitreous humor, retina, choroid,  optic nerve, and lamina cribrosa." title="Anatomy of the eye; two-panel drawing showing the outside and inside of the eye. The top panel shows the outside of the eye, including the eyelid, pupil, sclera, and iris. The bottom panel shows the inside of the eye, including the ciliary body, canal of Schlemm, cornea, lens, vitreous humor, retina, choroid,  optic nerve, and lamina cribrosa." src="https://www.cancer.gov/images/cdr/live/CDR765179-750.jpg"><figcaption class="caption-container">Figure 1.  Anatomy of the eye showing the outside and inside of the eye, including the eyelid, pupil, sclera, iris, ciliary body, canal of Schlemm, cornea, lens, vitreous humor, retina, choroid,  optic nerve, and lamina cribrosa. The vitreous humor is a gel that fills the center of the eye.</figcaption></figure></p></section><section id="_722"><h3 id="_722_toc">Screening</h3><p id="_789" tabindex="-1">The following screening and monitoring strategies reflect common practices in the management of retinoblastoma.</p><p id="_723" tabindex="-1">In children with a positive family history of retinoblastoma, early-in-life screening by fundus exam is performed under general anesthesia at regular intervals according to a schedule based on the absolute estimated risk, as determined by the identification of the <em>RB1</em> mutation in the family and the presence of the <em>RB1</em> mutation in the child. Infants born to affected parents have a dilated eye examination under anesthesia as soon as possible in the first month of life, and a genetic evaluation is performed. Infants with a positive genetic test are examined under anesthesia on a monthly basis. In infants who do not develop disease, monthly exams continue throughout the first year; the frequency of those studies may be decreased progressively during the second and subsequent years. Screening exams can improve prognosis in terms of globe sparing and use of less intensive, ocular-salvage treatments in children with a positive family history of retinoblastoma.[<a href="#cit/section_1.2">2</a>] </p><p id="_724" tabindex="-1">Common practice for the parents and siblings of patients with retinoblastoma is to have screening ophthalmic examinations to exclude an unknown familial disease. Siblings continue to be screened until age 3 to 5 years or until it is confirmed that they do not have an <em>RB1</em> gene mutation. </p></section><section id="_718"><h3 id="_718_toc">Clinical Presentation</h3><p id="_803" tabindex="-1">Age at presentation correlates with laterality; patients with bilateral disease present at a younger age, usually in the first 12 months of life.</p><p id="_719" tabindex="-1">Most cases present with leukocoria, which is occasionally first noticed after a flash photograph is taken. Strabismus is the second most common presenting sign and usually correlates with macular involvement. Very advanced intraocular tumors present with pain, orbital cellulitis, glaucoma, or buphthalmos. As the tumor progresses, patients may present with orbital or metastatic disease. Metastases occur in the preauricular and laterocervical lymph nodes, in the CNS, or  systemically (commonly in the bones, bone marrow, and liver).</p><p id="_787" tabindex="-1">In the United States, children of Hispanic origin and children living in lower socioeconomic conditions have been noted to present with more advanced disease.[<a href="#cit/section_1.3">3</a>]</p></section><section id="_720"><h3 id="_720_toc">Diagnostic Evaluation</h3><p id="_721" tabindex="-1">The diagnosis of intraocular retinoblastoma is usually made without pathologic confirmation. An examination under anesthesia with a maximally dilated pupil and scleral indentation is required to examine the entire retina. A very detailed documentation of the number, location, and size of tumors; the presence of retinal detachment and subretinal fluid; and the presence of subretinal and vitreous seeds must be performed.</p><p id="_804" tabindex="-1">Bidimensional ocular ultrasound and magnetic resonance imaging (MRI) can be useful to differentiate retinoblastoma from other causes of leukocoria and in the evaluation of extrascleral and extraocular extension in children with advanced intraocular retinoblastoma. Optic nerve enhancement by MRI does not necessarily indicate involvement; cautious interpretation of those findings is needed.[<a href="#cit/section_1.4">4</a>] The detection of the synthetase of ganglioside GD2 mRNA by reverse transcriptase&#x2013;polymerase chain reaction in the cerebrospinal fluid at the time of diagnosis may be a marker for CNS disease.[<a href="#cit/section_1.5">5</a>]</p><p id="_731" tabindex="-1">Evaluation for the presence of metastatic disease also needs to be considered in the subgroup of patients with suspected extraocular extension by imaging or high-risk pathology in the enucleated eye (i.e., massive choroidal invasion or involvement of the sclera or the optic nerve beyond the lamina cribrosa). Patients presenting with these pathological features in the enucleated eye are at high risk of developing metastases. In these cases, bone scintigraphy, bone marrow aspirates and biopsies, and lumbar puncture may be performed.[<a href="#cit/section_1.6">6</a>] </p><p id="_732" tabindex="-1">Genetic counseling is recommended for all patients with retinoblastoma. (Refer to the  <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_790">Genetic Counseling</a> section of this summary for more information.)</p></section><section id="_488"><h3 id="_488_toc">Heritable and Nonheritable Forms of Retinoblastoma</h3><section id="_sm_CDR0000779398_6"><p id="_sm_CDR0000779398_489" tabindex="-1">Retinoblastoma is a tumor that occurs in heritable (25%&#x2013;30%) and nonheritable (70%&#x2013;75%) forms. Heritable disease is defined by the presence of a germline mutation of the <em>RB1</em> gene. This germline mutation may have been inherited from an affected progenitor (25% of cases) or may have occurred in a germ cell before conception or <em>in utero</em> during early embryogenesis in patients with sporadic disease (75% of cases). The presence of positive family history or bilateral or multifocal disease is suggestive of heritable disease. </p><p id="_sm_CDR0000779398_643" tabindex="-1">Heritable retinoblastoma may manifest as  unilateral or bilateral
            disease. The penetrance of the <em>RB1</em> mutation (laterality, age at diagnosis, and number of tumors) is probably dependent on concurrent genetic modifiers such as <em>MDM2</em> and <em>MDM4</em> polymorphisms.[<a href="#cit/section_1.7">7</a>,<a href="#cit/section_1.8">8</a>]  All children with bilateral disease
            and approximately 15% of patients with unilateral disease are presumed to have the   heritable form, even though only 25% have an affected parent.</p><p id="_sm_CDR0000779398_644" tabindex="-1">In heritable retinoblastoma, tumors tend to be diagnosed at a younger age than  in the nonheritable form of the disease.
            Unilateral retinoblastoma in children younger than 1 year raises concern for heritable disease,
            whereas older children with a unilateral tumor are more likely to have  the nonheritable form of the disease.[<a href="#cit/section_1.9">9</a>]</p><p id="_sm_CDR0000779398_645" tabindex="-1">The genomic landscape of retinoblastoma is driven by  alterations in <em>RB1</em> that lead to biallelic inactivation.[<a href="#cit/section_1.10">10</a>,<a href="#cit/section_1.11">11</a>]  A rare cause of <em>RB1</em> inactivation is chromothripsis, which may be difficult to detect by conventional methods.[<a href="#cit/section_1.12">12</a>] Other recurring genomic changes that occur in a small minority of tumors include <em>BCOR</em> mutation/deletion, <em>MYCN</em> amplification, and <em>OTX2</em> amplification.[<a href="#cit/section_1.10">10</a>-<a href="#cit/section_1.12">12</a>] A study of 1,068 unilateral nonfamilial retinoblastoma tumors reported that a small percentage of cases (approximately 3%) lacked evidence of <em>RB1</em> loss. Approximately one-half of these cases with no evidence of <em>RB1</em> loss (representing approximately 1.5% of all unilateral nonfamilial retinoblastoma) showed <em>MYCN</em> amplification.[<a href="#cit/section_1.11">11</a>] The functional status of the retinoblastoma protein (pRb) is inferred  to be inactive in retinoblastoma with <em>MYCN</em> amplification.  This suggests that inactivation of <em>RB1</em> by mutation or inactive pRb is a requirement for the development of retinoblastoma, independent of <em>MYCN</em> amplification.[<a href="#cit/section_1.13">13</a>]</p></section></section><section id="_528"><h3 id="_528_toc">Postdiagnosis Surveillance</h3><p id="_529" tabindex="-1">Children with a germline <em>RB1</em> mutation may continue to develop new tumors for a few years after diagnosis and treatment; for this reason, they need to be examined frequently. It is common practice for examinations to occur every 2 to 4 months for at least 28 months.[<a href="#cit/section_1.14">14</a>] The interval between exams is based on the stability of the disease and age of the child (i.e., less frequent visits as the child ages).</p><p id="_645" tabindex="-1">A proportion of children who present with unilateral retinoblastoma will eventually develop disease in the opposite eye. Periodic examinations of the unaffected eye are performed until the germline status of the <em>RB1</em> gene is determined.</p><p id="_788" tabindex="-1">Because of the poor prognosis for patients with trilateral retinoblastoma, screening with neuroimaging until age 5 years  is a common practice in the monitoring of children with the heritable form of the disease. (Refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_496">Trilateral retinoblastoma</a> section in the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_493">Causes of Retinoblastoma-Related Mortality</a> section of this summary for more information.)</p></section><section id="_646"><h3 id="_646_toc">Genetic Testing</h3><p id="_647" tabindex="-1">Blood and tumor samples can be tested to determine whether a patient with retinoblastoma has a mutation in the <em>RB1</em> gene. Once the patient's genetic mutation has been identified, other family members can be screened directly for the mutation with targeted sequencing. </p><p id="_648" tabindex="-1">A multistep assay that includes the following may be performed for a complete genetic evaluation of the <em>RB1</em> gene:[<a href="#cit/section_1.15">15</a>]</p><div class="pdq-content-list"><ul id="_751"><li>DNA sequencing to identify mutations within coding exons and immediate flanking intronic regions.</li><li>Southern blot analysis to characterize genomic rearrangements.</li><li>Transcript analysis to characterize potential splicing mutations buried within introns.</li></ul></div><p id="_752" tabindex="-1">In cases of somatic mosaicism or cytogenetic abnormalities, the mutations may not be easily detected; more exhaustive techniques such as karyotyping, multiplex ligation-dependent probe amplification, fluorescence <em>in situ</em> hybridization, and methylation analysis of the <em>RB1</em> promoter may be needed. Allele-specific deep (2500x) sequencing of an <em>RB1</em> genomic amplicon from lymphocyte DNA can reveal low-level mosaicism.[<a href="#cit/section_1.16">16</a>] Because mosaicism is caused by a postzygotic mutation, such a finding obviates the need for serial examination of siblings under anesthesia. Some <em>RB1</em> mutations thought to be heterozygous with Sanger sequencing were also found to be mosaic. Deep sequencing will not discover some mosaic mutations with very low levels of amplification, mutations outside of the <em>RB1</em> amplicon, mutations not found in lymphocytes but in other tissues, or mosaic large rearrangements of <em>RB1</em>.[<a href="#cit/section_1.16">16</a>] Combining the above techniques, a germline mutation may be detected in more than 90% of patients with heritable retinoblastoma.[<a href="#cit/section_1.17">17</a>,<a href="#cit/section_1.18">18</a>]</p><p id="_649" tabindex="-1">The absence of detectable somatic <em>RB1</em> mutations in approximately 3% of unilateral, nonheritable retinoblastoma cases suggests that alternative genetic mechanisms may underlie the development of retinoblastoma.[<a href="#cit/section_1.19">19</a>] In one-half of these cases, high levels of <em>MYCN</em> amplification have been reported; these patients had distinct, aggressive histologic features and a median age at diagnosis of 4 months.[<a href="#cit/section_1.11">11</a>] In another small subset of tumors without detectable somatic <em>RB1</em> mutations, chromothripsis is responsible for inactivating the <em>RB1 </em>gene.[<a href="#cit/section_1.12">12</a>]</p></section><section id="_790"><h3 id="_790_toc">Genetic Counseling</h3><p id="_791" tabindex="-1">Genetic counseling is an integral part of the management of patients with retinoblastoma and their families, regardless of clinical presentation;  counseling assists  parents in understanding the genetic consequences of each form of retinoblastoma and in estimating the risk of disease in family members.[<a href="#cit/section_1.17">17</a>] Genetic counseling, however, is not always straightforward. Approximately 10% of children with retinoblastoma have somatic genetic mosaicism, which contributes to the difficulty of genetic counseling.[<a href="#cit/section_1.20">20</a>] In addition, for one specific mutation, the risk of retinoblastoma in a sibling may depend, in part, on whether the mutation is inherited from the mother or father.[<a href="#cit/section_1.21">21</a>] (Refer to the PDQ summary on <a href="/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Cancer Genetics Risk Assessment and Counseling</a> for more information.)</p></section><section id="_493"><h3 id="_493_toc">Causes of Retinoblastoma-Related Mortality</h3><p id="_508" tabindex="-1">While retinoblastoma is a highly curable disease, the challenge for those who treat retinoblastoma is to preserve life and to prevent the loss of an eye, blindness, and other serious effects of treatment that reduce the patient's life span or quality of life. With improvements in the diagnosis and management of retinoblastoma over the past several decades, metastatic retinoblastoma is observed less frequently in the United States and other developed nations. As a result, other causes, such as   trilateral retinoblastoma and subsequent neoplasms (SNs), have become significant contributors to retinoblastoma-related mortality in the first and subsequent decades of life.</p><p id="_805" tabindex="-1">Death from a second neoplasm is the most common cause of death and contributes to about 50% of deaths in patients with bilateral disease and genetically defined heritable retinoblastoma.[<a href="#cit/section_1.22">22</a>,<a href="#cit/section_1.23">23</a>] In the United States, before the advent of chemoreduction as a means of treating heritable or bilateral disease and the implementation of neuroimaging screening, trilateral retinoblastoma contributed to more than 50% of retinoblastoma-related mortality in the first decade after diagnosis.[<a href="#cit/section_1.24">24</a>]</p><section id="_496"><h4 id="_496_toc">Trilateral retinoblastoma</h4><p id="_497" tabindex="-1">Trilateral retinoblastoma is a well-recognized syndrome that occurs in 5% to 15% of patients with heritable retinoblastoma. It is defined by the development of an intracranial
            midline neuroblastic tumor, which typically develops between the ages of 20 and 36 months.[<a href="#cit/section_1.25">25</a>]   </p><p id="_846" tabindex="-1">Trilateral retinoblastoma has been the principal cause of death from retinoblastoma in the United States during the first decade of life.[<a href="#cit/section_1.26">26</a>] Because of the poor prognosis for patients with trilateral retinoblastoma and the apparent improved survival with early detection and aggressive treatment, screening with routine neuroimaging could potentially detect most cases within 2 years of first diagnosis.[<a href="#cit/section_1.25">25</a>] Routine baseline brain MRI is recommended at diagnosis because it may detect trilateral retinoblastoma at a subclinical stage.  In a small series of patients, the 5-year overall survival rate was 67% for those detected at baseline, compared with 11% for the group with a delayed diagnosis.[<a href="#cit/section_1.27">27</a>] Although it is not clear whether early diagnosis can impact survival, screening with MRI has been recommended as often as every 6 months for 5 years for patients suspected of having heritable disease or those with unilateral disease and a positive family history.[<a href="#cit/section_1.28">28</a>] Computed tomography scans are generally avoided for routine screening in these children because of the risk related to ionizing radiation exposure.</p><p id="_792" tabindex="-1">A cystic pineal gland, which is commonly detected by surveillance MRI, needs to be distinguished from a cystic variant of pineoblastoma. In children without retinoblastoma, the incidence of pineal cysts has been reported to be 55.8%.[<a href="#cit/section_1.29">29</a>] In a case-control study that included 77 children with retinoblastoma and 77 controls, the incidence of pineal cysts was similar (61% and 69%, respectively), and the size and volume of the pineal gland was not significantly different between the groups.[<a href="#cit/section_1.30">30</a>] However, a cystic component has been described in up to 57% of patients with histologically confirmed trilateral retinoblastoma.[<a href="#cit/section_1.27">27</a>] An excessive increase in the size of the pineal gland seems to be the strongest parameter indicating a malignant process.[<a href="#cit/section_1.30">30</a>]</p></section><section id="_499"><h4 id="_499_toc">Subsequent neoplasms (SNs)</h4><p id="_653" tabindex="-1">Survivors of retinoblastoma have a high risk of developing SNs. Factors that influence this risk include the following:</p><div class="pdq-content-list"><ul id="_654"><li><strong>Heritable retinoblastoma.</strong> Patients with heritable retinoblastoma have a markedly increased
            incidence of SNs, independent of treatment with radiation therapy.[<a href="#cit/section_1.22">22</a>,<a href="#cit/section_1.23">23</a>,<a href="#cit/section_1.31">31</a>] In a German series of 643 patients with heritable retinoblastoma, chemotherapy with or without radiation therapy was the only significant risk factor for the onset of second cancers outside the periorbital region.[<a href="#cit/section_1.23">23</a>] A possible association between the type of <em>RB1</em> mutation and incidence of SNs may exist, with complete loss of <em>RB1</em> activity associated with a higher incidence of SNs.[<a href="#cit/section_1.32">32</a>] With the increase in survival of patients with heritable retinoblastoma, it has become apparent that they are also at risk of developing epithelial cancers late in adulthood. A marked increase in mortality from lung, bladder, and other epithelial cancers has been described.[<a href="#cit/section_1.33">33</a>,<a href="#cit/section_1.34">34</a>] <p id="_806" tabindex="-1">Among retinoblastoma survivors with heritable retinoblastoma, those with an inherited germline mutation are at a slightly higher risk of developing an SN than are those with a de novo mutation; this increase appears to be most significant for melanoma.[<a href="#cit/section_1.35">35</a>]</p></li><li><strong>Past treatment for retinoblastoma with radiation therapy.</strong> The cumulative incidence of SNs was reported to be 26% (&#xB1; 10%) in nonirradiated patients and 58% (&#xB1; 10%) in irradiated patients by 50
            years after diagnosis of retinoblastoma&#x2014;a rate of about 1% per year.[<a href="#cit/section_1.36">36</a>] A German series of 633 patients with heritable retinoblastoma demonstrated a 5-year survival of 93%; however, 40 years later, only 80% of patients survived, with most  succumbing to radiation-induced SNs (hazard ratio, approximately 3).[<a href="#cit/section_1.37">37</a>] Other studies analyzing cohorts of patients treated with more advanced radiation planning and delivery technology have reported the SN rates to be about 9.4% in nonirradiated patients and about 30.4% in irradiated patients.[<a href="#cit/section_1.38">38</a>]   In a nonrandomized study that compared two contemporary cohorts of patients with hereditary retinoblastoma who were treated with either photon (n = 31) or proton (n = 55) therapy, the 10-year cumulative incidence of radiation-induced SNs was significantly different between the two groups (0% for proton radiation vs. 14% for photon radiation, <em>P</em> = .015).[<a href="#cit/section_1.39">39</a>] A longer follow-up will be required to further define the risk of SNs associated with proton radiation.<p id="_734" tabindex="-1">The most common SN is sarcoma, specifically osteosarcoma, followed by soft tissue sarcoma and melanoma; these malignancies may occur inside or outside of the radiation field, although most are radiation induced. The carcinogenic effect of radiation therapy is associated with the dose delivered, particularly for subsequent sarcomas; a step-wise increase is apparent at all dose categories. In irradiated patients, two-thirds of SNs occur within irradiated tissue, and one-third of SNs occur outside the radiation field.[<a href="#cit/section_1.31">31</a>,<a href="#cit/section_1.36">36</a>,<a href="#cit/section_1.38">38</a>,<a href="#cit/section_1.40">40</a>]</p></li><li><strong>Age at time of radiation therapy.</strong> The risk of SNs also appears to depend on the patient's age at the time that external-beam radiation therapy (EBRT) is administered, especially in children younger than 12 months, and the histopathologic types of SNs may be influenced by age.[<a href="#cit/section_1.38">38</a>,<a href="#cit/section_1.41">41</a>,<a href="#cit/section_1.42">42</a>]</li><li><strong>Previous SN.</strong> Those who survive SNs are at a sevenfold increased risk for developing another SN.[<a href="#cit/section_1.43">43</a>] The risk increases an additional threefold for patients treated with radiation therapy.[<a href="#cit/section_1.44">44</a>]</li></ul></div><p id="_840" tabindex="-1">The issue of balancing long-term tumor control with the consequences of chemotherapy is unresolved.    Most patients who receive chemotherapy are exposed to etoposide, which has been associated with secondary leukemia in patients without a predisposition to cancer, but at modest rates when compared with the risks associated with EBRT in   heritable retinoblastoma.   Despite the known increased risk of acute myeloid leukemia (AML) associated with the use of etoposide, patients with heritable retinoblastoma are not at an increased risk of developing this SN.[<a href="#cit/section_1.45">45</a>-<a href="#cit/section_1.47">47</a>] An initial report conducted by informal survey methods described 15 patients who developed AML after chemotherapy. One-half of the patients also received radiation therapy.[<a href="#cit/section_1.46">46</a>] This finding has not been substantiated by formal studies. In a  single-institution study of 245 patients who received etoposide, only 1 patient had acute promyelocytic leukemia after 79 months.[<a href="#cit/section_1.45">45</a>] Additionally, the Surveillance, Epidemiology, and End Results (SEER) Program calculated standardized incidence rates for secondary hematopoietic malignancies in 34,867 survivors of childhood cancer. The observed-to-expected ratio of secondary AML in patients treated for retinoblastoma was zero.[<a href="#cit/section_1.48">48</a>]</p><p id="_658" tabindex="-1">Survival from SNs is certainly suboptimal and varies widely across studies.[<a href="#cit/section_1.33">33</a>,<a href="#cit/section_1.49">49</a>-<a href="#cit/section_1.53">53</a>]  However, with advances in therapy, it is essential that all SNs in survivors of retinoblastoma be treated with curative intent.[<a href="#cit/section_1.54">54</a>] </p></section></section><section id="_525"><h3 id="_525_toc">Late Effects from Retinoblastoma Therapy</h3><p id="_807" tabindex="-1">In a report from the Retinoblastoma Survivor Study (N = 470), 87% of survivors of retinoblastoma (mean age, 43 years; median follow-up, 42 years) had at least one medical condition and 71% had a severe or life-threatening condition.  The adjusted relative risk of a chronic condition in survivors, compared with nonretinoblastoma controls, was 1.4 (<em>P</em> &lt; .01); the relative risk of a grade 3 or 4 condition was 7.6 (<em>P</em> &lt; .01).  After excluding ocular conditions and SNs, this excess risk was found to persist only for those with bilateral disease.[<a href="#cit/section_1.55">55</a>]</p><p id="_659" tabindex="-1">As previously discussed, patients with heritable retinoblastoma have an increased incidence of SNs. (Refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_499">Subsequent neoplasms [SNs]</a> section in the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_493">Causes of Retinoblastoma-Related Mortality</a> section of this summary for more information.) Other late effects that may occur after treatment for retinoblastoma include the following:</p><div class="pdq-content-list"><ul id="_660"><li><strong>Diminished orbital growth.</strong> Orbital growth is somewhat diminished after enucleation; however, the impact of enucleation on orbital volume may be less after placement of an orbital implant.[<a href="#cit/section_1.56">56</a>]</li><li><strong>Visual-field deficits.</strong> Patients with retinoblastoma demonstrate a variety of long-term visual-field defects after treatment for their intraocular disease.  These defects are related to tumor size, location,  and treatment method.[<a href="#cit/section_1.57">57</a>] <p id="_661" tabindex="-1">One study of visual acuity after treatment with systemic chemotherapy and local ophthalmic therapy was conducted in 54 eyes in 40 children. After a mean follow-up of 68 months, 27 eyes (50%) had a final visual acuity of 20/40 or better, and 36 eyes (67%) had final visual acuity of 20/200 or better. The clinical factors that predicted visual acuity of 20/40 or better were a tumor margin of at least 3 mm from the foveola and optic disc and an absence of subretinal fluid.[<a href="#cit/section_1.58">58</a>]</p></li><li><strong>Hearing loss.</strong> Because systemic carboplatin is now commonly used in the treatment of retinoblastoma (refer to  the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_740">Treatment of Intraocular Retinoblastoma</a> and <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_77">Treatment of Extraocular Retinoblastoma</a> sections of this summary for more information), concern has been raised about hearing loss related to therapy. While two large studies that included children treated with six cycles of carboplatin-containing therapy (18.6 mg/kg per cycle) showed an incidence of treatment-related hearing loss of lower than 1%,[<a href="#cit/section_1.59">59</a>,<a href="#cit/section_1.60">60</a>] a separate series documented some degree of hearing loss in 17% of patients.[<a href="#cit/section_1.61">61</a>] In the latter study, age younger than 6 months at the time of treatment and higher carboplatin systemic exposures correlated with an increased risk of ototoxicity.[<a href="#cit/section_1.61">61</a>,<a href="#cit/section_1.62">62</a>]</li></ul></div><p id="_784" tabindex="-1">Refer to the PDQ summary on <a href="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</a>  for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_1.1">Ries LA, Smith MA, Gurney JG, et al., eds.: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649. <a href="https://seer.cancer.gov/archive/publications/childhood/" title="https://seer.cancer.gov/archive/publications/childhood/">Also available online.</a> Last accessed August 16, 2018.</li><li id="section_1.2">Rothschild PR, L&#xE9;vy D, Savignoni A, et al.: Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study. Eye (Lond) 25 (12): 1555-61, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21921957&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21921957&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Truong B, Green AL, Friedrich P, et al.: Ethnic, Racial, and Socioeconomic Disparities in Retinoblastoma. JAMA Pediatr 169 (12): 1096-104, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26436436&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26436436&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Khurana A, Eisenhut CA, Wan W, et al.: Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma. Eur Radiol 23 (5): 1271-80, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23160663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23160663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.5">Laurent VE, Sampor C, Solernou V, et al.: Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur J Cancer 49 (13): 2892-9, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23721779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23721779&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.6">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.7">Cast&#xE9;ra L, Sabbagh A, Dehainault C, et al.: MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst 102 (23): 1805-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21051655&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21051655&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.8">de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB, et al.: Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. Pediatr Blood Cancer 59 (1): 39-43, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22180099&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22180099&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.9">Zajaczek S, Jakubowska A, Kurzawski G, et al.: Age at diagnosis to discriminate those patients for whom constitutional DNA sequencing is appropriate in sporadic unilateral retinoblastoma. Eur J Cancer 34 (12): 1919-21, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10023315&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10023315&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.10">Zhang J, Benavente CA, McEvoy J, et al.: A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481 (7381): 329-34, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22237022&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22237022&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.11">Rushlow DE, Mol BM, Kennett JY, et al.: Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 14 (4): 327-34, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23498719&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23498719&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.12">McEvoy J, Nagahawatte P, Finkelstein D, et al.: RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 5 (2): 438-50, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24509483&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24509483&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.13">Ewens KG, Bhatti TR, Moran KA, et al.: Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma. Cancer Med 6 (3): 619-630, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28211617&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28211617&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.14">Abramson DH, Mendelsohn ME, Servodidio CA, et al.: Familial retinoblastoma: where and when? Acta Ophthalmol Scand 76 (3): 334-8, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9686848&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9686848&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.15">Clark R: Retinoblastoma: genetic testing and counseling. In: Singh A, Damato B: Clinical Ophthalmic Oncology. Philadelphia, Pa: Saunders Elsevier, 2007, pp 441-6.</li><li id="section_1.16">Amitrano S, Marozza A, Somma S, et al.: Next generation sequencing in sporadic retinoblastoma patients reveals somatic mosaicism. Eur J Hum Genet 23 (11): 1523-30, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25712084&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25712084&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.17">Richter S, Vandezande K, Chen N, et al.: Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 72 (2): 253-69, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12541220&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12541220&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.18">Sagi M, Frenkel A, Eilat A, et al.: Genetic screening in patients with Retinoblastoma in Israel. Fam Cancer 14 (3): 471-80, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25754945&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25754945&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.19">Nichols KE, Houseknecht MD, Godmilow L, et al.: Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene. Hum Mutat 25 (6): 566-74, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15884040&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15884040&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.20">Dommering CJ, Mol BM, Moll AC, et al.: RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients. J Med Genet 51 (6): 366-74, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24688104&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24688104&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.21">Eloy P, Dehainault C, Sefta M, et al.: A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C&gt;T/p.Arg661Trp Mutation of RB1. PLoS Genet 12 (2): e1005888, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925970&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925970&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.22">Shinohara ET, DeWees T, Perkins SM: Subsequent malignancies and their effect on survival in patients with retinoblastoma. Pediatr Blood Cancer 61 (1): 116-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23918737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23918737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.23">Temming P, Arendt M, Viehmann A, et al.: Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer 64 (1): 71-80, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27567086&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27567086&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.24">Broaddus E, Topham A, Singh AD: Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93 (1): 24-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.25">de Jong MC, Kors WA, de Graaf P, et al.: Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 15 (10): 1157-67, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.26">Blach LE, McCormick B, Abramson DH, et al.: Trilateral retinoblastoma--incidence and outcome: a decade of experience. Int J Radiat Oncol Biol Phys 29 (4): 729-33, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.27">Rodjan F, de Graaf P, Brisse HJ, et al.: Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission. J Neurooncol 109 (3): 535-44, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.28">Kivel&#xE4; T: Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 17 (6): 1829-37, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.29">Sirin S, de Jong MC, Galluzzi P, et al.: MRI-based assessment of the pineal gland in a large population of children aged 0-5&#xA0;years and comparison with pineoblastoma: part II, the cystic gland. Neuroradiology 58 (7): 713-21, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27130617&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27130617&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.30">Pham TT, Siebert E, Asbach P, et al.: Magnetic resonance imaging based morphologic evaluation of the pineal gland for suspected pineoblastoma in retinoblastoma patients and age-matched controls. J Neurol Sci 359 (1-2): 185-92, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26671110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26671110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.31">MacCarthy A, Bayne AM, Brownbill PA, et al.: Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer 108 (12): 2455-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23674091&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23674091&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.32">Dommering CJ, Marees T, van der Hout AH, et al.: RB1 mutations and second primary malignancies after hereditary retinoblastoma. Fam Cancer 11 (2): 225-33, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205104&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205104&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.33">Fletcher O, Easton D, Anderson K, et al.: Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96 (5): 357-63, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14996857&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14996857&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.34">Marees T, van Leeuwen FE, de Boer MR, et al.: Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer 45 (18): 3245-53, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19493675&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19493675&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.35">Kleinerman RA, Yu CL, Little MP, et al.: Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol 30 (9): 950-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22355046&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22355046&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.36">Wong FL, Boice JD Jr, Abramson DH, et al.: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278 (15): 1262-7, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9333268&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9333268&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.37">Temming P, Arendt M, Viehmann A, et al.: How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. J Clin Oncol 34 (26): 3183-8, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.38">Kleinerman RA, Tucker MA, Tarone RE, et al.: Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23 (10): 2272-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15800318&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15800318&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.39">Sethi RV, Shih HA, Yeap BY, et al.: Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 120 (1): 126-33, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.40">Kleinerman RA, Tucker MA, Abramson DH, et al.: Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99 (1): 24-31, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17202110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17202110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.41">Abramson DH, Frank CM: Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 105 (4): 573-9; discussion 579-80, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9544627&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9544627&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.42">Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al.: Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology 108 (6): 1109-14, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11382638&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11382638&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.43">Abramson DH, Melson MR, Dunkel IJ, et al.: Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 108 (10): 1868-76, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11581064&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11581064&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.44">Marees T, van Leeuwen FE, Schaapveld M, et al.: Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur J Cancer 46 (11): 2052-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20400293&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20400293&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.45">Turaka K, Shields CL, Meadows AT, et al.: Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 59 (1): 121-5, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21826785&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21826785&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.46">Gombos DS, Hungerford J, Abramson DH, et al.: Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 114 (7): 1378-83, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17613328&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17613328&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.47">Tamboli D, Topham A, Singh N, et al.: Retinoblastoma: A SEER Dataset Evaluation for Treatment Patterns, Survival, and Second Malignant Neoplasms. Am J Ophthalmol 160 (5): 953-8, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26255575&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26255575&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.48">Rihani R, Bazzeh F, Faqih N, et al.: Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer 116 (18): 4385-94, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20549819&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20549819&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.49">Yu CL, Tucker MA, Abramson DH, et al.: Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 101 (8): 581-91, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19351917&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19351917&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.50">Aerts I, Pacquement H, Doz F, et al.: Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 40 (10): 1522-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15196536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15196536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.51">Eng C, Li FP, Abramson DH, et al.: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85 (14): 1121-8, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8320741&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8320741&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.52">Dunkel IJ, Gerald WL, Rosenfield NS, et al.: Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 30 (1): 59-62, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9371391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9371391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.53">Marees T, Moll AC, Imhof SM, et al.: Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100 (24): 1771-9, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19066271&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19066271&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.54">Moll AC, Imhof SM, Bouter LM, et al.: Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic Genet 18 (1): 27-34, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9134547&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9134547&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.55">Friedman DN, Chou JF, Oeffinger KC, et al.: Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study. Cancer 122 (5): 773-81, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26755259&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26755259&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.56">Chojniak MM, Chojniak R, Testa ML, et al.: Abnormal orbital growth in children submitted to enucleation for retinoblastoma treatment. J Pediatr Hematol Oncol 34 (3): e102-5, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22258347&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22258347&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.57">Abramson DH, Melson MR, Servodidio C: Visual fields in retinoblastoma survivors. Arch Ophthalmol 122 (9): 1324-30, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.58">Demirci H, Shields CL, Meadows AT, et al.: Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 123 (11): 1525-30, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16286614&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16286614&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.59">Lambert MP, Shields C, Meadows AT: A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 50 (2): 223-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17278120&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17278120&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.60">Batra A, Thakar A, Bakhshi S: Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: A cross-sectional study of 116 patients. Pediatr Blood Cancer 62 (11): 2060, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26053139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26053139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.61">Qaddoumi I, Bass JK, Wu J, et al.: Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30 (10): 1034-41, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.62">Leahey A: A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol 30 (10): 1023-4, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370322&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _13
      field_pdq_section_title:
        - format: plain_text
          value: 'Tumor Pathology of Retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_13" class="pdq-sections"><p id="_14" tabindex="-1">Cone precursor cells are the cell of origin in retinoblastoma.[<a href="#cit/section_2.1">1</a>] Microscopically, the appearance of retinoblastoma depends on the degree of differentiation. Undifferentiated retinoblastoma is composed of small, round, densely packed cells with hypochromatic nuclei and scant cytoplasm. Several degrees of photoreceptor differentiation have been described and are characterized by distinctive arrangements of tumor cells, as follows:</p><div class="pdq-content-list"><ul id="_808"><li>Flexner-Wintersteiner rosettes are specific to retinoblastoma; these structures consist of a cluster of low columnar cells arranged around a central lumen that is bounded by an eosinophilic membrane analogous to the external membrane of the normal retina. The lumen contains rosettes that are seen in 70% of tumors.</li><li>Homer Wright rosettes  are composed of irregular circlets of tumor cells arranged around a tangle of fibrils with no lumen or internal-limiting membrane. Horner Wright rosettes are infrequently seen in retinoblastoma and are most often seen in other neuroblastic tumors, such as neuroblastoma and medulloblastoma.
            </li></ul></div><p id="_662" tabindex="-1">Retinoblastomas
            are characterized by marked cell proliferation, as evidenced by high mitosis
            counts, extremely high MIB-1 labeling indices, and strong diffuse nuclear immunoreactivity for cone-rod homeobox, also known as <em>CRX</em>, a useful marker to discriminate retinoblastoma from other malignant, small, round cell tumors.[<a href="#cit/section_2.2">2</a>,<a href="#cit/section_2.3">3</a>]</p><p id="_735" tabindex="-1">Cavitary retinoblastoma, a rare variant of retinoblastoma, has ophthalmoscopically visible lucent cavities within the tumor. The cavitary spaces appear hollow on ultrasonography and hypofluorescent on angiography. Histopathologically, the cavitary spaces have been shown to represent areas of photoreceptor differentiation.[<a href="#cit/section_2.4">4</a>] These tumors have been associated with minimal visible tumor response to chemotherapy, which is thought to be a sign of tumor differentiation.[<a href="#cit/section_2.5">5</a>] </p><p id="_809" tabindex="-1">A pathologist experienced in ocular pathology and retinoblastoma should examine the enucleated specimen. This is particularly relevant to determine risk features of extraocular dissemination (refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_740">Treatment of Intraocular Retinoblastoma</a> section of this summary for more information).</p><h6 do-not-show="toc">References</h6><ol><li id="section_2.1">Xu XL, Singh HP, Wang L, et al.: Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature 514 (7522): 385-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25252974&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25252974&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Terry J, Calicchio ML, Rodriguez-Galindo C, et al.: Immunohistochemical expression of CRX in extracranial malignant small round cell tumors. Am J Surg Pathol 36 (8): 1165-9, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22790857&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22790857&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Schwimer CJ, Prayson RA: Clinicopathologic study of retinoblastoma including MIB-1, p53, and CD99 immunohistochemistry. Ann Diagn Pathol 5 (3): 148-54, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11436168&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11436168&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Palamar M, Pirondini C, Shields CL, et al.: Cavitary retinoblastoma: ultrasonographic and fluorescein angiographic findings in 3 cases. Arch Ophthalmol 126 (11): 1598-600, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19001231&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19001231&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Mashayekhi A, Shields CL, Eagle RC Jr, et al.: Cavitary changes in retinoblastoma: relationship to chemoresistance. Ophthalmology 112 (6): 1145-50, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15885779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15885779&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _15
      field_pdq_section_title:
        - format: plain_text
          value: 'Staging and Grouping Systems for Retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_15" class="pdq-sections"><p id="_640" tabindex="-1">The staging of patients with retinoblastoma requires close coordination of radiologists, pediatric oncologists, and ophthalmologists. Several staging and grouping systems have been proposed for retinoblastoma.[<a href="#cit/section_3.1">1</a>] Overall assessment of retinoblastoma extension is documented by staging systems; intraocular extension, which is relevant for ocular salvage, is documented by grouping systems. For treatment purposes, retinoblastoma is categorized
            into intraocular and extraocular disease.
            </p><section id="_17"><h3 id="_17_toc">Intraocular Retinoblastoma</h3><p id="_19" tabindex="-1">Intraocular retinoblastoma is localized to the eye; it may be confined to the
            retina or may extend to involve other structures such as the choroid, ciliary body, anterior chamber, and optic nerve head. Intraocular retinoblastoma, however, does not extend beyond
            the eye into the tissues around the eye or to other parts of the body.
            </p></section><section id="_20"><h3 id="_20_toc">Extraocular Retinoblastoma</h3><p id="_22" tabindex="-1">Extraocular retinoblastoma extends beyond the eye.  It may be confined to
            the tissues around the eye (orbital retinoblastoma), it may have spread to the central
            nervous system (CNS), or it may have spread systemically to the bone marrow or lymph nodes (metastatic retinoblastoma).
            </p></section><section id="_613"><h3 id="_613_toc">Staging Systems</h3><section id="_607"><h4 id="_607_toc">American Joint Committee on Cancer (AJCC) staging system</h4><p id="_608" tabindex="-1">Several staging systems have been proposed over the years. The AJCC clinical and pathological classifications represent a consensus opinion around which a common language is used. However, the AJCC's TNM (tumor, node, metastasis) staging system is not widely used for pediatric retinoblastoma and patients are not stratified on the basis of prognostic stage groups.</p></section><section id="_611"><h4 id="_611_toc">International Retinoblastoma Staging System</h4><p id="_612" tabindex="-1">The more simplified International Retinoblastoma Staging System (IRSS) has been proposed by an international consortium of ophthalmologists and pediatric oncologists;[<a href="#cit/section_3.2">2</a>] it is more widely used in the clinical setting than the AJCC staging system (refer to <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_631">Table 1</a>). A retrospective German study found that the IRSS predicted survival in 633 children with heritable retinoblastoma, of which 582 patients presented with IRSS stage 0 or I disease.[<a href="#cit/section_3.3">3</a>]</p><table id="_631" class="table-default expandable-container"><caption>Table 1.  International Retinoblastoma Staging System</caption><colgroup><col width="23.52%"><col width="27.76%"><col width="48.70%"></colgroup><THead><tr><th>Stage</th><th colspan="2">Description</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="3">CNS = central nervous system; CSF = cerebrospinal fluid.</td></tr></TFoot><tbody><tr><td>Stage 0</td><td colspan="2">Eye has not been enucleated and no dissemination of disease (refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_509">International Classification of Retinoblastoma</a> section of this summary for more information).</td></tr><tr><td>Stage I</td><td colspan="2">Eye enucleated, completely resected histologically</td></tr><tr><td>Stage II</td><td colspan="2">Eye enucleated, microscopic residual tumor</td></tr><tr><td rowspan="2">Stage III</td><td rowspan="2">Regional extension</td><td>a.	Overt orbital disease</td></tr><tr><td>b.	Preauricular or cervical lymph node extension</td></tr><tr><td rowspan="7">Stage IV</td><td rowspan="7">Metastatic disease</td><td>a.	Hematogenous metastasis (without CNS involvement)</td></tr><tr><td>&#x2014;Single lesion</td></tr><tr><td>&#x2014;Multiple lesions</td></tr><tr><td>b.	CNS extension (with or without any other site of regional or metastatic disease)</td></tr><tr><td>&#x2014;Prechiasmatic lesion</td></tr><tr><td>&#x2014;CNS mass </td></tr><tr><td>&#x2014;Leptomeningeal and CSF disease</td></tr></tbody></table></section></section><section id="_614"><h3 id="_614_toc">Grouping Systems</h3><p id="_615" tabindex="-1">Grouping systems are relevant for assessment of intraocular disease extension and are helpful predictors of ocular salvage.</p><section id="_23"><h4 id="_23_toc">Reese-Ellsworth Classification for Intraocular Tumors</h4><p id="_24" tabindex="-1">   Reese and Ellsworth developed a classification system for
            intraocular retinoblastoma    that has been shown to have prognostic significance
            for maintenance of sight and control of local disease at a time when surgery and external-beam radiation therapy (EBRT) were the primary treatment options.  However, developments in the conservative management of intraocular retinoblastoma have made the <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=782667&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000782667&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet'); return(false);">Reese-Ellsworth grouping system</a> less predictive for eye salvage and less helpful in guiding treatment.[<a href="#cit/section_3.4">4</a>] This grouping system is seldom used.</p></section><section id="_509"><h4 id="_509_toc">International Classification of Retinoblastoma</h4><p id="_510" tabindex="-1">The new International Classification of Retinoblastoma staging system has been developed with the goal of providing a simpler, more user-friendly classification that is more applicable to current therapies. This new system is based on the extent of tumor seeding within the vitreous cavity and subretinal space, rather than on tumor size and location. This system seems to be a better predictor of treatment success.[<a href="#cit/section_3.4">4</a>-<a href="#cit/section_3.7">7</a>] The International Classification of Retinoblastoma system may also help predict high-risk histopathology. In a study of more than 500 patients with retinoblastoma, histopathologic evidence of high-risk disease was noted in 17% of Group D eyes and 24% of Group E eyes.  This can be helpful in counseling parents regarding the potential need for postoperative systemic therapy.[<a href="#cit/section_3.8">8</a>]</p><div class="pdq-content-list"><ul id="_511"><li><em><strong>Group A: </strong></em> Small intraretinal tumors away from foveola and disc.<div class="pdq-content-list"><ul id="_216" class="list-dash"><li>All tumors are 3 mm or smaller in greatest dimension, confined to the retina <em>and</em></li><li>All tumors are located further than 3 mm from the foveola and 1.5 mm from the optic disc.</li></ul></div></li><li><em><strong>Group B:</strong></em> All remaining discrete tumors confined to the retina.<div class="pdq-content-list"><ul id="_217" class="list-dash"><li>All other tumors confined to the retina not in Group A.</li><li>Tumor-associated subretinal fluid less than 3 mm from the tumor with no subretinal seeding.</li></ul></div></li><li><em><strong>Group C:</strong></em> Discrete local disease with minimal subretinal or vitreous seeding.<div class="pdq-content-list"><ul id="_218" class="list-dash"><li>Tumor(s) are discrete.</li><li>Subretinal fluid, present or past, without seeding involving up to one-fourth of the  retina.</li><li>Local fine vitreous seeding may be present close to discrete tumor. </li><li>Local subretinal seeding less than 3 mm (2 DD) from the tumor.</li></ul></div></li><li><em><strong>Group D:</strong></em> Diffuse disease with significant vitreous or subretinal seeding.<div class="pdq-content-list"><ul id="_219" class="list-dash"><li>Tumor(s) may be  massive or diffuse.</li><li>Subretinal fluid present or past without seeding, involving up to total retinal detachment.</li><li>Diffuse or massive vitreous disease may include  &#x201C;greasy&#x201D; seeds or avascular tumor masses. </li><li>Diffuse subretinal seeding may include subretinal plaques or tumor nodules.</li></ul></div></li><li><em><strong>Group E:</strong></em> Presence of any one or more of the following poor prognosis features.<div class="pdq-content-list"><ul id="_220" class="list-dash"><li>Tumor touching the lens.</li><li>Tumor anterior to anterior vitreous face involving ciliary body or anterior segment.</li><li>Diffuse infiltrating retinoblastoma.</li><li>Neovascular glaucoma.</li><li>Opaque media from hemorrhage.</li><li>Tumor necrosis with aseptic orbital cellulites.</li><li>Phthisis bulbi.</li></ul></div></li></ul></div></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_3.1">Chantada GL, Sampor C, Bosaleh A, et al.: Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA Ophthalmol 131 (9): 1127-34, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23787805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23787805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Chantada G, Doz F, Antoneli CB, et al.: A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 47 (6): 801-5, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16358310&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16358310&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Temming P, Arendt M, Viehmann A, et al.: How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. J Clin Oncol 34 (26): 3183-8, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Shields CL, Mashayekhi A, Au AK, et al.: The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113 (12): 2276-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Murphree L: Staging and grouping of retinoblastoma. In: Singh A, Damato B: Clinical Ophthalmic Oncology. Philadelphia, Pa: Saunders Elsevier, 2007, pp 422-7.</li><li id="section_3.6">Zage PE, Reitman AJ, Seshadri R, et al.: Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer 50 (3): 567-72, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Novetsky DE, Abramson DH, Kim JW, et al.: Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies--an analysis of impact. Ophthalmic Genet 30 (1): 40-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19172510&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19172510&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _53
      field_pdq_section_title:
        - format: plain_text
          value: 'Treatment Option Overview for Retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_53" class="pdq-sections"><p id="_54" tabindex="-1">Treatment planning by a multidisciplinary team of cancer specialists&#x2014;including a pediatric oncologist, ophthalmologist, and radiation oncologist&#x2014;with
            experience treating ocular tumors of childhood is required to optimize treatment outcomes.[<a href="#cit/section_4.1">1</a>] Evaluation at specialized treatment centers is highly recommended before the initiation of treatment to improve the likelihood of ocular salvage and vision preservation.</p><p id="_512" tabindex="-1">The goals of therapy are the following:     </p><div class="pdq-content-list"><ul id="_663"><li>Eradicate the disease to save the patient's life.</li><li>Preserve as much vision as possible.</li><li>Decrease risk of late sequelae from treatment, particularly subsequent neoplasms (SNs).</li></ul></div><p id="_736" tabindex="-1">Treatment of retinoblastoma is tailored to the intraocular and extraocular disease burden, disease laterality,  germline <em>RB1</em> gene status, and potential for preserving vision. For patients presenting with intraocular disease, particularly those with bilateral eye involvement, a conservative approach consisting of tumor reduction with intravenous or ophthalmic artery chemotherapy, coupled with aggressive local therapy, may result in high ocular salvage rates.[<a href="#cit/section_4.2">2</a>] Radiation therapy, one of the most effective treatments in retinoblastoma, is usually reserved for cases of intraocular or extraocular disease progression. Many treatments considered to be standard of care have not been studied in a randomized fashion.</p><p id="_737" tabindex="-1">A risk-adapted, judicious combination of the following therapeutic options should be considered:</p><div class="pdq-content-list"><ul id="_810"><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_811">Enucleation</a>.</li><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_813">Local treatment (cryotherapy, laser therapy, and brachytherapy)</a>.</li><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_816">Systemic chemotherapy</a>.</li><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_821">Ophthalmic artery infusion of chemotherapy (intra-arterial chemotherapy)</a>.</li><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_824">Intravitreal chemotherapy</a>.</li><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_827">Subtenon chemotherapy (subconjunctival chemotherapy)</a>.</li><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_830">Radiation therapy (external-beam radiation therapy [EBRT], brachytherapy)</a>.</li></ul></div><p id="_748" tabindex="-1">The treatment options for intraocular, extraocular, and recurrent retinoblastoma are described in <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_749">Table 2</a>.</p><table id="_749" class="table-default expandable-container"><caption>Table 2.  Treatment Options for Retinoblastoma</caption><colgroup><col width="9.69%"><col width="28.51%"><col width="61.78%"></colgroup><THead><tr><th colspan="2">Treatment Group</th><th>Treatment Options</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="3">CNS = central nervous system; EBRT = external-beam radiation therapy.</td></tr></TFoot><tbody><tr><td colspan="2">Intraocular retinoblastoma:</td><td>&#xA0;</td></tr><tr><td rowspan="4">&#xA0;</td><td rowspan="4">Unilateral retinoblastoma</td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_725">Enucleation followed by chemotherapy</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_726">Conservative ocular salvage approaches:</a></td></tr><tr><td>&#x2014;Chemoreduction with either  systemic  or ophthalmic artery infusion chemotherapy with or without intravitreal chemotherapy </td></tr><tr><td>&#x2014;Local treatments  (cryotherapy, thermotherapy, and plaque radiation therapy)</td></tr><tr><td rowspan="5">&#xA0;</td><td rowspan="5">Bilateral retinoblastoma</td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_686">Enucleation for large intraocular tumors, followed by risk-adapted chemotherapy when the eye and vision cannot be saved</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_686">Conservative ocular salvage approaches when the eye and vision can be saved:</a></td></tr><tr><td>&#x2014;Chemoreduction with either systemic or ophthalmic artery infusion chemotherapy with or without intravitreal chemotherapy</td></tr><tr><td>&#x2014;Local treatments (cryotherapy, thermotherapy, and plaque radiation therapy)</td></tr><tr><td>&#x2014;EBRT</td></tr><tr><td>&#xA0;</td><td>Cavitary retinoblastoma</td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_833">Systemic and/or intra-arterial chemotherapy</a></td></tr><tr><td colspan="2">Extraocular retinoblastoma:</td><td>&#xA0;</td></tr><tr><td rowspan="2">&#xA0;</td><td rowspan="2">Orbital and locoregional retinoblastoma</td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_697">Chemotherapy</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_697">Radiation therapy</a></td></tr><tr><td rowspan="2">&#xA0;</td><td rowspan="2">CNS disease</td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_702">Systemic chemotherapy and CNS-directed therapy
            </a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_702">Systemic chemotherapy followed by myeloablative chemotherapy and stem cell rescue</a></td></tr><tr><td rowspan="2">&#xA0;</td><td rowspan="2">Trilateral retinoblastoma</td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_705">Systemic chemotherapy followed by surgery and myeloablative chemotherapy with stem cell rescue</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_705">Systemic chemotherapy followed by surgery and radiation therapy</a></td></tr><tr><td>&#xA0;</td><td>Extracranial metastatic retinoblastoma</td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_709">Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation therapy</a></td></tr><tr><td rowspan="5" colspan="2">Progressive or recurrent intraocular retinoblastoma </td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_711">Enucleation
            </a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_711">Radiation therapy (EBRT or plaque radiation therapy)</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_711">Local treatments (cryotherapy or thermotherapy)</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_711">Salvage chemotherapy (systemic or intra-arterial)</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_711">Intravitreal chemotherapy</a></td></tr><tr><td rowspan="2" colspan="2">Progressive or recurrent extraocular retinoblastoma </td><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_744">Systemic chemotherapy and radiation therapy for orbital disease</a></td></tr><tr><td><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_744">Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue, and radiation therapy for extraorbital disease</a></td></tr></tbody></table><section id="_811"><h3 id="_811_toc">Enucleation</h3><p id="_812" tabindex="-1">Upfront removal of the eye is indicated for large tumors filling the vitreous for which there is little or no likelihood of restoring vision,  in cases of extension to the anterior chamber, or in the presence of neovascular glaucoma. Patients must be monitored closely  for orbital recurrence of disease, particularly in the first 2 years after enucleation.[<a href="#cit/section_4.3">3</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiA</a>] Enucleation is also used as a salvage treatment in cases of disease progression or recurrence in patients receiving eye-salvage management. The pathology specimen must be carefully examined to identify patients who are at high risk of extraocular dissemination and who may require adjuvant chemotherapy.</p></section><section id="_813"><h3 id="_813_toc">Local Treatment (Cryotherapy, Laser Therapy, and Brachytherapy)</h3><p id="_814" tabindex="-1">For patients undergoing eye-salvage treatment, aggressive local therapy is always required. Local treatment is administered by the ophthalmologist directly to the tumor.</p><div class="pdq-content-list"><ul id="_815"><li><strong>Cryotherapy:</strong> Cryotherapy is based on the application of a cryoprobe to the sclera in the immediate vicinity of the retinal tumor. Cryotherapy is used as  primary therapy or with chemotherapy for tumors smaller than 4 disc diameters (DD)  in the
            anterior portion of the retina.
            </li><li><strong>Laser therapy:</strong>  Laser therapy may be used as primary therapy for small tumors or in combination with chemotherapy for larger tumors. Traditional photocoagulation (argon laser), in which the laser was applied around the tumor to target the tumor vasculature, has given way to thermotherapy (diode laser). Thermotherapy is delivered directly to the tumor surface via infrared wavelengths of light.[<a href="#cit/section_4.4">4</a>,<a href="#cit/section_4.5">5</a>]</li><li><strong>Brachytherapy (plaque radiation therapy):</strong> For larger tumors that are not amenable to cryotherapy or laser therapy, brachytherapy can provide an effective means for local control (refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_830">Radiation Therapy</a> section of this summary for more information).</li></ul></div></section><section id="_816"><h3 id="_816_toc">Systemic Chemotherapy</h3><p id="_817" tabindex="-1">Systemic chemotherapy plays a role in the following:</p><div class="pdq-content-list"><ul id="_818"><li>Adjuvant setting for patients with high-risk pathology. Different regimens have been used in the management of patients with high-risk pathology in the enucleated specimen. Most regimens include a three-drug combination of vincristine, etoposide, and carboplatin, either alone or alternating with cyclophosphamide and an anthracycline.[<a href="#cit/section_4.6">6</a>-<a href="#cit/section_4.9">9</a>]</li><li>Treatment of patients with extraocular and metastatic disease. Patients with extraocular disease benefit from more intensive therapy. While a standard treatment has not been determined, responses to cisplatin-based regimens, with consolidation with high-dose chemotherapy and autologous hematopoietic stem cell rescue for patients with extraorbital disease, have been reported.[<a href="#cit/section_4.10">10</a>-<a href="#cit/section_4.13">13</a>]</li><li>Chemoreductive treatment in conjunction with aggressive local treatment for patients undergoing ocular salvage treatments.</li></ul></div><p id="_819" tabindex="-1">During the past two decades, the standard of care has been systemic chemotherapy to reduce tumor
            volume (chemoreduction) to facilitate the use of local treatments and to avoid the long-term effects of radiation
            therapy.[<a href="#cit/section_4.14">14</a>,<a href="#cit/section_4.15">15</a>]; [<a href="#cit/section_4.16">16</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2Di</a>]; [<a href="#cit/section_4.17">17</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiA</a>]; [<a href="#cit/section_4.18">18</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335149&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335149&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDiii</a>]  The success rate for eye salvage varies from center to center, but overall good ocular outcomes are consistently obtained for discrete tumors without vitreous seeding.[<a href="#cit/section_4.14">14</a>,<a href="#cit/section_4.15">15</a>,<a href="#cit/section_4.19">19</a>,<a href="#cit/section_4.20">20</a>] Chemotherapy may also be continued or initiated with concurrent local control.[<a href="#cit/section_4.21">21</a>] Eye grouping as defined by the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_509">International Classification of Retinoblastoma</a> is the best predictor of ocular salvage using this approach. In a single-institution, nonrandomized study of 345 patients diagnosed with Group D or E tumors, primary enucleation and adjuvant chemotherapy for high-risk pathology was compared with systemic chemotherapy with or without subsequent enucleation as needed. The incidence of local recurrence and metastasis was less than 1%, regardless of the approach. As opposed to 100% enucleation, subsequent enucleation was performed in only 41% of children who received systemic chemoreduction, none of whom were found to have high-risk pathology in the chemoreduced eye.[<a href="#cit/section_4.22">22</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335148&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335148&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDii</a>] In a retrospective study of Group D eyes that were treated primarily with intravenous chemotherapy and never enucleated, more than 50% of patients had visual acuity of less than 20/200 and 75% of patients had strabismus.[<a href="#cit/section_4.23">23</a>]</p><p id="_820" tabindex="-1">Local tumor recurrence is not uncommon in the first few years after treatment [<a href="#cit/section_4.20">20</a>] and can often be successfully treated with  local therapy.[<a href="#cit/section_4.24">24</a>]  Among patients with heritable disease, younger patients and those with a positive family history are more likely to form new tumors. Chemotherapy may treat small, previously undetected lesions by slowing their growth, and this may improve overall salvage with local therapy.[<a href="#cit/section_4.25">25</a>]</p></section><section id="_821"><h3 id="_821_toc">Ophthalmic Artery Infusion of Chemotherapy (Intra-arterial Chemotherapy)</h3><p id="_822" tabindex="-1">Direct delivery of chemotherapy into the eye via cannulation of the ophthalmic artery is a feasible and effective method for ocular salvage.</p><p id="_793" tabindex="-1">Melphalan is the most common and most effective agent used. It is often combined with topotecan or carboplatin when responses are suboptimal or there is very advanced intraocular disease.[<a href="#cit/section_4.26">26</a>-<a href="#cit/section_4.30">30</a>]</p><p id="_794" tabindex="-1">For patients with treatment-naive eyes, the 2-year radiation-free ocular survival rate is 86% to 90%.[<a href="#cit/section_4.2">2</a>,<a href="#cit/section_4.26">26</a>,<a href="#cit/section_4.28">28</a>,<a href="#cit/section_4.30">30</a>,<a href="#cit/section_4.31">31</a>] Outcome after intra-arterial chemotherapy correlates with the extent of intraocular burden, as follows: </p><div class="pdq-content-list"><ul id="_823"><li>Patients with early intraocular disease (Group B and C eyes) have an excellent outcome and may be treated with single-agent therapy.[<a href="#cit/section_4.27">27</a>,<a href="#cit/section_4.29">29</a>]</li><li>Group D eyes have a worse outcome, with radiation-free ocular survival rates of 80% for eyes with subretinal seeding and 65% for eyes with vitreous seeding.[<a href="#cit/section_4.32">32</a>,<a href="#cit/section_4.33">33</a>] Some centers have reported higher ocular salvage rates for unilateral Group D and E eyes using a three-drug chemotherapy regimen.[<a href="#cit/section_4.2">2</a>] For patients with very advanced intraocular disease, an alternative treatment is the use of systemic chemotherapy followed by consolidation with intra-arterial melphalan.[<a href="#cit/section_4.34">34</a>]</li><li>Ocular salvage rates when intra-arterial chemotherapy administration is used as salvage treatment for patients with recurrent or progressive disease are consistently lower, with globe survival rates of 50% to 60%.[<a href="#cit/section_4.28">28</a>,<a href="#cit/section_4.30">30</a>-<a href="#cit/section_4.32">32</a>,<a href="#cit/section_4.35">35</a>,<a href="#cit/section_4.36">36</a>] However, the use of a more intensive three-drug regimen with melphalan, topotecan, and carboplatin in patients who have progressed after standard systemic and focal therapies has reported radiation-free ocular salvage rates of 75% at 2 years.[<a href="#cit/section_4.37">37</a>]</li></ul></div><p id="_795" tabindex="-1">Patients with bilateral disease can undergo tandem intra-arterial administration.[<a href="#cit/section_4.38">38</a>] In those circumstances, patients are at higher risk of systemic toxicity caused by melphalan exposure,[<a href="#cit/section_4.39">39</a>] and single-agent carboplatin may be used to treat the less-advanced eye during the tandem procedure.[<a href="#cit/section_4.40">40</a>] For neonates and very young infants where the cannulization of the ophthalmic artery is not feasible, <em>bridge</em> treatment with single-agent systemic carboplatin until the infant is aged 3 months  or weighs 6 kg, followed by consolidation with intra-arterial chemotherapy, has been shown to be very effective, with a 1-year radiation-free ocular survival rate of 95%.[<a href="#cit/section_4.41">41</a>]</p><p id="_796" tabindex="-1">While subretinal seeds can be well controlled with intra-arterial chemotherapy,[<a href="#cit/section_4.36">36</a>] vitreous seeds may be difficult to control with intra-arterial or intravenous chemotherapy alone. Anterior chamber seeding after intra-arterial or intravenous chemotherapy can occur, as detected clinically in one series of 6 of 12 eyes (50%) and histopathologically in 8 of 12 eyes (67%). This finding suggests that intra-arterial chemotherapy may have greater efficacy in posterior segment disease.[<a href="#cit/section_4.42">42</a>] The addition of intravitreal chemotherapy to intra-arterial chemotherapy appears to markedly improve the overall effectiveness in eyes with vitreous seeds, especially those with vitreous seed clouds (refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_824">Intravitreal Chemotherapy</a> section of this summary for more information).[<a href="#cit/section_4.43">43</a>,<a href="#cit/section_4.44">44</a>] Similarly, the addition of intravitreal chemotherapy to intravenous chemotherapy is more effective in the treatment of vitreous seeds; as with primary intra-arterial chemotherapy,[<a href="#cit/section_4.44">44</a>]  control of seed dust, spheres, and clouds require progressively more cycles of intravitreal chemotherapy.[<a href="#cit/section_4.45">45</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335158&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335158&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiDiii</a>]
            </p><p id="_797" tabindex="-1">Complications related to intra-arterial chemotherapy include the following:[<a href="#cit/section_4.31">31</a>]</p><div class="pdq-content-list"><ul id="_798"><li>Retinal detachment (up to 19.3%).[<a href="#cit/section_4.46">46</a>]</li><li>Vitreous hemorrhage (18.1%).</li><li>Ptosis (13.6%).</li><li>Dysmotility (6.5%).</li><li>Vascular and ischemic effects (6.2%).</li><li>Optic atrophy (3.4%).</li><li>Phthisis (2.7%).</li></ul></div><p id="_799" tabindex="-1">Major vascular complications related to the procedure are very rare; no strokes or significant acute neurological events have been reported by the most experienced groups.[<a href="#cit/section_4.28">28</a>,<a href="#cit/section_4.31">31</a>,<a href="#cit/section_4.47">47</a>,<a href="#cit/section_4.48">48</a>] However, stenosis of the ophthalmic artery and occlusion of the retinal artery have been documented;[<a href="#cit/section_4.48">48</a>] the risk of thrombosis is significantly increased in children with thrombophilia.[<a href="#cit/section_4.49">49</a>]</p><p id="_800" tabindex="-1">The impact of the intraocular vascular changes on vision has not been fully assessed because of the young age of the first cohorts of patients treated. Most patients do not have substantial electroretinographic changes,[<a href="#cit/section_4.50">50</a>] and preservation of central vision has been reported.[<a href="#cit/section_4.51">51</a>] A proportion of patients with abnormal electroretinograms (ERGs) with or without retinal detachment may have improved ERGs in the years after intra-arterial chemotherapy.[<a href="#cit/section_4.52">52</a>] For 72 eyes with advanced retinoblastoma and baseline ERGs indistinguishable from noise (<em>extinguished</em>) or flicker ERG amplitudes less than 25 &#xB5;V (<em>poor</em>), ERGs were obtained before ophthalmic artery chemosurgery and at 3 months, 1 year, and 2 years after ophthalmic artery chemosurgery. At 3 months, 1 year, and 2 years after ophthalmic artery chemosurgery, <em>extinguished</em> eyes showed 9 of 15, 4 of 11, and 2 of 6 detectable ERGs, respectively;  <em>poor</em> eyes showed 19 of 55, 14 of 30, and 8 of 18 ERGs exceeding 25 &#x3BC;V, respectively.[<a href="#cit/section_4.52">52</a>] However, in patients with heavily pretreated eyes, intensive intra-arterial chemotherapy may result in worsening of retinal function.[<a href="#cit/section_4.37">37</a>]</p><p id="_801" tabindex="-1">Another risk associated with intra-arterial chemotherapy is the exposure to ionizing radiation during fluoroscopy. Radiation doses per procedure can be as high as 191 mGy to the affected eye and 35 mGy to the contralateral eye,[<a href="#cit/section_4.53">53</a>] although doses as low as 1 mGy per procedure have been reported.[<a href="#cit/section_4.54">54</a>] After multiple procedures, cumulative doses can reach 0.1 to 0.2 Gy, which can be cataractogenic and potentially carcinogenic in this susceptible population.[<a href="#cit/section_4.53">53</a>] There is no increase in the incidence of second malignancies;[<a href="#cit/section_4.47">47</a>,<a href="#cit/section_4.55">55</a>] however, longer follow-up will be required to fully ascertain the risks associated with the procedure.</p><p id="_802" tabindex="-1">The risk of metastatic progression with direct ocular delivery of chemotherapy appears to be very low;[<a href="#cit/section_4.2">2</a>] however, up to 20 cases of patients treated with intra-arterial chemotherapy who subsequently developed metastases have been reported.[<a href="#cit/section_4.31">31</a>]</p></section><section id="_824"><h3 id="_824_toc">Intravitreal Chemotherapy</h3><p id="_825" tabindex="-1"> Studies suggest that direct intravitreal injection of melphalan or topotecan may be effective in controlling active vitreous seeds.[<a href="#cit/section_4.56">56</a>,<a href="#cit/section_4.57">57</a>]; [<a href="#cit/section_4.58">58</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335147&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335147&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDi</a>]; [<a href="#cit/section_4.59">59</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335158&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335158&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiDiii</a>] A retrospective study  of 264 eyes (250 children) treated with intravitreal melphalan for vitreous seeds over a two-decade period reported a 68% complete remission rate.  There was a low incidence of extraocular spread that occurred in children with high-risk features.[<a href="#cit/section_4.60">60</a>][<a href="/Common/PopUps/popDefinition.aspx?id=716085&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000716085&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiD</a>]  Because of initial concerns about the potential for tumor dissemination,  the use of intravitreal chemotherapy was limited. However, a review calculated that the proportion of patients with extraocular tumor spread, potentially as the result of intravitreal injection, is negligible.[<a href="#cit/section_4.61">61</a>] </p><p id="_826" tabindex="-1">A meta-analysis reported that significant side effects are uncommon, although each injection results in a small decrease in retinal function, as measured by ERG.[<a href="#cit/section_4.62">62</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587991&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587991&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiDiv</a>] The current era of retinoblastoma management using intra-arterial chemotherapy plus  intravitreal chemotherapy (as needed for vitreous seeding) has improved globe salvage in eyes with advanced retinoblastoma when compared with children who were treated in earlier years with intra-arterial chemotherapy alone.[<a href="#cit/section_4.43">43</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335148&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335148&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDii</a>] A second study, also performed across different eras (2006&#x2013;2010 vs. 2011&#x2013;2016), retrospectively addressed 40 eyes presenting with vitreous seed clouds (class 3 seeds). The children treated in the first era received primary treatment with intra-arterial chemotherapy, while the children treated in the later era received simultaneously both intravitreal and intra-arterial chemotherapy. Compared with the children treated in the earlier era, children treated in the later era demonstrated shorter time to regression, fewer recurrences, fewer enucleations, and no increased toxicity, including no difference in loss of retinal function by ERG.[<a href="#cit/section_4.44">44</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDiv</a>] Generally, each dose of intravitreal chemotherapy results in a further small decrement of retinal function, as measured by ERG.[<a href="#cit/section_4.63">63</a>]</p></section><section id="_827"><h3 id="_827_toc">Subtenon Chemotherapy (Subconjunctival Chemotherapy)</h3><p id="_828" tabindex="-1">Periocular delivery of carboplatin results in high intraocular concentrations of the agent, and this treatment is often used in ocular salvage approaches, particularly when there is a high vitreal tumor burden. Carboplatin is administered by the treating ophthalmologist into the subtenon space, and it  is generally used in conjunction with systemic chemotherapy and local ophthalmic therapies for patients with vitreous disease.[<a href="#cit/section_4.64">64</a>,<a href="#cit/section_4.65">65</a>] Responses have also been noted with subtenon topotecan.[<a href="#cit/section_4.66">66</a>]</p><p id="_829" tabindex="-1">With the development of new treatments for retinoblastoma, such as intra-arterial and intravitreal delivery of chemotherapy, subtenon chemotherapy is being used less often in the clinical setting.</p></section><section id="_830"><h3 id="_830_toc">Radiation Therapy</h3><div class="pdq-content-list"><ul id="_831"><li><strong>EBRT:</strong> Retinoblastoma is a very radiosensitive malignancy. EBRT doses ranging from 35 Gy to 46 Gy usually result in long-term remissions.
            Because of the need to sedate young children and the intricacies of field
            planning, special expertise in pediatric radiation therapy is important.
            Radiation therapy is used in cases of progression after conservative approaches, in patients with extraocular extension, and as part of the management of patients with metastatic disease.<p id="_760" tabindex="-1">Newer methods of delivering EBRT are being applied in an attempt to reduce adverse long-term effects.   This includes <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=335073&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000335073&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet'); return(false);">intensity-modulated radiation therapy</a> and proton-beam radiation therapy (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=534234&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000534234&amp;version=healthprofessional&amp;language=English&amp;dictionary=NotSet'); return(false);">charged-particle radiation therapy</a>).[<a href="#cit/section_4.67">67</a>-<a href="#cit/section_4.70">70</a>] Preliminary data suggest that proton radiation therapy is associated with a lower risk of radiation-induced malignancy in survivors of heritable retinoblastoma. In a nonrandomized study that compared two contemporary cohorts of patients with heritable retinoblastoma who were treated with either photon or proton radiation therapy, the 10-year cumulative incidence of radiation-induced SNs was significantly different between the two groups (0% for proton radiation vs. 14% for photon radiation, <em>P</em> = .015).[<a href="#cit/section_4.71">71</a>]</p><p id="_666" tabindex="-1">EBRT in infants causes growth failure of the orbital bones and results in cosmetic deformity. EBRT also increases the risk of SNs in children with heritable retinoblastoma.</p></li><li><strong>Brachytherapy (plaque radiation therapy):</strong> Indications for plaque radiation therapy include solitary tumors with a diameter ranging between 6 mm and 15 mm, tumor thickness of 10 mm or less, and tumor location of more than 3 mm from the optic disc or fovea. The most commonly used radioisotope is  iodine I 125, although others such as iridium Ir 192 and ruthenium Ru 106 are also effective. In combination with appropriate use of chemotherapy and other forms of focal consolidation, brachytherapy can be very effective in the treatment of localized retinal tumors that are not amenable to other means of local therapy.[<a href="#cit/section_4.24">24</a>,<a href="#cit/section_4.72">72</a>,<a href="#cit/section_4.73">73</a>]</li></ul></div></section><section id="_841"><h3 id="_841_toc">Special Considerations for the Treatment of Children with Cancer</h3><p id="_842" tabindex="-1">Cancer in children and adolescents is rare, although the overall incidence of childhood cancer has been slowly increasing since 1975.[<a href="#cit/section_4.74">74</a>]  Children and adolescents with
            cancer should be referred to medical centers that have a multidisciplinary team
            of cancer specialists with experience treating the cancers that occur during
            childhood and adolescence.  This multidisciplinary team approach is particularly important in the management of retinoblastoma; this approach incorporates the skills
            of the following health care professionals and others to ensure that children
            receive treatment, supportive care, and rehabilitation that will provide
            optimal survival and quality of life:   </p><div class="pdq-content-list"><ul id="_843"><li>An ophthalmologist with extensive experience in the treatment of children with retinoblastoma.</li><li>Primary care physician.</li><li>Pediatric surgical subspecialists.</li><li>Radiation oncologists.</li><li>Pediatric medical oncologists/hematologists.</li><li>Rehabilitation specialists.</li><li>Pediatric nurse specialists.</li><li>Social workers.</li></ul></div><p id="_844" tabindex="-1">Guidelines for pediatric cancer centers
            and their role in the treatment of pediatric patients with cancer have been
            outlined by the American Academy of Pediatrics.[<a href="#cit/section_4.75">75</a>]  At these pediatric cancer
            centers, clinical trials are available for most  types of cancer
            that occur in children and adolescents, and the opportunity to participate in
            these trials is offered to most patients and their families.  Clinical trials for
            children and adolescents with cancer are generally designed to compare
            potentially better therapy with therapy that is currently accepted as standard.
            Most of the progress made in identifying curative therapies for
            childhood cancers has been achieved through clinical trials.  Information about
            ongoing clinical trials is available from the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials">NCI website</a>.</p><p id="_845" tabindex="-1">Dramatic improvements in survival have been achieved for children and adolescents with cancer.[<a href="#cit/section_4.74">74</a>,<a href="#cit/section_4.76">76</a>,<a href="#cit/section_4.77">77</a>] Between 1975 and 2010, childhood cancer mortality decreased by more than 50%.[<a href="#cit/section_4.74">74</a>,<a href="#cit/section_4.76">76</a>,<a href="#cit/section_4.77">77</a>]  Childhood and adolescent cancer survivors require close monitoring because cancer therapy side effects may persist or develop months or years after treatment.  (Refer to the PDQ summary on <a href="/types/childhood-cancers/late-effects-hp-pdq">Late Effects of Treatment for Childhood Cancer</a>  for specific information about the incidence, type, and monitoring of late effects in childhood and adolescent cancer survivors.)</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_4.1">Chintagumpala M, Chevez-Barrios P, Paysse EA, et al.: Retinoblastoma: review of current management. Oncologist 12 (10): 1237-46, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17962617&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17962617&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Abramson DH, Fabius AW, Issa R, et al.: Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. PLoS One 10 (12): e0145436, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Kim JW, Kathpalia V, Dunkel IJ, et al.: Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 93 (4): 463-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Shields CL, Santos MC, Diniz W, et al.: Thermotherapy for retinoblastoma. Arch Ophthalmol 117 (7): 885-93, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408452&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408452&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Francis JH, Abramson DH, Brodie SE, et al.: Indocyanine green enhanced transpupillary thermotherapy in combination with ophthalmic artery chemosurgery for retinoblastoma. Br J Ophthalmol 97 (2): 164-8, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143908&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143908&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Chantada GL, Fandi&#xF1;o AC, Guitter MR, et al.: Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer 55 (1): 60-6, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Aerts I, Sastre-Garau X, Savignoni A, et al.: Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 31 (11): 1458-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Sullivan EM, Wilson MW, Billups CA, et al.: Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol 36 (6): e335-40, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24577551&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24577551&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Dunkel IJ, Khakoo Y, Kernan NA, et al.: Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer 55 (1): 55-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Matsubara H, Makimoto A, Higa T, et al.: A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 35 (8): 763-6, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of metastatic retinoblastoma. Ophthalmology 110 (6): 1237-40, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Kremens B, Wieland R, Reinhard H, et al.: High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31 (4): 281-4, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Friedman DL, Himelstein B, Shields CL, et al.: Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 18 (1): 12-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10623688&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10623688&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Shields CL, Honavar SG, Meadows AT, et al.: Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133 (5): 657-64, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Friedman DL, Krailo M, Villaluna D, et al.: Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Pediatr Blood Cancer 64 (7): , 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28019092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28019092&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Brennan RC, Qaddoumi I, Mao S, et al.: Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35 (1): 72-77, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Shields CL, Palamar M, Sharma P, et al.: Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol 127 (3): 282-90, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19273791&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19273791&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 21 (10): 2019-25, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Shields CL, Mashayekhi A, Cater J, et al.: Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 138 (3): 329-37, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Lumbroso L, Doz F, Urbieta M, et al.: Chemothermotherapy in the management of retinoblastoma. Ophthalmology 109 (6): 1130-6, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12045055&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12045055&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Berry JL, Kogachi K, Aziz HA, et al.: Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatr Blood Cancer 64 (4): , 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28221729&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28221729&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Fabian ID, Naeem Z, Stacey AW, et al.: Long-term Visual Acuity, Strabismus, and Nystagmus Outcomes Following Multimodality Treatment in Group D Retinoblastoma Eyes. Am J Ophthalmol 179: 137-144, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28501391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28501391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Shields CL, Mashayekhi A, Sun H, et al.: Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology 113 (11): 2087-92, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16949158&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16949158&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Wilson MW, Haik BG, Billups CA, et al.: Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114 (11): 2077-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Abramson DH, Dunkel IJ, Brodie SE, et al.: Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 117 (8): 1623-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.27">Francis JH, Gobin YP, Dunkel IJ, et al.: Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One 8 (8): e72441, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23991112&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23991112&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.28">Gobin YP, Dunkel IJ, Marr BP, et al.: Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129 (6): 732-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.29">Abramson DH, Marr BP, Brodie SE, et al.: Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS One 7 (4): e34120, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.30">Schaiquevich P, Ceciliano A, Millan N, et al.: Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 60 (5): 766-70, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.31">Yousef YA, Soliman SE, Astudillo PP, et al.: Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review. JAMA Ophthalmol : , 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26986443&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26986443&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.32">Abramson DH, Marr BP, Dunkel IJ, et al.: Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 96 (4): 499-502, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22053101&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22053101&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.33">Abramson DH, Daniels AB, Marr BP, et al.: Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. PLoS One 11 (1): e0146582, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756643&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756643&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.34">Shields CL, Kaliki S, Al-Dahmash S, et al.: Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina 33 (10): 2103-9, 2013 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23873161&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23873161&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.35">Shields CL, Bianciotto CG, Jabbour P, et al.: Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129 (11): 1399-406, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670328&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670328&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.36">Say EA, Iyer PG, Hasanreisoglu M, et al.: Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes. J AAPOS 20 (4): 337-42, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.37">Marr BP, Brodie SE, Dunkel IJ, et al.: Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol 96 (10): 1300-3, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22863945&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22863945&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.38">Abramson DH, Marr BP, Francis JH, et al.: Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy). PLoS One 11 (6): e0156806, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27258771&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27258771&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.39">Schaiquevich P, Buitrago E, Taich P, et al.: Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 53 (7): 4205-12, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.40">Francis JH, Gobin YP, Brodie SE, et al.: Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. Br J Ophthalmol 96 (9): 1270-1, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.41">Gobin YP, Dunkel IJ, Marr BP, et al.: Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One 7 (9): e44322, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23028521&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23028521&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.42">Pavlidou E, Burris C, Thaung C, et al.: Anterior Segment Seeding in Eyes With Retinoblastoma Failing to Respond to Intraophthalmic Artery Chemotherapy. JAMA Ophthalmol 133 (12): 1455-8, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26334520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26334520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.43">Shields CL, Alset AE, Say EA, et al.: Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus 53 (5): 275-84, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27486728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27486728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.44">Francis JH, Iyer S, Gobin YP, et al.: Retinoblastoma Vitreous Seed Clouds (Class 3): A Comparison of Treatment with Ophthalmic Artery Chemosurgery with or without Intravitreous and Periocular Chemotherapy. Ophthalmology 124 (10): 1548-1555, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28545735&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28545735&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.45">Berry JL, Bechtold M, Shah S, et al.: Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in&#xA0;Retinoblastoma. Ophthalmology 124 (12): 1817-1825, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28655537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28655537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.46">Shields CL, Say EAT, Pefkianaki M, et al.: RHEGMATOGENOUS RETINAL DETACHMENT AFTER INTRAARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA: The 2016 Founders Award Lecture. Retina 37 (8): 1441-1450, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787452&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787452&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.47">Suzuki S, Yamane T, Mohri M, et al.: Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 118 (10): 2081-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21715012&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21715012&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.48">Shields CL, Bianciotto CG, Jabbour P, et al.: Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol 129 (11): 1407-15, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670326&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670326&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.49">Francis JH, Gobin YP, Nagiel A, et al.: Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery. Arch Ophthalmol 130 (12): 1605-8, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23229706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23229706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.50">Abramson DH: Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 129 (11): 1492-4, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22084221&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22084221&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.51">Brodie SE, Munier FL, Francis JH, et al.: Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol 126 (1): 79-84, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.52">Abdelhakim AH, Francis JH, Marr BP, et al.: Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function. Br J Ophthalmol 101 (5): 623-628, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27539090&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27539090&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.53">Vijayakrishnan R, Shields CL, Ramasubramanian A, et al.: Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol 128 (11): 1427-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060044&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060044&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.54">Gobin YP, Rosenstein LM, Marr BP, et al.: Radiation exposure during intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 130 (3): 403-4; author reply 404-5, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22411679&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22411679&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.55">Habib LA, Francis JH, Fabius AW, et al.: Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: the first 10 years. Br J Ophthalmol 102 (2): 272-275, 2018.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28600304&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28600304&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.56">Francis JH, Abramson DH, Gaillard MC, et al.: The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology 122 (6): 1173-9, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25795478&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25795478&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.57">Shields CL, Manjandavida FP, Arepalli S, et al.: Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol 132 (3): 319-25, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24407202&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24407202&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.58">Ghassemi F, Shields CL: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 130 (10): 1268-71, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23044940&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23044940&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.59">Munier FL, Gaillard MC, Balmer A, et al.: Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 96 (8): 1078-83, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22694968&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22694968&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.60">Suzuki S, Aihara Y, Fujiwara M, et al.: Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol 59 (3): 164-72, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25808017&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25808017&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.61">Smith SJ, Smith BD: Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol 97 (10): 1231-6, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23740960&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23740960&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.62">Smith SJ, Smith BD, Mohney BG: Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol 98 (3): 292-7, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24187047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24187047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.63">Francis JH, Brodie SE, Marr B, et al.: Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience. Ophthalmology 124 (4): 488-495, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28089679&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28089679&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.64">Abramson DH, Frank CM, Dunkel IJ: A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106 (10): 1947-50, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10519590&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10519590&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.65">Marr BP, Dunkel IJ, Linker A, et al.: Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity. Br J Ophthalmol 96 (6): 881-3, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22328819&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22328819&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.66">Mallipatna AC, Dimaras H, Chan HS, et al.: Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 129 (6): 738-45, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670340&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670340&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.67">Krasin MJ, Crawford BT, Zhu Y, et al.: Intensity-modulated radiation therapy for children with intraocular retinoblastoma: potential sparing of the bony orbit. Clin Oncol (R Coll Radiol) 16 (3): 215-22, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15191011&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15191011&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.68">Reisner ML, Vi&#xE9;gas CM, Grazziotin RZ, et al.: Retinoblastoma--comparative analysis of external radiotherapy techniques, including an IMRT technique. Int J Radiat Oncol Biol Phys 67 (3): 933-41, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17293242&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17293242&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.69">Lee CT, Bilton SD, Famiglietti RM, et al.: Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 63 (2): 362-72, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.70">Mouw KW, Sethi RV, Yeap BY, et al.: Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys 90 (4): 863-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25227498&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25227498&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.71">Sethi RV, Shih HA, Yeap BY, et al.: Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 120 (1): 126-33, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.72">Shields CL, Shields JA, Cater J, et al.: Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology 108 (11): 2116-21, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11713089&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11713089&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.73">Merchant TE, Gould CJ, Wilson MW, et al.: Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer 43 (2): 134-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15236279&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15236279&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.74">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.75">Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.76">Childhood cancer. In: Howlader  N, Noone  AM, Krapcho  M, et al., eds.: SEER Cancer Statistics Review, 1975-2010. Bethesda, Md: National Cancer Institute, 2013, Section 28. <a href="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_28_childhood_cancer.pdf" title="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_28_childhood_cancer.pdf">Also available online</a>. Last accessed June 29, 2018.</li><li id="section_4.77">Childhood cancer by the ICCC. In: Howlader  N, Noone  AM, Krapcho  M, et al., eds.: SEER Cancer Statistics Review, 1975-2010. Bethesda, Md: National Cancer Institute, 2013, Section 29. <a href="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_29_childhood_cancer_iccc.pdf" title="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_29_childhood_cancer_iccc.pdf">Also available online</a>. Last accessed June 29, 2018.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _740
      field_pdq_section_title:
        - format: plain_text
          value: 'Treatment of Intraocular Retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_740" class="pdq-sections"><section id="_672"><h3 id="_672_toc">Treatment Options for Unilateral Intraocular Retinoblastoma</h3><p id="_673" tabindex="-1">Treatment options for unilateral intraocular retinoblastoma include the following:</p><div class="pdq-content-list"><ol id="_674"><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_725">Enucleation for large intraocular tumors, followed by risk-adapted chemotherapy when the eye cannot be saved</a>.</li><li><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_726">Conservative ocular salvage approaches when the eye and vision can be saved</a>.<div class="pdq-content-list"><ul id="_675"><li>Chemoreduction with either  systemic  or ophthalmic artery infusion chemotherapy with or without intravitreal chemotherapy.</li><li>Local treatments, including cryotherapy, thermotherapy, and plaque radiation therapy.</li></ul></div></li></ol></div><section id="_725"><h4 id="_725_toc">Enucleation followed by chemotherapy</h4><p id="_676" tabindex="-1">Because  unilateral disease is usually massive and often there is no
            expectation that useful vision can be preserved, up-front surgery (enucleation) is
            commonly performed. Careful examination of the enucleated specimen by an experienced pathologist is necessary to determine whether high-risk features for metastatic disease are present. These <strong>high-risk features</strong> include the following:[<a href="#cit/section_5.1">1</a>-<a href="#cit/section_5.5">5</a>]</p><div class="pdq-content-list"><ul id="_677"><li>Anterior chamber seeding.</li><li>Massive choroidal involvement.</li><li>Tumor beyond the lamina cribrosa.</li><li>Scleral and extrascleral extension.</li></ul></div><p id="_678" tabindex="-1">Pre-enucleation magnetic resonance imaging has low sensitivity and specificity for the detection of high-risk pathology.[<a href="#cit/section_5.6">6</a>]</p><p id="_1816" tabindex="-1">High-risk pathology has been associated with the presence of minimal dissemination in bone marrow and cerebrospinal fluid using quantitative polymerase chain reaction for detection of cone-rod homeobox (CRX) or GD2 synthase. In a group of 96 children with nonmetastatic retinoblastoma and high-risk pathology, the 3-year disease-free survival was 78% for patients with detectable minimal dissemination, compared with 98% for those without detectable disease (<em>P</em> = .004).[<a href="#cit/section_5.7">7</a>]</p><p id="_742" tabindex="-1">Systemic adjuvant therapy with vincristine, doxorubicin, and cyclophosphamide or with vincristine, carboplatin, and etoposide has been used to prevent the development of metastatic disease in patients with certain high-risk features assessed by pathologic review after enucleation.[<a href="#cit/section_5.3">3</a>,<a href="#cit/section_5.8">8</a>,<a href="#cit/section_5.9">9</a>]; [<a href="#cit/section_5.10">10</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335132&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335132&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2A</a>]</p></section><section id="_726"><h4 id="_726_toc">Conservative ocular salvage approaches</h4><p id="_679" tabindex="-1">Conservative ocular salvage approaches, such as systemic chemotherapy and local-control treatments, may be offered in an attempt to save the eye and preserve vision.[<a href="#cit/section_5.11">11</a>] Ocular salvage rates correlate with intraocular grouping. While the possibility of saving the eye without the use of external-beam radiation therapy (EBRT) exceeds 80% for children with early intraocular disease, the ocular outcomes for children with advanced intraocular disease are poor, with less than 40% ocular salvage rates, even after the use of EBRT.[<a href="#cit/section_5.12">12</a>]</p><p id="_681" tabindex="-1">Thus, caution must be exerted with extended systemic chemotherapy administration and delayed enucleation when tumor control does not appear to be possible, particularly for Group E eyes. Pre-enucleation chemotherapy for eyes with advanced intraocular disease may result in downstaging and underestimate the pathological evidence of extraretinal and extraocular disease, thus increasing the risk of dissemination.[<a href="#cit/section_5.13">13</a>]</p><p id="_682" tabindex="-1">The delivery of chemotherapy via ophthalmic artery cannulation as initial treatment for advanced unilateral retinoblastoma appears to be more effective than does systemic chemotherapy for chemoreduction, particularly for Group D eyes.[<a href="#cit/section_5.14">14</a>,<a href="#cit/section_5.15">15</a>]; [<a href="#cit/section_5.16">16</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDiv</a>] In the setting of a multidisciplinary state-of-the-art center, intra-arterial chemotherapy may result in ocular salvage rates of approximately 80% to 90% for patients with advanced intraocular unilateral retinoblastoma.[<a href="#cit/section_5.15">15</a>-<a href="#cit/section_5.17">17</a>]; [<a href="#cit/section_5.18">18</a>,<a href="#cit/section_5.19">19</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335155&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335155&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiDii</a>]; [<a href="#cit/section_5.20">20</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587991&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587991&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiDiv</a>] (Refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_821">Ophthalmic Artery Infusion of Chemotherapy [Intra-arterial Chemotherapy]</a> section of this summary for more information.)</p><p id="_683" tabindex="-1">Because a proportion of children who present with unilateral retinoblastoma
            will eventually develop disease in the opposite eye, these children undergo genetic counseling and testing and periodic examinations
            of the unaffected eye, regardless of the treatment they receive.  Asynchronous bilateral disease occurs most
            frequently in patients with affected parents and in children diagnosed during the first months of life.</p></section></section><section id="_684"><h3 id="_684_toc">Treatment Options for Bilateral Intraocular Retinoblastoma</h3><p id="_686" tabindex="-1">Treatment options for bilateral intraocular retinoblastoma include the following:</p><div class="pdq-content-list"><ol id="_687"><li>Enucleation for large intraocular tumors, followed by risk-adapted chemotherapy when the eye and vision cannot be saved.</li><li>Conservative ocular salvage approaches when the eye and vision can be saved.<div class="pdq-content-list"><ul id="_688"><li>Chemoreduction with either systemic or ophthalmic artery infusion chemotherapy with or without intravitreal chemotherapy.</li><li>Local treatments, including cryotherapy, thermotherapy, and plaque radiation therapy.</li><li>EBRT.</li></ul></div></li></ol></div><p id="_832" tabindex="-1">The goal of therapy for bilateral retinoblastoma is ocular and vision preservation and the delay or avoidance of EBRT and enucleation. Intraocular tumor burden is usually asymmetric, and treatment is dictated by the most advanced eye.
            Systemic therapy is generally  selected on the basis of the eye with more extensive disease. Treatment options described for unilateral disease may be applied to one or both affected eyes in patients with bilateral disease. While up-front enucleation of an advanced eye and risk-adapted adjuvant chemotherapy may be required, a more conservative approach using primary chemoreduction with close monitoring for response and aggressive local treatment is usually the treatment of choice.
            EBRT is now reserved for patients whose eyes do not respond adequately to primary systemic or intra-arterial chemotherapy and local consolidation.[<a href="#cit/section_5.21">21</a>]</p><p id="_690" tabindex="-1">A number of large centers have published trial results that used systemic chemotherapy in conjunction with aggressive local consolidation for patients with bilateral disease.[<a href="#cit/section_5.11">11</a>,<a href="#cit/section_5.22">22</a>-<a href="#cit/section_5.30">30</a>] The backbone of the chemoreduction has generally been carboplatin, etoposide, and vincristine. While the less toxic combination of vincristine and carboplatin can provide disease control for a significant proportion of patients,[<a href="#cit/section_5.26">26</a>] ocular salvage appears to be superior when etoposide is included in the regimen.[<a href="#cit/section_5.31">31</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335131&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335131&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 1iiDiii</a>] Similar results were achieved in one single-institution study when topotecan was substituted for etoposide in a combination regimen.[<a href="#cit/section_5.32">32</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiA</a>] Chemotherapy shrinks the tumors (chemoreduction), allowing greater efficacy of subsequent local therapy.[<a href="#cit/section_5.11">11</a>]  Treatment strategies often differ in terms of chemotherapy regimens and local control measures. Using this approach, the International Classification of Retinoblastoma grouping system has been proven to predict ocular salvage.[<a href="#cit/section_5.33">33</a>,<a href="#cit/section_5.34">34</a>]; [<a href="#cit/section_5.35">35</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDiv</a>] </p><div class="pdq-content-list"><ul id="_693"><li><strong>Groups A and B:</strong> Systemic chemotherapy in conjunction with local control have resulted in ocular salvage rates exceeding 90% for early intraocular disease.[<a href="#cit/section_5.34">34</a>-<a href="#cit/section_5.36">36</a>]</li><li><strong>Groups C and D:</strong> Ocular salvage rates using this approach are 70% to 90% for Group C eyes and 40% to 50% for Group D eyes.[<a href="#cit/section_5.34">34</a>-<a href="#cit/section_5.36">36</a>] However, for patients with more advanced intraocular disease (typically Group D eyes), EBRT is frequently required for ocular salvage.[<a href="#cit/section_5.35">35</a>]; [<a href="#cit/section_5.36">36</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335149&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335149&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDiii</a>] <p id="_694" tabindex="-1">For patients with large intraocular tumor burden with subretinal or vitreous seeds (Groups D eyes), the administration of higher doses of carboplatin, coupled with subtenon carboplatin, and the addition of lower doses of EBRT (36 Gy) for patients with persistent disease have been explored. Using this intensive approach, eye survival may approach a rate of 70% at 60 months.[<a href="#cit/section_5.37">37</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587988&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587988&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 2Div</a>]</p></li><li><strong>Group E:</strong> The treatment for Group E eyes is usually up-front enucleation. The use of prolonged systemic chemotherapy for Group E eyes to avoid or delay enucleation has been associated with lower disease-specific survival.[<a href="#cit/section_5.13">13</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335151&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335151&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiiB</a>]</li></ul></div><p id="_695" tabindex="-1">Delivery of chemotherapy via ophthalmic artery cannulation has also been shown to be feasible and effective as tandem administration and in the salvage setting in patients with newly diagnosed bilateral disease.[<a href="#cit/section_5.18">18</a>,<a href="#cit/section_5.19">19</a>,<a href="#cit/section_5.38">38</a>,<a href="#cit/section_5.39">39</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335148&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335148&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDii</a>] Bilateral administrations increase the risk of systemic toxicity caused by melphalan exposure.[<a href="#cit/section_5.40">40</a>] In these circumstances, intra-arterial chemotherapy with single-agent carboplatin may be used to treat the less-advanced eye during the tandem procedure.[<a href="#cit/section_5.41">41</a>] These treatments should only be performed in  an experienced center with a state-of-the-art treatment infrastructure and a dedicated multidisciplinary team.</p></section><section id="_602"><h3 id="_602_toc">Treatment Options for Cavitary Retinoblastoma</h3><p id="_833" tabindex="-1">Treatment options for cavitary retinoblastoma include the following:</p><div class="pdq-content-list"><ol id="_834"><li>Systemic and/or intra-arterial chemotherapy.</li></ol></div><p id="_603" tabindex="-1">In patients with cavitary retinoblastoma, minimal visual response is seen after intravenous chemotherapy and/or intra-arterial chemotherapy. Despite the blunted clinical response, cavitary retinoblastoma has a favorable long-term outcome, with stable tumor regression and globe salvage. Aggressive or prolonged chemotherapy or adjunctive therapies are generally not necessary. In a retrospective series of 26 cavitary retinoblastomas that were treated with intravenous chemoreduction and/or intra-arterial chemotherapy, the mean reduction in tumor base was 22%, and the mean reduction in tumor thickness was 29%. Despite minimal reduction, tumor recurrence was noted in only one eye, globe salvage was achieved in 22 eyes, and there were no cases of metastasis or death during 49 months (range, 6&#x2013;189 months) of follow-up.[<a href="#cit/section_5.42">42</a>]</p></section><section id="_TrialSearch_740_sid_5"><h3 id="_TrialSearch_740_sid_5_toc">Current Clinical Trials</h3><p id="_TrialSearch_740_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_5.1">Chantada GL, Guitter MR, Fandi&#xF1;o AC, et al.: Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer 52 (2): 218-22, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18937327&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18937327&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Eagle RC Jr: High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med 133 (8): 1203-9, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653710&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653710&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Aerts I, Sastre-Garau X, Savignoni A, et al.: Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 31 (11): 1458-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Sastre X, Chantada GL, Doz F, et al.: Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med 133 (8): 1199-202, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653709&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653709&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Chawla B, Sharma S, Sen S, et al.: Correlation between clinical features, magnetic resonance imaging, and histopathologic findings in retinoblastoma: a prospective study. Ophthalmology 119 (4): 850-6, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22218144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22218144&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.7">Laurent VE, Torbidoni AV, Sampor C, et al.: Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival. JAMA Ophthalmol 134 (12): 1374-1379, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Chantada GL, Dunkel IJ, de D&#xE1;vila MT, et al.: Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol 88 (8): 1069-73, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15258027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15258027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Cuenca A, Giron F, Castro D, et al.: Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol 127 (8): 1006-10, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19667337&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19667337&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Chantada GL, Fandi&#xF1;o AC, Guitter MR, et al.: Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer 55 (1): 60-6, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Shields CL, Honavar SG, Meadows AT, et al.: Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133 (5): 657-64, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Shields CL, Honavar SG, Meadows AT, et al.: Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 120 (12): 1653-8, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12470138&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12470138&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Zhao J, Dimaras H, Massey C, et al.: Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol 29 (7): 845-51, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21282531&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21282531&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Abramson DH, Fabius AW, Issa R, et al.: Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. PLoS One 10 (12): e0145436, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Munier FL, Mosimann P, Puccinelli F, et al.: First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20&#x2005;years of treatment. Br J Ophthalmol 101 (8): 1086-1093, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27927678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27927678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Shields CL, Jorge R, Say EA, et al.: Unilateral Retinoblastoma Managed With Intravenous Chemotherapy Versus Intra-Arterial Chemotherapy. Outcomes Based on the International Classification of Retinoblastoma. Asia Pac J Ophthalmol (Phila) 5 (2): 97-103, 2016 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26765038&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26765038&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Abramson DH, Marr BP, Brodie SE, et al.: Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS One 7 (4): e34120, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Abramson DH, Dunkel IJ, Brodie SE, et al.: Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 117 (8): 1623-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Gobin YP, Dunkel IJ, Marr BP, et al.: Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129 (6): 732-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Peterson EC, Elhammady MS, Quintero-Wolfe S, et al.: Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg 114 (6): 1603-8, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21294621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21294621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Orman A, Koru-Sengul T, Miao F, et al.: The modern role of radiation therapy in treating advanced-stage retinoblastoma: long-term outcomes and racial differences. Int J Radiat Oncol Biol Phys 90 (5): 1037-43, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25442037&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25442037&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.22">Beck MN, Balmer A, Dessing C, et al.: First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 18 (15): 2881-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10920136&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10920136&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.23">Murphree AL, Villablanca JG, Deegan WF 3rd, et al.: Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114 (11): 1348-56, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906025&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906025&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.24">Shields CL, Mashayekhi A, Cater J, et al.: Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 138 (3): 329-37, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.25">Gallie BL, Budning A, DeBoer G, et al.: Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114 (11): 1321-8, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906022&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906022&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.26">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 21 (10): 2019-25, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.27">Wilson MW, Haik BG, Billups CA, et al.: Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114 (11): 2077-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.28">Rodriguez-Galindo C, Chantada GL, Haik BG, et al.: Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol 9 (4): 294-307, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17580009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17580009&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.29">Shields CL, Mashayekhi A, Cater J, et al.: Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Arch Ophthalmol 123 (6): 765-73, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15955977&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15955977&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.30">Qaddoumi I, Billups CA, Tagen M, et al.: Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 118 (22): 5663-70, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22516936&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22516936&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.31">Lumbroso-Le Rouic L, Aerts I, Hajage D, et al.: Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy. Eye (Lond) 30 (1): 46-52, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26427984&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26427984&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.32">Brennan RC, Qaddoumi I, Mao S, et al.: Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35 (1): 72-77, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.33">Zage PE, Reitman AJ, Seshadri R, et al.: Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer 50 (3): 567-72, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.34">Shields CL, Mashayekhi A, Au AK, et al.: The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113 (12): 2276-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.35">Lumbroso-Le Rouic L, Aerts I, L&#xE9;vy-Gabriel C, et al.: Conservative treatments of intraocular retinoblastoma. Ophthalmology 115 (8): 1405-10, 1410.e1-2, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18222001&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18222001&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.36">Cohen VM, Kingston J, Hungerford JL: The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol 93 (7): 887-90, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18703556&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18703556&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.37">Berry JL, Jubran R, Kim JW, et al.: Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer 60 (4): 688-93, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22997170&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22997170&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.38">Abramson DH, Dunkel IJ, Brodie SE, et al.: Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol 128 (3): 370-2, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20212212&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20212212&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.39">Palioura S, Gobin YP, Brodie SE, et al.: Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (&gt;50%) retinal detachment. Pediatr Blood Cancer 59 (5): 859-64, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22492689&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22492689&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.40">Schaiquevich P, Buitrago E, Taich P, et al.: Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 53 (7): 4205-12, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.41">Francis JH, Gobin YP, Brodie SE, et al.: Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. Br J Ophthalmol 96 (9): 1270-1, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.42">Rojanaporn D, Kaliki S, Bianciotto CG, et al.: Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results. Arch Ophthalmol 130 (5): 585-90, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22652844&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22652844&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _77
      field_pdq_section_title:
        - format: plain_text
          value: 'Treatment of Extraocular Retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_77" class="pdq-sections"><p id="_78" tabindex="-1"> In high-income countries, few patients with retinoblastoma present with extraocular
            disease.  Extraocular disease may be localized to the soft tissues surrounding
            the eye or to the optic nerve beyond the margin of resection.  However, further
            extension may progress into the brain and meninges, with subsequent seeding of the
            spinal fluid and as distant metastatic disease involving the lungs, bones,
            and bone marrow.  </p><section id="_117"><h3 id="_117_toc">Treatment Options for Extraocular Retinoblastoma</h3><section id="_539"><h4 id="_539_toc">Orbital and locoregional retinoblastoma</h4><p id="_697" tabindex="-1">Treatment options for extraocular retinoblastoma (orbital and locoregional) include the following:</p><div class="pdq-content-list"><ol id="_698"><li>Chemotherapy.</li><li>Radiation therapy.</li></ol></div><p id="_540" tabindex="-1">Orbital retinoblastoma occurs as a result of progression of the tumor through the emissary vessels and sclera. For this reason, transscleral disease is considered to be extraocular and should be treated as such. Orbital retinoblastoma is isolated in 60% to 70% of cases. </p><p id="_699" tabindex="-1">Treatment includes systemic chemotherapy and radiation therapy; with this approach, 60% to 85% of patients can be cured. Because most recurrences occur in the central nervous system (CNS), regimens using drugs with well-documented CNS penetration are used. Different chemotherapy regimens have proven to be effective, including vincristine, cyclophosphamide, and doxorubicin and platinum- and epipodophyllotoxin-based regimens, or a combination of both.[<a href="#cit/section_6.1">1</a>-<a href="#cit/section_6.3">3</a>] </p><p id="_700" tabindex="-1">For patients with macroscopic orbital disease, delay of surgery until response to chemotherapy is achieved (usually two or three courses of treatment) has been effective. Patients then undergo enucleation  and receive an additional four to six courses of chemotherapy. Next, local control is consolidated with orbital irradiation (40 Gy to 45 Gy). Using this approach, orbital exenteration is not indicated.[<a href="#cit/section_6.3">3</a>] </p><p id="_701" tabindex="-1">Patients with isolated involvement of the optic nerve at the transsection level are considered to have extraocular disease and are treated using  systemic therapy, similar to that used for macroscopic orbital disease, and irradiation of the entire orbit (36 Gy) with a 10 Gy boost to the chiasm (total of 46 Gy).[<a href="#cit/section_6.2">2</a>]</p></section><section id="_541"><h4 id="_541_toc">CNS disease</h4><p id="_702" tabindex="-1">Treatment options for extraocular retinoblastoma (CNS disease) include the following:</p><div class="pdq-content-list"><ol id="_703"><li>Systemic chemotherapy  and CNS-directed therapy.</li><li>Systemic chemotherapy followed by myeloablative chemotherapy and stem cell rescue.</li></ol></div><p id="_542" tabindex="-1">Intracranial dissemination occurs by direct extension through the optic nerve, and its prognosis is dismal. Treatment for these patients includes platinum-based, intensive systemic chemotherapy and CNS-directed therapy. Although intrathecal chemotherapy has been used traditionally, there is no preclinical or clinical evidence to support its use. The administration of radiation therapy to these patients is controversial. Responses have been observed with craniospinal radiation using 25 Gy to 35 Gy to the entire craniospinal axis and a boost (10 Gy) to sites of measurable disease. </p><p id="_704" tabindex="-1">Therapeutic intensification with high-dose, marrow-ablative chemotherapy and autologous hematopoietic progenitor cell rescue has been explored, but its role is not yet clear.[<a href="#cit/section_6.4">4</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiA</a>]</p></section><section id="_543"><h4 id="_543_toc">Trilateral retinoblastoma</h4><p id="_705" tabindex="-1">Treatment options for trilateral retinoblastoma include the following:</p><div class="pdq-content-list"><ol id="_706"><li>Systemic chemotherapy followed by surgery and myeloablative chemotherapy with stem cell rescue.</li><li>Systemic chemotherapy followed by surgery and radiation therapy.</li></ol></div><p id="_544" tabindex="-1">Trilateral retinoblastoma is usually associated with a pineal lesion or, less commonly, a suprasellar lesion.[<a href="#cit/section_6.5">5</a>-<a href="#cit/section_6.7">7</a>] In patients with the heritable form of retinoblastoma, CNS disease is less likely the result of metastatic or regional spread than of a primary intracranial focus, such as a pineal tumor. The prognosis for patients with trilateral retinoblastoma is very poor; most patients die of disseminated neuraxis disease in less than 9 months.[<a href="#cit/section_6.8">8</a>,<a href="#cit/section_6.9">9</a>] However, with increased surveillance  and aggressive therapy, there has been improvement in survival, from 6% (patients treated before 1995) to 44% (patients treated after 1996).[<a href="#cit/section_6.10">10</a>]  </p><p id="_707" tabindex="-1">While pineoblastomas occurring in older patients are sensitive to radiation therapy, current strategies are directed towards avoiding radiation by using intensive chemotherapy followed by consolidation with myeloablative chemotherapy and autologous hematopoietic progenitor cell rescue, an approach similar to those being used in the treatment of brain tumors in infants.[<a href="#cit/section_6.11">11</a>]</p><p id="_847" tabindex="-1">(Refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_496">Trilateral retinoblastoma</a> section in the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_493">Causes of Retinoblastoma-Related Mortality</a> section of this summary for more information about trilateral retinoblastoma, including screening with neuroimaging.)</p></section><section id="_546"><h4 id="_546_toc">Extracranial metastatic retinoblastoma</h4><p id="_709" tabindex="-1">Treatment options for extracranial metastatic retinoblastoma include the following:</p><div class="pdq-content-list"><ol id="_710"><li>Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation therapy.</li></ol></div><p id="_547" tabindex="-1">Hematogenous metastases may develop in the bones, bone marrow and, less frequently, the liver. Although long-term survival has been reported with conventional chemotherapy, these reports should be considered anecdotal; metastatic retinoblastoma is not curable with conventional chemotherapy. In the last two decades, however, studies of small series of patients have shown that metastatic retinoblastoma can be cured using high-dose, marrow-ablative chemotherapy and autologous hematopoietic stem cell rescue.[<a href="#cit/section_6.12">12</a>-<a href="#cit/section_6.18">18</a>]; [<a href="#cit/section_6.19">19</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiA</a>]</p></section></section><section id="_TrialSearch_77_sid_6"><h3 id="_TrialSearch_77_sid_6_toc">Current Clinical Trials</h3><p id="_TrialSearch_77_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section><h6 do-not-show="toc">References</h6><ol><li id="section_6.1">Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, et al.: The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol 29 (10): 700-4, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17921851&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17921851&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Aerts I, Sastre-Garau X, Savignoni A, et al.: Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 31 (11): 1458-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Radhakrishnan V, Kashyap S, Pushker N, et al.: Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology 119 (7): 1470-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22463820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22463820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Dunkel IJ, Chan HS, Jubran R, et al.: High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer 55 (1): 149-52, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Rodjan F, de Graaf P, Brisse HJ, et al.: Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission. J Neurooncol 109 (3): 535-44, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Paulino AC: Trilateral retinoblastoma: is the location of the intracranial tumor important? Cancer 86 (1): 135-41, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391573&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391573&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Blach LE, McCormick B, Abramson DH, et al.: Trilateral retinoblastoma--incidence and outcome: a decade of experience. Int J Radiat Oncol Biol Phys 29 (4): 729-33, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Kivel&#xE4; T: Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 17 (6): 1829-37, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Marcus DM, Brooks SE, Leff G, et al.: Trilateral retinoblastoma: insights into histogenesis and management. Surv Ophthalmol 43 (1): 59-70, 1998 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9716194&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9716194&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">de Jong MC, Kors WA, de Graaf P, et al.: Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 15 (10): 1157-67, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Dunkel IJ, Jubran RF, Gururangan S, et al.: Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer 54 (3): 384-7, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19908299&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19908299&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Namouni F, Doz F, Tanguy ML, et al.: High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 33 (14): 2368-75, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9616283&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9616283&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Kremens B, Wieland R, Reinhard H, et al.: High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31 (4): 281-4, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.14">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of metastatic retinoblastoma. Ophthalmology 110 (6): 1237-40, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.15">Dunkel IJ, Aledo A, Kernan NA, et al.: Successful treatment of metastatic retinoblastoma. Cancer 89 (10): 2117-21, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11066053&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11066053&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.16">Matsubara H, Makimoto A, Higa T, et al.: A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 35 (8): 763-6, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.17">Jubran RF, Erdreich-Epstein A, Butturini A, et al.: Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience. J Pediatr Hematol Oncol 26 (1): 31-4, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14707710&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14707710&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.18">Palma J, Sasso DF, Dufort G, et al.: Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant 47 (4): 522-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21602901&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21602901&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.19">Dunkel IJ, Khakoo Y, Kernan NA, et al.: Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer 55 (1): 55-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _85
      field_pdq_section_title:
        - format: plain_text
          value: 'Treatment of Progressive or Recurrent Retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_85" class="pdq-sections"><p id="_86" tabindex="-1">The prognosis for a patient with progressive or recurrent retinoblastoma
            depends on the site and extent of the progression or recurrence and previous treatment received. Intraocular and extraocular recurrences have very different prognoses and are treated in distinctly different ways. </p><section id="_848"><h3 id="_848_toc">Treatment Options for Progressive or Recurrent Intraocular Retinoblastoma</h3><p id="_711" tabindex="-1">Treatment options for progressive or recurrent intraocular retinoblastoma include the following:</p><div class="pdq-content-list"><ol id="_712"><li>Enucleation.</li><li>Radiation therapy (external-beam or plaque radiation therapy).</li><li>Local treatments (cryotherapy or thermotherapy).</li><li>Salvage chemotherapy (systemic or intra-arterial chemotherapy).[<a href="#cit/section_7.1">1</a>]</li><li>Intravitreal administration of chemotherapy, especially for refractory or recurrent vitreous seeding, instead of treatment with intra-arterial or intravenous chemotherapy.[<a href="#cit/section_7.2">2</a>]</li></ol></div><p id="_835" tabindex="-1">New intraocular tumors can arise in patients with the heritable form of disease whose eyes have been treated with local control measures only, because every cell in the retina carries the <em>RB1</em> mutation; this should not be considered a recurrence. Even with previous treatment consisting of chemoreduction and local control measures in very young patients with heritable retinoblastoma, surveillance may detect new tumors at an early stage, and additional local control therapy, including plaque radiation therapy, can be successful in eradicating tumor.[<a href="#cit/section_7.3">3</a>-<a href="#cit/section_7.7">7</a>]</p><p id="_836" tabindex="-1">When the recurrence or progression of retinoblastoma is confined to the eye and is small, the prognosis for sight and survival may be excellent with local therapy only.[<a href="#cit/section_7.8">8</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiDiv</a>]  If the recurrence or progression is confined to the
            eye but is extensive, the prognosis for sight is poor; however, survival
            remains excellent. Intra-arterial chemotherapy into the ophthalmic artery has been effective in patients who relapse after systemic chemotherapy and radiation therapy.[<a href="#cit/section_7.9">9</a>,<a href="#cit/section_7.10">10</a>] <em>Rescue</em> intra-arterial chemotherapy has been used after primary intra-arterial chemotherapy.  However, patients often require other treatment methods because of disease progression after second-line intra-arterial chemotherapy.[<a href="#cit/section_7.1">1</a>]  Radiation therapy should be considered for patients who have not been previously irradiated. Finally, enucleation may be required in cases of progressive disease after all eye-salvaging treatments have failed. </p></section><section id="_849"><h3 id="_849_toc">Treatment Options for Progressive or Recurrent Extraocular Retinoblastoma</h3><p id="_744" tabindex="-1">Treatment options for progressive or recurrent extraocular retinoblastoma include the following:</p><div class="pdq-content-list"><ol id="_747"><li>Systemic chemotherapy and radiation therapy for orbital disease.</li><li>Systemic chemotherapy followed by myeloablative chemotherapy with stem cell rescue and radiation therapy for extraorbital disease.</li></ol></div><p id="_715" tabindex="-1">If the recurrence or progression is extraocular, the
            chance of survival is poor.[<a href="#cit/section_7.11">11</a>]  However, the use of intensive systemic chemotherapy and consolidation with high-dose chemotherapy and autologous hematopoietic stem cell rescue may improve the chance of a cure, particularly for patients with extracranial recurrence (refer to the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_77">Treatment of Extraocular Retinoblastoma</a> section of this summary for more information). For patients with disease recurrence after those intensive approaches, clinical trials
            may be considered.</p><p id="_837" tabindex="-1">Recurrence in the orbit after enucleation is treated with aggressive chemotherapy in addition to local radiation therapy because of the high risk of metastatic disease.[<a href="#cit/section_7.12">12</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=English" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=English'); return(false);">Level of evidence: 3iiA</a>] After enucleation for recurrence, high-resolution magnetic resonance imaging with orbital coils can be helpful in distinguishing orbital recurrence from postsurgical enhancement.[<a href="#cit/section_7.13">13</a>]</p></section><section id="_1796"><h3 id="_1796_toc">Treatment Options Under Clinical Evaluation for Progressive or Recurrent Retinoblastoma</h3><p id="_1817" tabindex="-1">Information about National Cancer Institute (NCI)&#x2013;supported clinical trials can be found on the <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search">NCI website</a>. For information about clinical trials sponsored by other organizations, refer to the <a href="https://clinicaltrials.gov/" title="https://clinicaltrials.gov/">ClinicalTrials.gov website</a>.</p><p id="_1797" tabindex="-1">The following is an example of a national and/or institutional clinical trial that is currently being conducted:</p><div class="pdq-content-list"><ul id="_1798"><li><strong><a href="/clinicaltrials/NCT03155620">APEC1621 (NCT03155620)</a></strong> (Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders)<strong>:</strong> NCI&#x2013;Children's Oncology Group Pediatric Molecular Analysis for Therapeutic Choice (MATCH), referred to as Pediatric MATCH, will match targeted agents with specific molecular changes identified using a next-generation sequencing targeted assay of more than 3,000 different mutations across more than 160 genes in refractory and recurrent solid tumors.   Children and adolescents aged 1 to 21 years are eligible for the trial.<p id="_1795" tabindex="-1">Tumor tissue from progressive or recurrent disease must be available for molecular characterization.  Patients with tumors that have molecular variants addressed by treatment arms included in the trial will be offered treatment on Pediatric MATCH.  Additional information can be obtained on the <a href="https://clinicaltrials.gov/" title="https://clinicaltrials.gov/">ClinicalTrials.gov website</a> for <a href="https://clinicaltrials.gov/ct2/show/NCT03155620" title="https://clinicaltrials.gov/ct2/show/NCT03155620">APEC1621 (NCT03155620)</a>.</p>
            </li></ul></div><section id="_TrialSearch_1796_sid_6"><h4 id="_TrialSearch_1796_sid_6_toc">Current Clinical Trials</h4><p id="_TrialSearch_1796_22" tabindex="-1">Use our <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">advanced clinical trial search</a> to find NCI-supported cancer clinical trials that are now enrolling patients. The search can be narrowed by location of the trial, type of treatment, name of the drug, and other criteria. <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/">General information</a> about clinical trials is also available.</p></section></section><h6 do-not-show="toc">References</h6><ol><li id="section_7.1">Francis JH, Abramson DH, Gobin YP, et al.: Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma. Ophthalmology 122 (5): 1016-22, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25616769&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25616769&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.2">Ghassemi F, Shields CL, Ghadimi H, et al.: Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol 132 (8): 936-41, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24789622&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24789622&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.3">Shields CL, Honavar SG, Shields JA, et al.: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120 (4): 460-4, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11934319&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11934319&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.4">Gombos DS, Kelly A, Coen PG, et al.: Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol 86 (1): 80-3, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11801509&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11801509&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.5">Shields CL, Shelil A, Cater J, et al.: Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 121 (11): 1571-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.6">Lee TC, Hayashi NI, Dunkel IJ, et al.: New retinoblastoma tumor formation in children initially treated with systemic carboplatin. Ophthalmology 110 (10): 1989-94; discussion 1994-5, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14522776&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14522776&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.7">Wilson MW, Haik BG, Billups CA, et al.: Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114 (11): 2077-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.8">Chan MP, Hungerford JL, Kingston JE, et al.: Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol 93 (7): 891-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19329423&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19329423&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.9">Schaiquevich P, Ceciliano A, Millan N, et al.: Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 60 (5): 766-70, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.10">Say EA, Iyer PG, Hasanreisoglu M, et al.: Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes. J AAPOS 20 (4): 337-42, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.11">Broaddus E, Topham A, Singh AD: Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93 (1): 24-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.12">Kim JW, Kathpalia V, Dunkel IJ, et al.: Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 93 (4): 463-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.13">Sirin S, de Jong MC, de Graaf P, et al.: High-Resolution Magnetic Resonance Imaging Can Reliably Detect Orbital Tumor Recurrence after Enucleation in Children with Retinoblastoma. Ophthalmology 123 (3): 635-45, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26692298&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26692298&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _131
      field_pdq_section_title:
        - format: plain_text
          value: 'Changes to This Summary (08/22/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_131" class="pdq-sections"><p id="_147" tabindex="-1">The PDQ cancer information summaries are reviewed regularly and updated as
            new information becomes available.  This section describes the latest
            changes made to this summary as of the date above.</p><p id="_1827" tabindex="-1"><strong><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_1">General Information About Retinoblastoma</a></strong></p><p id="_1828" tabindex="-1">Added <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_488">text</a> to state that the functional status of the retinoblastoma protein (pRb) is inferred  to be inactive in retinoblastoma with <em>MYCN</em> amplification.  This suggests that inactivation of <em>RB1</em> by mutation or inactive pRb is a requirement for the development of retinoblastoma, independent of <em>MYCN</em> amplification (cited Ewens et al. as reference 13).</p><p id="_1829" tabindex="-1"><strong><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_53">Treatment Option Overview for Retinoblastoma</a></strong></p><p id="_1830" tabindex="-1">Added Say et al. as <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_823">reference 36</a>.</p><p id="_1831" tabindex="-1">Revised <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_796">text</a> to state that while subretinal seeds can be well controlled with intra-arterial chemotherapy, vitreous seeds may be difficult to control with intra-arterial or intravenous chemotherapy alone. Also added text to state that the addition of intravitreal chemotherapy to intravenous chemotherapy is more effective in the treatment of vitreous seeds; as with primary intra-arterial chemotherapy, control of seed dust, spheres, and clouds require progressively more cycles of intravitreal chemotherapy (cited Berry et al. as reference 45 and level of evidence 3iiiDiii).</p><p id="_1832" tabindex="-1">Added Shields et al. as <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_798">reference 46</a>.</p><p id="_1833" tabindex="-1"><strong><a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_85">Treatment of Progressive or Recurrent Retinoblastoma</a></strong></p><p id="_1834" tabindex="-1">Added Say et al. as <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_836">reference 10</a>.</p><p id="_disclaimerHP_3" tabindex="-1">This summary is written and maintained by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</a>, which is
            editorially independent of NCI.  The summary reflects an independent review of
            the literature and does not represent a policy statement of NCI or NIH.  More
            information about summary policies and the role of the PDQ Editorial Boards  in
            maintaining the PDQ summaries can be found on the <a href="/types/retinoblastoma/hp/retinoblastoma-treatment-pdq#link/_AboutThis_1">About This PDQ Summary</a> and <a href="https://www.cancer.gov/publications/pdq" title="https://www.cancer.gov/publications/pdq">PDQ&#xAE; - NCI's Comprehensive Cancer Database</a> pages.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'About This PDQ Summary'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Purpose of This Summary</h3><p id="_AboutThis_3" tabindex="-1">This PDQ cancer information summary for health professionals provides comprehensive, peer-reviewed, evidence-based information about the treatment of retinoblastoma. It is intended as a resource to inform and assist clinicians who care for cancer patients.  It does not provide formal guidelines or recommendations for making health care decisions.</p></section><section id="_AboutThis_4"><h3 id="_AboutThis_4_toc">Reviewers and Updates</h3><p id="_AboutThis_5" tabindex="-1">This summary is reviewed regularly and updated as necessary by the <a href="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment" title="https://www.cancer.gov/publications/pdq/editorial-boards/pediatric-treatment">PDQ Pediatric Treatment Editorial Board</a>, which is editorially independent of the National Cancer Institute (NCI).  The summary reflects an independent review of the literature and does not represent a policy statement of NCI or the National Institutes of Health (NIH).</p><p id="_AboutThis_22" tabindex="-1"> Board members review recently published articles each month to determine whether an article should:</p><div class="pdq-content-list"><ul id="_AboutThis_6"><li>be discussed at a meeting,</li><li>be cited with text, or</li><li>replace or update an existing article that is already cited.</li></ul></div><p id="_AboutThis_7" tabindex="-1">Changes to the summaries are made through a consensus process in which Board members evaluate the strength of the evidence in  the published articles and determine how the article should be included in the summary.</p><p id="" tabindex="-1">The lead reviewers for Retinoblastoma Treatment are:</p><div class="pdq-content-list"><ul id=""><li>Christopher N. Frantz, MD (Alfred I. duPont Hospital for Children)</li><li>Karen J. Marcus, MD (Dana-Farber Cancer Institute/Boston Children's Hospital)</li><li>Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)</li><li>Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)</li><li>Nita Louise Seibel, MD (National Cancer Institute)</li></ul></div><p id="_AboutThis_9" tabindex="-1">Any comments or questions about the summary content should be submitted to Cancer.gov through the NCI website's <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>. Do not contact the individual Board Members with questions or comments about the summaries. Board members will not respond to individual inquiries.</p></section><section id="_AboutThis_10"><h3 id="_AboutThis_10_toc">Levels of Evidence</h3><p id="_AboutThis_11" tabindex="-1">Some of the reference citations in this summary are accompanied by a level-of-evidence designation. These designations are intended to help readers assess the strength of the evidence supporting the use of specific interventions or approaches. The PDQ Pediatric Treatment Editorial Board uses a <a href="/publications/pdq/levels-evidence/treatment">formal evidence ranking system</a> in developing its level-of-evidence designations.</p></section><section id="_AboutThis_12"><h3 id="_AboutThis_12_toc">Permission to Use This Summary</h3><p id="_AboutThis_13" tabindex="-1">PDQ is a registered trademark. Although the content of PDQ documents can be used freely as text, it cannot be identified as an NCI PDQ cancer information summary unless it is presented in its entirety and is regularly updated. However, an author would be permitted to write a sentence such as &#x201C;NCI&#x2019;s PDQ cancer information summary about breast cancer prevention states the risks succinctly: [include excerpt from the summary].&#x201D;</p><p id="_AboutThis_14" tabindex="-1">The preferred citation for this PDQ summary is:</p><p id="_AboutThis_15" tabindex="-1">PDQ&#xAE; Pediatric Treatment Editorial Board. PDQ Retinoblastoma Treatment. Bethesda, MD: National Cancer Institute. Updated  &lt;MM/DD/YYYY&gt;. Available at: <a href="https://www.cancer.gov/types/retinoblastoma/hp/retinoblastoma-treatment-pdq" title="https://www.cancer.gov/types/retinoblastoma/hp/retinoblastoma-treatment-pdq">https://www.cancer.gov/types/retinoblastoma/hp/retinoblastoma-treatment-pdq</a>.  Accessed &lt;MM/DD/YYYY&gt;. [PMID: 26389442]</p><p id="_AboutThis_16" tabindex="-1">Images in this summary are used with permission of the author(s), artist, and/or publisher for use within the PDQ summaries only. Permission to use images outside the context of PDQ information must be obtained from the owner(s) and cannot be granted by  the National Cancer Institute. Information about using the illustrations in this summary, along with many other cancer-related images, is available in <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, a collection of over 2,000 scientific images.
            </p></section><section id="_AboutThis_17"><h3 id="_AboutThis_17_toc">Disclaimer</h3><p id="_AboutThis_18" tabindex="-1">Based on the strength of the available evidence, treatment options may be described as either &#x201C;standard&#x201D; or &#x201C;under clinical evaluation.&#x201D; These classifications should not be used as a basis for insurance reimbursement determinations. More information on insurance coverage is available on Cancer.gov on the <a href="https://www.cancer.gov/about-cancer/managing-care" title="https://www.cancer.gov/about-cancer/managing-care">Managing Cancer Care</a> page.</p></section><section id="_AboutThis_20"><h3 id="_AboutThis_20_toc">Contact Us</h3><p id="_AboutThis_21" tabindex="-1">More information about contacting us or receiving help with the Cancer.gov website can be found on our <a href="https://www.cancer.gov/contact" title="https://www.cancer.gov/contact">Contact Us for Help</a> page. Questions can also be submitted to Cancer.gov through the website&#x2019;s <a href="https://www.cancer.gov/contact/email-us" title="https://www.cancer.gov/contact/email-us">Email Us</a>.</p></section></div>
  title__ES:
    value: 'Tratamiento del retinoblastoma (PDQ®)–Versión para profesionales de salud'
  status__ES:
    value: 1
  langcode__ES:
    value: es
  moderation_state__ES:
    value: published
  field_pdq_url__ES:
    value: /tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq
  field_pdq_cdr_id__ES:
    value: 256693
  field_pdq_audience__ES:
    value: Health Professionals
  field_pdq_summary_type__ES:
    value: Treatment
  field_date_posted__ES:
    value: '2019-03-11'
  field_date_updated__ES:
    value: '2018-09-26'
  field_browser_title__ES:
    value: 'Tratamiento del retinoblastoma'
  field_page_description__ES:
    value: 'Resumen de información revisada por expertos acerca del tratamiento del retinoblastoma en niños.'
  field_public_use__ES:
    value: 1
  field_summary_sections__ES:
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información general sobre el retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_1" class="pdq-sections"><div class="pdq-hp-patient-toggle"><a href="/espanol/tipos/retinoblastoma/paciente/tratamiento-retinoblastoma-pdq">Vaya a la versi&#xF3;n para pacientes</a></div><p id="_729" tabindex="-1">El retinoblastoma es un c&#xE1;ncer infantil que exige una cuidadosa integraci&#xF3;n de la atenci&#xF3;n multidisciplinaria. El tratamiento del retinoblastoma tiene como objetivo salvar la vida del paciente y preservar la visi&#xF3;n &#xFA;til; por lo tanto, se debe personalizar. El tratamiento del retinoblastoma intraocular ha evolucionado hacia un enfoque m&#xE1;s adaptado al riesgo para reducir al m&#xED;nimo la exposici&#xF3;n sist&#xE9;mica a f&#xE1;rmacos, optimizar la administraci&#xF3;n de f&#xE1;rmacos oculares y preservar la visi&#xF3;n &#xFA;til. Los pacientes que presentan retinoblastoma extraocular necesitan un tratamiento con quimioterapia intensiva, que incluya consolidaci&#xF3;n con quimioterapia de dosis alta y rescate aut&#xF3;geno de c&#xE9;lulas madre hematopoy&#xE9;ticas. Aunque la mayor&#xED;a de los pacientes con enfermedad orbitaria y una gran proporci&#xF3;n de pacientes con met&#xE1;stasis sist&#xE9;micas fuera del sistema nervioso central (SNC) se pueden curar, el pron&#xF3;stico para los pacientes con enfermedad intracraneal es muy desalentador.</p><section id="_486"><h3 id="_486_toc">Incidencia</h3><p id="_487" tabindex="-1">El retinoblastoma es un tumor de la ni&#xF1;ez relativamente poco frecuente que se origina en la retina y representa alrededor de 3&#xA0;% de los c&#xE1;nceres en los ni&#xF1;os menores de 15 a&#xF1;os.</p><p id="_730" tabindex="-1">El retinoblastoma es un c&#xE1;ncer que afecta a ni&#xF1;os muy peque&#xF1;os; dos tercios de todos los casos de retinoblastoma se diagnostican antes de los 2 a&#xF1;os.[<a href="#cit/section_1.1">1</a>] En consecuencia, si bien el c&#xE1;lculo de la incidencia anual en los Estados Unidos es de aproximadamente 4 casos por mill&#xF3;n de ni&#xF1;os menores de 15 a&#xF1;os, la incidencia anual ajustada por edad en ni&#xF1;os de 0 a 4 a&#xF1;os es de 10 a 14 casos por mill&#xF3;n (alrededor de 1 en 14&#xA0;000&#x2013;18&#xA0;000 nacidos vivos).</p></section><section id="_731"><h3 id="_731_toc">Caracter&#xED;sticas anat&#xF3;micas</h3><p id="_732" tabindex="-1">El retinoblastoma surge de la retina y suele crecer debajo de esta y hacia el cuerpo v&#xED;treo. El compromiso de las membranas oculares y el nervio &#xF3;ptico se produce en una secuencia de complicaciones a medida que el tumor progresa. La invasi&#xF3;n de la membrana coroides es frecuente, aunque la aparici&#xF3;n de invasi&#xF3;n masiva habitualmente se limita a la enfermedad avanzada. Despu&#xE9;s de la invasi&#xF3;n de la coroides, el tumor llega a la circulaci&#xF3;n sist&#xE9;mica y crea la posibilidad de met&#xE1;stasis. La progresi&#xF3;n adicional a trav&#xE9;s de las membranas oculares conduce a la invasi&#xF3;n de la escler&#xF3;tica y la &#xF3;rbita. En la porci&#xF3;n delantera, el tumor que invade la c&#xE1;mara anterior puede acceder a la circulaci&#xF3;n sist&#xE9;mica a trav&#xE9;s del canal de Schlemm. La progresi&#xF3;n a trav&#xE9;s del nervio &#xF3;ptico y m&#xE1;s all&#xE1; de la l&#xE1;mina cribosa aumenta el riesgo de diseminaci&#xF3;n sist&#xE9;mica y por el SNC (consultar la <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_839">Figura 1</a>).</p><p id="_733" tabindex="-1"><figure id="figure_839" class="image-center"><a href="https://www.cancer.gov/images/cdr/live/CDR765491.jpg" target="_blank" class="article-image-enlarge">Ampliar</a><img id="_839" alt="Anatom&#xED;a del ojo; en la ilustraci&#xF3;n de dos paneles, se muestra el exterior y el interior del ojo. En el panel superior, se muestra el exterior del ojo, incluso el p&#xE1;rpado, la pupila, la escler&#xF3;tica y el iris. En el panel inferior, se muestra el interior del ojo, incluso el cuerpo ciliar, el canal de Schlemm, la c&#xF3;rnea, el cristalino, el humor v&#xED;treo, la retina, la coroides, el nervio &#xF3;ptico y la l&#xE1;mina cribosa." title="Anatom&#xED;a del ojo; en la ilustraci&#xF3;n de dos paneles, se muestra el exterior y el interior del ojo. En el panel superior, se muestra el exterior del ojo, incluso el p&#xE1;rpado, la pupila, la escler&#xF3;tica y el iris. En el panel inferior, se muestra el interior del ojo, incluso el cuerpo ciliar, el canal de Schlemm, la c&#xF3;rnea, el cristalino, el humor v&#xED;treo, la retina, la coroides, el nervio &#xF3;ptico y la l&#xE1;mina cribosa." src="https://www.cancer.gov/images/cdr/live/CDR765491-750.jpg"><figcaption class="caption-container">Figura 1.  Anatom&#xED;a del ojo en la que se observa la parte  exterior e interior, incluso el p&#xE1;rpado, la pupila, la escler&#xF3;tica, el iris, el cuerpo ciliar, el canal de Schlemm, la c&#xF3;rnea, el cristalino, el humor v&#xED;treo, la retina, la coroides, el nervio &#xF3;ptico y la l&#xE1;mina cribosa. El humor v&#xED;treo es  un gel que llena el centro del ojo.</figcaption></figure></p></section><section id="_851"><h3 id="_851_toc">Ex&#xE1;menes de detecci&#xF3;n</h3><p id="_852" tabindex="-1">Las siguientes estrategias de detecci&#xF3;n y vigilancia reflejan las pr&#xE1;cticas habituales en el abordaje del retinoblastoma.</p><p id="_853" tabindex="-1">En los ni&#xF1;os con antecedentes familiares de retinoblastoma se llevan a cabo ex&#xE1;menes de detecci&#xF3;n al comienzo de la vida mediante oftalmoscopia con anestesia general, que se hace a intervalos regulares de acuerdo con el c&#xE1;lculo del riesgo absoluto a partir de la identificaci&#xF3;n de la mutaci&#xF3;n de  <em>RB1</em> en el ni&#xF1;o y en su familia. Si alguno de los padres tiene esta mutaci&#xF3;n, el reci&#xE9;n nacido se somete a una exploraci&#xF3;n ocular con dilataci&#xF3;n pupilar y anestesia general tan pronto como sea posible durante el primer mes de vida, y tambi&#xE9;n se efect&#xFA;a una evaluaci&#xF3;n gen&#xE9;tica. Los lactantes cuya prueba gen&#xE9;tica da un resultado positivo se someten a ex&#xE1;menes mensuales con anestesia. Los lactantes que no contraen la enfermedad contin&#xFA;an con ex&#xE1;menes mensuales  durante el primer a&#xF1;o de vida y luego se reduce  progresivamente la frecuencia de estos ex&#xE1;menes durante el segundo a&#xF1;o y los siguientes a&#xF1;os. Los ex&#xE1;menes de detecci&#xF3;n pueden mejorar el pron&#xF3;stico en t&#xE9;rminos de preservaci&#xF3;n del globo ocular gracias al empleo de tratamientos menos radicales que preservan el globo ocular en los ni&#xF1;os con antecedentes familiares de retinoblastoma.[<a href="#cit/section_1.2">2</a>]</p><p id="_854" tabindex="-1">Es una pr&#xE1;ctica habitual que los padres  y hermanos de pacientes con retinoblastoma se sometan a ex&#xE1;menes oftalmol&#xF3;gicos de detecci&#xF3;n con el fin de excluir una enfermedad familiar inadvertida. Los hermanos contin&#xFA;an con la detecci&#xF3;n hasta los 3 a 5 a&#xF1;os de edad, o hasta que se corrobore que no tienen una mutaci&#xF3;n del gen <em>RB1</em>.</p></section><section id="_734"><h3 id="_734_toc">Cuadro cl&#xED;nico inicial</h3><p id="_855" tabindex="-1">La edad en el momento de las manifestaciones iniciales se correlaciona con lateralidad; los pacientes que tienen enfermedad bilateral exhiben manifestaciones a una edad m&#xE1;s temprana, por lo general, en los primeros 12 meses de vida.</p><p id="_735" tabindex="-1"> La mayor&#xED;a de los casos presenta leucocoria, que en ocasiones se observa por primera vez despu&#xE9;s de tomar una fotograf&#xED;a con <em>flash</em>. El estrabismo es el segundo signo de presentaci&#xF3;n m&#xE1;s frecuente y, por lo habitual, se correlaciona con compromiso macular. Los tumores intraoculares muy avanzados producen dolor, celulitis orbitaria, glaucoma o buftalmia. A medida que el tumor progresa, los pacientes pueden presentar enfermedad orbitaria o metast&#xE1;sica. Las met&#xE1;stasis se encuentran en los ganglios linf&#xE1;ticos preauriculares y laterocervicales, en el SNC o en forma sist&#xE9;mica (con frecuencia, en los huesos, la m&#xE9;dula &#xF3;sea y el h&#xED;gado).</p><p id="_856" tabindex="-1">En los Estados Unidos, se ha observado que los ni&#xF1;os de ascendencia hispana y aquellos que viven en condiciones socioecon&#xF3;micas precarias presentan una enfermedad m&#xE1;s avanzada.[<a href="#cit/section_1.3">3</a>]</p></section><section id="_736"><h3 id="_736_toc">Evaluaci&#xF3;n diagn&#xF3;stica</h3><p id="_737" tabindex="-1">El diagn&#xF3;stico de retinoblastoma intraocular habitualmente se realiza sin confirmaci&#xF3;n patol&#xF3;gica. Para examinar la retina completa, es necesario un examen con anestesia, una pupila dilatada al m&#xE1;ximo e indentaci&#xF3;n escleral. Se debe documentar en gran detalle el n&#xFA;mero, la ubicaci&#xF3;n y el tama&#xF1;o de los tumores; la presencia de desprendimiento de retina y de l&#xED;quido subretiniano; y la presencia de diseminaci&#xF3;n subretiniana y v&#xED;trea.</p><p id="_857" tabindex="-1">La ecograf&#xED;a ocular bidimensional y las im&#xE1;genes por resonancia magn&#xE9;tica (IRM) son &#xFA;tiles para diferenciar el retinoblastoma de otras causas de leucocoria y para evaluar la diseminaci&#xF3;n fuera de la escler&#xF3;tica y del ojo en ni&#xF1;os con  retinoblastoma intraocular avanzado. El realce del nervio &#xF3;ptico en la IRM no indica necesariamente que hay compromiso por lo que estos hallazgos se deben interpretar con cautela.[<a href="#cit/section_1.4">4</a>] La detecci&#xF3;n de ARNm de la sintasa de gangli&#xF3;sido GD2 mediante reacci&#xF3;n en cadena de la polimerasa con retrotranscripci&#xF3;n en el l&#xED;quido cefalorraqu&#xED;deo en el momento del diagn&#xF3;stico podr&#xED;a servir de marcador de enfermedad en el SNC.[<a href="#cit/section_1.5">5</a>]</p><p id="_738" tabindex="-1">En caso de sospechar extensi&#xF3;n extraocular, tambi&#xE9;n es necesario sopesar si se eval&#xFA;a la presencia de enfermedad metast&#xE1;sica mediante im&#xE1;genes o evaluaci&#xF3;n de caracter&#xED;sticas patol&#xF3;gicas de riesgo alto en el ojo enucleado (es decir, invasi&#xF3;n masiva de la coroides o compromiso de la escler&#xF3;tica o el nervio &#xF3;ptico m&#xE1;s all&#xE1; de la l&#xE1;mina cribrosa). Los pacientes que presentan estas caracter&#xED;sticas patol&#xF3;gicas en el ojo enucleado tienen un riesgo alto de met&#xE1;stasis. En estos casos, se puede realizar  una centellograf&#xED;a &#xF3;sea, aspiraci&#xF3;n de la m&#xE9;dula &#xF3;sea y biopsias, as&#xED; como una punci&#xF3;n lumbar.[<a href="#cit/section_1.6">6</a>]</p><p id="_739" tabindex="-1">Se recomienda la orientaci&#xF3;n gen&#xE9;tica para todos los pacientes de retinoblastoma. (Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario  <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_859">Orientaci&#xF3;n gen&#xE9;tica</a>).</p></section><section id="_488"><h3 id="_488_toc">Formas hereditarias y no hereditarias de retinoblastoma</h3><section id="_sm_CDR0000780118_6"><p id="_sm_CDR0000780118_489" tabindex="-1">El retinoblastoma es un tumor que se presenta en formas hereditarias (25&#x2013;30&#xA0;%) y no hereditarias (70&#x2013;75&#xA0;%). La enfermedad hereditaria se define por la presencia de una mutaci&#xF3;n de l&#xED;nea germinal en el gen <em>RB1</em>. Esta mutaci&#xF3;n en la l&#xED;nea germinal se hereda de un progenitor afectado (25&#xA0;% de los casos) o sucede en una c&#xE9;lula germinal antes de la concepci&#xF3;n o en el &#xFA;tero durante la embriog&#xE9;nesis temprana en pacientes con enfermedad espor&#xE1;dica (75&#xA0;% de los casos). La presencia de antecedentes familiares de retinoblastoma, o enfermedad bilateral o multifocal puede indicar enfermedad hereditaria.</p><p id="_sm_CDR0000780118_643" tabindex="-1">El retinoblastoma hereditario se manifiesta como enfermedad unilateral o bilateral. Es probable que la penetrancia de la mutaci&#xF3;n en <em>RB1</em> (lateralidad, edad en el momento del diagn&#xF3;stico y n&#xFA;mero de tumores) dependa de modificadores gen&#xE9;ticos simult&#xE1;neos, como los polimorfismos de <em>MDM2</em> y <em>MDM4</em>.[<a href="#cit/section_1.7">7</a>,<a href="#cit/section_1.8">8</a>] Se presume que todos los ni&#xF1;os con enfermedad bilateral y cerca de 15&#xA0;% de los pacientes con enfermedad unilateral tienen la forma hereditaria, a pesar de que solo 25&#xA0;% tienen un padre afectado.</p><p id="_sm_CDR0000780118_644" tabindex="-1">En el caso del retinoblastoma hereditario, los tumores tienden a diagnosticarse a una edad m&#xE1;s temprana que en la forma no hereditaria de la enfermedad. El retinoblastoma unilateral en ni&#xF1;os menores de 1 a&#xF1;o plantea la sospecha de una enfermedad hereditaria, mientras que es m&#xE1;s probable que los ni&#xF1;os mayores con un tumor unilateral presenten la forma no hereditaria de la enfermedad.[<a href="#cit/section_1.9">9</a>]</p><p id="_sm_CDR0000780118_649" tabindex="-1">El panorama actual de las caracter&#xED;sticas gen&#xF3;micas del retinoblastoma se orienta por las alteraciones en <em>RB1</em> que producen inactivaci&#xF3;n bial&#xE9;lica.[<a href="#cit/section_1.10">10</a>,<a href="#cit/section_1.11">11</a>]  Una causa poco frecuente de inactivaci&#xF3;n de <em>RB1</em> es la cromotripsis, que puede ser dif&#xED;cil de detectar con los m&#xE9;todos convencionales.[<a href="#cit/section_1.12">12</a>] Otros cambios gen&#xF3;micos recurrentes que se presentan en una peque&#xF1;a minor&#xED;a de los tumores son la mutaci&#xF3;n o deleci&#xF3;n en <em>BCOR</em>, la amplificaci&#xF3;n de <em>MYCN</em> y la amplificaci&#xF3;n de <em>OTX2</em>.[<a href="#cit/section_1.10">10</a>-<a href="#cit/section_1.12">12</a>] En un estudio de 1068 casos de tumores unilaterales de retinoblastoma no familiar, se notific&#xF3; que un porcentaje peque&#xF1;o de casos (casi 3&#xA0;%) carec&#xED;an de pruebas de p&#xE9;rdida de <em>RB1</em>. En alrededor de la mitad de estos casos sin p&#xE9;rdida de <em>RB1</em> (casi 1,5&#xA0;% de todos los casos de retinoblastoma no familiar de tipo unilateral) se exhibi&#xF3; amplificaci&#xF3;n de <em>MYCN</em>.[<a href="#cit/section_1.11">11</a>] Se infiere que el estado funcional de la prote&#xED;na del retinoblastoma (pRb) es inactivo en el retinoblastoma con amplificaci&#xF3;n de <em>MYCN</em>. Esto indica que la inactivaci&#xF3;n de <em>RB1</em> por mutaci&#xF3;n o la prote&#xED;na pRb inactiva es un requisito para la presentaci&#xF3;n de un retinoblastoma, de manera independiente a la amplificaci&#xF3;n de <em>MYCN</em>.[<a href="#cit/section_1.13">13</a>] </p></section></section><section id="_528"><h3 id="_528_toc">Vigilancia posterior al diagn&#xF3;stico</h3><p id="_529" tabindex="-1">Los ni&#xF1;os con una mutaci&#xF3;n de la l&#xED;nea germinal en <em>RB1</em> pueden continuar presentando tumores nuevos durante unos pocos a&#xF1;os despu&#xE9;s del diagn&#xF3;stico y tratamiento; por esta raz&#xF3;n, es necesario examinarlos con frecuencia. Es una pr&#xE1;ctica habitual que se hagan ex&#xE1;menes cada 2 a 4 meses durante por lo menos 28 meses.[<a href="#cit/section_1.14">14</a>] El intervalo entre ex&#xE1;menes se basa en la estabilidad de la enfermedad y la edad del ni&#xF1;o (es decir, visitas menos frecuentes a medida que el ni&#xF1;o crece).</p><p id="_742" tabindex="-1">Una proporci&#xF3;n de los ni&#xF1;os que presentan retinoblastoma unilateral, con el tiempo, presentar&#xE1;n la enfermedad en el ojo opuesto. Por este motivo, se realizan ex&#xE1;menes peri&#xF3;dicos del ojo no afectado hasta que se determine el estado de la l&#xED;nea germinal del gen <em>RB1</em>.</p><p id="_858" tabindex="-1">Debido al pron&#xF3;stico precario de los pacientes con  retinoblastoma trilateral, es una pr&#xE1;ctica habitual realizar ex&#xE1;menes de detecci&#xF3;n con neuroimaginolog&#xED;a hasta los 5 a&#xF1;os de edad durante la vigilancia de los ni&#xF1;os con formas hereditarias de la enfermedad. (Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_496">Retinoblastoma trilateral</a> en la secci&#xF3;n de este sumario <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_493">Causas de la mortalidad relacionada con el retinoblastoma</a>).</p></section><section id="_743"><h3 id="_743_toc">Pruebas gen&#xE9;ticas</h3><p id="_744" tabindex="-1">Para determinar si un paciente de retinoblastoma tiene una mutaci&#xF3;n en el gen <em>RB1</em>, se examinan muestras de sangre o del tumor. Una vez que se identifique la mutaci&#xF3;n gen&#xE9;tica del paciente, se procede a examinar a otros miembros de la familia para detectar directamente la mutaci&#xF3;n mediante secuenciaci&#xF3;n dirigida.</p><p id="_745" tabindex="-1">Es posible realizar una evaluaci&#xF3;n gen&#xE9;tica completa del gen <em>RB1</em> mediante  un an&#xE1;lisis que incluye los siguientes pasos m&#xFA;ltiples:[<a href="#cit/section_1.15">15</a>]</p><div class="pdq-content-list"><ul id="_746"><li>Secuenciaci&#xF3;n del ADN para identificar mutaciones dentro de los exones codificadores y las regiones intr&#xF3;nicas complementarias circundantes.</li><li>An&#xE1;lisis con la t&#xE9;cnica de Southern para describir reordenamientos gen&#xF3;micos.</li><li>An&#xE1;lisis de trascripci&#xF3;n para describir posibles  mutaciones de  empalme ocultas dentro de los intrones.</li></ul></div><p id="_747" tabindex="-1"> En casos de mosaicismo som&#xE1;tico o anomal&#xED;as citogen&#xE9;ticas, es posible que las mutaciones no se detecten con facilidad y que se deban utilizar t&#xE9;cnicas m&#xE1;s minuciosas, como el cariotipado, la amplificaci&#xF3;n m&#xFA;ltiple de sondas dependiente de ligadura, la hibridaci&#xF3;n fluorescente in situ y el an&#xE1;lisis de metilaci&#xF3;n del promotor de <em>RB1</em>.   Es posible que se descubra un mosaicismo de grado bajo en la secuenciaci&#xF3;n masiva (2500 veces) de alelos espec&#xED;ficos en un amplic&#xF3;n gen&#xF3;mico de <em>RB1</em> obtenido del ADN de un linfocito.[<a href="#cit/section_1.16">16</a>] Debido a que la causa del mosaicismo es una mutaci&#xF3;n poscig&#xF3;tica, dicho resultado  hace innecesaria la evaluaci&#xF3;n de los hermanos con anestesia general.  Tambi&#xE9;n se encontr&#xF3; que algunas mutaciones de <em>RB1</em> que se cre&#xED;an heterocig&#xF3;ticas seg&#xFA;n la secuenciaci&#xF3;n de Sanger, eran de tipo mosaico. La secuenciaci&#xF3;n masiva no detectar&#xE1; algunas mutaciones mosaicas que tienen grados bajos de amplificaci&#xF3;n, las mutaciones ubicadas fuera del amplic&#xF3;n de <em>RB1</em>, las mutaciones en otros tejidos  no linfocitarios ni los reordenamientos masivos de <em>RB1</em> tipo mosaico.[<a href="#cit/section_1.16">16</a>] Al combinar las t&#xE9;cnicas antes descritas es posible detectar mutaciones de l&#xED;nea germinal en m&#xE1;s de 90&#xA0;% de los pacientes con retinoblastoma hereditario.[<a href="#cit/section_1.17">17</a>,<a href="#cit/section_1.18">18</a>]</p><p id="_748" tabindex="-1">La ausencia de mutaciones som&#xE1;ticas detectables en <em>RB1</em> en cerca de 3&#xA0;% de los casos de retinoblastoma unilateral no hereditario,  indica que puede haber mecanismos subyacentes alternos que explican la formaci&#xF3;n de un retinoblastoma.[<a href="#cit/section_1.19">19</a>] En la mitad de estos casos, se notificaron grados altos de amplificaci&#xF3;n de <em>MYCN</em>, caracter&#xED;sticas histol&#xF3;gicas distintivas y de gran malignidad, y una mediana de edad de 4 meses en el momento del diagn&#xF3;stico.[<a href="#cit/section_1.11">11</a>] En otro peque&#xF1;o subconjunto de tumores en los que no se logran detectar mutaciones som&#xE1;ticas en <em>RB1</em>, la cromotripsis es la  causa de la inactivaci&#xF3;n del gen <em>RB1</em>.[<a href="#cit/section_1.12">12</a>]</p></section><section id="_859"><h3 id="_859_toc">Orientaci&#xF3;n gen&#xE9;tica</h3><p id="_860" tabindex="-1">La orientaci&#xF3;n gen&#xE9;tica es una parte integral del abordaje de los pacientes con retinoblastoma y sus familias, independientemente de la presentaci&#xF3;n cl&#xED;nica. La orientaci&#xF3;n ayuda a que los padres comprendan las consecuencias gen&#xE9;ticas de cada forma de retinoblastoma y permite calcular el riesgo de la enfermedad en los miembros de la familia.[<a href="#cit/section_1.17">17</a>] Sin embargo, la orientaci&#xF3;n gen&#xE9;tica no siempre es simple. Aproximadamente 10&#xA0;% de los ni&#xF1;os con retinoblastoma presentan mosaicismo gen&#xE9;tico som&#xE1;tico, que dificulta la orientaci&#xF3;n gen&#xE9;tica.[<a href="#cit/section_1.20">20</a>] Adem&#xE1;s, para una mutaci&#xF3;n espec&#xED;fica, el riesgo de retinoblastoma en los hermanos var&#xED;a, en parte, seg&#xFA;n la hereden de la madre o del padre.[<a href="#cit/section_1.21">21</a>] (Para obtener m&#xE1;s informaci&#xF3;n en ingl&#xE9;s, consultar el sumario del PDQ sobre <a href="/about-cancer/causes-prevention/genetics/risk-assessment-pdq">Evaluaci&#xF3;n y orientaci&#xF3;n gen&#xE9;tica del riesgo de c&#xE1;ncer</a>).</p></section><section id="_493"><h3 id="_493_toc">Causas de la mortalidad relacionada con el retinoblastoma</h3><p id="_508" tabindex="-1">Si bien el retinoblastoma es una enfermedad muy curable, el reto para aquellos que tratan el retinoblastoma es preservar la vida y prevenir la p&#xE9;rdida de un ojo, la ceguera y otros efectos graves del tratamiento que reducen la longevidad o la calidad de vida del paciente. En los Estados Unidos y en otros pa&#xED;ses desarrollados, el retinoblastoma metast&#xE1;sico es menos frecuente gracias a las mejoras en el diagn&#xF3;stico y tratamiento del retinoblastoma de las &#xFA;ltimas d&#xE9;cadas. Por este motivo, otras causas de mortalidad por retinoblastoma, como el retinoblastoma trilateral y las neoplasias subsiguientes (NS), cobran mayor importancia durante los primeros 10 a&#xF1;os de vida y los a&#xF1;os posteriores.</p><p id="_861" tabindex="-1">La muerte por una segunda neoplasia maligna es la causa de defunci&#xF3;n m&#xE1;s com&#xFA;n y representa cerca de 50&#xA0;% de las defunciones de pacientes con enfermedad bilateral y retinoblastoma definido como hereditario desde el punto de vista gen&#xE9;tico.[<a href="#cit/section_1.22">22</a>,<a href="#cit/section_1.23">23</a>] En los Estados Unidos, antes del advenimiento de la quimiorreducci&#xF3;n para tratar la enfermedad hereditaria o bilateral, y antes de la implementaci&#xF3;n de los ex&#xE1;menes de detecci&#xF3;n con neuroimaginolog&#xED;a, el retinoblastoma trilateral era el factor responsable de m&#xE1;s de 50&#xA0;% de la mortalidad relacionada con el retinoblastoma en los primeros 10 a&#xF1;os  posteriores al diagn&#xF3;stico.[<a href="#cit/section_1.24">24</a>]</p><section id="_496"><h4 id="_496_toc">Retinoblastoma trilateral</h4><p id="_497" tabindex="-1">El retinoblastoma trilateral es un s&#xED;ndrome bien reconocido que se presenta en 5 a 15&#xA0;% de los pacientes con la forma hereditaria del retinoblastoma. Se define por la formaci&#xF3;n de un tumor neurobl&#xE1;stico en la l&#xED;nea media intracraneal que, por lo general, se presenta entre los 20 y 36 meses de vida.[<a href="#cit/section_1.25">25</a>]</p><p id="_862" tabindex="-1">En los Estados Unidos, el retinoblastoma trilateral ha sido la principal causa de muerte por retinoblastoma en los primeros 10 a&#xF1;os de vida.[<a href="#cit/section_1.26">26</a>] Puesto que los pacientes con  retinoblastoma trilateral tienen un pron&#xF3;stico adverso, y ya que la detecci&#xF3;n temprana y el tratamiento radical aparentemente mejoran la supervivencia, parece que los ex&#xE1;menes de detecci&#xF3;n peri&#xF3;dicos con neuroim&#xE1;genes permiten la detecci&#xF3;n de la mayor&#xED;a de casos dentro de los 2 a&#xF1;os del diagn&#xF3;stico inicial.[<a href="#cit/section_1.25">25</a>] Se recomienda que se lleve a cabo de manera rutinaria una IRM encef&#xE1;lica inicial en el momento del diagn&#xF3;stico porque esta puede detectar el retinoblastoma trilateral en un estadio subcl&#xED;nico.  En una serie de pacientes poco numerosa, la tasa de supervivencia general a 5 a&#xF1;os fue de 67&#xA0;% en los pacientes con detecci&#xF3;n inicial de la enfermedad, en comparaci&#xF3;n con 11&#xA0;% en el grupo de diagn&#xF3;stico tard&#xED;o.[<a href="#cit/section_1.27">27</a>] Aunque no est&#xE1; claro si el diagn&#xF3;stico temprano logra mejorar la supervivencia, se ha recomendado la IRM a intervalos de hasta 6 meses durante 5 a&#xF1;os en los pacientes en quienes se sospecha una enfermedad hereditaria o que tienen enfermedad unilateral con antecedentes familiares confirmados.[<a href="#cit/section_1.28">28</a>] Por lo general, se evitan las exploraciones con tomograf&#xED;a computarizada  para la detecci&#xF3;n de  rutina en estos ni&#xF1;os dado el riesgo de la exposici&#xF3;n a la  radiaci&#xF3;n ionizante.</p><p id="_863" tabindex="-1">Una gl&#xE1;ndula pineal qu&#xED;stica, que por lo com&#xFA;n se detecta con la IRM de vigilancia, debe diferenciarse de una variante qu&#xED;stica de pineoblastoma. Se notific&#xF3; que la incidencia de quistes pineales es de 55,8&#xA0;% en  ni&#xF1;os que no tienen retinoblastoma.[<a href="#cit/section_1.29">29</a>] En un estudio de casos y controles que incluy&#xF3; a 77 ni&#xF1;os con retinoblastoma y 77 controles, se encontr&#xF3; que la incidencia de quistes pineales fue semejante (61&#xA0;y 69&#xA0;%, respectivamente), y el tama&#xF1;o y volumen de la gl&#xE1;ndula pineal no vari&#xF3; de manera significativa entre los grupos.[<a href="#cit/section_1.30">30</a>] Sin embargo, se describi&#xF3; un componente qu&#xED;stico en casi el  57&#xA0;% de los pacientes con  retinoblastoma trilateral confirmado por estudios histol&#xF3;gicos.[<a href="#cit/section_1.27">27</a>] Un aumento excesivo en el tama&#xF1;o de la gl&#xE1;ndula pineal debe considerarse como un par&#xE1;metro  s&#xF3;lido que indica un proceso neopl&#xE1;sico.[<a href="#cit/section_1.30">30</a>]</p></section><section id="_499"><h4 id="_499_toc">Neoplasias subsiguientes</h4><p id="_752" tabindex="-1">Los sobrevivientes de retinoblastoma tienen un riesgo alto de presentar una neoplasia subsiguiente (NS). A continuaci&#xF3;n se incluyen algunos de los factores que influyen en este riesgo:</p><div class="pdq-content-list"><ul id="_753"><li><strong>Retinoblastoma hereditario.</strong> Los pacientes de retinoblastoma hereditario tienen un aumento marcado de la incidencia de NS, que es independiente del tratamiento con radioterapia.[<a href="#cit/section_1.22">22</a>,<a href="#cit/section_1.23">23</a>,<a href="#cit/section_1.31">31</a>] En una serie alemana de 643 pacientes con retinoblastoma hereditario, la quimioterapia con radioterapia, o sin esta, fue el &#xFA;nico factor de riesgo significativo de inicio de segundos c&#xE1;nceres fuera de la regi&#xF3;n periorbitaria.[<a href="#cit/section_1.23">23</a>] Es posible que haya una relaci&#xF3;n entre el tipo de mutaci&#xF3;n en <em>RB1</em> y la incidencia de NS; la p&#xE9;rdida completa de actividad en <em>RB1</em> se relaciona con una incidencia m&#xE1;s alta de NS.[<a href="#cit/section_1.32">32</a>] Con el aumento de la supervivencia de los pacientes de retinoblastoma hereditario, se ha hecho evidente que ellos tambi&#xE9;n est&#xE1;n en riesgo de c&#xE1;nceres epiteliales tarde en la edad adulta. Se ha descrito un marcado aumento de mortalidad por c&#xE1;ncer de pulm&#xF3;n, vejiga y otros c&#xE1;nceres epiteliales.[<a href="#cit/section_1.33">33</a>,<a href="#cit/section_1.34">34</a>]<p id="_864" tabindex="-1"> Entre los sobrevivientes de retinoblastoma hereditario, las personas con una mutaci&#xF3;n heredada en la l&#xED;nea germinal tienen un riesgo un poco m&#xE1;s alto de NS que las que tienen una mutaci&#xF3;n <em>de novo</em>; seg&#xFA;n parece este aumento es m&#xE1;s importante para el melanoma.[<a href="#cit/section_1.35">35</a>]</p></li><li><strong>Tratamiento previo del retinoblastoma con radioterapia.</strong> Se notific&#xF3; que la incidencia acumulada de NS es de 26&#xA0;% (&#xB1; 10&#xA0;%) en pacientes no irradiados y de 58&#xA0;% (&#xB1; 10&#xA0;%) en pacientes irradiados, 50
            a&#xF1;os despu&#xE9;s del diagn&#xF3;stico de retinoblastoma &#x2014;una tasa anual de alrededor de 1&#xA0;%&#x2014;.[<a href="#cit/section_1.36">36</a>] En una serie alemana de 633 pacientes con retinoblastoma hereditario se observ&#xF3; una supervivencia a 5 a&#xF1;os de 93&#xA0;%; no obstante, 40 a&#xF1;os despu&#xE9;s, solo 80&#xA0;% de los pacientes sobrevivieron,  la mayor&#xED;a padeci&#xF3; de NS causadas por radiaci&#xF3;n  (cociente de riesgos instant&#xE1;neos, aproximadamente 3).[<a href="#cit/section_1.37">37</a>] En otros estudios, en los que se analizaron cohortes de pacientes que recibieron radioterapia con  planificaci&#xF3;n y t&#xE9;cnicas de administraci&#xF3;n m&#xE1;s avanzadas, se notificaron tasas de NS de alrededor de 9,4&#xA0;% en pacientes no irradiados y de 30,4&#xA0;% en pacientes irradiados.[<a href="#cit/section_1.38">38</a>] En un estudio sin aleatorizaci&#xF3;n en el que se compararon dos cohortes contempor&#xE1;neas de pacientes con retinoblastoma hereditario tratados con terapia con fotones (n = 31) o terapia con protones (n = 55), la incidencia acumulada a 10 a&#xF1;os de NS fue significativamente diferente en los dos grupos (0&#xA0;% para la radiaci&#xF3;n con protones vs. 14&#xA0;% para la radiaci&#xF3;n con fotones, <em>P</em> = 0,015).[<a href="#cit/section_1.39">39</a>] Se necesitar&#xE1; un seguimiento m&#xE1;s prolongado para definir mejor el riesgo de NS relacionadas con la radiaci&#xF3;n con protones.<p id="_754" tabindex="-1">La NS m&#xE1;s com&#xFA;n es el sarcoma, en especial, el osteosarcoma, seguido de sarcoma de tejido blando y melanoma; si bien estas neoplasias malignas se pueden presentar dentro y fuera del campo de radiaci&#xF3;n, la mayor&#xED;a son inducidas por la radiaci&#xF3;n. El efecto cancer&#xED;geno de la radioterapia se relaciona con la dosis administrada, en particular, para sarcomas subsiguientes; se observa un aumento por etapas en todas las categor&#xED;as de dosis. En pacientes irradiados, dos tercios de las NS se presentan dentro del tejido irradiado y un tercio, fuera del campo de radiaci&#xF3;n.[<a href="#cit/section_1.31">31</a>,<a href="#cit/section_1.36">36</a>,<a href="#cit/section_1.38">38</a>,<a href="#cit/section_1.40">40</a>]</p></li><li><strong>Edad en el momento de la radioterapia.</strong> Al parecer el riesgo de NS depende de la edad del paciente en el momento en que se administra la radioterapia de haz externo (RHE); en particular, en ni&#xF1;os menores de 12 meses; adem&#xE1;s la edad parece afectar los tipos histopatol&#xF3;gicos de NS.[<a href="#cit/section_1.38">38</a>,<a href="#cit/section_1.41">41</a>,<a href="#cit/section_1.42">42</a>]</li><li><strong>NS previas.</strong> Quienes sobreviven a una NS tienen un riesgo siete veces mayor de presentar otra NS.[<a href="#cit/section_1.43">43</a>] El riesgo aumenta tres veces m&#xE1;s para los pacientes que reciben radioterapia.[<a href="#cit/section_1.44">44</a>]</li></ul></div><p id="_865" tabindex="-1">La cuesti&#xF3;n del equilibrio entre el control tumoral a largo plazo y las consecuencias de la quimioterapia no se ha resuelto. La mayor&#xED;a de los pacientes que reciben quimioterapia se exponen a etop&#xF3;sido, que se ha relacionado con leucemia secundaria en pacientes sin predisposici&#xF3;n al c&#xE1;ncer, pero en tasas moderadas en comparaci&#xF3;n con los riesgos vinculados a la RHE para el retinoblastoma hereditario. A pesar de que se sabe del aumento de riesgo de leucemia mieloide aguda  (LMA) relacionado con el empleo de etop&#xF3;sido, los pacientes con retinoblastoma hereditario no tienen riesgo alto de padecer esta NS.[<a href="#cit/section_1.45">45</a>-<a href="#cit/section_1.47">47</a>] En un informe inicial realizado mediante encuestas informales, se describi&#xF3; a 15 pacientes que presentaron LMA despu&#xE9;s de la quimioterapia. La mitad de los pacientes tambi&#xE9;n recibieron radioterapia.[<a href="#cit/section_1.46">46</a>] Este hallazgo no se corrobor&#xF3; en estudios formales. En un estudio de una sola instituci&#xF3;n con 245 pacientes que recibieron etop&#xF3;sido, solo 1 paciente padeci&#xF3; de leucemia promieloc&#xED;tica aguda despu&#xE9;s de  79 meses.[<a href="#cit/section_1.45">45</a>] Adem&#xE1;s, en el Surveillance, Epidemiology, and End Result Registry (SEER) Program se calcularon las tasas de incidencia estandarizadas de neoplasias malignas hematopoy&#xE9;ticas secundarias en 34&#xA0;867 sobrevivientes de c&#xE1;ncer infantil. El cociente entre la incidencia  observada y la esperada de LMA secundaria en pacientes que recibieron tratamiento para retinoblastoma fue de 0.[<a href="#cit/section_1.48">48</a>]</p><p id="_756" tabindex="-1">La supervivencia a partir de NS es definitivamente sub&#xF3;ptima y var&#xED;a ampliamente entre los estudios.[<a href="#cit/section_1.33">33</a>,<a href="#cit/section_1.49">49</a>-<a href="#cit/section_1.53">53</a>] Sin embargo, dados los avances en el tratamiento, es fundamental que todas las NS en los sobrevivientes de retinoblastoma se traten con intenci&#xF3;n de curar.[<a href="#cit/section_1.54">54</a>]</p></section></section><section id="_525"><h3 id="_525_toc">Efectos tard&#xED;os del tratamiento del retinoblastoma</h3><p id="_866" tabindex="-1">En un informe del Retinoblastoma Survivor Study (N = 470), 87&#xA0;% de los sobrevivientes de retinoblastoma (mediana de edad, 43 a&#xF1;os; mediana de seguimiento, 42 a&#xF1;os) presentaron al menos una afecci&#xF3;n y 71&#xA0;% padecieron una afecci&#xF3;n potencialmente mortal.  El riesgo relativo ajustado de padecer de una afecci&#xF3;n cr&#xF3;nica en los sobrevivientes, comparado con el riesgo de los controles sin retinoblastoma, fue de 1,4 (<em>P</em> &lt; 0,01); el riesgo relativo de una afecci&#xF3;n de grado 3 o 4 fue de 7,6 (<em>P</em> &lt; 0,01).  Despu&#xE9;s de excluir las afecciones oculares y las NS, se encontr&#xF3; que este riesgo excesivo solo persisti&#xF3; en los pacientes con enfermedad bilateral.[<a href="#cit/section_1.55">55</a>]</p><p id="_757" tabindex="-1">Como se indic&#xF3; m&#xE1;s arriba, los pacientes de retinoblastoma hereditario tienen un aumento de la incidencia de NS. (Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n  sobre <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_499">Neoplasias subsiguientes</a> en la secci&#xF3;n <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_493">Causas de la mortalidad relacionada con el retinoblastoma</a> de este sumario). Otros efectos tard&#xED;os que se presentan despu&#xE9;s del tratamiento del retinoblastoma son los siguientes:</p><div class="pdq-content-list"><ul id="_758"><li><strong>Disminuci&#xF3;n del crecimiento orbitario.</strong> El crecimiento orbitario disminuye, en cierta medida, despu&#xE9;s de la enucleaci&#xF3;n; sin embargo, el efecto de la enucleaci&#xF3;n en el volumen orbitario puede ser menor despu&#xE9;s de la colocaci&#xF3;n de un implante orbitario.[<a href="#cit/section_1.56">56</a>]</li><li><strong>Deficiencia del campo visual.</strong> Los pacientes de retinoblastoma presentan una variedad de efectos visuales a largo plazo despu&#xE9;s del tratamiento de su enfermedad intraocular. Estos defectos se relacionan con el tama&#xF1;o del tumor, su ubicaci&#xF3;n y el m&#xE9;todo de tratamiento.[<a href="#cit/section_1.57">57</a>]<p id="_759" tabindex="-1">Se realiz&#xF3; un estudio de agudeza visual despu&#xE9;s del tratamiento con quimioterapia sist&#xE9;mica y terapia oft&#xE1;lmica local en 54 ojos de 40 ni&#xF1;os. Despu&#xE9;s de una media de seguimiento de 68 meses, 27 ojos (50&#xA0;%) tuvieron una agudeza visual final de 20/40 o mejor, y 36 ojos (67&#xA0;%) una agudeza visual final de 20/200 o mejor. Los factores cl&#xED;nicos que permitieron pronosticar una agudeza visual de 20/40 o mejor fueron un margen tumoral de por lo menos 3&#xA0;mm desde la fov&#xE9;ola y la papila &#xF3;ptica, y la ausencia de l&#xED;quido subretiniano.[<a href="#cit/section_1.58">58</a>]</p></li><li><strong>Hipoacusia.</strong> Debido a que el carboplatino sist&#xE9;mico se usa con regularidad en el tratamiento del retinoblastoma (para obtener m&#xE1;s informaci&#xF3;n, consultar las secciones de este sumario sobre <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_780">Tratamiento del retinoblastoma intraocular</a>, y <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_77">Tratamiento del retinoblastoma extraocular</a>), surgi&#xF3; una preocupaci&#xF3;n sobre la hipoacusia relacionada con el tratamiento. Pese a que en 2 estudios numerosos de ni&#xF1;os sometidos a 6 ciclos de terapia con carboplatino (18,6 mg/kg por ciclo), se observ&#xF3; una incidencia menor del 1&#xA0;% de hipoacusia relacionada con el tratamiento,[<a href="#cit/section_1.59">59</a>,<a href="#cit/section_1.60">60</a>] en una serie diferente se document&#xF3; cierto grado de hipoacusia en 17&#xA0;% de los pacientes.[<a href="#cit/section_1.61">61</a>] En un estudio posterior, la edad menor de 6 meses en el momento del tratamiento y las exposiciones a dosis m&#xE1;s altas de carboplatino sist&#xE9;mico se correlacionaron con un riesgo m&#xE1;s elevado de ototoxicidad.[<a href="#cit/section_1.61">61</a>,<a href="#cit/section_1.62">62</a>]</li></ul></div><p id="_867" tabindex="-1">Para obtener informaci&#xF3;n espec&#xED;fica sobre la incidencia, el tipo y la vigilancia de los efectos tard&#xED;os en la ni&#xF1;ez y adolescencia, consultar el sumario del PDQ <a href="/espanol/tipos/infantil/efectos-tardios-pro-pdq">Efectos tard&#xED;os del tratamiento anticanceroso en la ni&#xF1;ez</a>.</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_1.1">Ries LA, Smith MA, Gurney JG, et al., eds.: Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. Bethesda, Md: National Cancer Institute, SEER Program, 1999. NIH Pub.No. 99-4649. <a href="https://seer.cancer.gov/archive/publications/childhood/" title="https://seer.cancer.gov/archive/publications/childhood/">Also available online.</a> Last accessed August 16, 2018.</li><li id="section_1.2">Rothschild PR, L&#xE9;vy D, Savignoni A, et al.: Familial retinoblastoma: fundus screening schedule impact and guideline proposal. A retrospective study. Eye (Lond) 25 (12): 1555-61, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21921957&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21921957&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.3">Truong B, Green AL, Friedrich P, et al.: Ethnic, Racial, and Socioeconomic Disparities in Retinoblastoma. JAMA Pediatr 169 (12): 1096-104, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26436436&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26436436&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.4">Khurana A, Eisenhut CA, Wan W, et al.: Comparison of the diagnostic value of MR imaging and ophthalmoscopy for the staging of retinoblastoma. Eur Radiol 23 (5): 1271-80, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23160663&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23160663&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.5">Laurent VE, Sampor C, Solernou V, et al.: Detection of minimally disseminated disease in the cerebrospinal fluid of children with high-risk retinoblastoma by reverse transcriptase-polymerase chain reaction for GD2 synthase mRNA. Eur J Cancer 49 (13): 2892-9, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23721779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23721779&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.6">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.7">Cast&#xE9;ra L, Sabbagh A, Dehainault C, et al.: MDM2 as a modifier gene in retinoblastoma. J Natl Cancer Inst 102 (23): 1805-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21051655&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21051655&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.8">de Oliveira Reis AH, de Carvalho IN, de Sousa Damasceno PB, et al.: Influence of MDM2 and MDM4 on development and survival in hereditary retinoblastoma. Pediatr Blood Cancer 59 (1): 39-43, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22180099&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22180099&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.9">Zajaczek S, Jakubowska A, Kurzawski G, et al.: Age at diagnosis to discriminate those patients for whom constitutional DNA sequencing is appropriate in sporadic unilateral retinoblastoma. Eur J Cancer 34 (12): 1919-21, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10023315&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10023315&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.10">Zhang J, Benavente CA, McEvoy J, et al.: A novel retinoblastoma therapy from genomic and epigenetic analyses. Nature 481 (7381): 329-34, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22237022&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22237022&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.11">Rushlow DE, Mol BM, Kennett JY, et al.: Characterisation of retinoblastomas without RB1 mutations: genomic, gene expression, and clinical studies. Lancet Oncol 14 (4): 327-34, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23498719&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23498719&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.12">McEvoy J, Nagahawatte P, Finkelstein D, et al.: RB1 gene inactivation by chromothripsis in human retinoblastoma. Oncotarget 5 (2): 438-50, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24509483&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24509483&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.13">Ewens KG, Bhatti TR, Moran KA, et al.: Phosphorylation of pRb: mechanism for RB pathway inactivation in MYCN-amplified retinoblastoma. Cancer Med 6 (3): 619-630, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28211617&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28211617&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.14">Abramson DH, Mendelsohn ME, Servodidio CA, et al.: Familial retinoblastoma: where and when? Acta Ophthalmol Scand 76 (3): 334-8, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9686848&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9686848&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.15">Clark R: Retinoblastoma: genetic testing and counseling. In: Singh A, Damato B: Clinical Ophthalmic Oncology. Philadelphia, Pa: Saunders Elsevier, 2007, pp 441-6.</li><li id="section_1.16">Amitrano S, Marozza A, Somma S, et al.: Next generation sequencing in sporadic retinoblastoma patients reveals somatic mosaicism. Eur J Hum Genet 23 (11): 1523-30, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25712084&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25712084&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.17">Richter S, Vandezande K, Chen N, et al.: Sensitive and efficient detection of RB1 gene mutations enhances care for families with retinoblastoma. Am J Hum Genet 72 (2): 253-69, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12541220&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12541220&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.18">Sagi M, Frenkel A, Eilat A, et al.: Genetic screening in patients with Retinoblastoma in Israel. Fam Cancer 14 (3): 471-80, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25754945&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25754945&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.19">Nichols KE, Houseknecht MD, Godmilow L, et al.: Sensitive multistep clinical molecular screening of 180 unrelated individuals with retinoblastoma detects 36 novel mutations in the RB1 gene. Hum Mutat 25 (6): 566-74, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15884040&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15884040&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.20">Dommering CJ, Mol BM, Moll AC, et al.: RB1 mutation spectrum in a comprehensive nationwide cohort of retinoblastoma patients. J Med Genet 51 (6): 366-74, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24688104&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24688104&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.21">Eloy P, Dehainault C, Sefta M, et al.: A Parent-of-Origin Effect Impacts the Phenotype in Low Penetrance Retinoblastoma Families Segregating the c.1981C&gt;T/p.Arg661Trp Mutation of RB1. PLoS Genet 12 (2): e1005888, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925970&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26925970&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.22">Shinohara ET, DeWees T, Perkins SM: Subsequent malignancies and their effect on survival in patients with retinoblastoma. Pediatr Blood Cancer 61 (1): 116-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23918737&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23918737&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.23">Temming P, Arendt M, Viehmann A, et al.: Incidence of second cancers after radiotherapy and systemic chemotherapy in heritable retinoblastoma survivors: A report from the German reference center. Pediatr Blood Cancer 64 (1): 71-80, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27567086&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27567086&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.24">Broaddus E, Topham A, Singh AD: Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93 (1): 24-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.25">de Jong MC, Kors WA, de Graaf P, et al.: Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 15 (10): 1157-67, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.26">Blach LE, McCormick B, Abramson DH, et al.: Trilateral retinoblastoma--incidence and outcome: a decade of experience. Int J Radiat Oncol Biol Phys 29 (4): 729-33, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.27">Rodjan F, de Graaf P, Brisse HJ, et al.: Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission. J Neurooncol 109 (3): 535-44, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.28">Kivel&#xE4; T: Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 17 (6): 1829-37, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.29">Sirin S, de Jong MC, Galluzzi P, et al.: MRI-based assessment of the pineal gland in a large population of children aged 0-5&#xA0;years and comparison with pineoblastoma: part II, the cystic gland. Neuroradiology 58 (7): 713-21, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27130617&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27130617&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.30">Pham TT, Siebert E, Asbach P, et al.: Magnetic resonance imaging based morphologic evaluation of the pineal gland for suspected pineoblastoma in retinoblastoma patients and age-matched controls. J Neurol Sci 359 (1-2): 185-92, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26671110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26671110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.31">MacCarthy A, Bayne AM, Brownbill PA, et al.: Second and subsequent tumours among 1927 retinoblastoma patients diagnosed in Britain 1951-2004. Br J Cancer 108 (12): 2455-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23674091&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23674091&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.32">Dommering CJ, Marees T, van der Hout AH, et al.: RB1 mutations and second primary malignancies after hereditary retinoblastoma. Fam Cancer 11 (2): 225-33, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205104&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22205104&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.33">Fletcher O, Easton D, Anderson K, et al.: Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst 96 (5): 357-63, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14996857&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14996857&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.34">Marees T, van Leeuwen FE, de Boer MR, et al.: Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer 45 (18): 3245-53, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19493675&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19493675&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.35">Kleinerman RA, Yu CL, Little MP, et al.: Variation of second cancer risk by family history of retinoblastoma among long-term survivors. J Clin Oncol 30 (9): 950-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22355046&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22355046&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.36">Wong FL, Boice JD Jr, Abramson DH, et al.: Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 278 (15): 1262-7, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9333268&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9333268&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.37">Temming P, Arendt M, Viehmann A, et al.: How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. J Clin Oncol 34 (26): 3183-8, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.38">Kleinerman RA, Tucker MA, Tarone RE, et al.: Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 23 (10): 2272-9, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15800318&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15800318&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.39">Sethi RV, Shih HA, Yeap BY, et al.: Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 120 (1): 126-33, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.40">Kleinerman RA, Tucker MA, Abramson DH, et al.: Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst 99 (1): 24-31, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17202110&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17202110&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.41">Abramson DH, Frank CM: Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology 105 (4): 573-9; discussion 579-80, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9544627&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9544627&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.42">Moll AC, Imhof SM, Schouten-Van Meeteren AY, et al.: Second primary tumors in hereditary retinoblastoma: a register-based study, 1945-1997: is there an age effect on radiation-related risk? Ophthalmology 108 (6): 1109-14, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11382638&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11382638&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.43">Abramson DH, Melson MR, Dunkel IJ, et al.: Third (fourth and fifth) nonocular tumors in survivors of retinoblastoma. Ophthalmology 108 (10): 1868-76, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11581064&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11581064&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.44">Marees T, van Leeuwen FE, Schaapveld M, et al.: Risk of third malignancies and death after a second malignancy in retinoblastoma survivors. Eur J Cancer 46 (11): 2052-8, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20400293&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20400293&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.45">Turaka K, Shields CL, Meadows AT, et al.: Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer 59 (1): 121-5, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21826785&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21826785&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.46">Gombos DS, Hungerford J, Abramson DH, et al.: Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology 114 (7): 1378-83, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17613328&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17613328&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.47">Tamboli D, Topham A, Singh N, et al.: Retinoblastoma: A SEER Dataset Evaluation for Treatment Patterns, Survival, and Second Malignant Neoplasms. Am J Ophthalmol 160 (5): 953-8, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26255575&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26255575&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.48">Rihani R, Bazzeh F, Faqih N, et al.: Secondary hematopoietic malignancies in survivors of childhood cancer: an analysis of 111 cases from the Surveillance, Epidemiology, and End Result-9 registry. Cancer 116 (18): 4385-94, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20549819&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20549819&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.49">Yu CL, Tucker MA, Abramson DH, et al.: Cause-specific mortality in long-term survivors of retinoblastoma. J Natl Cancer Inst 101 (8): 581-91, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19351917&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19351917&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.50">Aerts I, Pacquement H, Doz F, et al.: Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 40 (10): 1522-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15196536&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15196536&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.51">Eng C, Li FP, Abramson DH, et al.: Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst 85 (14): 1121-8, 1993.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8320741&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8320741&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.52">Dunkel IJ, Gerald WL, Rosenfield NS, et al.: Outcome of patients with a history of bilateral retinoblastoma treated for a second malignancy: the Memorial Sloan-Kettering experience. Med Pediatr Oncol 30 (1): 59-62, 1998.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9371391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9371391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.53">Marees T, Moll AC, Imhof SM, et al.: Risk of second malignancies in survivors of retinoblastoma: more than 40 years of follow-up. J Natl Cancer Inst 100 (24): 1771-9, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19066271&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19066271&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.54">Moll AC, Imhof SM, Bouter LM, et al.: Second primary tumors in patients with retinoblastoma. A review of the literature. Ophthalmic Genet 18 (1): 27-34, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9134547&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9134547&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.55">Friedman DN, Chou JF, Oeffinger KC, et al.: Chronic medical conditions in adult survivors of retinoblastoma: Results of the Retinoblastoma Survivor Study. Cancer 122 (5): 773-81, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26755259&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26755259&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.56">Chojniak MM, Chojniak R, Testa ML, et al.: Abnormal orbital growth in children submitted to enucleation for retinoblastoma treatment. J Pediatr Hematol Oncol 34 (3): e102-5, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22258347&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22258347&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.57">Abramson DH, Melson MR, Servodidio C: Visual fields in retinoblastoma survivors. Arch Ophthalmol 122 (9): 1324-30, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364711&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364711&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.58">Demirci H, Shields CL, Meadows AT, et al.: Long-term visual outcome following chemoreduction for retinoblastoma. Arch Ophthalmol 123 (11): 1525-30, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16286614&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16286614&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.59">Lambert MP, Shields C, Meadows AT: A retrospective review of hearing in children with retinoblastoma treated with carboplatin-based chemotherapy. Pediatr Blood Cancer 50 (2): 223-6, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17278120&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17278120&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.60">Batra A, Thakar A, Bakhshi S: Ototoxicity in retinoblastoma survivors treated with carboplatin based chemotherapy: A cross-sectional study of 116 patients. Pediatr Blood Cancer 62 (11): 2060, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26053139&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26053139&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.61">Qaddoumi I, Bass JK, Wu J, et al.: Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol 30 (10): 1034-41, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370329&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370329&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_1.62">Leahey A: A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol 30 (10): 1023-4, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370322&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22370322&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _13
      field_pdq_section_title:
        - format: plain_text
          value: 'Características patológicas tumorales del retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_13" class="pdq-sections"><p id="_14" tabindex="-1">El retinoblastoma surge en las c&#xE9;lulas precursoras de los conos retinianos.[<a href="#cit/section_2.1">1</a>] Desde el punto de vista microsc&#xF3;pico, el aspecto del retinoblastoma depende del grado de diferenciaci&#xF3;n. El retinoblastoma indiferenciado se compone de paquetes densos de c&#xE9;lulas peque&#xF1;as, redondas, con n&#xFA;cleos hipocr&#xF3;micos y citoplasma escaso. Se describieron varios grados de diferenciaci&#xF3;n de los fotorreceptores que se caracterizan por distribuciones caracter&#xED;sticas de las c&#xE9;lulas tumorales que se describen a continuaci&#xF3;n:</p><div class="pdq-content-list"><ul id="_868"><li>Las rosetas de Flexner-Wintersteiner son espec&#xED;ficas del retinoblastoma; estas estructuras se componen de un grupo de c&#xE9;lulas cil&#xED;ndricas cortas, dispuestas alrededor de un lumen central delimitado por una membrana eosinof&#xED;lica an&#xE1;loga a la membrana externa de la retina normal. El lumen contiene rosetas que se observan en 70&#xA0;% de los tumores.</li><li>Las rosetas de Homer Wright se componen de anillos irregulares de c&#xE9;lulas tumorales dispuestas alrededor de una mara&#xF1;a de fibrillas sin lumen ni membrana interna limitante. Las rosetas de Homer Wright no se suelen observar en el retinoblastoma y se ven m&#xE1;s a menudo en otros tumores neurobl&#xE1;sticos, como el neuroblastoma y meduloblastoma.</li></ul></div><p id="_760" tabindex="-1">Los retinoblastomas se caracterizan por una proliferaci&#xF3;n celular marcada, como lo demuestra el recuento alto de mitosis e &#xED;ndices de rotulaci&#xF3;n MIB-1 extremadamente altos, as&#xED; como una inmunorreactividad nuclear difusa potente para la homeosecuencia de conos y bastones, que tambi&#xE9;n se conoce como <em>CRX</em>, un marcador &#xFA;til para discriminar un retinoblastoma de otros tumores malignos de c&#xE9;lulas peque&#xF1;as y redondas.[<a href="#cit/section_2.2">2</a>,<a href="#cit/section_2.3">3</a>]</p><p id="_761" tabindex="-1">El retinoblastoma cavitario, una variante poco frecuente de retinoblastoma, presenta cavidades transl&#xFA;cidas intratumorales visibles mediante oftalmoscopia. Los espacios cavitarios se ven como huecos en la ecograf&#xED;a y son hipofluorescentes en la angiograf&#xED;a. Desde el punto de vista histopatol&#xF3;gico, se ha observado que los espacios cavitarios representan &#xE1;reas de diferenciaci&#xF3;n de fotorreceptores.[<a href="#cit/section_2.4">4</a>] Estos tumores se relacionaron con una m&#xED;nima respuesta tumoral visible a la quimioterapia, lo que se piensa que es un signo de diferenciaci&#xF3;n tumoral.[<a href="#cit/section_2.5">5</a>]</p><p id="_869" tabindex="-1">Un pat&#xF3;logo con experiencia en patolog&#xED;a ocular y retinoblastoma debe examinar el esp&#xE9;cimen de enucleaci&#xF3;n. Este an&#xE1;lisis patol&#xF3;gico es especialmente importante para determinar las caracter&#xED;sticas de riesgo  de diseminaci&#xF3;n extraocular (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_780">Tratamiento del retinoblastoma intraocular</a>).</p><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_2.1">Xu XL, Singh HP, Wang L, et al.: Rb suppresses human cone-precursor-derived retinoblastoma tumours. Nature 514 (7522): 385-8, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25252974&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25252974&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.2">Terry J, Calicchio ML, Rodriguez-Galindo C, et al.: Immunohistochemical expression of CRX in extracranial malignant small round cell tumors. Am J Surg Pathol 36 (8): 1165-9, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22790857&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22790857&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.3">Schwimer CJ, Prayson RA: Clinicopathologic study of retinoblastoma including MIB-1, p53, and CD99 immunohistochemistry. Ann Diagn Pathol 5 (3): 148-54, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11436168&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11436168&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.4">Palamar M, Pirondini C, Shields CL, et al.: Cavitary retinoblastoma: ultrasonographic and fluorescein angiographic findings in 3 cases. Arch Ophthalmol 126 (11): 1598-600, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19001231&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19001231&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_2.5">Mashayekhi A, Shields CL, Eagle RC Jr, et al.: Cavitary changes in retinoblastoma: relationship to chemoresistance. Ophthalmology 112 (6): 1145-50, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15885779&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15885779&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _15
      field_pdq_section_title:
        - format: plain_text
          value: 'Sistemas de estadificación y agrupación del retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_15" class="pdq-sections"><p id="_762" tabindex="-1">La estadificaci&#xF3;n de los pacientes de retinoblastoma exige una estrecha coordinaci&#xF3;n de radi&#xF3;logos, onc&#xF3;logos pediatras y oftalm&#xF3;logos. Se han propuesto varios sistemas de estadificaci&#xF3;n y agrupaci&#xF3;n del retinoblastoma.[<a href="#cit/section_3.1">1</a>] La evaluaci&#xF3;n general de la extensi&#xF3;n del retinoblastoma se documenta mediante sistemas de estadificaci&#xF3;n; la extensi&#xF3;n intraocular, que es importante para el rescate ocular, se documenta mediante sistemas de agrupaci&#xF3;n. Para prop&#xF3;sitos de tratamiento, el retinoblastoma se clasifica
            como enfermedad intraocular y enfermedad extraocular.</p><section id="_17"><h3 id="_17_toc">Retinoblastoma intraocular</h3><p id="_19" tabindex="-1">El retinoblastoma intraocular se localiza en el ojo, se puede limitar a la retina, o diseminar hasta comprometer otras estructuras, como la coroides, el cuerpo ciliar, la c&#xE1;mara anterior y la papila &#xF3;ptica. Sin embargo, el retinoblastoma intraocular no se disemina m&#xE1;s all&#xE1; del ojo hacia los tejidos circundantes u otras partes del cuerpo.</p></section><section id="_20"><h3 id="_20_toc">Retinoblastoma extraocular</h3><p id="_22" tabindex="-1">El retinoblastoma extraocular se extiende fuera del ojo. Se puede limitar a los tejidos alrededor del ojo (retinoblastoma orbitario), diseminar por el sistema nervioso central (SNC), o de manera sist&#xE9;mica a la m&#xE9;dula &#xF3;sea o los ganglios linf&#xE1;ticos (retinoblastoma metast&#xE1;sico).</p></section><section id="_613"><h3 id="_613_toc">Sistemas de estadificaci&#xF3;n</h3><section id="_607"><h4 id="_607_toc">Sistema de estadificaci&#xF3;n del American Joint Committee on Cancer</h4><p id="_608" tabindex="-1">En los &#xFA;ltimos a&#xF1;os se propusieron varios sistemas de estadificaci&#xF3;n. Las clasificaciones cl&#xED;nicas y patol&#xF3;gicas del American Joint Committee on Cancer (AJCC) representan una opini&#xF3;n de consenso en torno a la que se utiliza un lenguaje com&#xFA;n. Sin embargo, en la actualidad el sistema de estadificaci&#xF3;n de TNM (tumor, ganglio linf&#xE1;tico, met&#xE1;stasis) del AJCC no se utiliza mucho para el retinoblastoma infantil y los pacientes no se estratifican a partir de los grupos de estadio pron&#xF3;stico.</p></section><section id="_611"><h4 id="_611_toc">International Retinoblastoma Staging System</h4><p id="_612" tabindex="-1">Un consorcio internacional de oftalm&#xF3;logos y onc&#xF3;logos pediatras propuso una versi&#xF3;n m&#xE1;s simple, el International Retinoblastoma Staging System (IRSS);[<a href="#cit/section_3.2">2</a>] este se utiliza mucho m&#xE1;s en el entorno cl&#xED;nico que el sistema de estadificaci&#xF3;n del AJCC (consultar el <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_631">Cuadro 1</a>). En un estudio retrospectivo alem&#xE1;n se encontr&#xF3; que el  IRSS permiti&#xF3; predecir la supervivencia de 633 ni&#xF1;os con retinoblastoma hereditario, entre ellos, 582 pacientes que presentaron enfermedad en estadio IRSS 0 o I.[<a href="#cit/section_3.3">3</a>]</p><table id="_631" class="table-default expandable-container"><caption>Cuadro  1.  International Retinoblastoma Staging System</caption><colgroup><col width="25.00%"><col width="25.00%"><col width="25.00%"><col width="25.00%"></colgroup>
            <THead>
            <tr>
            <th>Estadio</th>
            <th colspan="3">Descripci&#xF3;n</th>
            </tr>
            </THead>
            <TFoot class="pdq-footer">
            <tr>
            <td colspan="4">LCR = l&#xED;quido cefalorraqu&#xED;deo; SNC = sistema nervioso central.</td>
            </tr>
            </TFoot>
            <tbody>
            <tr>
            <td>Estadio 0</td>
            <td colspan="3">El ojo no se someti&#xF3; a enucleaci&#xF3;n y no hay diseminaci&#xF3;n de la enfermedad (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_509">International Classification of Retinoblastoma</a>).</td>
            </tr>
            <tr>
            <td>Estadio I</td>
            <td colspan="3">Ojo enucleado, con resecci&#xF3;n histol&#xF3;gica completa</td>
            </tr>
            <tr>
            <td>Estadio II</td>
            <td colspan="3">Ojo enucleado, tumor residual microsc&#xF3;pico</td>
            </tr>
            <tr>
            <td rowspan="2">Estadio III</td>
            <td rowspan="2">Diseminaci&#xF3;n regional</td>
            <td colspan="2">a. Enfermedad orbitaria manifiesta</td>
            </tr>
            <tr>
            <td colspan="2">b. Diseminaci&#xF3;n a ganglio linf&#xE1;tico periauricular o cervical</td>
            </tr>
            <tr>
            <td rowspan="7">Estadio IV</td>
            <td rowspan="7">Enfermedad metast&#xE1;sica</td>
            <td colspan="2">a. Met&#xE1;stasis hem&#xE1;tica (sin compromiso del SNC)</td>
            </tr>
            <tr>
            <td colspan="2">&#x2014;Lesi&#xF3;n &#xFA;nica</td>
            </tr><tr><td colspan="2">&#x2014;Lesiones m&#xFA;ltiples</td></tr>
            <tr>
            <td colspan="2">b. Diseminaci&#xF3;n al SNC (con cualquier otro sitio de enfermedad regional o metast&#xE1;sica, o sin este)</td>
            </tr>
            <tr>
            <td colspan="2">&#x2014;Lesi&#xF3;n prequiasm&#xE1;tica </td>
            </tr><tr><td colspan="2">&#x2014;Masa en el SNC </td></tr><tr><td colspan="2">&#x2014;Enfermedad leptomen&#xED;ngea y en el LCR</td></tr>
            </tbody>
            </table></section></section><section id="_614"><h3 id="_614_toc">Sistemas de agrupaci&#xF3;n</h3><p id="_615" tabindex="-1">Los sistemas de agrupaci&#xF3;n son importantes para evaluar la diseminaci&#xF3;n intraocular de la enfermedad y son &#xFA;tiles para pronosticar un rescate ocular.</p><section id="_23"><h4 id="_23_toc">Reese-Ellsworth Classification for Intraocular Tumors</h4><p id="_24" tabindex="-1">   Reese y Ellsworth formularon un sistema de clasificaci&#xF3;n para el retinoblastoma intraocular que demostr&#xF3; importancia pron&#xF3;stica para el  mantenimiento de la vista y el control de la enfermedad local en la &#xE9;poca en que la cirug&#xED;a y la radioterapia de haz externo (RHE) eran las opciones principales de tratamiento. Sin embargo, los avances en el tratamiento conservador del retinoblastoma intraocular han hecho que el <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=782667&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000782667&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=NotSet'); return(false);">Sistema de clasificaci&#xF3;n de Reese-Ellsworth</a> sea menos pron&#xF3;stico del rescate ocular y menos &#xFA;til para guiar el tratamiento.[<a href="#cit/section_3.4">4</a>] Este sistema de agrupaci&#xF3;n se usa con poca frecuencia.</p></section><section id="_509"><h4 id="_509_toc">International Classification of Retinoblastoma</h4><p id="_510" tabindex="-1"> El nuevo sistema de estadificaci&#xF3;n International Classification of Retinoblastoma se formul&#xF3; con el objetivo de proporcionar una clasificaci&#xF3;n m&#xE1;s simple y f&#xE1;cil de usar que se pueda aplicar mejor a los tratamientos actuales. Este nuevo sistema se basa en la extensi&#xF3;n de la diseminaci&#xF3;n tumoral dentro de la cavidad v&#xED;trea y el espacio subretiniano, en lugar del tama&#xF1;o y la ubicaci&#xF3;n del tumor; este sistema parece pronosticar mejor el &#xE9;xito del tratamiento.[<a href="#cit/section_3.4">4</a>-<a href="#cit/section_3.7">7</a>] Asimismo, el sistema International Classification of Retinoblastoma permite pronosticar las caracter&#xED;sticas histopatol&#xF3;gicas de riesgo alto. En un estudio de m&#xE1;s de 500 pacientes de retinoblastoma, se observaron hallazgos histopatol&#xF3;gicos de enfermedad de riesgo alto en 17&#xA0;% de los ojos del Grupo D y en 24&#xA0;% de los ojos del Grupo E, lo que parece ser &#xFA;til para asesorar a los padres sobre la posible necesidad de tratamiento sist&#xE9;mico posoperatorio.[<a href="#cit/section_3.8">8</a>]</p><div class="pdq-content-list"><ul id="_511"><li><em><strong>Grupo A:</strong></em> tumores intrarretinianos peque&#xF1;os fuera de la fov&#xE9;ola y la papila &#xF3;ptica.<div class="pdq-content-list"><ul id="_216" class="list-dash"><li>Todos los tumores miden 3 mm o menos en su dimensi&#xF3;n mayor, se limitan a la retina <em>y</em></li><li>Todos los tumores se localizan a m&#xE1;s de 3 mm de la fov&#xE9;ola y a 1,5 mm de la papila &#xF3;ptica.</li></ul></div></li><li><em><strong>Grupo B:</strong></em> todos los tumores aislados se limitan a la retina.<div class="pdq-content-list"><ul id="_217" class="list-dash"><li>Todos los dem&#xE1;s tumores limitados a la retina que no est&#xE1;n en el Grupo A.</li><li>El l&#xED;quido subretiniano relacionado con el tumor est&#xE1; a menos de 3 mm del tumor, sin diseminaci&#xF3;n subretiniana.</li></ul></div></li><li><em><strong>Grupo C:</strong></em> enfermedad local aislada, con diseminaci&#xF3;n subretiniana o v&#xED;trea m&#xED;nimas.<div class="pdq-content-list"><ul id="_218" class="list-dash"><li>Tumor(es) aislado(s).</li><li>L&#xED;quido subretiniano, presente o pasado, sin diseminaci&#xF3;n que comprometa hasta un cuarto de la retina.</li><li>La diseminaci&#xF3;n v&#xED;trea local fina puede estar presente cerca de un tumor aislado.</li><li>Diseminaci&#xF3;n subretiniana local a menos de 3 mm (2 DD) del tumor.</li></ul></div></li><li><em><strong>Grupo D:</strong></em> enfermedad difusa con diseminaci&#xF3;n v&#xED;trea o subretiniana importante.<div class="pdq-content-list"><ul id="_219" class="list-dash"><li>Tumor(es) que puede(n) ser voluminoso(s) o difuso(s).</li><li>L&#xED;quido subretiniano presente o pasado sin diseminaci&#xF3;n que compromete hasta la totalidad del desprendimiento de la retina.</li><li>Enfermedad v&#xED;trea difusa o s&#xF3;lida que puede incluir diseminaci&#xF3;n "grasosa" o masas tumorales avasculares.</li><li>Diseminaci&#xF3;n subretiniana difusa que puede incluir placas subretinianas o n&#xF3;dulos tumorales.</li></ul></div></li><li><em><strong>Grupo E:</strong></em> presencia de una o m&#xE1;s de las siguientes caracter&#xED;sticas de pron&#xF3;stico precario.<div class="pdq-content-list"><ul id="_220" class="list-dash"><li>Tumor que toca el cristalino.</li><li>Tumor situado por delante de la porci&#xF3;n anterior del cuerpo v&#xED;treo  que compromete el cuerpo ciliar o el segmento anterior del ojo.</li><li>Retinoblastoma infiltrante difuso.</li><li>Glaucoma neovascular.</li><li>Opacidad de la t&#xFA;nica media causada por hemorragia.</li><li>Necrosis tumoral con celulitis orbitaria as&#xE9;ptica.</li><li>Tuberculosis del globo ocular.</li></ul></div></li></ul></div></section></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_3.1">Chantada GL, Sampor C, Bosaleh A, et al.: Comparison of staging systems for extraocular retinoblastoma: analysis of 533 patients. JAMA Ophthalmol 131 (9): 1127-34, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23787805&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23787805&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.2">Chantada G, Doz F, Antoneli CB, et al.: A proposal for an international retinoblastoma staging system. Pediatr Blood Cancer 47 (6): 801-5, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16358310&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16358310&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.3">Temming P, Arendt M, Viehmann A, et al.: How Eye-Preserving Therapy Affects Long-Term Overall Survival in Heritable Retinoblastoma Survivors. J Clin Oncol 34 (26): 3183-8, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27382102&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.4">Shields CL, Mashayekhi A, Au AK, et al.: The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113 (12): 2276-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.5">Murphree L: Staging and grouping of retinoblastoma. In: Singh A, Damato B: Clinical Ophthalmic Oncology. Philadelphia, Pa: Saunders Elsevier, 2007, pp 422-7.</li><li id="section_3.6">Zage PE, Reitman AJ, Seshadri R, et al.: Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer 50 (3): 567-72, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.7">Novetsky DE, Abramson DH, Kim JW, et al.: Published international classification of retinoblastoma (ICRB) definitions contain inconsistencies--an analysis of impact. Ophthalmic Genet 30 (1): 40-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19172510&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19172510&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_3.8">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _53
      field_pdq_section_title:
        - format: plain_text
          value: 'Aspectos generales de las opciones de tratamiento del retinoblastoma'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_53" class="pdq-sections"><p id="_54" tabindex="-1">Para optimizar los desenlaces del tratamiento, es necesario que su planificaci&#xF3;n est&#xE9; a cargo de un equipo multidisciplinario de especialistas en c&#xE1;ncer con experiencia en el abordaje de tumores oculares infantiles, incluso un onc&#xF3;logo pediatra, un oftalm&#xF3;logo y un radionc&#xF3;logo.[<a href="#cit/section_4.1">1</a>] La evaluaci&#xF3;n en centros oncol&#xF3;gicos especializados es muy recomendable antes de iniciar el tratamiento con el fin de aumentar la probabilidad de rescate ocular y preservaci&#xF3;n de la vista.</p><p id="_512" tabindex="-1">Los objetivos del tratamiento son los siguientes:</p><div class="pdq-content-list"><ul id="_763"><li>Erradicar la enfermedad para salvar la vida del paciente.</li><li>Preservar la vista tanto como sea posible.</li><li>Disminuir el riesgo de secuelas tard&#xED;as del tratamiento; en particular, neoplasias subsiguientes (NS).</li></ul></div><p id="_764" tabindex="-1">El tratamiento del retinoblastoma se adapta a la carga de enfermedad intraocular y extraocular, la lateralidad de la enfermedad, el estado de la l&#xED;nea germinal del gen <em>RB1</em> y la posibilidad de preservar la vista. En los pacientes que presentan enfermedad intraocular, en particular, aquellos con compromiso ocular bilateral, un enfoque conservador que consiste en la reducci&#xF3;n del tumor con quimioterapia intravenosa o en la arteria oft&#xE1;lmica, acompa&#xF1;ada por terapia local intensiva, puede dar lugar a tasas altas de rescate ocular.[<a href="#cit/section_4.2">2</a>] La radioterapia, uno de los tratamientos m&#xE1;s eficaces para el retinoblastoma, se suele reservar para los casos de progresi&#xF3;n de la enfermedad intraocular o extraocular. Muchos tratamientos que se consideraban el est&#xE1;ndar de atenci&#xF3;n no han sido sometidos a estudio con m&#xE9;todos aleatorizados.</p><p id="_835" tabindex="-1">Se debe considerar una combinaci&#xF3;n razonable y adaptada al riesgo de las siguientes opciones de tratamiento:</p><div class="pdq-content-list"><ul id="_917"><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_870">Enucleaci&#xF3;n</a>.</li><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_872">Tratamiento local (crioterapia, terapia con l&#xE1;ser y braquiterapia)</a>.</li><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_875">Quimioterapia sist&#xE9;mica</a>.</li><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_880">Infusi&#xF3;n de quimioterapia en la arteria oft&#xE1;lmica (quimioterapia intrarterial)</a>.</li><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_893">Quimioterapia intrav&#xED;trea</a>.</li><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_896">Quimioterapia debajo de la c&#xE1;psula de Tenon (quimioterapia subconjuntival)</a>.</li><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_899">Radioterapia (radioterapia de haz externo [RHE], braquiterapia)</a>.</li></ul></div><p id="_778" tabindex="-1">Las opciones de tratamiento est&#xE1;ndar del retinoblastoma intraocular, extraocular y recidivante se describen en el <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_779">Cuadro 2</a>.</p><table id="_779" class="table-default expandable-container"><caption>Cuadro 2.  Opciones de tratamiento del retinoblastoma</caption><colgroup><col width="9.23%"><col width="29.08%"><col width="18.92%"><col width="42.75%"></colgroup><THead><tr><th colspan="2">Grupo de tratamiento</th><th colspan="2">Opciones de tratamiento</th></tr></THead><TFoot class="pdq-footer"><tr><td colspan="4">RHE = radioterapia de haz externo; SNC = sistema nervioso central.</td></tr></TFoot><tbody><tr><td colspan="2">Retinoblastoma intraocular:</td><td colspan="2">&#xA0;</td></tr><tr><td rowspan="4">&#xA0;</td><td rowspan="4">Retinoblastoma unilateral </td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_786">Enucleaci&#xF3;n seguida de quimioterapia</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_791">Abordajes conservadores de rescate ocular:</a></td></tr><tr><td colspan="2">&#x2014;Quimiorreducci&#xF3;n con infusi&#xF3;n de quimioterapia en la arteria oft&#xE1;lmica o por v&#xED;a sist&#xE9;mica, con quimioterapia intrav&#xED;trea o sin esta</td></tr><tr><td colspan="2">&#x2014;Tratamientos locales (crioterapia, termoterapia y radioterapia con placas)</td></tr><tr><td rowspan="5">&#xA0;</td><td rowspan="5">Retinoblastoma bilateral </td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_798">Enucleaci&#xF3;n para tumores intraoculares grandes, seguida de quimioterapia adaptada al riesgo cuando no es posible salvar el ojo ni la vista</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_798">Abordajes conservadores de rescate ocular cuando es posible salvar el ojo y la vista:</a></td></tr><tr><td colspan="2">&#x2014;Quimiorreducci&#xF3;n con infusi&#xF3;n de quimioterapia en la arteria oft&#xE1;lmica  o v&#xED;a sist&#xE9;mica, con quimioterapia intrav&#xED;trea o sin esta </td></tr><tr><td colspan="2">&#x2014;Tratamientos locales (crioterapia, termoterapia y radioterapia con placas)</td></tr><tr><td colspan="2">&#x2014;RHE</td></tr><tr><td>&#xA0;</td><td>Retinoblastoma cavitario</td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_918">Quimioterapia sist&#xE9;mica o intrarterial</a></td></tr><tr><td colspan="2">Retinoblastoma extraocular:</td><td colspan="2">&#xA0;</td></tr><tr><td rowspan="2">&#xA0;</td><td rowspan="2">Retinoblastoma orbitario y locorregional</td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_812">Quimioterapia</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_812">Radioterapia</a></td></tr><tr><td rowspan="2">&#xA0;</td><td rowspan="2">Enfermedad en el SNC</td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_817">Quimioterapia sist&#xE9;mica y terapia dirigida al SNC</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_817">Quimioterapia sist&#xE9;mica seguida de quimioterapia mielosupresora y rescate de c&#xE9;lulas madre</a></td></tr><tr><td rowspan="2">&#xA0;</td><td rowspan="2">Retinoblastoma trilateral</td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_820">Quimioterapia sist&#xE9;mica seguida de cirug&#xED;a y quimioterapia mielosupresora con rescate de c&#xE9;lulas madre</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_820">Quimioterapia sist&#xE9;mica seguida de cirug&#xED;a y radioterapia</a></td></tr><tr><td>&#xA0;</td><td>Retinoblastoma extracraneal metast&#xE1;sico</td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_824">Quimioterapia sist&#xE9;mica seguida de quimioterapia mielosupresora con rescate de c&#xE9;lulas madre y radioterapia</a></td></tr><tr><td rowspan="5" colspan="2">Retinoblastoma intraocular progresivo o recidivante</td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_826">Enucleaci&#xF3;n</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_826">Radioterapia (RHE o radioterapia con placas)</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_826">Tratamientos locales (crioterapia o termoterapia)</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_826">Quimioterapia de rescate (sist&#xE9;mica o intrarterial)</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_826">Quimioterapia intrav&#xED;trea</a></td></tr><tr><td rowspan="2" colspan="2">Retinoblastoma extraocular progresivo o recidivante</td><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_828">Quimioterapia sist&#xE9;mica y radioterapia para la enfermedad orbitaria</a></td></tr><tr><td colspan="2"><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_828">Quimioterapia sist&#xE9;mica seguida de quimioterapia mielosupresora con rescate de c&#xE9;lulas madre y radioterapia para la enfermedad extraorbitaria</a></td></tr></tbody></table><section id="_870"><h3 id="_870_toc">Enucleaci&#xF3;n</h3><p id="_871" tabindex="-1">Se indica la resecci&#xF3;n inicial del ojo para tumores grandes que llenan el cuerpo v&#xED;treo con poca o ninguna probabilidad de restaurar la visi&#xF3;n, y en casos de extensi&#xF3;n a la c&#xE1;mara anterior o en presencia de glaucoma neovascular. Se debe vigilar atentamente a los pacientes para detectar una recidiva orbitaria de la enfermedad, sobre todo durante los dos primeros a&#xF1;os despu&#xE9;s de la enucleaci&#xF3;n.[<a href="#cit/section_4.3">3</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiA</a>] La enucleaci&#xF3;n tambi&#xE9;n se usa como tratamiento de rescate en casos de progresi&#xF3;n o recidiva de la enfermedad. El esp&#xE9;cimen de patolog&#xED;a se debe examinar minuciosamente para identificar a los pacientes que tienen riesgo algo de diseminaci&#xF3;n extraocular y que podr&#xED;an necesitar quimioterapia adyuvante.</p></section><section id="_872"><h3 id="_872_toc">Tratamiento local (crioterapia, terapia con l&#xE1;ser y braquiterapia)</h3><p id="_873" tabindex="-1">Los pacientes sometidos a tratamiento de rescate ocular siempre necesitan terapia local intensiva. Un oftalm&#xF3;logo aplica el tratamiento local directamente en el tumor.</p><div class="pdq-content-list"><ul id="_874"><li><strong>Crioterapia:</strong> la crioterapia se basa en la aplicaci&#xF3;n de una criosonda a la escler&#xF3;tica en la vecindad inmediata del tumor retiniano. Se usa como tratamiento primario o con quimioterapia para tumores menores de 4 di&#xE1;metros discales (DD)  ubicados en la parte anterior de la retina.</li><li><strong>Terapia con l&#xE1;ser:</strong>  la terapia con l&#xE1;ser se puede usar como tratamiento primario de tumores peque&#xF1;os, o combinada con quimioterapia para tumores m&#xE1;s grandes. La fotocoagulaci&#xF3;n tradicional (l&#xE1;ser de arg&#xF3;n), en la que se aplicaba el rayo l&#xE1;ser alrededor del tumor para incidir sobre la vasculatura del tumor se dej&#xF3; de lado y dio paso a la termoterapia (l&#xE1;ser de diodo). La termoterapia se administra directamente en la superficie del tumor mediante rayos de longitud de onda en el espectro infrarrojo.[<a href="#cit/section_4.4">4</a>,<a href="#cit/section_4.5">5</a>]</li><li><strong>Braquiterapia (radioterapia con placas):</strong> para tumores grandes que no  son susceptibles a la crioterapia o terapia con l&#xE1;ser, la braquiterapia proporciona un mecanismo eficaz para el control local (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre  <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_899">Radioterapia</a>).</li></ul></div></section><section id="_875"><h3 id="_875_toc">Quimioterapia sist&#xE9;mica</h3><p id="_876" tabindex="-1">La quimioterapia sist&#xE9;mica cumple con una funci&#xF3;n en los siguientes casos:</p><div class="pdq-content-list"><ul id="_877"><li>Entorno adyuvante para pacientes con caracter&#xED;sticas patol&#xF3;gicas de riesgo alto. Se han utilizado diferentes esquemas de tratamiento para los pacientes con caracter&#xED;sticas patol&#xF3;gicas de riesgo alto en el esp&#xE9;cimen de enucleaci&#xF3;n. La mayor&#xED;a de los esquemas de tratamiento incluyen una combinaci&#xF3;n de tres f&#xE1;rmacos  con vincristina, etop&#xF3;sido y carboplatino, ya sea solos o en alternancia con  ciclofosfamida y una antraciclina.[<a href="#cit/section_4.6">6</a>-<a href="#cit/section_4.9">9</a>]</li><li>Tratamiento de pacientes con enfermedad extraocular y metast&#xE1;sica. Los pacientes con enfermedad extraocular se benefician  de un tratamiento m&#xE1;s radical. Aunque no se ha establecido el  tratamiento est&#xE1;ndar, se inform&#xF3; de reacciones favorables a los esquemas con cisplatino que incluyen consolidaci&#xF3;n con quimioterapia de dosis altas y rescate aut&#xF3;geno de c&#xE9;lulas madre hematopoy&#xE9;ticas para los pacientes que tienen enfermedad extraorbitaria.[<a href="#cit/section_4.10">10</a>-<a href="#cit/section_4.13">13</a>]</li><li>Tratamiento quimiorreductor combinado con terapia local intensiva para pacientes sometidos a tratamiento de rescate ocular.</li></ul></div><p id="_878" tabindex="-1">Durante los &#xFA;ltimos 20 a&#xF1;os, el est&#xE1;ndar de atenci&#xF3;n ha sido la quimioterapia sist&#xE9;mica para reducir el volumen tumoral (quimiorreducci&#xF3;n), facilitar la administraci&#xF3;n de tratamientos locales y evitar los efectos a largo plazo de la radioterapia.[<a href="#cit/section_4.14">14</a>,<a href="#cit/section_4.15">15</a>]; [<a href="#cit/section_4.16">16</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335135&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335135&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 2Di</a>]; [<a href="#cit/section_4.17">17</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiA</a>]; [<a href="#cit/section_4.18">18</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335149&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335149&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDiii</a>]  La tasa de &#xE9;xito del rescate ocular difiere entre las instituciones, pero en general, se han obtenido desenlaces oculares favorables en tumores individuales sin diseminaci&#xF3;n v&#xED;trea.[<a href="#cit/section_4.14">14</a>,<a href="#cit/section_4.15">15</a>,<a href="#cit/section_4.19">19</a>,<a href="#cit/section_4.20">20</a>] Tambi&#xE9;n se puede iniciar o continuar la quimioterapia junto  con control local simult&#xE1;neo.[<a href="#cit/section_4.21">21</a>] El grupo  asignado a los ojos, seg&#xFA;n la definici&#xF3;n de la <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_509">International Classification of Retinoblastoma</a>, es el mejor factor pron&#xF3;stico de rescate ocular cuando se utiliza este abordaje.  En un estudio sin aleatorizaci&#xF3;n realizado en una sola instituci&#xF3;n de 345 pacientes con tumores de Grupos D o E, se compar&#xF3; la enucleaci&#xF3;n primaria y la quimioterapia adyuvante para las caracter&#xED;sticas patol&#xF3;gicas de riesgo alto con la quimioterapia sist&#xE9;mica seguida de enucleaci&#xF3;n o sin esta, seg&#xFA;n estuviera indicado.  La incidencia de recidiva local y met&#xE1;stasis fue de menos de  1&#xA0;%, con independencia del tipo de abordaje. En contraste con 100&#xA0;% de enucleaci&#xF3;n, las enucleaciones posteriores se realizaron  en solo 41&#xA0;% de los ni&#xF1;os que recibieron quimiorreducci&#xF3;n sist&#xE9;mica, ninguno de estos ni&#xF1;os present&#xF3; caracter&#xED;sticas patol&#xF3;gicas de riesgo alto en el ojo tratado con quimiorreducci&#xF3;n.[<a href="#cit/section_4.22">22</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335148&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335148&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDii</a>] En un estudio retrospectivo de pacientes con tumores del Grupo D, cuyos ojos recibieron tratamiento primario con quimioterapia intravenosa y nunca se enuclearon, m&#xE1;s del 50&#xA0;% de los pacientes ten&#xED;an una agudeza visual menor de 20/200 y 75&#xA0;% de los pacientes presentaban estrabismo.[<a href="#cit/section_4.23">23</a>]</p><p id="_879" tabindex="-1">La recidiva local del tumor es frecuente en los primeros a&#xF1;os posteriores al tratamiento  [<a href="#cit/section_4.20">20</a>] y, a menudo, se puede tratar con &#xE9;xito con terapia local.[<a href="#cit/section_4.24">24</a>]  Es m&#xE1;s probable que los pacientes con enfermedad hereditaria, los m&#xE1;s j&#xF3;venes y aquellos con antecedentes familiares de esta enfermedad presenten tumores nuevos. La quimioterapia sirve para tratar lesiones peque&#xF1;as que no se detectaron antes ya que retarda el crecimiento, lo cual mejora en general el rescate ocular  mediante terapia local.[<a href="#cit/section_4.25">25</a>]</p></section><section id="_880"><h3 id="_880_toc">Infusi&#xF3;n de quimioterapia en la arteria oft&#xE1;lmica (quimioterapia intrarterial)</h3><p id="_881" tabindex="-1">La administraci&#xF3;n directa de quimioterapia en el ojo mediante canulaci&#xF3;n de la arteria oft&#xE1;lmica es un m&#xE9;todo factible y eficaz de rescate ocular.</p><p id="_882" tabindex="-1">El melfal&#xE1;n es el f&#xE1;rmaco que se utiliza con mayor frecuencia y eficacia. A menudo, se combina con  topotec&#xE1;n o carboplatino cuando la reacci&#xF3;n fue sub&#xF3;ptima o hay enfermedad intraocular muy avanzada.[<a href="#cit/section_4.26">26</a>-<a href="#cit/section_4.30">30</a>]</p><p id="_883" tabindex="-1">En los pacientes que no han recibido tratamiento ocular, la tasa de supervivencia a los 2 a&#xF1;os sin radiaci&#xF3;n ocular es de  86&#xA0;a 90&#xA0;%.[<a href="#cit/section_4.2">2</a>,<a href="#cit/section_4.26">26</a>,<a href="#cit/section_4.28">28</a>,<a href="#cit/section_4.30">30</a>,<a href="#cit/section_4.31">31</a>] El desenlace tras la quimioterapia intrarterial se relaciona con el grado de compromiso intraocular de la siguiente manera:</p><div class="pdq-content-list"><ul id="_884"><li>Los pacientes con enfermedad intraocular temprana (ojos de los Grupos B y C) tiene desenlaces satisfactorios y se les puede tratar con monoterapia.[<a href="#cit/section_4.27">27</a>,<a href="#cit/section_4.29">29</a>]</li><li>Los ojos del Grupo D presentan desenlaces m&#xE1;s precarios: tasas de supervivencia sin radiaci&#xF3;n ocular de 80&#xA0;% para los ojos con diseminaci&#xF3;n subretiniana y de  65&#xA0;% para los ojos con diseminaci&#xF3;n v&#xED;trea.[<a href="#cit/section_4.32">32</a>,<a href="#cit/section_4.33">33</a>] En algunos centros se notificaron tasas m&#xE1;s altas de rescate ocular en los ojos  de Grupos D y E unilaterales cuando se us&#xF3; un r&#xE9;gimen de quimioterapia con tres f&#xE1;rmacos.[<a href="#cit/section_4.2">2</a>] En los pacientes con enfermedad intraocular muy avanzada una alternativa de tratamiento  es emplear quimioterapia sist&#xE9;mica seguida de consolidaci&#xF3;n con  melfal&#xE1;n intrarterial.[<a href="#cit/section_4.34">34</a>]</li><li>Las tasas de rescate ocular cuando se administra quimioterapia intrarterial como  tratamiento de rescate para los pacientes con enfermedad recidivante o progresiva son, de modo sistem&#xE1;tico, m&#xE1;s bajas; las tasas de supervivencia general son de 50&#xA0;a&#xA0;60&#xA0;%.[<a href="#cit/section_4.28">28</a>,<a href="#cit/section_4.30">30</a>-<a href="#cit/section_4.32">32</a>,<a href="#cit/section_4.35">35</a>,<a href="#cit/section_4.36">36</a>] No obstante, se inform&#xF3; de tasas de rescate ocular sin radioterapia a los 2 a&#xF1;os de 75&#xA0;% con el empleo de un esquema farmacol&#xF3;gico m&#xE1;s intensivo con tres f&#xE1;rmacos (melfal&#xE1;n, topotec&#xE1;n y carboplatino) en los pacientes cuya enfermedad progres&#xF3; despu&#xE9;s del tratamiento est&#xE1;ndar sist&#xE9;mico y local.[<a href="#cit/section_4.37">37</a>]</li></ul></div><p id="_885" tabindex="-1">Los pacientes con enfermedad bilateral se pueden someter a una administraci&#xF3;n intrarterial en t&#xE1;ndem.[<a href="#cit/section_4.38">38</a>] En dichas circunstancias,  los pacientes tienen un riesgo m&#xE1;s alto de efectos t&#xF3;xicos sist&#xE9;micos de la exposici&#xF3;n al melfal&#xE1;n,[<a href="#cit/section_4.39">39</a>] as&#xED; que, durante el procedimiento en t&#xE1;ndem, se puede usar carboplatino en monoterapia con el fin de tratar el ojo con enfermedad menos avanzada.[<a href="#cit/section_4.40">40</a>] En los neonatos y lactantes muy peque&#xF1;os en quienes la canulaci&#xF3;n de arteria oft&#xE1;lmica no es viable, se observ&#xF3; que el tratamiento <em>puente</em> con carboplatino sist&#xE9;mico en monoterapia hasta que el lactante cumpla 3 meses o pese 6&#xA0;kg seguido de consolidaci&#xF3;n con quimioterapia intrarterial es muy eficaz, su tasa de supervivencia ocular sin radiaci&#xF3;n a 1 a&#xF1;o fue de 95&#xA0;%.[<a href="#cit/section_4.41">41</a>]</p><p id="_886" tabindex="-1">Si bien la diseminaci&#xF3;n v&#xED;trea subretiniana se puede controlar bien con quimioterapia intrarterial,[<a href="#cit/section_4.36">36</a>] es posible que sea dif&#xED;cil de  controlar solo con quimioterapia intrarterial o intravenosa. Se puede presentar diseminaci&#xF3;n a la c&#xE1;mara anterior despu&#xE9;s de la quimioterapia intrarterial  o intravenosa, tal como se describi&#xF3;  en una serie en donde  se detect&#xF3; diseminaci&#xF3;n mediante examen cl&#xED;nico en 6 de 12 ojos (50&#xA0;%) y mediante examen histopatol&#xF3;gico en  8 de 12 ojos (67&#xA0;%). Este resultado indica que la quimioterapia intrarterial parece ofrecer eficacia superior para la enfermedad del segmento posterior.[<a href="#cit/section_4.42">42</a>] Seg&#xFA;n parece, la adici&#xF3;n de quimioterapia intrav&#xED;trea a la quimioterapia intrarterial mejora de forma notable la eficacia general del tratamiento en los ojos con diseminaci&#xF3;n v&#xED;trea; en especial, en el caso de diseminaci&#xF3;n v&#xED;trea difusa (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_893">Quimioterapia intrav&#xED;trea</a> de este sumario).[<a href="#cit/section_4.43">43</a>,<a href="#cit/section_4.44">44</a>] De manera similar, la adici&#xF3;n de quimioterapia intrarterial a la quimioterapia intravenosa es m&#xE1;s eficaz para tratar la diseminaci&#xF3;n v&#xED;trea; al igual que con la quimioterapia intrarterial primaria,[<a href="#cit/section_4.44">44</a>] se necesitan cada vez m&#xE1;s ciclos de quimioterapia intrav&#xED;trea para el control del polvo, las esferas y las nubes de las semillas.[<a href="#cit/section_4.45">45</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335158&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335158&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiiDiii</a>]
            </p><p id="_887" tabindex="-1">Las complicaciones relacionadas con la  quimioterapia intrarterial son las siguientes:[<a href="#cit/section_4.31">31</a>]</p><div class="pdq-content-list"><ul id="_888"><li>Desprendimiento de retina (hasta 19,3&#xA0;%).[<a href="#cit/section_4.46">46</a>]</li><li>Hemorragia v&#xED;trea (18,1&#xA0;%).</li><li>Ptosis (13,6&#xA0;%).</li><li>Alteraciones motrices (6,5&#xA0;%).</li><li>Efectos vasculares e isqu&#xE9;micos (6,2&#xA0;%).</li><li>Atrofia &#xF3;ptica (3,4&#xA0;%).</li><li>Atrofia del globo ocular (2,7&#xA0;%).</li></ul></div><p id="_889" tabindex="-1">Las complicaciones vasculares graves relacionadas con el procedimiento son muy poco comunes; los grupos de mayor experiencia no han notificado accidentes cerebrovasculares o complicaciones neurol&#xF3;gicas agudas de importancia.[<a href="#cit/section_4.28">28</a>,<a href="#cit/section_4.31">31</a>,<a href="#cit/section_4.47">47</a>,<a href="#cit/section_4.48">48</a>] Sin embargo, se document&#xF3; estenosis de la arteria oft&#xE1;lmica y oclusi&#xF3;n de la arteria  central de la retina;[<a href="#cit/section_4.48">48</a>] el riesgo de trombosis aumenta de manera significativa en ni&#xF1;os con trombofilias.[<a href="#cit/section_4.49">49</a>]</p><p id="_890" tabindex="-1">No se ha evaluado por completo el  efecto de los cambios vasculares intraoculares en la vista debido a la corta edad de las primeras cohortes de pacientes tratados. En la mayor parte de los pacientes no ocurren cambios electrorretinogr&#xE1;ficos apreciables,[<a href="#cit/section_4.50">50</a>] y se inform&#xF3; de conservaci&#xF3;n de la visi&#xF3;n central.[<a href="#cit/section_4.51">51</a>]  Es posible que una proporci&#xF3;n de pacientes con electrorretinogramas (ERG) anormales, con desprendimiento de retina o sin este, presenten un ERG mejorado a&#xF1;os despu&#xE9;s de recibir quimioterapia intrarterial.[<a href="#cit/section_4.52">52</a>]  Para 72 ojos con retinoblastoma avanzado que tuvieron ERG de referencia indiferenciados de ERG con ruido (<em>extintos</em>) o con destellos en amplitudes inferiores a 25 &#xB5;V (<em>deficientes</em>), se obtuvieron ERG antes de la quimiocirug&#xED;a de la arteria oft&#xE1;lmica y despu&#xE9;s de esta a los 3 meses, 1 a&#xF1;o y 2 a&#xF1;os. A los 3 meses, 1 a&#xF1;o y 2 a&#xF1;os despu&#xE9;s de la quimiocirug&#xED;a de la arteria oft&#xE1;lmica, se observaron ojos  <em>extintos</em> en 9 de 15, 4 de 11 y 2 de 6 ERG detectables, respectivamente;  se observaron ojos <em>deficientes</em> en 19 de 55, 14 de 30 y 8 de 18 ERG con amplitudes superiores a 25 &#x3BC;V, respectivamente.[<a href="#cit/section_4.52">52</a>] No obstante, la quimioterapia  intrarterial podr&#xED;a empeorar el funcionamiento de la retina en los pacientes que antes recibieron tratamientos oculares muy intensivos.[<a href="#cit/section_4.37">37</a>]</p><p id="_891" tabindex="-1">Otro riesgo relacionado con la quimioterapia intrarterial es la exposici&#xF3;n a la radiaci&#xF3;n ionizante durante la fluoroscopia. Las dosis de radiaci&#xF3;n por procedimiento  llegan a ser de hasta 191&#xA0;mGy en el ojo afectado y de 35&#xA0;mGy en el ojo contralateral,[<a href="#cit/section_4.53">53</a>] aunque se ha informado de dosis tan bajas como  1&#xA0;mGy por procedimiento.[<a href="#cit/section_4.54">54</a>] Despu&#xE9;s de m&#xFA;ltiples procedimientos, las dosis acumuladas alcanzan 0,1 a 0,2&#xA0;Gy, lo que podr&#xED;a causar cataratas y un efecto carcinog&#xE9;nico en esta poblaci&#xF3;n susceptible.[<a href="#cit/section_4.53">53</a>] Aunque no hay un incremento en la incidencia de segundas neoplasias,[<a href="#cit/section_4.47">47</a>,<a href="#cit/section_4.55">55</a>] se necesitan seguimientos m&#xE1;s prolongados para determinar  cabalmente los riesgos  relacionados con el procedimiento.</p><p id="_892" tabindex="-1">Parece que el  riesgo de progresi&#xF3;n metast&#xE1;sica de la administraci&#xF3;n ocular directa de quimioterapia  es muy bajo;[<a href="#cit/section_4.2">2</a>] sin embargo, se notificaron hasta 20 casos de pacientes tratados con quimioterapia intrarterial que luego presentaron met&#xE1;stasis.[<a href="#cit/section_4.31">31</a>]</p></section><section id="_893"><h3 id="_893_toc">Quimioterapia intrav&#xED;trea</h3><p id="_894" tabindex="-1"> En estudios se indic&#xF3; que la inyecci&#xF3;n intrav&#xED;trea directa de melfal&#xE1;n o topotec&#xE1;n quiz&#xE1; sea eficaz para neutralizar la diseminaci&#xF3;n activa en el cuerpo v&#xED;treo.[<a href="#cit/section_4.56">56</a>,<a href="#cit/section_4.57">57</a>]; [<a href="#cit/section_4.58">58</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335147&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335147&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDi</a>]; [<a href="#cit/section_4.59">59</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335158&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335158&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiiDiii</a>] En un estudio retrospectivo de  264 ojos (250&#xA0;ni&#xF1;os) tratados con melfal&#xE1;n intrav&#xED;treo para el control de la diseminaci&#xF3;n v&#xED;trea  durante un per&#xED;odo de 20 a&#xF1;os, se inform&#xF3; de una tasa de remisi&#xF3;n completa de 68&#xA0;%.  La incidencia de diseminaci&#xF3;n extraocular fue baja y se present&#xF3; en los ni&#xF1;os que ten&#xED;an caracter&#xED;sticas de riesgo alto.[<a href="#cit/section_4.60">60</a>][<a href="/Common/PopUps/popDefinition.aspx?id=716085&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000716085&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiD</a>]  Debido a preocupaciones iniciales sobre el potencial de diseminaci&#xF3;n tumoral se ha limitado el uso de la quimioterapia intrav&#xED;trea. Sin embargo, en una revisi&#xF3;n se calcul&#xF3; que la proporci&#xF3;n de pacientes que presentan diseminaci&#xF3;n tumoral extraocular, posiblemente como consecuencia de la inyecci&#xF3;n en el cuerpo v&#xED;treo, es insignificante.[<a href="#cit/section_4.61">61</a>]</p><p id="_895" tabindex="-1">En un metan&#xE1;lisis se inform&#xF3; que los efectos secundarios importantes de la quimioterapia intrav&#xED;trea son poco comunes, aunque cada inyecci&#xF3;n produce una disminuci&#xF3;n peque&#xF1;a en el funcionamiento de la retina, seg&#xFA;n la medici&#xF3;n con ERG.[<a href="#cit/section_4.62">62</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587991&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000587991&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiiDiv</a>] En la etapa actual de tratamiento del retinoblastoma  con quimioterapia intrarterial y quimioterapia intrav&#xED;trea  (seg&#xFA;n indicaci&#xF3;n por diseminaci&#xF3;n v&#xED;trea) se ha mejorado el  rescate del globo ocular en ojos con retinoblastoma en estadio avanzado en comparaci&#xF3;n con ni&#xF1;os tratados en a&#xF1;os anteriores con quimioterapia intrarterial sola.[<a href="#cit/section_4.43">43</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335148&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335148&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDii</a>] En un segundo estudio retrospectivo, tambi&#xE9;n realizado en distintas &#xE9;pocas (2006&#x2013;2010 vs. 2011&#x2013;2016), se examinaron 40 ojos con diseminaci&#xF3;n v&#xED;trea difusa (semillas de clase 3). Los ni&#xF1;os tratados durante la primera &#xE9;poca recibieron tratamiento primario con quimioterapia intrarterial,  mientras que los ni&#xF1;os tratados en la &#xE9;poca posterior recibieron quimioterapia intrav&#xED;trea e intrarterial al mismo tiempo. En comparaci&#xF3;n con los ni&#xF1;os que se trataron en la primera &#xE9;poca, los ni&#xF1;os que se trataron en la &#xE9;poca posterior tuvieron una regresi&#xF3;n en menos tiempo, menos recidivas, menos enucleaciones y ninguna toxicidad, incluso ninguna diferencia en cuanto a la p&#xE9;rdida de funci&#xF3;n retiniana seg&#xFA;n las mediciones de un ERG.[<a href="#cit/section_4.44">44</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDiv</a>] Por lo general, cada dosis de quimioterapia intrav&#xED;trea produce una disminuci&#xF3;n peque&#xF1;a del funcionamiento retiniano, seg&#xFA;n las mediciones de un ERG.[<a href="#cit/section_4.63">63</a>]</p></section><section id="_896"><h3 id="_896_toc">Quimioterapia debajo de la c&#xE1;psula de Tenon (quimioterapia subconjuntival)</h3><p id="_897" tabindex="-1">La administraci&#xF3;n periocular de carboplatino, que produce altas concentraciones intraoculares de este f&#xE1;rmaco, se emplea con frecuencia como  abordaje de rescate ocular, en particular, cuando la carga tumoral v&#xED;trea es alta. El oftalm&#xF3;logo administra el carboplatino en el espacio debajo de la c&#xE1;psula de Tenon.  En general, se combina con quimioterapia sist&#xE9;mica y terapias oft&#xE1;lmicas locales en pacientes con enfermedad v&#xED;trea.[<a href="#cit/section_4.64">64</a>,<a href="#cit/section_4.65">65</a>] Tambi&#xE9;n se han observado reacciones favorables cuando se administra el topotec&#xE1;n debajo de la c&#xE1;psula de Tenon.[<a href="#cit/section_4.66">66</a>]</p><p id="_898" tabindex="-1">Ante la formulaci&#xF3;n de nuevos tratamientos para el retinoblastoma, como la administraci&#xF3;n de quimioterapia por v&#xED;a intrarterial o intrav&#xED;trea, la quimioterapia debajo de la c&#xE1;psula de Tenon ha ca&#xED;do en desuso en el entorno cl&#xED;nico.</p></section><section id="_899"><h3 id="_899_toc">Radioterapia</h3><div class="pdq-content-list"><ul id="_900"><li><strong>RHE:</strong> el retinoblastoma es una neoplasia maligna muy sensible a la radiaci&#xF3;n. Las dosis de RHE que oscilan entre 35 y 46&#xA0;Gy generalmente producen remisiones a largo plazo.
            Debido a la necesidad de sedar a los ni&#xF1;os peque&#xF1;os y las complejidades de planificar la zona de irradiaci&#xF3;n, es importante la pericia t&#xE9;cnica en radioterapia pedi&#xE1;trica.
            La radioterapia se usa en casos de progresi&#xF3;n despu&#xE9;s de aplicar abordajes conservadores en pacientes con diseminaci&#xF3;n extraocular y como parte del tratamiento de los pacientes con enfermedad metast&#xE1;sica.<p id="_901" tabindex="-1">Los m&#xE9;todos m&#xE1;s recientes de administraci&#xF3;n de la RHE se aplican con la intenci&#xF3;n de reducir los efectos adversos a largo plazo.   Estos son la <a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=335073&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000335073&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=NotSet'); return(false);">radioterapia de intensidad modulada</a> y la radioterapia con haz de protones (<a class="definition" type="GlossaryTermRefs" href="/Common/PopUps/popDefinition.aspx?id=534234&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=NotSet" onclick="javascript:popWindow('defbyid','CDR0000534234&amp;version=healthprofessional&amp;language=Spanish&amp;dictionary=NotSet'); return(false);">radioterapia con part&#xED;culas cargadas</a>).[<a href="#cit/section_4.67">67</a>-<a href="#cit/section_4.70">70</a>] Los datos preliminares indican que la radioterapia de protones se vincula con un riesgo m&#xE1;s bajo de malignidad inducida por la radiaci&#xF3;n en los sobrevivientes de retinoblastoma hereditario. En un estudio sin aleatorizaci&#xF3;n en el que se compararon dos cohortes contempor&#xE1;neas de pacientes de retinoblastoma hereditario tratados con radioterapia con fotones o radioterapia con protones, la incidencia acumulada de 10 a&#xF1;os de NS inducidas por radiaci&#xF3;n fue significativamente diferente entre los dos grupos (0&#xA0;% para la radiaci&#xF3;n con protones vs. 14&#xA0;% para la radiaci&#xF3;n con fotones, <em>P</em> = 0,015).[<a href="#cit/section_4.71">71</a>]</p><p id="_902" tabindex="-1">La RHE administrada a lactantes impide el crecimiento de los huesos orbitarios y produce deformidades cosm&#xE9;ticas. La RHE tambi&#xE9;n aumenta el riesgo de NS  en ni&#xF1;os con retinoblastoma hereditario.</p></li><li><strong>Braquiterapia (radioterapia con placas):</strong> una de las indicaciones de la radioterapia con placas son los tumores solitarios con un di&#xE1;metro que oscila entre 6&#xA0;y 15&#xA0;mm, grosor de 10&#xA0;mm o menos y ubicaci&#xF3;n del tumor a m&#xE1;s de 3&#xA0;mm de la papila &#xF3;ptica o f&#xF3;vea. El radiois&#xF3;topo que se usa con mayor frecuencia es el yodo&#xA0;I 125, aunque otros como el iridio&#xA0;Ir 192 y el rutenio&#xA0;Ru 106 tambi&#xE9;n son eficaces. En combinaci&#xF3;n con el uso adecuado de   quimioterapia y otras formas de consolidaci&#xF3;n focal, la braquiterapia puede ser muy eficaz  para el tratamiento de tumores localizados en la retina que no son susceptibles a otros m&#xE9;todos de terapia local.[<a href="#cit/section_4.24">24</a>,<a href="#cit/section_4.72">72</a>,<a href="#cit/section_4.73">73</a>]</li></ul></div></section><section id="_903"><h3 id="_903_toc">Consideraciones especiales para el tratamiento de ni&#xF1;os con c&#xE1;ncer</h3><p id="_904" tabindex="-1">El c&#xE1;ncer en ni&#xF1;os y adolescentes es poco frecuente,  aunque la incidencia general de c&#xE1;ncer infantil ha aumentado paulatinamente desde 1975.[<a href="#cit/section_4.74">74</a>]  Los ni&#xF1;os y adolescentes con c&#xE1;ncer se deben  derivan a centros m&#xE9;dicos que cuentan con un equipo multidisciplinario de especialistas con experiencia en el tratamiento de los c&#xE1;nceres que se presentan en la ni&#xF1;ez y la adolescencia.  Este enfoque de equipo multidisciplinario es de particular importancia en el tratamiento del retinoblastoma ya que incorpora la pericia de los siguientes profesionales de la salud y otros para asegurar que los ni&#xF1;os reciban el tratamiento, los cuidados m&#xE9;dicos de apoyo y la rehabilitaci&#xF3;n que les permitan lograr una supervivencia y calidad de vida &#xF3;ptimas:</p><div class="pdq-content-list"><ul id="_905"><li>Oftalm&#xF3;logo con amplia experiencia en el tratamiento de ni&#xF1;os con retinoblastoma.</li><li>M&#xE9;dico de atenci&#xF3;n primaria.</li><li>Subespecialistas en cirug&#xED;a pedi&#xE1;trica.</li><li>Radionc&#xF3;logos.</li><li>Onc&#xF3;logos y hemat&#xF3;logos pediatras.</li><li>Especialistas en rehabilitaci&#xF3;n.</li><li>Especialistas en enfermer&#xED;a pedi&#xE1;trica.</li><li>Trabajadores sociales.</li></ul></div><p id="_906" tabindex="-1">La American Academy of Pediatrics estableci&#xF3; pautas para los centros de oncolog&#xED;a pedi&#xE1;trica y su funci&#xF3;n en el tratamiento de los pacientes pedi&#xE1;tricos con c&#xE1;ncer.[<a href="#cit/section_4.75">75</a>]  En estos centros de oncolog&#xED;a infantil, se dispone de ensayos cl&#xED;nicos para la mayor&#xED;a de los tipos de c&#xE1;ncer que se presentan en ni&#xF1;os y adolescentes, y se ofrece la oportunidad de participar a la mayor&#xED;a de los pacientes y familiares. Los ensayos cl&#xED;nicos para adolescentes y ni&#xF1;os con c&#xE1;ncer por lo general se dise&#xF1;an con el fin de comparar un tratamiento presuntamente mejor con el tratamiento que se acepta en el presente como est&#xE1;ndar. La mayor&#xED;a de los avances logrados en la identificaci&#xF3;n de tratamientos curativos para los c&#xE1;nceres infantiles se alcanzaron mediante ensayos cl&#xED;nicos.  Para obtener m&#xE1;s informaci&#xF3;n sobre ensayos cl&#xED;nicos en curso, consultar el <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">portal de Internet del NCI</a>.</p><p id="_907" tabindex="-1">Se han logrado mejoras notables en la supervivencia de ni&#xF1;os y adolescentes con c&#xE1;ncer.[<a href="#cit/section_4.74">74</a>,<a href="#cit/section_4.76">76</a>,<a href="#cit/section_4.77">77</a>] Entre 1975 y 2010, la mortalidad por c&#xE1;ncer infantil disminuy&#xF3; en m&#xE1;s de 50&#xA0;%.[<a href="#cit/section_4.74">74</a>,<a href="#cit/section_4.76">76</a>,<a href="#cit/section_4.77">77</a>]  Los ni&#xF1;os y adolescentes sobrevivientes de c&#xE1;ncer necesitan un seguimiento minucioso, ya que los efectos secundarios del tratamiento del c&#xE1;ncer pueden persistir o presentarse meses o a&#xF1;os despu&#xE9;s de este.  (Para obtener m&#xE1;s informaci&#xF3;n sobre la incidencia, el tipo y el seguimiento de los efectos tard&#xED;os en ni&#xF1;os y adolescentes con c&#xE1;ncer, consultar el sumario del PDQ <a href="/espanol/tipos/infantil/efectos-tardios-pro-pdq">Efectos tard&#xED;os del tratamiento anticanceroso en la ni&#xF1;ez</a>).</p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_4.1">Chintagumpala M, Chevez-Barrios P, Paysse EA, et al.: Retinoblastoma: review of current management. Oncologist 12 (10): 1237-46, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17962617&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17962617&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.2">Abramson DH, Fabius AW, Issa R, et al.: Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. PLoS One 10 (12): e0145436, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.3">Kim JW, Kathpalia V, Dunkel IJ, et al.: Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 93 (4): 463-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.4">Shields CL, Santos MC, Diniz W, et al.: Thermotherapy for retinoblastoma. Arch Ophthalmol 117 (7): 885-93, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408452&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10408452&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.5">Francis JH, Abramson DH, Brodie SE, et al.: Indocyanine green enhanced transpupillary thermotherapy in combination with ophthalmic artery chemosurgery for retinoblastoma. Br J Ophthalmol 97 (2): 164-8, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143908&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143908&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.6">Chantada GL, Fandi&#xF1;o AC, Guitter MR, et al.: Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer 55 (1): 60-6, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.7">Aerts I, Sastre-Garau X, Savignoni A, et al.: Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 31 (11): 1458-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.8">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.9">Sullivan EM, Wilson MW, Billups CA, et al.: Pathologic risk-based adjuvant chemotherapy for unilateral retinoblastoma following enucleation. J Pediatr Hematol Oncol 36 (6): e335-40, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24577551&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24577551&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.10">Dunkel IJ, Khakoo Y, Kernan NA, et al.: Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer 55 (1): 55-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.11">Matsubara H, Makimoto A, Higa T, et al.: A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 35 (8): 763-6, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.12">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of metastatic retinoblastoma. Ophthalmology 110 (6): 1237-40, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.13">Kremens B, Wieland R, Reinhard H, et al.: High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31 (4): 281-4, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.14">Friedman DL, Himelstein B, Shields CL, et al.: Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 18 (1): 12-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10623688&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10623688&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.15">Shields CL, Honavar SG, Meadows AT, et al.: Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133 (5): 657-64, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.16">Friedman DL, Krailo M, Villaluna D, et al.: Systemic neoadjuvant chemotherapy for Group B intraocular retinoblastoma (ARET0331): A report from the Children's Oncology Group. Pediatr Blood Cancer 64 (7): , 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28019092&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28019092&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.17">Brennan RC, Qaddoumi I, Mao S, et al.: Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35 (1): 72-77, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.18">Shields CL, Palamar M, Sharma P, et al.: Retinoblastoma regression patterns following chemoreduction and adjuvant therapy in 557 tumors. Arch Ophthalmol 127 (3): 282-90, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19273791&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19273791&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.19">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 21 (10): 2019-25, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.20">Shields CL, Mashayekhi A, Cater J, et al.: Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 138 (3): 329-37, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.21">Lumbroso L, Doz F, Urbieta M, et al.: Chemothermotherapy in the management of retinoblastoma. Ophthalmology 109 (6): 1130-6, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12045055&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12045055&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.22">Berry JL, Kogachi K, Aziz HA, et al.: Risk of metastasis and orbital recurrence in advanced retinoblastoma eyes treated with systemic chemoreduction versus primary enucleation. Pediatr Blood Cancer 64 (4): , 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28221729&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28221729&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.23">Fabian ID, Naeem Z, Stacey AW, et al.: Long-term Visual Acuity, Strabismus, and Nystagmus Outcomes Following Multimodality Treatment in Group D Retinoblastoma Eyes. Am J Ophthalmol 179: 137-144, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28501391&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28501391&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.24">Shields CL, Mashayekhi A, Sun H, et al.: Iodine 125 plaque radiotherapy as salvage treatment for retinoblastoma recurrence after chemoreduction in 84 tumors. Ophthalmology 113 (11): 2087-92, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16949158&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16949158&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.25">Wilson MW, Haik BG, Billups CA, et al.: Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114 (11): 2077-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.26">Abramson DH, Dunkel IJ, Brodie SE, et al.: Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 117 (8): 1623-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.27">Francis JH, Gobin YP, Dunkel IJ, et al.: Carboplatin +/- topotecan ophthalmic artery chemosurgery for intraocular retinoblastoma. PLoS One 8 (8): e72441, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23991112&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23991112&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.28">Gobin YP, Dunkel IJ, Marr BP, et al.: Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129 (6): 732-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.29">Abramson DH, Marr BP, Brodie SE, et al.: Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS One 7 (4): e34120, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.30">Schaiquevich P, Ceciliano A, Millan N, et al.: Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 60 (5): 766-70, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.31">Yousef YA, Soliman SE, Astudillo PP, et al.: Intra-arterial Chemotherapy for Retinoblastoma: A Systematic Review. JAMA Ophthalmol : , 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26986443&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26986443&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.32">Abramson DH, Marr BP, Dunkel IJ, et al.: Intra-arterial chemotherapy for retinoblastoma in eyes with vitreous and/or subretinal seeding: 2-year results. Br J Ophthalmol 96 (4): 499-502, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22053101&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22053101&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.33">Abramson DH, Daniels AB, Marr BP, et al.: Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma. PLoS One 11 (1): e0146582, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756643&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26756643&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.34">Shields CL, Kaliki S, Al-Dahmash S, et al.: Management of advanced retinoblastoma with intravenous chemotherapy then intra-arterial chemotherapy as alternative to enucleation. Retina 33 (10): 2103-9, 2013 Nov-Dec.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23873161&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23873161&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.35">Shields CL, Bianciotto CG, Jabbour P, et al.: Intra-arterial chemotherapy for retinoblastoma: report No. 1, control of retinal tumors, subretinal seeds, and vitreous seeds. Arch Ophthalmol 129 (11): 1399-406, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670328&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670328&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.36">Say EA, Iyer PG, Hasanreisoglu M, et al.: Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes. J AAPOS 20 (4): 337-42, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.37">Marr BP, Brodie SE, Dunkel IJ, et al.: Three-drug intra-arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol 96 (10): 1300-3, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22863945&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22863945&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.38">Abramson DH, Marr BP, Francis JH, et al.: Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy). PLoS One 11 (6): e0156806, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27258771&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27258771&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.39">Schaiquevich P, Buitrago E, Taich P, et al.: Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 53 (7): 4205-12, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.40">Francis JH, Gobin YP, Brodie SE, et al.: Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. Br J Ophthalmol 96 (9): 1270-1, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.41">Gobin YP, Dunkel IJ, Marr BP, et al.: Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma. PLoS One 7 (9): e44322, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23028521&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23028521&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.42">Pavlidou E, Burris C, Thaung C, et al.: Anterior Segment Seeding in Eyes With Retinoblastoma Failing to Respond to Intraophthalmic Artery Chemotherapy. JAMA Ophthalmol 133 (12): 1455-8, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26334520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26334520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.43">Shields CL, Alset AE, Say EA, et al.: Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era. J Pediatr Ophthalmol Strabismus 53 (5): 275-84, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27486728&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27486728&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.44">Francis JH, Iyer S, Gobin YP, et al.: Retinoblastoma Vitreous Seed Clouds (Class 3): A Comparison of Treatment with Ophthalmic Artery Chemosurgery with or without Intravitreous and Periocular Chemotherapy. Ophthalmology 124 (10): 1548-1555, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28545735&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28545735&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.45">Berry JL, Bechtold M, Shah S, et al.: Not All Seeds Are Created Equal: Seed Classification Is Predictive of Outcomes in&#xA0;Retinoblastoma. Ophthalmology 124 (12): 1817-1825, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28655537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28655537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.46">Shields CL, Say EAT, Pefkianaki M, et al.: RHEGMATOGENOUS RETINAL DETACHMENT AFTER INTRAARTERIAL CHEMOTHERAPY FOR RETINOBLASTOMA: The 2016 Founders Award Lecture. Retina 37 (8): 1441-1450, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787452&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787452&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.47">Suzuki S, Yamane T, Mohri M, et al.: Selective ophthalmic arterial injection therapy for intraocular retinoblastoma: the long-term prognosis. Ophthalmology 118 (10): 2081-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21715012&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21715012&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.48">Shields CL, Bianciotto CG, Jabbour P, et al.: Intra-arterial chemotherapy for retinoblastoma: report No. 2, treatment complications. Arch Ophthalmol 129 (11): 1407-15, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670326&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670326&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.49">Francis JH, Gobin YP, Nagiel A, et al.: Thrombophilia in patients with retinoblastoma receiving ophthalmic artery chemosurgery. Arch Ophthalmol 130 (12): 1605-8, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23229706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23229706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.50">Abramson DH: Chemosurgery for retinoblastoma: what we know after 5 years. Arch Ophthalmol 129 (11): 1492-4, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22084221&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22084221&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.51">Brodie SE, Munier FL, Francis JH, et al.: Persistence of retinal function after intravitreal melphalan injection for retinoblastoma. Doc Ophthalmol 126 (1): 79-84, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143758&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23143758&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.52">Abdelhakim AH, Francis JH, Marr BP, et al.: Retinal reattachment and ERG recovery after ophthalmic artery chemosurgery for advanced retinoblastoma in eyes with minimal baseline retinal function. Br J Ophthalmol 101 (5): 623-628, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27539090&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27539090&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.53">Vijayakrishnan R, Shields CL, Ramasubramanian A, et al.: Irradiation toxic effects during intra-arterial chemotherapy for retinoblastoma: should we be concerned? Arch Ophthalmol 128 (11): 1427-31, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060044&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21060044&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.54">Gobin YP, Rosenstein LM, Marr BP, et al.: Radiation exposure during intra-arterial chemotherapy for retinoblastoma. Arch Ophthalmol 130 (3): 403-4; author reply 404-5, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22411679&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22411679&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.55">Habib LA, Francis JH, Fabius AW, et al.: Second primary malignancies in retinoblastoma patients treated with intra-arterial chemotherapy: the first 10 years. Br J Ophthalmol 102 (2): 272-275, 2018.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28600304&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28600304&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.56">Francis JH, Abramson DH, Gaillard MC, et al.: The classification of vitreous seeds in retinoblastoma and response to intravitreal melphalan. Ophthalmology 122 (6): 1173-9, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25795478&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25795478&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.57">Shields CL, Manjandavida FP, Arepalli S, et al.: Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results. JAMA Ophthalmol 132 (3): 319-25, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24407202&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24407202&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.58">Ghassemi F, Shields CL: Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol 130 (10): 1268-71, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23044940&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23044940&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.59">Munier FL, Gaillard MC, Balmer A, et al.: Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol 96 (8): 1078-83, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22694968&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22694968&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.60">Suzuki S, Aihara Y, Fujiwara M, et al.: Intravitreal injection of melphalan for intraocular retinoblastoma. Jpn J Ophthalmol 59 (3): 164-72, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25808017&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25808017&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.61">Smith SJ, Smith BD: Evaluating the risk of extraocular tumour spread following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol 97 (10): 1231-6, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23740960&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23740960&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.62">Smith SJ, Smith BD, Mohney BG: Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol 98 (3): 292-7, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24187047&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24187047&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.63">Francis JH, Brodie SE, Marr B, et al.: Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience. Ophthalmology 124 (4): 488-495, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28089679&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28089679&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.64">Abramson DH, Frank CM, Dunkel IJ: A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma. Ophthalmology 106 (10): 1947-50, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10519590&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10519590&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.65">Marr BP, Dunkel IJ, Linker A, et al.: Periocular carboplatin for retinoblastoma: long-term report (12 years) on efficacy and toxicity. Br J Ophthalmol 96 (6): 881-3, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22328819&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22328819&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.66">Mallipatna AC, Dimaras H, Chan HS, et al.: Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 129 (6): 738-45, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670340&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21670340&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.67">Krasin MJ, Crawford BT, Zhu Y, et al.: Intensity-modulated radiation therapy for children with intraocular retinoblastoma: potential sparing of the bony orbit. Clin Oncol (R Coll Radiol) 16 (3): 215-22, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15191011&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15191011&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.68">Reisner ML, Vi&#xE9;gas CM, Grazziotin RZ, et al.: Retinoblastoma--comparative analysis of external radiotherapy techniques, including an IMRT technique. Int J Radiat Oncol Biol Phys 67 (3): 933-41, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17293242&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17293242&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.69">Lee CT, Bilton SD, Famiglietti RM, et al.: Treatment planning with protons for pediatric retinoblastoma, medulloblastoma, and pelvic sarcoma: how do protons compare with other conformal techniques? Int J Radiat Oncol Biol Phys 63 (2): 362-72, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168831&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16168831&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.70">Mouw KW, Sethi RV, Yeap BY, et al.: Proton radiation therapy for the treatment of retinoblastoma. Int J Radiat Oncol Biol Phys 90 (4): 863-9, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25227498&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25227498&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.71">Sethi RV, Shih HA, Yeap BY, et al.: Second nonocular tumors among survivors of retinoblastoma treated with contemporary photon and proton radiotherapy. Cancer 120 (1): 126-33, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24122173&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.72">Shields CL, Shields JA, Cater J, et al.: Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology 108 (11): 2116-21, 2001.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11713089&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11713089&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.73">Merchant TE, Gould CJ, Wilson MW, et al.: Episcleral plaque brachytherapy for retinoblastoma. Pediatr Blood Cancer 43 (2): 134-9, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15236279&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15236279&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.74">Smith MA, Altekruse SF, Adamson PC, et al.: Declining childhood and adolescent cancer mortality. Cancer 120 (16): 2497-506, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24853691&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.75">Corrigan JJ, Feig SA; American Academy of Pediatrics: Guidelines for pediatric cancer centers. Pediatrics 113 (6): 1833-5, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173520&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15173520&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_4.76">Childhood cancer. In: Howlader  N, Noone  AM, Krapcho  M, et al., eds.: SEER Cancer Statistics Review, 1975-2010. Bethesda, Md: National Cancer Institute, 2013, Section 28. <a href="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_28_childhood_cancer.pdf" title="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_28_childhood_cancer.pdf">Also available online</a>. Last accessed June 29, 2018.</li><li id="section_4.77">Childhood cancer by the ICCC. In: Howlader  N, Noone  AM, Krapcho  M, et al., eds.: SEER Cancer Statistics Review, 1975-2010. Bethesda, Md: National Cancer Institute, 2013, Section 29. <a href="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_29_childhood_cancer_iccc.pdf" title="http://seer.cancer.gov/csr/1975_2010/results_merged/sect_29_childhood_cancer_iccc.pdf">Also available online</a>. Last accessed June 29, 2018.</li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _780
      field_pdq_section_title:
        - format: plain_text
          value: 'Tratamiento del retinoblastoma intraocular'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_780" class="pdq-sections"><section id="_781"><h3 id="_781_toc">Opciones de tratamiento del retinoblastoma intraocular unilateral</h3><p id="_782" tabindex="-1">Las opciones de tratamiento del retinoblastoma intraocular unilateral son las siguientes:</p><div class="pdq-content-list"><ol id="_783"><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_786">Enucleaci&#xF3;n para tumores intraoculares grandes, seguida de quimioterapia adaptada al riesgo cuando no es posible salvar el ojo</a>.</li><li><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_791">Abordajes conservadores de rescate ocular cuando es posible salvar el ojo y la vista</a>.<div class="pdq-content-list"><ul id="_784"><li>Quimiorreducci&#xF3;n con infusi&#xF3;n de quimioterapia en la arteria oft&#xE1;lmica o por v&#xED;a sist&#xE9;mica, con quimioterapia intrav&#xED;trea o sin esta.</li><li>Tratamientos locales, incluso crioterapia, termoterapia y radioterapia con placas.</li></ul></div></li></ol></div><section id="_786"><h4 id="_786_toc">Enucleaci&#xF3;n seguida de quimioterapia</h4><p id="_787" tabindex="-1">Debido a que la enfermedad unilateral es habitualmente masiva y, a menudo, no hay ninguna expectativa de que se pueda preservar una visi&#xF3;n &#xFA;til, por lo general, se realiza directamente una cirug&#xED;a (enucleaci&#xF3;n). Es necesario que un pat&#xF3;logo experto realice el examen meticuloso del esp&#xE9;cimen enucleado para determinar la presencia de caracter&#xED;sticas de riesgo alto de enfermedad metast&#xE1;sica. Estas <strong>caracter&#xED;sticas de riesgo alto</strong> son las siguientes:[<a href="#cit/section_5.1">1</a>-<a href="#cit/section_5.5">5</a>]</p><div class="pdq-content-list"><ul id="_788"><li>Diseminaci&#xF3;n en la c&#xE1;mara anterior.</li><li>Compromiso coroideo masivo.</li><li>Tumor que se extiende m&#xE1;s all&#xE1; de la l&#xE1;mina cribrosa.</li><li> Diseminaci&#xF3;n escleral y extraescleral.</li></ul></div><p id="_789" tabindex="-1">Las im&#xE1;genes por resonancia magn&#xE9;tica antes de la enucleaci&#xF3;n tienen sensibilidad y especificidad bajas para detectar caracter&#xED;sticas patol&#xF3;gicas de riesgo alto.[<a href="#cit/section_5.6">6</a>]</p><p id="_942" tabindex="-1">La enfermedad de riesgo alto se ha relacionado con la presencia de diseminaci&#xF3;n m&#xED;nima en la m&#xE9;dula &#xF3;sea y el l&#xED;quido cefalorraqu&#xED;deo mediante el uso cuantitativo de la reacci&#xF3;n en cadena de la polimerasa para la detecci&#xF3;n de la homeosecuencia de conos y bastones (CRX) o de la  GD2 sintasa. En un grupo de  96 ni&#xF1;os con retinoblastoma no metast&#xE1;sico y caracter&#xED;sticas patol&#xF3;gicas de riesgo alto, la supervivencia sin enfermedad a los 3 a&#xF1;os fue de 78&#xA0;% en los pacientes con diseminaci&#xF3;n m&#xED;nima detectable, en comparaci&#xF3;n con 98&#xA0;% en los pacientes sin enfermedad detectable (<em>P</em> = 0,004).[<a href="#cit/section_5.7">7</a>]</p><p id="_790" tabindex="-1"> Se ha usado la terapia sist&#xE9;mica adyuvante con vincristina, doxorrubicina y ciclofosfamida, o con vincristina, carboplatino y etop&#xF3;sido para prevenir la enfermedad metast&#xE1;sica en pacientes con ciertas caracter&#xED;sticas de riesgo alto evaluadas mediante una revisi&#xF3;n patol&#xF3;gica despu&#xE9;s de la enucleaci&#xF3;n.[<a href="#cit/section_5.3">3</a>,<a href="#cit/section_5.8">8</a>,<a href="#cit/section_5.9">9</a>]; [<a href="#cit/section_5.10">10</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335132&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335132&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 2A</a>]  </p></section><section id="_791"><h4 id="_791_toc">Abordajes conservadores de rescate ocular</h4><p id="_792" tabindex="-1">Es posible ofrecer abordajes conservadores de rescate ocular, como la quimioterapia sist&#xE9;mica y los tratamientos de control local, para intentar salvar el ojo y preservar la vista.[<a href="#cit/section_5.11">11</a>] Las tasas de rescate ocular se correlacionan con el grupo asignado. Aunque la posibilidad de salvar el ojo sin administrar radioterapia de haz externo (RHE) fue mayor de 80&#xA0;% en los ni&#xF1;os con enfermedad intraocular en estadio inicial, los resultados oculares en los ni&#xF1;os con enfermedad intraocular en estadio avanzado fueron deficientes, con tasas de recate ocular menores de 40&#xA0;% incluso despu&#xE9;s de la administraci&#xF3;n de RHE.[<a href="#cit/section_5.12">12</a>] </p><p id="_793" tabindex="-1">Por tanto, la quimioterapia sist&#xE9;mica prolongada se debe administrar con cautela y la enucleaci&#xF3;n se debe diferir cuando el control tumoral no parezca posible, en particular, en ojos del Grupo E. La quimioterapia antes de la enucleaci&#xF3;n en ojos con enfermedad intraocular avanzada puede dar lugar a una estadificaci&#xF3;n inferior y a subestimar las pruebas patol&#xF3;gicas de enfermedad extrarretiniana y extraocular y, en consecuencia, aumentar el riesgo de diseminaci&#xF3;n.[<a href="#cit/section_5.13">13</a>]</p><p id="_794" tabindex="-1">Seg&#xFA;n parece, la administraci&#xF3;n de quimioterapia mediante una c&#xE1;nula en la arteria oft&#xE1;lmica como tratamiento inicial del retinoblastoma unilateral en estadio avanzado es m&#xE1;s eficaz que la quimiorreducci&#xF3;n con quimioterapia sist&#xE9;mica, en particular, para los ojos del Grupo D.[<a href="#cit/section_5.14">14</a>,<a href="#cit/section_5.15">15</a>]; [<a href="#cit/section_5.16">16</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDiv</a>]. En el entorno de un centro multidisciplinario de vanguardia, la quimioterapia intrarterial produce tasas de preservaci&#xF3;n ocular de alrededor de 80&#xA0;a 90&#xA0;% en pacientes de retinoblastoma unilateral intraocular avanzado.[<a href="#cit/section_5.15">15</a>-<a href="#cit/section_5.17">17</a>]; [<a href="#cit/section_5.18">18</a>,<a href="#cit/section_5.19">19</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335155&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335155&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiiDii</a>]; [<a href="#cit/section_5.20">20</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587991&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000587991&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiiDiv</a>] (Para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_880">Infusi&#xF3;n de quimioterapia en la arteria oft&#xE1;lmica [quimioterapia intrarterial]</a>).</p><p id="_795" tabindex="-1">Debido a que una proporci&#xF3;n de ni&#xF1;os con retinoblastoma unilateral presentar&#xE1; con el tiempo la enfermedad en el ojo opuesto, estos ni&#xF1;os se someten a orientaci&#xF3;n y pruebas gen&#xE9;ticas, as&#xED; como a ex&#xE1;menes peri&#xF3;dicos del ojo no afectado, independientemente del tratamiento que reciban. La enfermedad bilateral asincr&#xF3;nica se presenta, con mayor frecuencia, en pacientes con padres afectados y en ni&#xF1;os diagnosticados durante los primeros meses de vida.</p></section></section><section id="_796"><h3 id="_796_toc">Opciones de tratamiento del retinoblastoma intraocular bilateral</h3><p id="_798" tabindex="-1">Las opciones de tratamiento del retinoblastoma intraocular bilateral son las siguientes:</p><div class="pdq-content-list"><ol id="_799"><li>Enucleaci&#xF3;n para tumores intraoculares grandes, seguida de quimioterapia adaptada al riesgo cuando no  es posible salvar el ojo ni la vista.</li><li>Abordajes conservadores de rescate ocular cuando es posible salvar el ojo y la vista.<div class="pdq-content-list"><ul id="_800"><li>Quimiorreducci&#xF3;n con infusi&#xF3;n de quimioterapia en la arteria oft&#xE1;lmica o infusi&#xF3;n sist&#xE9;mica, con quimioterapia intrav&#xED;trea o sin esta.</li><li>Tratamientos locales, como crioterapia, termoterapia y radioterapia con placas.</li><li>RHE.</li></ul></div></li></ol></div><p id="_908" tabindex="-1">El objetivo del tratamiento del  retinoblastoma bilateral es preservar el ojo y la vista, as&#xED; como retardar o evitar la RHE y la enucleaci&#xF3;n.  En general, la carga de tumor intraocular es asim&#xE9;trica y el tratamiento se determina seg&#xFA;n el ojo con enfermedad m&#xE1;s avanzada. El tratamiento sist&#xE9;mico se suele seleccionar a partir del ojo con mayor extensi&#xF3;n de enfermedad. En los pacientes con enfermedad bilateral, las opciones de tratamiento descritas para la enfermedad unilateral se utilizan en uno o ambos ojos afectados. Si bien es posible que se necesite la enucleaci&#xF3;n inicial de un ojo con enfermedad avanzada y la administraci&#xF3;n de quimioterapia adyuvante adaptada al riesgo, es usual que el tratamiento de elecci&#xF3;n sea un abordaje m&#xE1;s conservador que incluya la administraci&#xF3;n de quimiorreducci&#xF3;n primaria con seguimiento minucioso de la respuesta y tratamiento local intensivo. En la actualidad, la RHE se reserva para los pacientes cuyos ojos no reaccionan bien a la quimioterapia sist&#xE9;mica o intrarterial inicial, y a la consolidaci&#xF3;n local.[<a href="#cit/section_5.21">21</a>]</p><p id="_803" tabindex="-1">Varios centros grandes publicaron los resultados de ensayos en los que se us&#xF3; quimioterapia sist&#xE9;mica junto con una consolidaci&#xF3;n local intensiva en pacientes con enfermedad bilateral.[<a href="#cit/section_5.11">11</a>,<a href="#cit/section_5.22">22</a>-<a href="#cit/section_5.30">30</a>] Los f&#xE1;rmacos fundamentales para la quimiorreducci&#xF3;n han sido, generalmente, carboplatino, etop&#xF3;sido y vincristina. Aunque la combinaci&#xF3;n de vincristina y carboplatino, de toxicidad m&#xE1;s baja, logra controlar la enfermedad en una proporci&#xF3;n significativa de los pacientes,[<a href="#cit/section_5.26">26</a>] el rescate ocular es mejor cuando el r&#xE9;gimen incluye etop&#xF3;sido.[<a href="#cit/section_5.31">31</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335131&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335131&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 1iiDiii</a>]  Se obtuvieron resultados similares en un estudio de una instituci&#xF3;n en el que se us&#xF3; topotec&#xE1;n en lugar de etop&#xF3;sido en un r&#xE9;gimen de combinaci&#xF3;n.[<a href="#cit/section_5.32">32</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiA</a>] La quimioterapia reduce el tama&#xF1;o de los tumores (quimiorreducci&#xF3;n) y permite que la terapia local posterior sea m&#xE1;s eficaz.[<a href="#cit/section_5.11">11</a>] Las estrategias del tratamiento difieren a menudo en t&#xE9;rminos de reg&#xED;menes quimioterap&#xE9;uticos y medidas de control local. Mediante este abordaje, el sistema de agrupaci&#xF3;n de la International Classification of Retinoblastoma ha probado que permite pronosticar el rescate ocular.[<a href="#cit/section_5.33">33</a>,<a href="#cit/section_5.34">34</a>]; [<a href="#cit/section_5.35">35</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDiv</a>]</p><div class="pdq-content-list"><ul id="_804"><li><strong>Grupos A y B:</strong> la quimioterapia sist&#xE9;mica, junto con el control local condujo a tasas de rescate ocular mayores de 90&#xA0;% para la enfermedad intraocular en estadio temprano.[<a href="#cit/section_5.34">34</a>-<a href="#cit/section_5.36">36</a>]</li><li><strong>Grupos C y D:</strong> las tasas de rescate ocular con el uso de este abordaje son de 70 a 90&#xA0;% para los ojos del Grupo C y de 40 a 50&#xA0;% para los ojos del Grupo D.[<a href="#cit/section_5.34">34</a>-<a href="#cit/section_5.36">36</a>] Sin embargo, con frecuencia es necesaria la RHE para el rescate ocular de los pacientes de enfermedad intraocular m&#xE1;s avanzada (por lo general, en ojos del Grupo D).[<a href="#cit/section_5.35">35</a>]; [<a href="#cit/section_5.36">36</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335149&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335149&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDiii</a>]<p id="_805" tabindex="-1">Para los pacientes que presentan gran carga tumoral intraocular con diseminaci&#xF3;n subretiniana o v&#xED;trea (ojos del Grupos D), se explor&#xF3; la administraci&#xF3;n de dosis m&#xE1;s altas de carboplatino, junto con carboplatino debajo de la c&#xE1;psula de Tenon y la adici&#xF3;n de dosis m&#xE1;s bajas de RHE (36 Gy) para los pacientes con enfermedad persistente. Con este abordaje intensivo, la supervivencia ocular se puede acercar a una tasa de 70&#xA0;% a los 60 meses.[<a href="#cit/section_5.37">37</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587988&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000587988&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 2Div</a>]</p></li><li><strong>Grupo E:</strong> en general, el tratamiento de los ojos del Grupo E es la enucleaci&#xF3;n inicial. El uso prolongado de quimioterapia sist&#xE9;mica para ojos del Grupo E con la intenci&#xF3;n de evitar o diferir la enucleaci&#xF3;n se relacion&#xF3; con una menor supervivencia espec&#xED;fica a la enfermedad.[<a href="#cit/section_5.13">13</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335151&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335151&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiiB</a>]</li></ul></div><p id="_806" tabindex="-1">Tambi&#xE9;n se demostr&#xF3; que la administraci&#xF3;n de quimioterapia mediante la canulaci&#xF3;n de la arteria oft&#xE1;lmica es tan factible y eficaz como la administraci&#xF3;n en t&#xE1;ndem para el rescate ocular de los pacientes con enfermedad bilateral reci&#xE9;n diagnosticada.[<a href="#cit/section_5.18">18</a>,<a href="#cit/section_5.19">19</a>,<a href="#cit/section_5.38">38</a>,<a href="#cit/section_5.39">39</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335148&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335148&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDii</a>] La administraci&#xF3;n bilateral aumenta el riesgo de efectos t&#xF3;xicos sist&#xE9;micos causados por la exposici&#xF3;n al melfal&#xE1;n.[<a href="#cit/section_5.40">40</a>] En estas circunstancias, se puede utilizar quimioterapia intrarterial con carboplatino en monoterapia para tratar el ojo con enfermedad menos avanzada durante el procedimiento en t&#xE1;ndem.[<a href="#cit/section_5.41">41</a>] Estos tratamientos solo se deben administrar  en centros oncol&#xF3;gicos que posean una infraestructura de vanguardia y cuenten con un equipo multidisciplinario especializado.</p></section><section id="_807"><h3 id="_807_toc">Opciones de tratamiento del retinoblastoma cavitario</h3><p id="_918" tabindex="-1">La opci&#xF3;n de tratamiento del retinoblastoma cavitario es la siguiente:</p><div class="pdq-content-list"><ol id="_919"><li>Quimioterapia sist&#xE9;mica o intrarterial.</li></ol></div><p id="_808" tabindex="-1">En los pacientes con retinoblastoma cavitario, se observa una respuesta visual m&#xED;nima despu&#xE9;s de la quimioterapia intravenosa o intrarterial. A pesar de la disminuci&#xF3;n de la respuesta cl&#xED;nica, el retinoblastoma cavitario tiene un desenlace favorable a largo plazo con remisi&#xF3;n tumoral estable y rescate del globo ocular. Por lo general, no son necesarias la quimioterapia intensiva o prolongada, ni las terapias complementarias. En una serie retrospectiva de 26 retinoblastomas cavitarios tratados con quimiorreducci&#xF3;n intravenosa o quimioterapia intrarterial, la media de reducci&#xF3;n de la base tumoral fue de 22&#xA0;% y la media de reducci&#xF3;n del espesor tumoral fue de 29&#xA0;%. Pese a la reducci&#xF3;n m&#xED;nima, se observ&#xF3; la recidiva del tumor en solo un ojo, se logr&#xF3; el rescate del globo ocular en 22 ojos y no hubo casos de met&#xE1;stasis ni muerte durante 49 meses (intervalo, 6&#x2013;189 meses) de seguimiento.[<a href="#cit/section_5.42">42</a>]</p></section><section id="_TrialSearch_780_sid_5"><h3 id="_TrialSearch_780_sid_5_toc">Ensayos cl&#xED;nicos en curso</h3><p id="_TrialSearch_780_25" tabindex="-1">Realizar una <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">b&#xFA;squeda avanzada</a> en ingl&#xE9;s de los ensayos cl&#xED;nicos sobre c&#xE1;ncer auspiciados por el NCI que ahora aceptan pacientes. La b&#xFA;squeda se puede simplificar por ubicaci&#xF3;n del ensayo, tipo de tratamiento, nombre del f&#xE1;rmaco y otros criterios. Tambi&#xE9;n se dispone de <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">informaci&#xF3;n general</a> sobre los ensayos cl&#xED;nicos. </p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_5.1">Chantada GL, Guitter MR, Fandi&#xF1;o AC, et al.: Treatment results in patients with retinoblastoma and invasion to the cut end of the optic nerve. Pediatr Blood Cancer 52 (2): 218-22, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18937327&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18937327&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.2">Eagle RC Jr: High-risk features and tumor differentiation in retinoblastoma: a retrospective histopathologic study. Arch Pathol Lab Med 133 (8): 1203-9, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653710&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653710&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.3">Aerts I, Sastre-Garau X, Savignoni A, et al.: Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 31 (11): 1458-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.4">Kaliki S, Shields CL, Rojanaporn D, et al.: High-risk retinoblastoma based on international classification of retinoblastoma: analysis of 519 enucleated eyes. Ophthalmology 120 (5): 997-1003, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23399379&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.5">Sastre X, Chantada GL, Doz F, et al.: Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med 133 (8): 1199-202, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653709&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19653709&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.6">Chawla B, Sharma S, Sen S, et al.: Correlation between clinical features, magnetic resonance imaging, and histopathologic findings in retinoblastoma: a prospective study. Ophthalmology 119 (4): 850-6, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22218144&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22218144&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.7">Laurent VE, Torbidoni AV, Sampor C, et al.: Minimal Disseminated Disease in Nonmetastatic Retinoblastoma With High-Risk Pathologic Features and Association With Disease-Free Survival. JAMA Ophthalmol 134 (12): 1374-1379, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787537&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27787537&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.8">Chantada GL, Dunkel IJ, de D&#xE1;vila MT, et al.: Retinoblastoma patients with high risk ocular pathological features: who needs adjuvant therapy? Br J Ophthalmol 88 (8): 1069-73, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15258027&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15258027&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.9">Cuenca A, Giron F, Castro D, et al.: Microscopic scleral invasion in retinoblastoma: clinicopathological features and outcome. Arch Ophthalmol 127 (8): 1006-10, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19667337&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19667337&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.10">Chantada GL, Fandi&#xF1;o AC, Guitter MR, et al.: Results of a prospective study for the treatment of unilateral retinoblastoma. Pediatr Blood Cancer 55 (1): 60-6, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486172&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.11">Shields CL, Honavar SG, Meadows AT, et al.: Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 133 (5): 657-64, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11992863&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.12">Shields CL, Honavar SG, Meadows AT, et al.: Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 120 (12): 1653-8, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12470138&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12470138&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.13">Zhao J, Dimaras H, Massey C, et al.: Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis. J Clin Oncol 29 (7): 845-51, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21282531&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21282531&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.14">Abramson DH, Fabius AW, Issa R, et al.: Advanced Unilateral Retinoblastoma: The Impact of Ophthalmic Artery Chemosurgery on Enucleation Rate and Patient Survival at MSKCC. PLoS One 10 (12): e0145436, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26709699&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.15">Munier FL, Mosimann P, Puccinelli F, et al.: First-line intra-arterial versus intravenous chemotherapy in unilateral sporadic group D retinoblastoma: evidence of better visual outcomes, ocular survival and shorter time to success with intra-arterial delivery from retrospective review of 20&#x2005;years of treatment. Br J Ophthalmol 101 (8): 1086-1093, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27927678&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27927678&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.16">Shields CL, Jorge R, Say EA, et al.: Unilateral Retinoblastoma Managed With Intravenous Chemotherapy Versus Intra-Arterial Chemotherapy. Outcomes Based on the International Classification of Retinoblastoma. Asia Pac J Ophthalmol (Phila) 5 (2): 97-103, 2016 Mar-Apr.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26765038&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26765038&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.17">Abramson DH, Marr BP, Brodie SE, et al.: Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review. PLoS One 7 (4): e34120, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22545080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.18">Abramson DH, Dunkel IJ, Brodie SE, et al.: Superselective ophthalmic artery chemotherapy as primary treatment for retinoblastoma (chemosurgery). Ophthalmology 117 (8): 1623-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20381868&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.19">Gobin YP, Dunkel IJ, Marr BP, et al.: Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol 129 (6): 732-7, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21320950&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.20">Peterson EC, Elhammady MS, Quintero-Wolfe S, et al.: Selective ophthalmic artery infusion of chemotherapy for advanced intraocular retinoblastoma: initial experience with 17 tumors. J Neurosurg 114 (6): 1603-8, 2011.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21294621&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21294621&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.21">Orman A, Koru-Sengul T, Miao F, et al.: The modern role of radiation therapy in treating advanced-stage retinoblastoma: long-term outcomes and racial differences. Int J Radiat Oncol Biol Phys 90 (5): 1037-43, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25442037&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25442037&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.22">Beck MN, Balmer A, Dessing C, et al.: First-line chemotherapy with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 18 (15): 2881-7, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10920136&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10920136&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.23">Murphree AL, Villablanca JG, Deegan WF 3rd, et al.: Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 114 (11): 1348-56, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906025&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906025&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.24">Shields CL, Mashayekhi A, Cater J, et al.: Chemoreduction for retinoblastoma. Analysis of tumor control and risks for recurrence in 457 tumors. Am J Ophthalmol 138 (3): 329-37, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15364213&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.25">Gallie BL, Budning A, DeBoer G, et al.: Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 114 (11): 1321-8, 1996.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906022&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8906022&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.26">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 21 (10): 2019-25, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12743157&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.27">Wilson MW, Haik BG, Billups CA, et al.: Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114 (11): 2077-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.28">Rodriguez-Galindo C, Chantada GL, Haik BG, et al.: Treatment of retinoblastoma: current status and future perspectives. Curr Treat Options Neurol 9 (4): 294-307, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17580009&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17580009&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.29">Shields CL, Mashayekhi A, Cater J, et al.: Macular retinoblastoma managed with chemoreduction: analysis of tumor control with or without adjuvant thermotherapy in 68 tumors. Arch Ophthalmol 123 (6): 765-73, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15955977&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15955977&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.30">Qaddoumi I, Billups CA, Tagen M, et al.: Topotecan and vincristine combination is effective against advanced bilateral intraocular retinoblastoma and has manageable toxicity. Cancer 118 (22): 5663-70, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22516936&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22516936&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.31">Lumbroso-Le Rouic L, Aerts I, Hajage D, et al.: Conservative treatment of retinoblastoma: a prospective phase II randomized trial of neoadjuvant chemotherapy followed by local treatments and chemothermotherapy. Eye (Lond) 30 (1): 46-52, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26427984&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26427984&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.32">Brennan RC, Qaddoumi I, Mao S, et al.: Ocular Salvage and Vision Preservation Using a Topotecan-Based Regimen for Advanced Intraocular Retinoblastoma. J Clin Oncol 35 (1): 72-77, 2017.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=28034080&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.33">Zage PE, Reitman AJ, Seshadri R, et al.: Outcomes of a two-drug chemotherapy regimen for intraocular retinoblastoma. Pediatr Blood Cancer 50 (3): 567-72, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17729249&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.34">Shields CL, Mashayekhi A, Au AK, et al.: The International Classification of Retinoblastoma predicts chemoreduction success. Ophthalmology 113 (12): 2276-80, 2006.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=16996605&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.35">Lumbroso-Le Rouic L, Aerts I, L&#xE9;vy-Gabriel C, et al.: Conservative treatments of intraocular retinoblastoma. Ophthalmology 115 (8): 1405-10, 1410.e1-2, 2008.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18222001&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18222001&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.36">Cohen VM, Kingston J, Hungerford JL: The success of primary chemotherapy for group D heritable retinoblastoma. Br J Ophthalmol 93 (7): 887-90, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18703556&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18703556&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.37">Berry JL, Jubran R, Kim JW, et al.: Long-term outcomes of Group D eyes in bilateral retinoblastoma patients treated with chemoreduction and low-dose IMRT salvage. Pediatr Blood Cancer 60 (4): 688-93, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22997170&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22997170&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.38">Abramson DH, Dunkel IJ, Brodie SE, et al.: Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy. Arch Ophthalmol 128 (3): 370-2, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20212212&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20212212&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.39">Palioura S, Gobin YP, Brodie SE, et al.: Ophthalmic artery chemosurgery for the management of retinoblastoma in eyes with extensive (&gt;50%) retinal detachment. Pediatr Blood Cancer 59 (5): 859-64, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22492689&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22492689&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.40">Schaiquevich P, Buitrago E, Taich P, et al.: Pharmacokinetic analysis of melphalan after superselective ophthalmic artery infusion in preclinical models and retinoblastoma patients. Invest Ophthalmol Vis Sci 53 (7): 4205-12, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22628208&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.41">Francis JH, Gobin YP, Brodie SE, et al.: Experience of intra-arterial chemosurgery with single agent carboplatin for retinoblastoma. Br J Ophthalmol 96 (9): 1270-1, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22611138&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_5.42">Rojanaporn D, Kaliki S, Bianciotto CG, et al.: Intravenous chemoreduction or intra-arterial chemotherapy for cavitary retinoblastoma: long-term results. Arch Ophthalmol 130 (5): 585-90, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22652844&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22652844&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _77
      field_pdq_section_title:
        - format: plain_text
          value: 'Tratamiento del retinoblastoma extraocular'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_77" class="pdq-sections"><p id="_78" tabindex="-1"> En pa&#xED;ses de altos ingresos, pocos pacientes de retinoblastoma presentan inicialmente una enfermedad extraocular. La enfermedad extraocular se ubica en los tejidos blandos alrededor del ojo o en el nervio &#xF3;ptico m&#xE1;s all&#xE1; del margen de resecci&#xF3;n. Sin embargo, es posible que la enfermedad se extienda al enc&#xE9;falo y las meninges con diseminaci&#xF3;n subsiguiente al l&#xED;quido cefalorraqu&#xED;deo, as&#xED; como enfermedad metast&#xE1;sica a distancia que compromete pulmones, huesos y m&#xE9;dula &#xF3;sea.</p><section id="_117"><h3 id="_117_toc">Opciones de tratamiento del retinoblastoma extraocular</h3><section id="_539"><h4 id="_539_toc">Retinoblastoma orbitario y locorregional</h4><p id="_812" tabindex="-1">Las opciones de tratamiento del retinoblastoma extraocular (orbitario y locorregional) son las siguientes:</p><div class="pdq-content-list"><ol id="_813"><li>Quimioterapia.</li><li>Radioterapia.</li></ol></div><p id="_540" tabindex="-1">El retinoblastoma orbitario se presenta como resultado de la diseminaci&#xF3;n del tumor por los vasos emisarios y la escler&#xF3;tica. Por esta raz&#xF3;n, la enfermedad transescleral se considera extraocular y se deber&#xE1; tratar como tal. El retinoblastoma orbitario se presenta de forma aislada en 60 a 70&#xA0;% de los casos.</p><p id="_814" tabindex="-1">El tratamiento incluye quimioterapia sist&#xE9;mica y radioterapia; con este abordaje, se puede curar de 60 a 85&#xA0;% de los pacientes. Debido a que la mayor&#xED;a de las recidivas se presentan en el sistema nervioso central (SNC), se recomiendan los reg&#xED;menes con f&#xE1;rmacos de penetraci&#xF3;n comprobada en el SNC. Los diferentes reg&#xED;menes quimioterap&#xE9;uticos que resultaron eficaces son vincristina, ciclofosfamida y doxorrubicina, y reg&#xED;menes a base de  platino y epipodofilotoxina, o una combinaci&#xF3;n de ambos.[<a href="#cit/section_6.1">1</a>-<a href="#cit/section_6.3">3</a>]</p><p id="_815" tabindex="-1">En los pacientes con enfermedad orbitaria macrosc&#xF3;pica, se recomienda diferir la cirug&#xED;a hasta obtener una respuesta quimioterap&#xE9;utica (habitualmente, 2 o 3 tres ciclos de tratamiento). A continuaci&#xF3;n, los pacientes se someten a enucleaci&#xF3;n y reciben 4 a 6 ciclos adicionales de quimioterapia. Luego, se consolida el control local con irradiaci&#xF3;n orbitaria (40 a 45 Gy). Con este abordaje, no se indica la exenteraci&#xF3;n orbitaria.[<a href="#cit/section_6.3">3</a>]</p><p id="_816" tabindex="-1">Se considera que los pacientes con compromiso aislado del nervio &#xF3;ptico en el punto de la transecci&#xF3;n tienen enfermedad extraocular y se tratan con terapia sist&#xE9;mica, similar a la utilizada para la enfermedad orbitaria macrosc&#xF3;pica, e irradiaci&#xF3;n dirigida a toda la &#xF3;rbita (36 Gy) con un refuerzo de 10 Gy de irradiaci&#xF3;n dirigida al quiasma (total 46 Gy).[<a href="#cit/section_6.2">2</a>]</p></section><section id="_541"><h4 id="_541_toc">Enfermedad en el sistema nervioso central</h4><p id="_817" tabindex="-1">Las opciones de tratamiento del retinoblastoma extraocular (enfermedad en el SNC) son las siguientes:</p><div class="pdq-content-list"><ol id="_818"><li>Quimioterapia sist&#xE9;mica y terapia dirigida al SNC.</li><li>Quimioterapia sist&#xE9;mica seguida de quimioterapia mielosupresora y rescate de c&#xE9;lulas madre.</li></ol></div><p id="_542" tabindex="-1">La diseminaci&#xF3;n intracraneal se presenta por diseminaci&#xF3;n directa a trav&#xE9;s del nervio &#xF3;ptico y su pron&#xF3;stico es desalentador. Para estos pacientes, el tratamiento incluye quimioterapia sist&#xE9;mica intensiva a base de platino y terapia dirigida al SNC. Aunque tradicionalmente se us&#xF3; la quimioterapia intratecal, no hay datos probatorios precl&#xED;nicos o cl&#xED;nicos que respalden su uso. La administraci&#xF3;n de radioterapia en estos pacientes es pol&#xE9;mica. Se han observado respuestas con radiaci&#xF3;n craneoespinal de 25 a 35 Gy dirigida a todo el eje craneoespinal  y un refuerzo (10 Gy) dirigido a los sitios con enfermedad mensurable.</p><p id="_819" tabindex="-1">Se explor&#xF3; una intensificaci&#xF3;n del tratamiento con dosis altas de quimioterapia supresora de m&#xE9;dula &#xF3;sea y rescate aut&#xF3;geno de c&#xE9;lulas madre hematopoy&#xE9;ticas, pero su funci&#xF3;n todav&#xED;a no est&#xE1; clara.[<a href="#cit/section_6.4">4</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiA</a>]</p></section><section id="_543"><h4 id="_543_toc">Retinoblastoma trilateral</h4><p id="_820" tabindex="-1">Las opciones de tratamiento del retinoblastoma trilateral son las siguientes:</p><div class="pdq-content-list"><ol id="_821"><li>Quimioterapia sist&#xE9;mica seguida de cirug&#xED;a y quimioterapia mielosupresora con rescate de c&#xE9;lulas madre.</li><li>Quimioterapia sist&#xE9;mica seguida de cirug&#xED;a y radioterapia.</li></ol></div><p id="_544" tabindex="-1">El retinoblastoma trilateral habitualmente se relaciona con una lesi&#xF3;n pineal o, con menor frecuencia, con una lesi&#xF3;n supraselar.[<a href="#cit/section_6.5">5</a>-<a href="#cit/section_6.7">7</a>]  En pacientes con la forma hereditaria de retinoblastoma, es menos probable que la enfermedad en el SNC sea el resultado de la diseminaci&#xF3;n metast&#xE1;sica o regional que de un foco intracraneal primario, como un tumor pineal. El pron&#xF3;stico para los pacientes con retinoblastoma trilateral es muy precario; la mayor&#xED;a de los pacientes mueren en menos de 9 meses por una enfermedad del tubo neural diseminada.[<a href="#cit/section_6.8">8</a>,<a href="#cit/section_6.9">9</a>] Sin embargo, el aumento de la vigilancia y la administraci&#xF3;n de tratamiento intensivo produjo una mejora de la supervivencia de 6&#xA0;% (pacientes tratados antes de 1995) a 44&#xA0;% (pacientes tratados despu&#xE9;s de 1996).[<a href="#cit/section_6.10">10</a>]</p><p id="_822" tabindex="-1">Si bien los pineoblastomas que se presentan en pacientes de m&#xE1;s edad son sensibles a la radioterapia, las estrategias actuales se dirigen a evitar la radiaci&#xF3;n mediante el uso de quimioterapia intensiva seguida de consolidaci&#xF3;n con quimioterapia mielosupresora y rescate aut&#xF3;geno de c&#xE9;lulas madre hematopoy&#xE9;ticas, que es un abordaje similar al utilizado para tratar tumores encef&#xE1;licos en lactantes.[<a href="#cit/section_6.11">11</a>]</p><p id="_916" tabindex="-1">(Para obtener m&#xE1;s informaci&#xF3;n sobre el retinoblastoma trilateral, incluso ex&#xE1;menes de detecci&#xF3;n y neuroimaginolog&#xED;a, consultar la subsecci&#xF3;n <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_496">Retinoblastoma trilateral</a> en la secci&#xF3;n de este sumario <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_493">Causas de la mortalidad relacionada con el retinoblastoma</a>).</p></section><section id="_546"><h4 id="_546_toc">Retinoblastoma extracraneal metast&#xE1;sico</h4><p id="_824" tabindex="-1">La opci&#xF3;n de tratamiento del retinoblastoma extracraneal metast&#xE1;sico es la siguiente:</p><div class="pdq-content-list"><ol id="_825"><li>Quimioterapia sist&#xE9;mica seguida de quimioterapia mielosupresora con rescate de c&#xE9;lulas madre y radioterapia.</li></ol></div><p id="_547" tabindex="-1">Se pueden presentar met&#xE1;stasis hem&#xE1;ticas en los huesos, la m&#xE9;dula &#xF3;sea y, con menos frecuencia, el h&#xED;gado. Aunque se inform&#xF3; de  supervivencia a largo plazo con quimioterapia convencional, estos informes se deben considerar anecd&#xF3;ticos; el retinoblastoma metast&#xE1;sico no es curable con quimioterapia convencional. Sin embargo, en estudios de series peque&#xF1;as de pacientes realizados en los &#xFA;ltimos veinte a&#xF1;os, se demostr&#xF3; que es posible curar el retinoblastoma metast&#xE1;sico con dosis altas de quimioterapia supresora de m&#xE9;dula &#xF3;sea y rescate aut&#xF3;geno de c&#xE9;lulas madre hematopoy&#xE9;ticas.[<a href="#cit/section_6.12">12</a>-<a href="#cit/section_6.18">18</a>]; [<a href="#cit/section_6.19">19</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiA</a>]</p></section></section><section id="_TrialSearch_77_sid_6"><h3 id="_TrialSearch_77_sid_6_toc">Ensayos cl&#xED;nicos en curso</h3><p id="_TrialSearch_77_25" tabindex="-1">Realizar una <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">b&#xFA;squeda avanzada</a> en ingl&#xE9;s de los ensayos cl&#xED;nicos sobre c&#xE1;ncer auspiciados por el NCI que ahora aceptan pacientes. La b&#xFA;squeda se puede simplificar por ubicaci&#xF3;n del ensayo, tipo de tratamiento, nombre del f&#xE1;rmaco y otros criterios. Tambi&#xE9;n se dispone de <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">informaci&#xF3;n general</a> sobre los ensayos cl&#xED;nicos. </p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_6.1">Antoneli CB, Ribeiro KB, Rodriguez-Galindo C, et al.: The addition of ifosfamide/etoposide to cisplatin/teniposide improves the survival of children with retinoblastoma and orbital involvement. J Pediatr Hematol Oncol 29 (10): 700-4, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17921851&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17921851&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.2">Aerts I, Sastre-Garau X, Savignoni A, et al.: Results of a multicenter prospective study on the postoperative treatment of unilateral retinoblastoma after primary enucleation. J Clin Oncol 31 (11): 1458-63, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23460706&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.3">Radhakrishnan V, Kashyap S, Pushker N, et al.: Outcome, pathologic findings, and compliance in orbital retinoblastoma (International Retinoblastoma Staging System stage III) treated with neoadjuvant chemotherapy: a prospective study. Ophthalmology 119 (7): 1470-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22463820&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22463820&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.4">Dunkel IJ, Chan HS, Jubran R, et al.: High-dose chemotherapy with autologous hematopoietic stem cell rescue for stage 4B retinoblastoma. Pediatr Blood Cancer 55 (1): 149-52, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486181&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486181&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.5">Rodjan F, de Graaf P, Brisse HJ, et al.: Trilateral retinoblastoma: neuroimaging characteristics and value of routine brain screening on admission. J Neurooncol 109 (3): 535-44, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=22802019&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.6">Paulino AC: Trilateral retinoblastoma: is the location of the intracranial tumor important? Cancer 86 (1): 135-41, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391573&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10391573&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.7">Blach LE, McCormick B, Abramson DH, et al.: Trilateral retinoblastoma--incidence and outcome: a decade of experience. Int J Radiat Oncol Biol Phys 29 (4): 729-33, 1994.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=8040018&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.8">Kivel&#xE4; T: Trilateral retinoblastoma: a meta-analysis of hereditary retinoblastoma associated with primary ectopic intracranial retinoblastoma. J Clin Oncol 17 (6): 1829-37, 1999.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=10561222&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.9">Marcus DM, Brooks SE, Leff G, et al.: Trilateral retinoblastoma: insights into histogenesis and management. Surv Ophthalmol 43 (1): 59-70, 1998 Jul-Aug.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9716194&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9716194&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.10">de Jong MC, Kors WA, de Graaf P, et al.: Trilateral retinoblastoma: a systematic review and meta-analysis. Lancet Oncol 15 (10): 1157-67, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25126964&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.11">Dunkel IJ, Jubran RF, Gururangan S, et al.: Trilateral retinoblastoma: potentially curable with intensive chemotherapy. Pediatr Blood Cancer 54 (3): 384-7, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19908299&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19908299&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.12">Namouni F, Doz F, Tanguy ML, et al.: High-dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by a haematopoietic stem cell rescue in patients with high-risk retinoblastoma: a SFOP and SFGM study. Eur J Cancer 33 (14): 2368-75, 1997.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9616283&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=9616283&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.13">Kremens B, Wieland R, Reinhard H, et al.: High-dose chemotherapy with autologous stem cell rescue in children with retinoblastoma. Bone Marrow Transplant 31 (4): 281-4, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12621463&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.14">Rodriguez-Galindo C, Wilson MW, Haik BG, et al.: Treatment of metastatic retinoblastoma. Ophthalmology 110 (6): 1237-40, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=12799253&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.15">Dunkel IJ, Aledo A, Kernan NA, et al.: Successful treatment of metastatic retinoblastoma. Cancer 89 (10): 2117-21, 2000.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11066053&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11066053&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.16">Matsubara H, Makimoto A, Higa T, et al.: A multidisciplinary treatment strategy that includes high-dose chemotherapy for metastatic retinoblastoma without CNS involvement. Bone Marrow Transplant 35 (8): 763-6, 2005.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=15750608&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.17">Jubran RF, Erdreich-Epstein A, Butturini A, et al.: Approaches to treatment for extraocular retinoblastoma: Children's Hospital Los Angeles experience. J Pediatr Hematol Oncol 26 (1): 31-4, 2004.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14707710&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14707710&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.18">Palma J, Sasso DF, Dufort G, et al.: Successful treatment of metastatic retinoblastoma with high-dose chemotherapy and autologous stem cell rescue in South America. Bone Marrow Transplant 47 (4): 522-7, 2012.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21602901&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=21602901&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_6.19">Dunkel IJ, Khakoo Y, Kernan NA, et al.: Intensive multimodality therapy for patients with stage 4a metastatic retinoblastoma. Pediatr Blood Cancer 55 (1): 55-9, 2010.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=20486171&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _85
      field_pdq_section_title:
        - format: plain_text
          value: 'Tratamiento del retinoblastoma progresivo o recidivante'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_85" class="pdq-sections"><p id="_86" tabindex="-1">El pron&#xF3;stico de un paciente de retinoblastoma progresivo o recidivante depende de su ubicaci&#xF3;n y del grado de progresi&#xF3;n o recidiva, as&#xED; como del tratamiento previo. Las recidivas intra y extraoculares tienen pron&#xF3;sticos muy diferentes y se tratan de diferente manera.</p><section id="_909"><h3 id="_909_toc">Opciones de tratamiento de retinoblastoma intraocular progresivo o recidivante</h3><p id="_826" tabindex="-1">Las opciones de tratamiento del retinoblastoma intraocular progresivo o recidivante son las siguientes:</p><div class="pdq-content-list"><ol id="_827"><li>Enucleaci&#xF3;n.</li><li>Radioterapia (radioterapia de haz externo o con placas).</li><li>Tratamientos locales (crioterapia o termoterapia).</li><li>Quimioterapia de rescate (quimioterapia sist&#xE9;mica o intrarterial).[<a href="#cit/section_7.1">1</a>]</li><li>Administraci&#xF3;n de quimioterapia intrav&#xED;trea, particularmente para la diseminaci&#xF3;n intrav&#xED;trea resistente al tratamiento o recidivante, en lugar del tratamiento con quimioterapia intrarterial o intravenosa.[<a href="#cit/section_7.2">2</a>]</li></ol></div><p id="_910" tabindex="-1">Es posible que los pacientes con la forma hereditaria de la enfermedad, cuyos ojos fueron tratados solo con medidas de control local, presenten tumores intraoculares nuevos porque todas las c&#xE9;lulas de la retina tienen una mutaci&#xF3;n en el gen <em>RB1</em>; t&#xE9;cnicamente, estos tumores no se deben considerar como una recidiva. La vigilancia quiz&#xE1; permita detectar tumores nuevos en un estadio temprano incluso en pacientes muy j&#xF3;venes de retinoblastoma hereditario sometidos a tratamiento previo con quimiorreducci&#xF3;n e intervenciones de control local; la terapia adicional de control local, incluso la braquiterapia con placas, puede ser exitosa para erradicar el tumor.[<a href="#cit/section_7.3">3</a>-<a href="#cit/section_7.7">7</a>]</p><p id="_911" tabindex="-1">Cuando la recidiva o la progresi&#xF3;n del retinoblastoma son peque&#xF1;os y se limitan al ojo, el pron&#xF3;stico para la vista y la supervivencia puede ser excelente solo con terapia local.[<a href="#cit/section_7.8">8</a>][<a href="/Common/PopUps/popDefinition.aspx?id=587990&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000587990&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiDiv</a>] Si la recidiva o la progresi&#xF3;n son extensos y se limitan al ojo, el pron&#xF3;stico para la vista es adverso; no obstante, la supervivencia contin&#xFA;a siendo excelente. La quimioterapia intrarterial en la arteria oft&#xE1;lmica ha sido eficaz para pacientes que recaen despu&#xE9;s de recibir quimioterapia sist&#xE9;mica y radioterapia.[<a href="#cit/section_7.9">9</a>,<a href="#cit/section_7.10">10</a>] La quimioterapia intrarterial de <em>rescate</em> se ha usado despu&#xE9;s de la quimioterapia intrarterial primaria.  No obstante, los pacientes a menudo necesitan otros m&#xE9;todos de tratamiento cuando hay progresi&#xF3;n de la enfermedad despu&#xE9;s de la quimioterapia intrarterial  de segunda l&#xED;nea.[<a href="#cit/section_7.1">1</a>] Se debe considerar la administraci&#xF3;n de radioterapia en los pacientes que no la recibieron  antes. Por &#xFA;ltimo, quiz&#xE1; se necesite la enucleaci&#xF3;n en casos de enfermedad progresiva luego del fracaso de todos los tratamientos de rescate ocular.</p></section><section id="_912"><h3 id="_912_toc">Opciones de tratamiento de retinoblastoma extraocular progresivo o recidivante</h3><p id="_828" tabindex="-1">Las opciones de tratamiento del retinoblastoma extraocular progresivo o recidivante son las siguientes:</p><div class="pdq-content-list"><ol id="_829"><li>Quimioterapia sist&#xE9;mica y radioterapia para la enfermedad orbitaria.</li><li>Quimioterapia sist&#xE9;mica seguida de quimioterapia mielosupresora con rescate de c&#xE9;lulas madre y radioterapia para la enfermedad extraorbitaria.</li></ol></div><p id="_833" tabindex="-1">Si la recidiva o la progresi&#xF3;n son extraoculares, la probabilidad de supervivencia es baja.[<a href="#cit/section_7.11">11</a>] Sin embargo, la administraci&#xF3;n de quimioterapia intensiva, as&#xED; como la consolidaci&#xF3;n con dosis altas de quimioterapia y el rescate con trasplante aut&#xF3;geno de c&#xE9;lulas madre hematopoy&#xE9;ticas pueden mejorar la probabilidad de cura; en particular, en los pacientes con recidiva extracraneal (para obtener m&#xE1;s informaci&#xF3;n, consultar la secci&#xF3;n de este sumario sobre <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_77">Tratamiento del retinoblastoma extraocular</a>). Tras someterse a estos abordajes intensivos, los pacientes con enfermedad recidivante tal vez deseen considerar la participaci&#xF3;n en ensayos cl&#xED;nicos.</p><p id="_913" tabindex="-1">La recidiva en la &#xF3;rbita despu&#xE9;s de una enucleaci&#xF3;n se trata con quimioterapia intensiva adem&#xE1;s de radioterapia local  debido al riesgo elevado de enfermedad metast&#xE1;sica.[<a href="#cit/section_7.12">12</a>][<a href="/Common/PopUps/popDefinition.aspx?id=335144&amp;version=HealthProfessional&amp;language=Spanish" onclick="javascript:popWindow('defbyid','CDR0000335144&amp;version=HealthProfessional&amp;language=Spanish'); return(false);">Grado de comprobaci&#xF3;n: 3iiA</a>] Despu&#xE9;s de una enucleaci&#xF3;n por recidiva, una imagen de resonancia magn&#xE9;tica de alta resoluci&#xF3;n con bobinas  orbitarias es &#xFA;til para diferenciar una recidiva orbitaria de un realce posquir&#xFA;rgico.[<a href="#cit/section_7.13">13</a>]</p></section><section id="_921"><h3 id="_921_toc">Opciones de tratamiento en evaluaci&#xF3;n cl&#xED;nica para el retinoblastoma progresivo o recidivante</h3><p id="_940" tabindex="-1">La informaci&#xF3;n sobre los ensayos cl&#xED;nicos patrocinados por el Instituto Nacional del C&#xE1;ncer (NCI) se encuentra en el <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/search">portal de Internet del NCI</a>. Para obtener informaci&#xF3;n sobre ensayos cl&#xED;nicos patrocinados por otras organizaciones, consultar el enlace <a href="https://clinicaltrials.gov/" title="https://clinicaltrials.gov/">ClinicalTrials.gov</a>.</p><p id="_941" tabindex="-1">A continuaci&#xF3;n se presenta un ejemplo de un ensayo cl&#xED;nico nacional o institucional en curso:</p><div class="pdq-content-list"><ul id="_923"><li><strong><a href="/clinicaltrials/NCT03155620">APEC1621 (NCT03155620)</a></strong> (Pediatric MATCH: Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders)<strong>:</strong> en el NCI&#x2013;Children's Oncology Group Pediatric Molecular Analysis for Therapeutic Choice (MATCH), que se conoce como Pediatric MATCH, se emparejar&#xE1;n f&#xE1;rmacos de terapia dirigida con cambios moleculares espec&#xED;ficos identificados mediante ensayo de secuenciaci&#xF3;n dirigida de &#xFA;ltima generaci&#xF3;n para m&#xE1;s de  3000 mutaciones en m&#xE1;s de 160 genes presentes en tumores s&#xF3;lidos resistentes al tratamiento o recidivantes.   Los ni&#xF1;os y adolescentes de 1 a 21 a&#xF1;os son aptos para participar en este ensayo.<p id="_924" tabindex="-1">El tejido tumoral de la enfermedad progresiva o recidivante debe estar disponible para la caracterizaci&#xF3;n molecular. Se ofrecer&#xE1; tratamiento del Pediatric MATCH a los pacientes con tumores de variantes moleculares comprendidas en los grupos de tratamiento  del ensayo.  Para obtener m&#xE1;s informaci&#xF3;n, consultar el enlace <a href="https://clinicaltrials.gov/ct2/show/NCT03155620" title="https://clinicaltrials.gov/ct2/show/NCT03155620">APEC1621 (NCT03155620)</a> en el portal  de Internet <a href="https://clinicaltrials.gov/ct2/home" title="https://clinicaltrials.gov/ct2/home">ClinicalTrials.gov</a>.</p></li></ul></div><section id="_TrialSearch_921_sid_6"><h4 id="_TrialSearch_921_sid_6_toc">Ensayos cl&#xED;nicos en curso</h4><p id="_TrialSearch_921_25" tabindex="-1">Realizar una <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">b&#xFA;squeda avanzada</a> en ingl&#xE9;s de los ensayos cl&#xED;nicos sobre c&#xE1;ncer auspiciados por el NCI que ahora aceptan pacientes. La b&#xFA;squeda se puede simplificar por ubicaci&#xF3;n del ensayo, tipo de tratamiento, nombre del f&#xE1;rmaco y otros criterios. Tambi&#xE9;n se dispone de <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">informaci&#xF3;n general</a> sobre los ensayos cl&#xED;nicos. </p></section></section><section id="_TrialSearch_85_sid_7"><h3 id="_TrialSearch_85_sid_7_toc">Ensayos cl&#xED;nicos en curso</h3><p id="_TrialSearch_85_25" tabindex="-1">Realizar una <a href="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search" title="https://www.cancer.gov/about-cancer/treatment/clinical-trials/advanced-search">b&#xFA;squeda avanzada</a> en ingl&#xE9;s de los ensayos cl&#xED;nicos sobre c&#xE1;ncer auspiciados por el NCI que ahora aceptan pacientes. La b&#xFA;squeda se puede simplificar por ubicaci&#xF3;n del ensayo, tipo de tratamiento, nombre del f&#xE1;rmaco y otros criterios. Tambi&#xE9;n se dispone de <a href="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos" title="https://www.cancer.gov/espanol/cancer/tratamiento/estudios-clinicos">informaci&#xF3;n general</a> sobre los ensayos cl&#xED;nicos. </p></section><h6 do-not-show="toc">Bibliograf&#xED;a</h6><ol><li id="section_7.1">Francis JH, Abramson DH, Gobin YP, et al.: Efficacy and toxicity of second-course ophthalmic artery chemosurgery for retinoblastoma. Ophthalmology 122 (5): 1016-22, 2015.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25616769&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=25616769&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.2">Ghassemi F, Shields CL, Ghadimi H, et al.: Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma. JAMA Ophthalmol 132 (8): 936-41, 2014.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24789622&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=24789622&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.3">Shields CL, Honavar SG, Shields JA, et al.: Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 120 (4): 460-4, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11934319&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11934319&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.4">Gombos DS, Kelly A, Coen PG, et al.: Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age. Br J Ophthalmol 86 (1): 80-3, 2002.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11801509&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=11801509&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.5">Shields CL, Shelil A, Cater J, et al.: Development of new retinoblastomas after 6 cycles of chemoreduction for retinoblastoma in 162 eyes of 106 consecutive patients. Arch Ophthalmol 121 (11): 1571-6, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609913&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14609913&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.6">Lee TC, Hayashi NI, Dunkel IJ, et al.: New retinoblastoma tumor formation in children initially treated with systemic carboplatin. Ophthalmology 110 (10): 1989-94; discussion 1994-5, 2003.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14522776&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=14522776&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.7">Wilson MW, Haik BG, Billups CA, et al.: Incidence of new tumor formation in patients with hereditary retinoblastoma treated with primary systemic chemotherapy: is there a preventive effect? Ophthalmology 114 (11): 2077-82, 2007.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=17628684&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.8">Chan MP, Hungerford JL, Kingston JE, et al.: Salvage external beam radiotherapy after failed primary chemotherapy for bilateral retinoblastoma: rate of eye and vision preservation. Br J Ophthalmol 93 (7): 891-4, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19329423&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=19329423&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.9">Schaiquevich P, Ceciliano A, Millan N, et al.: Intra-arterial chemotherapy is more effective than sequential periocular and intravenous chemotherapy as salvage treatment for relapsed retinoblastoma. Pediatr Blood Cancer 60 (5): 766-70, 2013.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=23024125&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.10">Say EA, Iyer PG, Hasanreisoglu M, et al.: Secondary and tertiary intra-arterial chemotherapy for massive persistent or recurrent subretinal retinoblastoma seeds following previous chemotherapy exposure: long-term tumor control and globe salvage in 30 eyes. J AAPOS 20 (4): 337-42, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=27328850&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.11">Broaddus E, Topham A, Singh AD: Survival with retinoblastoma in the USA: 1975-2004. Br J Ophthalmol 93 (1): 24-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18718969&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.12">Kim JW, Kathpalia V, Dunkel IJ, et al.: Orbital recurrence of retinoblastoma following enucleation. Br J Ophthalmol 93 (4): 463-7, 2009.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=18757474&amp;dopt=Abstract">[PUBMED Abstract]</a></li><li id="section_7.13">Sirin S, de Jong MC, de Graaf P, et al.: High-Resolution Magnetic Resonance Imaging Can Reliably Detect Orbital Tumor Recurrence after Enucleation in Children with Retinoblastoma. Ophthalmology 123 (3): 635-45, 2016.&#xA0;<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26692298&amp;dopt=Abstract" title="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;list_uids=26692298&amp;dopt=Abstract">[PUBMED Abstract]</a></li></ol></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _640
      field_pdq_section_title:
        - format: plain_text
          value: 'Modificaciones a este sumario (09/26/2018)'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_640" class="pdq-sections"><p id="_642" tabindex="-1">Los sumarios del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer se revisan con regularidad y se actualizan a medida que se obtiene nueva informaci&#xF3;n.  Esta secci&#xF3;n describe los cambios m&#xE1;s recientes hechos a este sumario a partir de la fecha arriba indicada.</p><p id="_951" tabindex="-1"><strong><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_1">Informaci&#xF3;n general sobre el retinoblastoma</a></strong></p><p id="_952" tabindex="-1">Se a&#xF1;adi&#xF3; <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_488">texto</a> para indicar que se infiere que el estado funcional de la prote&#xED;na del retinoblastoma (pRb) es inactivo en el retinoblastoma con amplificaci&#xF3;n de <em>MYCN</em>. Esto indica que la inactivaci&#xF3;n de <em>RB1</em> por mutaci&#xF3;n o la pRb inactiva es un requisito para la presentaci&#xF3;n de un retinoblastoma, de manera independiente a la amplificaci&#xF3;n de <em>MYCN</em> (se cit&#xF3; a Ewens et al. como referencia 13).</p><p id="_943" tabindex="-1"><strong><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_53">Aspectos generales de las opciones de tratamiento del retinoblastoma</a></strong></p><p id="_953" tabindex="-1">Se a&#xF1;adi&#xF3; a Say et al. como <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_884">referencia 36</a>.</p><p id="_954" tabindex="-1">Se revis&#xF3; el <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_886">texto</a> para indicar que,  si bien la diseminaci&#xF3;n v&#xED;trea subretiniana se puede controlar bien con quimioterapia intrarterial, es posible que sea dif&#xED;cil de  controlar solo con quimioterapia intrarterial o intravenosa. es posible que sea dif&#xED;cil de  controlar con quimioterapia intrarterial o intravenosa solas. Tambi&#xE9;n se a&#xF1;adi&#xF3; texto para indicar que la adici&#xF3;n de quimioterapia intrav&#xED;trea a la quimioterapia a la quimioterapia intravenosa es m&#xE1;s eficaz para tratar la diseminaci&#xF3;n v&#xED;trea; al igual que con la quimioterapia intrarterial primaria, se necesitan cada vez m&#xE1;s ciclos de quimioterapia intrav&#xED;trea para el control del polvo, las esferas y las nubes de las semillas (se cit&#xF3; a Berry et al. como referencia 45 y grado de comprobaci&#xF3;n cient&#xED;fica 3iiiDiii).</p><p id="_955" tabindex="-1">Se a&#xF1;adi&#xF3; a Shields et al. como <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_888">referencia 46</a>.</p><p id="_956" tabindex="-1"><strong><a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_85">Tratamiento del retinoblastoma progresivo o recidivante</a></strong></p><p id="_957" tabindex="-1">Se a&#xF1;adi&#xF3; a Say et al. como <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_911">referencia 10</a>.</p><p id="_disclaimerHP_3" tabindex="-1">Este sumario est&#xE1; redactado y mantenido por el <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico">Consejo editorial del PDQ sobre el tratamiento pedi&#xE1;trico</a>, que es editorialmente independiente del NCI. El sumario refleja una revisi&#xF3;n independiente de la bibliograf&#xED;a y no representa una declaraci&#xF3;n de pol&#xED;ticas del NCI o de los NIH. Para mayor informaci&#xF3;n sobre las pol&#xED;ticas de los sumarios y la funci&#xF3;n de los  consejos editoriales  del PDQ que mantienen los sumarios del PDQ, consultar en <a href="/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq#link/_AboutThis_1">Informaci&#xF3;n sobre este sumario del PDQ</a> y  la p&#xE1;gina sobre <a href="https://www.cancer.gov/espanol/publicaciones/pdq" title="https://www.cancer.gov/espanol/publicaciones/pdq">Banco de datos de informaci&#xF3;n de c&#xE1;ncer - PDQ&#xAE;</a>.
            </p></div>
    - entity: paragraph
      type: pdq_summary_section
      field_pdq_section_id:
        value: _AboutThis_1
      field_pdq_section_title:
        - format: plain_text
          value: 'Información sobre este sumario del PDQ'
      field_pdq_section_html:
        - format: raw_html
          value: |
            <div id="_section_AboutThis_1" class="pdq-sections"><section id="_AboutThis_2"><h3 id="_AboutThis_2_toc">Prop&#xF3;sito de este sumario</h3><p id="_AboutThis_3" tabindex="-1">Este sumario del PDQ con informaci&#xF3;n sobre el c&#xE1;ncer para profesionales de la salud proporciona informaci&#xF3;n integral revisada por expertos y con fundamento en datos probatorios sobre el tratamiento del retinoblastoma. El prop&#xF3;sito es servir como fuente de informaci&#xF3;n y ayuda para los m&#xE9;dicos que atienden a pacientes de c&#xE1;ncer. No  ofrece pautas ni recomendaciones formales para tomar decisiones relacionadas con la atenci&#xF3;n sanitaria.</p></section><section id="_AboutThis_21"><h3 id="_AboutThis_21_toc">Revisores y actualizaciones</h3><p id="_AboutThis_22" tabindex="-1">El  <a href="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico" title="https://www.cancer.gov/espanol/publicaciones/pdq/consejos-editoriales/tratamiento-pediatrico">Consejo editorial del PDQ sobre el tratamiento pedi&#xE1;trico</a>, cuya funci&#xF3;n editorial es independiente del Instituto Nacional del C&#xE1;ncer (NCI), revisa con regularidad este sumario y, en caso necesario,   lo actualiza. Este sumario refleja una revisi&#xF3;n bibliogr&#xE1;fica independiente y no constituye una declaraci&#xF3;n de la pol&#xED;tica del Instituto Nacional del C&#xE1;ncer ni de los Institutos Nacionales de la Salud (NIH).</p><p id="_AboutThis_26" tabindex="-1">Cada mes, los miembros de este Consejo  examinan art&#xED;culos  publicados recientemente para determinar si se deben:</p><div class="pdq-content-list"><ul id="_AboutThis_23"><li>tratar en una reuni&#xF3;n,</li><li>citar textualmente, o</li><li>sustituir o actualizar, si ya se citaron con anterioridad.</li></ul></div><p id="_AboutThis_24" tabindex="-1">Los cambios en los sumarios se deciden mediante consenso, una vez que  los integrantes del Consejo eval&#xFA;an la solidez de los datos probatorios en los art&#xED;culos publicados y determinan la forma en que se incorporar&#xE1;n al sumario.</p><p id="" tabindex="-1">Los revisores principales del sumario sobre Tratamiento del retinoblastoma son:</p><div class="pdq-content-list"><ul id=""><li>Christopher N. Frantz, MD (Alfred I. duPont Hospital for Children)</li><li>Karen J. Marcus, MD (Dana-Farber Cancer Institute/Boston Children's Hospital)</li><li>Thomas A. Olson, MD (Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta - Egleston Campus)</li><li>Carlos Rodriguez-Galindo, MD (St. Jude Children's Research Hospital)</li><li>Nita Louise Seibel, MD (National Cancer Institute)</li></ul></div><p id="_AboutThis_25" tabindex="-1">Cualquier comentario o pregunta sobre el contenido de este sumario se debe enviar mediante el   <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario de comunicaci&#xF3;n</a> en Cancer.gov/espanol del NCI.  No comunicarse con los miembros del Consejo para enviar preguntas o comentarios sobre los sumarios.  Los miembros del Consejo no responder&#xE1;n a preguntas del p&#xFA;blico. </p></section><section id="_AboutThis_9"><h3 id="_AboutThis_9_toc">Grados de comprobaci&#xF3;n cient&#xED;fica</h3><p id="_AboutThis_10" tabindex="-1">En algunas referencias bibliogr&#xE1;ficas de este sumario se indica el grado de comprobaci&#xF3;n cient&#xED;fica. El prop&#xF3;sito de estas designaciones es ayudar al lector a evaluar la solidez de los datos probatorios que sustentan el uso de  ciertas intervenciones  o enfoques. El Consejo editorial del PDQ sobre el tratamiento pedi&#xE1;trico emplea un <a href="/espanol/publicaciones/pdq/grados-comprobacion/tratamiento">sistema de jerarquizaci&#xF3;n formal</a> para establecer  las designaciones del grado de comprobaci&#xF3;n cient&#xED;fica.</p></section><section id="_AboutThis_11"><h3 id="_AboutThis_11_toc">Permisos para el uso de este sumario</h3><p id="_AboutThis_12" tabindex="-1">PDQ (Physician Data Query) es una marca registrada. Se autoriza el libre uso del texto  de los documentos del PDQ. Sin embargo, no se podr&#xE1; identificar como un sumario de informaci&#xF3;n sobre c&#xE1;ncer del PDQ del  NCI,  salvo que se reproduzca en su totalidad y se actualice con regularidad. Por otra parte, se permitir&#xE1; que un autor  escriba una oraci&#xF3;n como &#x201C;En el sumario del PDQ  del NCI de informaci&#xF3;n sobre la prevenci&#xF3;n del c&#xE1;ncer de mama se describen, en breve, los siguientes riesgos: [incluir fragmento del sumario]&#x201D;.</p><p id="_AboutThis_13" tabindex="-1">Se sugiere citar la referencia bibliogr&#xE1;fica de este sumario del PDQ de la siguiente forma:</p><p id="_AboutThis_14" tabindex="-1">PDQ&#xAE; sobre el tratamiento pedi&#xE1;trico. PDQ Tratamiento del retinoblastoma. Bethesda, MD: National Cancer Institute. Actualizaci&#xF3;n:  &lt;MM/DD/YYYY&gt;. Disponible en: <a href="https://www.cancer.gov/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq" title="https://www.cancer.gov/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq">https://www.cancer.gov/espanol/tipos/retinoblastoma/pro/tratamiento-retinoblastoma-pdq</a>.  Fecha de acceso: &lt;MM/DD/YYYY&gt;. </p><p id="_AboutThis_15" tabindex="-1">Las im&#xE1;genes  en este sumario se reproducen  con el permiso del autor, el artista o la  editorial para uso exclusivo en los sumarios del PDQ. La utilizaci&#xF3;n de las im&#xE1;genes fuera del  PDQ requiere la autorizaci&#xF3;n del propietario, que el Instituto Nacional del C&#xE1;ncer no  puede otorgar. Para obtener m&#xE1;s informaci&#xF3;n sobre el uso de las ilustraciones de este sumario o de  otras im&#xE1;genes relacionadas con el c&#xE1;ncer, consultar <a href="https://visualsonline.cancer.gov/" title="https://visualsonline.cancer.gov/">Visuals Online</a>, una colecci&#xF3;n de m&#xE1;s de 2000 im&#xE1;genes cient&#xED;ficas.</p></section><section id="_AboutThis_16"><h3 id="_AboutThis_16_toc">Cl&#xE1;usula sobre el descargo de responsabilidad</h3><p id="_AboutThis_17" tabindex="-1">Seg&#xFA;n la solidez de los datos probatorios, las opciones de tratamiento se clasifican  como &#x201C;est&#xE1;ndar&#x201D; o &#x201C;en evaluaci&#xF3;n cl&#xED;nica&#x201D;. Estas clasificaciones no  deben fundamentar ninguna decisi&#xF3;n sobre reintegros de seguros. Para obtener m&#xE1;s informaci&#xF3;n  sobre cobertura de seguros, consultar la p&#xE1;gina <a href="https://www.cancer.gov/espanol/cancer/manejo-del-cancer" title="https://www.cancer.gov/espanol/cancer/manejo-del-cancer">Manejo de la atenci&#xF3;n del c&#xE1;ncer</a>
            disponible en Cancer.gov/espanol.</p></section><section id="_AboutThis_19"><h3 id="_AboutThis_19_toc">Para obtener m&#xE1;s informaci&#xF3;n</h3><p id="_AboutThis_20" tabindex="-1">En Cancer.gov/espanol,  se ofrece m&#xE1;s informaci&#xF3;n sobre c&#xF3;mo comunicarse o recibir ayuda en  <a href="https://www.cancer.gov/espanol/contactenos" title="https://www.cancer.gov/espanol/contactenos">&#xBF;En qu&#xE9; podemos ayudarle?</a>.
            Tambi&#xE9;n se puede enviar un mensaje de  correo electr&#xF3;nico  mediante este  <a href="https://www.cancer.gov/espanol/contactenos/correo-electronico" title="https://www.cancer.gov/espanol/contactenos/correo-electronico">formulario</a>.</p></section></div>
